










GENETIC SUSCEPTIBILITY TO MYELOPROLIFERATIVE NEOPLASMS 





ANA PAULA DA SILVA AZEVEDO  
 
Tese para obtenção do Grau de Doutor em Medicina 
Na Especialidade de Genética, Oncologia e Toxicologia Humana 

















GENETIC SUSCEPTIBILITY TO  
MYELOPROLIFERATIVE NEOPLASMS  




Ana Paula da Silva Azevedo 
 
Orientador: Professor Doutor José Rueff, Professor Catedrático 
 
 
Tese para obtenção do Grau de Doutor em Medicina 

























Aos meus pais, 
Aos meus filhos e ao meu marido, 




“O Homem é do tamanho do seu sonho” 
Fernando Pessoa
I 
TABLE OF CONTENTS 
FIGURE INDEX ........................................................................................................................ V 
TABLE INDEX ........................................................................................................................ VII 
AGRADECIMENTOS .............................................................................................................. IX 
LIST OF ACRONYMS ............................................................................................................. XI 
RESUMO ............................................................................................................................... XIII 
ABSTRACT ............................................................................................................................ XV 
LIST OF PUBLICATIONS .................................................................................................... XVII 
CHAPTER 1: GENERAL INTRODUCTION ............................................................................. 1 
1.1 – MYELOPROLIFERATIVE NEOPLASMS: PHILADELPHIA CHROMOSOME NEGATIVE 
DISORDERS .............................................................................................................................. 3 
1.1.1 – MOLECULAR PATHOPHYSIOLOGY .................................................................... 8 
1.1.2 – DIAGNOSIS, PROGNOSIS AND PREDICTIVE FACTORS .............................. ..30
1.1.3 – RISK STRATIFICATION, THERAPY MANAGEMENT AND RESPONSE 
EVALUATION .................................................................................................................... 52 
1.2 – INDIVUDUAL SUSCEPTIBILITY: GENETIC POLYMORPHISMS AND ASSOCIATION 
STUDIES .................................................................................................................................. 63 
1.3 – CASPASES AND APOPTOSIS ...................................................................................... 67 
1.4 – GENETIC LESION REPAIR: BASE EXCISION REPAIR ............................................... 75 
1.5 – REFERENCES ................................................................................................................ 82 
CHAPTER 2: STUDY AIMS AND STRUCTURE ................................................................... 95 
2.1 – STUDY AIMS................................................................................................................... 97 
2.2 – STUDY STRUCTURE ..................................................................................................... 99 
GENETIC SUSCEPTIBILITY TO MYELOPROLIFERATIVE NEOPLASMS AND THERAPEUTIC EFFICACY 
II 
CHAPTER 3: PREVALENCE OF JAK2 V617F MUTATION IN PHILADELPHIA-NEGATIVE 
MYELOPROLIFERATIVE NEOPLASMS IN A PORTUGUESE POPULATION ................. 103 
3.1 – INTRODUCTION ........................................................................................................... 105 
3.2 – MATERIALS AND METHODS ...................................................................................... 108 
3.2.1 – STUDY SUBJECTS ............................................................................................ 108 
3.2.2 – DNA EXTRACTION ............................................................................................ 108 
3.2.3 – GENOTYPING .................................................................................................... 109 
3.2.4 – STATISTICAL ANALYSIS .................................................................................. 109 
3.3 – RESULTS ...................................................................................................................... 109 
3.4 – DISCUSSION AND CONCLUSIONS ............................................................................ 111 
3.5 – REFERENCES .............................................................................................................. 114 
CHAPTER 4: ATYPICAL HEMATOLOGICAL PRESENTATION IN A CASE OF 
POLYCYTHEMIA VERA WITH A NEW VARIANT MUTATION DETECTED IN EXON 12 - 
C.1605G>T(P.MET535ILE) ................................................................................................... 119 
4.1 – INTRODUCTION........................................................................................................... 121 
4.2 – PATIENT AND METHODS ........................................................................................... 122 
4.3 – DISCUSSION ................................................................................................................124
4.4 –  REFERENCES ............................................................................................................. 128 
CHAPTER 5: CONCOMITANT PRESENCE OF JAK2 V617F MUTATION AND BCR-ABL 
TRANSLOCATION IN TWO PATIENTS: A NEW ENTITY OR A VARIANT OF 
MYELOPROLIFERATIVE NEOPLASMS ............................................................................. 131 
5.1 – INTRODUCTION........................................................................................................... 133 
5.2 – MATERIALS AND METHODS ...................................................................................... 134 
5.3 – DISCUSSION ................................................................................................................ 139 
5.4 –  REFERENCES ............................................................................................................. 143 
CHAPTER 6: BCR-ABL V280G MUTATION POTENTIAL ROLE IN IMATINIB 
RESISTANCE: FIRST CASE REPORT................................................................................ 145 
6.1 – INTRODUCTION........................................................................................................... 147 
6.2 – CASE REPORT ............................................................................................................. 147 
6.3 – DISCUSSION AND CONCLUSIONS............................................................................ 150 
6.4 –  REFERENCES ............................................................................................................. 153
TABLE OF CONTENTS 
III 
CHAPTER 7: THE ROLE OF CASPASE GENES POLYMORPHISMS IN GENETIC 
SUSCEPTIBILITY TO PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE 
NEOPLASMS IN A PORTUGUESE POPULATION ............................................................ 155 
7.1 – INTRODUCTION........................................................................................................... 157 
7.2 – MATERIALS AND METHODS ...................................................................................... 159 
7.2.1 – STUDY SUBJECTS ............................................................................................ 159 
7.2.2 – DNA EXTRACTION ............................................................................................ 159 
7.2.3 – SNP SELECTION (CASPASES) ........................................................................ 159 
7.2.4 – GENOTYPING .................................................................................................... 159 
7.2.5 – STATISTICAL ANALYSIS ..................................................................................160
7.3 – RESULTS ...................................................................................................................... 160 
7.3.1 – CHARACTERIZATION OF POPULATIONS ...................................................... 160 
7.3.2 – SNP’S GENOTYPING ........................................................................................161
7.3.3 – HAPLOGROUP ASSOCIATION ......................................................................... 164 
7.4 – DISCUSSION AND CONCLUSIONS............................................................................ 165 
7.5 – REFERENCES .............................................................................................................. 168 
CHAPTER 8: DNA REPAIR GENES POLYMORPHISMS AND GENETIC SUSCEPTIBILITY 
TO PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS IN A 
PORTUGUESE POPULATION: THE ROLE OF BASE EXCISION REPAIR GENES 
POLYMORPHISMS ............................................................................................................... 171 
8.1 – INTRODUCTION........................................................................................................... 173 
8.2 – MATERIALS AND METHODS ...................................................................................... 175 
8.2.1 – STUDY SUBJECTS ............................................................................................ 175 
8.2.2 – DNA EXTRACTION ............................................................................................ 175 
8.2.3 – SNP SELECTION (BASE EXCISION REPAIR PATHWAY) .............................. 175 
8.2.4 – GENOTYPING .................................................................................................... 176 
8.2.5 – STATISTICAL ANALYSIS .................................................................................. 176 
8.3 – RESULTS ...................................................................................................................... 176 
8.3.1 – CHARACTERIZATION OF POPULATIONS ...................................................... 176 
8.3.2 – SNP’S GENOTYPING ........................................................................................ 178 
8.3.3 – HAPLOGROUP ASSOCIATION ......................................................................... 180 
8.4 – DISCUSSION AND CONCLUSIONS............................................................................ 181 
8.5 – REFERENCES .............................................................................................................. 189 
GENETIC SUSCEPTIBILITY TO MYELOPROLIFERATIVE NEOPLASMS AND THERAPEUTIC EFFICACY 
IV 
CHAPTER 9: EFFECTS OF POLYMORPHIC DNA GENES INVOLVED IN BASE EXCISION 
REPAIR AND APOPTOSIS ON THE CLINICAL OUTCOME OF PHILADELPHIA-NEGATIVE 
MYELOPROLIFERATIVE NEOPLASMS UNDER TREATMENT ....................................... 195 
9.1 – INTRODUCTION ........................................................................................................... 197 
9.2 – MATERIALS AND METHODS ...................................................................................... 200 
9.2.1 – STUDY SUBJECTS ............................................................................................ 200 
9.2.2 – DNA EXTRACTION ............................................................................................ 201 
9.2.3 – SNP SELECTION (CASPASES AND BASE EXCISION REPAIR PATHWAY) 201 
9.2.4 – GENOTYPING .................................................................................................... 201 
9.2.5 – STATISTICAL ANALYSIS .................................................................................. 201 
9.3 – RESULTS ...................................................................................................................... 202 
9.3.1 – GENERAL CHARACTERISTICS OF PATIENTS AND SURVIVAL .................. 202 
9.3.2 – ANALYSIS OF PATIENTS WHO PROGRESSED TO SECONDARY MF/AML 206 
9.3.3 – ANALYSIS OF PATIENTS WHO DEVELOPED NEW NONMYELOID 
MALIGNANCIES ............................................................................................................. 209 
9.3.4 – ANALYSIS OF PATIENTS WHO PRESENTED WITH THROMBOTIC EVENTS
 ......................................................................................................................................... 211 
9.4 – DISCUSSION AND CONCLUSIONS ............................................................................ 214 
9.5 – REFERENCES .............................................................................................................. 220 
CHAPTER 10: CONCLUSIONS AND FINAL REMARKS ................................................... 223 
APPENDIX ............................................................................................................................. 233 
APPENDIX 1: INFORMED CONSENT AND MEDICAL QUESTIONNAIRE ......................... 235 
APPENDIX 2: CENTRO HOSPITALAR LISBOA OCIDENTAL ETHICAL COMISSION 
APPROVAL ............................................................................................................................ 239 
APPENDIX 3: NOVA MEDICAL SCHOOL ETHICAL COMISSION APPROVAL .................. 241 
V 
FIGURE INDEX 
Figure 1.1 – Timeline of the elucidation of genomic alterations in myeloproliferative neoplasms. ........5 
Figure 1.2 – Overview of hematopoiesis and affected myeloid cell lineages in PN-MPNs. ...................6 
Figure 1.3 – Frequency, distribution and pathogenetic relevance of acquired gene mutations in 
hematologic malignancies........................................................................................................................9 
Figure 1.4 – Variation frequency of driver and other mutations in PN-MPNs. .....................................10 
Figure 1.5 – Schematic representation of JAK2 gene and mutation hot spots. ...................................11 
Figure 1.6 – Schematic representation of JAK2 V617F positive PN-MPNs. ........................................12 
Figure 1.7 – Schematic representation of MPL gene and mutation hot spots. ....................................16 
Figure 1.8 – JAK and STAT protein structures. ....................................................................................20 
Figure 1.9 – Overview of molecular JAK signaling and regulation (ex: JAK2) and acquired genetic 
alterations involved in activation of components of JAK/STAT pathway...............................................22 
Figure 1.10 – Epigenetic regulators. .....................................................................................................26 
Figure 1.11 – Practical workflow for the diagnosis of PN-MPNs. .........................................................33 
Figure 1.12 – Spectrum of PN-MPNs phenotypes associated with JAK2 and MPL lesions. ...............34 
Figure 1.13 – Clinical presentation in classic PN-MPNs. .....................................................................36 
Figure 1.14 –  Bone marrow morphologic and histologic aspects from a PV patient. ..........................37 
Figure 1.15 – Peripheral blood smear and bone marrow morphologic aspects from an ET patient. ...39 
Figure 1.16 – Bone marrow histological aspects from an ET patient. ..................................................40 
Figure 1.17 – Peripheral blood smear morphological and bone marrow histological aspects from a PMF 
patient. ...................................................................................................................................................42 
Figure 1.18 – Clinical course in classic PN-MPNs................................................................................45 
Figure 1.19 – Disease course and complications associated with PN-MPNs. .....................................46 
Figure 1.20 – Mechanisms involved in the pathogenesis of thrombosis in PN-MPNs. ........................48 
Figure 1.21 – Contemporary treatment flow-chart in ET and PV. ........................................................55 
Figure 1.22 – Hydroxyurea (HU) molecule and its cellular effects. ......................................................57 
Figure 1.23 – Contemporary treatment flow-chart in myelofibrosis. .....................................................59 
Figure 1.24 – Caspases domain structures and functions. ..................................................................69 
Figure 1.25 – Diagrammatic representation of the extrinsic, intrinsic and perforin/granzyme apoptotic 
pathways. ...............................................................................................................................................70 
Figure 1.26 – DNA damage agents and repair mechanisms................................................................76 
Figure 1.27 – BER pathway. .................................................................................................................79 
Figure 4.1 – Exon 12 mutation of the JAK2 gene analysis in peripheral blood. ................................ 123 
GENETIC SUSCEPTIBILITY TO MYELOPROLIFERATIVE NEOPLASMS AND THERAPEUTIC EFFICACY 
VI 
Figure 4.2 – Bone marrow aspirate A) and biopsy B) and C) showing trilinear hyperplasia and 
pleomorphic mature megakaryocytes. ................................................................................................ 124 
Figure 5.1 – Case study 1: bone marrow aspirate. ............................................................................ 135 
Figure 5.2 – Case study 1: bone marrow biopsy. .............................................................................. 135 
Figure 5.3 – Case study 1: molecular biology test. ............................................................................ 136 
Figure 5.4 – Case study 2: FISH test. ................................................................................................ 138 
Figure 6.1 –  BCR-ABL tyrosine kinase domain mutation analysis in peripheral blood. ................... 149 
VII 
TABLE INDEX 
Table 1.1 – Cytokine and factors stimuli for JAK and STAT families activation. ..................................21 
Table 1.2 – Frequencies of gene mutations co-occurrence in the chronic phase of PN-MPNs, according 
to phenotype and driver mutation. .........................................................................................................27 
Table 1.3 –  WHO classification criteria for PN-MPNs diagnosis. ........................................................31 
Table 1.4 – Classical PN-MPNs clinical, morphological and molecular features. ................................35 
Table 1.5 – Myelofibrosis grading. ........................................................................................................43 
Table 1.6 – Classical PN-MPNs conventional and molecular risk factors influencing clinical outcome 
and affecting prognosis. .........................................................................................................................44 
Table 1.7 – International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) 
recommended criteria for post-PV and post-ET myelofibrosis. .............................................................50 
Table 1.8 – Prognostic models and risk stratification for PN-MPNs patients........................................52 
Table 1.9 – Morphological features of apoptosis and necrosis. ............................................................67 
Table 3.1 – General characteristics of the PN-MPNs case (n=133) and control populations (n=281).
 ............................................................................................................................................................ 110 
Table 3.2 – JAK2 V617F mutation allelic distribution in the PN-MPNs cases (n=133). .................... 110 
Table 4.1 – Complete blood counts and treatment prescription over time. ....................................... 123 
Table 4.2 – Clinical and demographic features of other published exon 12 cases. .......................... 127 
Table 5.1 – Results over time and therapy prescribed for case study 1. ........................................... 134 
Table 5.2 – Results over time and therapy prescribed for case study 2. ........................................... 137 
Table 6.1 – Complete blood count results over time. ......................................................................... 148 
Table 6.2 –  BCR-ABL transcript levels evaluation and treatment over time. .................................... 148 
Table 7.1 – General characteristics for the PN-MPNs case and control populations and gender 
distribution for the PN-MPNs cases. ................................................................................................... 161 
Table 7.2 – Selected SNPs and detailed information on the corresponding base and amino acid 
exchanges as well as minor allele frequency. .................................................................................... 162 
Table 7.3 – Genotype distribution and myeloproliferative risk. .......................................................... 163 
Table 7.4 – ORs (95% ci) for CASP9 (Phe36Phe) polymorphisms and PN-MPNs association. ....... 164 
Table 7.5 – Haplogroup association response for SNPs of CASP9 gene. ........................................ 165 
Table 7.6 – Haplogroup association response for SNPs present in all effector caspases studied. .. 165 
GENETIC SUSCEPTIBILITY TO MYELOPROLIFERATIVE NEOPLASMS AND THERAPEUTIC EFFICACY 
VIII 
Table 8.1 – Selected SNPs and detailed information on the corresponding base and amino acid 
exchanges, as well as MAF. ............................................................................................................... 175 
Table 8.2 – Gender distribution for the PN-MPNs cases. .................................................................. 177 
Table 8.3 – General characteristics of the PN-MPNs case and control populations. ........................ 177 
Table 8.4 – Genotype distribution and myeloproliferative risk. .......................................................... 179 
Table 8.5 – ORs (95% CI) for MUTYH (gln335his) and XRCC1 (gln399arg) polymorphisms and PN-
MPNs association. .............................................................................................................................. 180 
Table 8.6 – Haplogroup frequencies for the SNPs under study. ....................................................... 181 
Table 8.7 – Haplogroup association response for the SNPs under study. .........................................181 
Table 9.1 – Characteristics of patients according to the type of MPN. .............................................. 202 
Table 9.2 – Selected caspases and BER pathway SNPs and detailed information on the corresponding 
base and amino acid exchanges as well as MAF............................................................................... 204 
Table 9.3 – Factors influencing survival. ............................................................................................ 205 
Table 9.4 – Factors investigated for their association with fibrotic/leukemic progression in ET and PV.
 ............................................................................................................................................................ 207 
Table 9.5 – Factors investigated for their association with new nonmyeloid malignancy in ET, PV and 
PMF. .................................................................................................................................................... 210 
Table 9.6 – Factors investigated for their association with thrombotic events in ET, PV and PMF. . 212 
Table 9.7 – ORs (95% CI) for polymorphisms and PN-MPNs association. ....................................... 214 
IX 
AGRADECIMENTOS 
O trabalho desenvolvido nos últimos anos e que possibilitou a elaboração desta dissertação, 
teve a colaboração de um conjunto de pessoas e instituições que, de alguma forma, me 
acompanharam e a quem gostaria de expressar o meu sincero reconhecimento e agradecimento. 
Ao Professor Doutor José Rueff, Diretor do Centre for Toxicogenomics and Human Health 
Genetics, Oncology and Human Toxicology, da Universidade Nova de Lisboa agradeço a orientação e 
a oportunidade que me concedeu para a realização do meu projecto no seu Laboratório, todo o apoio, 
empenho e dedicação incansáveis e o contributo científico na elaboração da minha tese. Agradeço a 
amizade e o entusiasmo com que aborda a Genética e a Medicina, que me contagiou enquanto sua 
aluna na Faculdade e que me conduziu até aqui.  
À Professora Susana Nunes da Silva agradeço toda a dedicação, apoio, empenho e 
disponibilidade sem limites e o contributo científico na elaboração da minha tese. Agradeço a amizade 
demonstrada desde o início e que se consolidou ao longo destes anos, a compreensão e as palavras 
de alento e de incentivo que chegaram sempre no momento certo e que marcaram a diferença em 
diversas ocasiões. 
Ao Professor Doutor Jorge Gaspar, que infelizmente já não se encontra entre nós, agradeço a 
amizade e o voto de confiança que depositou em mim ao lançar-me este desafio, incentivando-me 
continuamente a prosseguir, sobretudo nos momentos mais difíceis. 
À Dra. Alice Reichert agradeço a amizade, o contributo para a minha formação na área das 
neoplasias mieloproliferativas e todo o apoio prestado na seleção e acompanhamento dos doentes 
incluídos no estudo. 
Ao Dr. Fernando Lima, Diretor do Serviço de Hematologia Clínica do Centro Hospitalar de 
Lisboa Ocidental e a todos os colegas deste Serviço e do Serviço de Imunohemoterapia, entre os quais 
destaco a Dra. Paula Santos, a Dra. Filipa Mousinho e a Dra. Amélia Pita, agradeço a amizade e a 
colaboração no seguimento dos doentes envolvidos neste projecto, permitindo a sua realização.  
À Dra. Esmeraldina Correia Júnior e ao Dr. João Faro Viana, respectivamente anterior e actual 
Diretores do Serviço de Patologia Clínica do Centro Hospitalar de Lisboa Ocidental, agradeço a 
amizade e incentivo, permitindo que o trabalho fosse executado.  
À Dra. Sância Ramos e à Dra. Vanessa Henriques agradeço a simpatia e disponibilidade na 
cedência das imagens de exame histológico de medula óssea, incluídas nesta tese.  
Ao Professor Sebastião Rodrigues e às colegas da Genomed, Dra. Sónia Matos e Professora 
Sónia Santos agradeço a disponibilidade e apoio prestado sempre que solicitado. 
Às Técnicas Luísa Limão, Sílvia Amaro e Inês Santos agradeço a simpatia e colaboração. 
A todos os doentes que participaram neste trabalho e que constituiram a principal motivação 
para a sua realização, agradeço a simpatia, interesse e disponibilidade.  
 
GENETIC SUSCEPTIBILITY TO MYELOPROLIFERATIVE NEOPLASMS AND THERAPEUTIC EFFICACY  
 X 
À Professora Doutora Julieta Esperança Pina agradeço a amizade, o exemplo de força e 
preseverança e o apoio no “abraço” a este desafio e à atividade académica. 
Ao Dr. Valdemar Teixeira e à Dra. Cristina Gamelas agradeço a amizade, o exemplo de 
dedicação e entusiasmo pela Hematologia e os ensinamentos que me transmitiram e que foram fulcrais 
no período inicial da minha formação, fazendo despertar o meu interesse por esta área da Medicina. 
À Dra. Ana Batalha Reis, ao Dr. Cândido Silva, à Dra. Susana Matos e à Dra. Flora Meireles 
agradeço o apoio, a amizade e a equipa de trabalho que juntos formamos, pautada pelo rigor, exigência 
e diferenciação, contribuindo para o meu “crescimento” como especialista.  
À Dra. Maria Ana Pessanha, à Dra. Maria Jorge Arroz, à Professora Doutora Teresa Marques 
e ao Professor Doutor Miguel Seabra agradeço o apoio e amizade demonstrados. 
Aos vários colegas, entre os quais destaco o Professor António Almeida, agradeço pela 
qualidade e inspiração das inúmeras palestras às quais tive o privilégio de assistir e que muito 
contribuiram para o meu interesse e conhecimento sobre o tema. 
A todos os meus colegas do Serviço de Patologia Clínica do Centro Hospitalar de Lisboa 
Ocidental, do Centre for Toxicogenomics and Human Health Genetics, Oncology and Human 
Toxicology da Universidade Nova de Lisboa, e amigos agradeço a simpatia, amizade e apoio ao longo 
dos anos. 
Aos meus filhos e ao meu marido, agradeço todo o carinho, apoio e compreensão pela minha 
pouca disponibilidade em muitos momentos destes últimos anos. 
Aos meus pais, agradeço por nunca se terem poupado a esforços para me proporcionarem a 
melhor educação e formação, por sempre me apoiarem e incentivarem incondicionalmente. Aos dois 
devo tudo aquilo que hoje sou… 













LIST OF ACRONYMS 
AML   Acute Myeloid Leukemia 
ARMS-PCR Amplification Refractory Mutation System Polymerase Chain Reaction 
BER  Base Excision Repair 
BM  Bone Marrow 
CALR  Calreticulin 
CASP  Caspase 
CI  Confidence Interval 
CML  Chronic Myeloid Leukemia 
DNA  Desoxirribonucleic Acid 
ELN  European Leukemia Net 
EMH  Extramedullary Hematopoiesis 
EPO   Erythropoietin 
EPO-R  Erythropoietin-Receptor 
ET  Essential Thrombocythemia 
FISH  Fluorescent In Situ Hybridization 
G-CSF  Granulocyte Colony Stimulating Factor 
GWAS  Genome-Wide Association Studies 
HRM-PCR High Resolution Melting Polymerase Chain Reaction 
HSC  Hematopoietic Stem Cell 
HU  Hydroxyurea  
IFN  Interferon   
IPSS  International Prognostic Scoring System 
IWG-MRT International Working Group-Myeloproliferative Neoplasms Research and Treatment 
JAK   Janus Kinase family 
LD  Linkage Disequilibrium 
LOH  Loss of heterozygosity 
MAF  Minor Allele Frequency 
MDS  Myelodysplastic Syndromes 
MPL  Myeloproliferative Leukemia virus oncogene 
MPN  Myeloproliferative Neoplasms 
OR  Odds Ratio 
PB  Peripheral Blood 
PCR  Polymerase Chain Reaction 
Ph  Philadelphia chromosome 
 
GENETIC SUSCEPTIBILITY TO MYELOPROLIFERATIVE NEOPLASMS AND THERAPEUTIC EFFICACY  
 XII 
PLT  Platelets 
PMF   Primary Myelofibrosis 
PN-MPNs Philadelphia-negative Myeloproliferative Neoplasms 
PV  Polycythemia Vera 
qRT-PCR Quantitative Real Time Polymerase Chain Reaction 
RBC  Red Blood Cells 
ROS  Reactive Oxygen Species 
SNP  Single Nucleotide Polymorphism 
STAT  Signal Transducers and Activators of Transcription 
TPO  Thrombopoietin 
TPO-R  Thrombopoietin Receptor 
UPD  Uniparental Disomy 
UTR  Untranslated Region 
WBC  White Blood Cells 





SYMBOLS OF AMINO ACIDS 
 
A or Ala Alanin 
C or Cys Cystein 
D or Asp Aspartat 
E or Glu Glutamic acid 
F or Phe Phenilalanin 
G or Gly Glycin 
H or Hys Hystidin 
I or Ile  Isoleucin 
K or Lys Lysin 
L or Leu Leucin 
M or Met  Metionin 
N or Asn Asparagin 
P or Pro Prolin 
Q or Gln Glutamin 
R or Arg Arginin 
S or Ser  Serin 
T or Tre Treonin 
V or Val Valin 
W or Trp Triptophan 










As neoplasias mieloproliferativas são classicamente divididas em neoplasias 
mieloproliferativas BCR-ABL1 (cromossoma Philadelphia) positivas, como é o caso da leucemia 
mieloide crónica, e BCR-ABL1 negativas, incluindo a policitémia vera, a trombocitémia essencial e a 
mielofibrose primária. Estas entidades nosológicas têm origem na transformação maligna das stem-
cells hematopoiéticas, levando a amplificação anormal e à proliferação das células das linhagens 
mielóides. 
A diversidade fenotípica das neoplasias mieloproliferativas Philadelphia negativas resulta da 
combinação de mutações somáticas já identificadas e caracterizadas, variabilidade genética 
hereditária, regulação pós-genética e condicionantes individuais. De acordo com a literatura, vários 
polimorfismos genéticos foram identificados, podendo influenciar os mecanismos de apoptose e de 
capacidade de reparação do DNA, comprometendo a transcrição genética e/ou a atividade celular, 
conferindo predisposição genética para a doença, incluindo o caso das neoplasias mieloproliferativas, 
e condicionando a resposta terapêutica, a evolução clínica e o prognóstico. 
O presente trabalho teve como objetivo caraterizar a população portuguesa de acordo com o 
tipo de neoplasia mieloproliferativa Philadelphia negativa, a sua prevalência e a presença da mutação 
JAK2, dando especial ênfase a alguns doentes em particular; investigar o papel dos polimorfismos nos 
genes envolvidos nas vias de apoptose e de reparação por excisão de bases na susceptibilidade para 
estas doenças e, juntamente com outros fatores de risco, na sobrevivência, evolução clínica e 
prognóstico. 
Foram realizados estudos caso-controlo numa amostragem de 133 doentes Portugueses 
caucasianos e 281 indivíduos saudáveis correspondentes e foram selecionados nove e oito 
polimorfismos de genes envolvidos nas vias de apoptose e de reparação por excisão de bases, 
respectivamente, que foram genotipados utilizando a técnica de Polymerase Chain Reaction em tempo 
real. A análise estatística foi realizada com recurso ao software SPSS versão 22.0. 
Os resultados deste estudo revelaram uma distribuição dos doentes por patologia de 60,2% 
com trombocitémia essencial, 29,3% com policitémia vera e 10,5% com mielofibrose primária, um 
discreto predomínio nas mulheres e 75,0% dos doentes positivos para a presença da mutação JAK2 
V617F, evidenciando uma incidência mais elevada na trombocitémia essencial e mais reduzida na 
policitémia vera, relativamente ao esperado. 
Entre os doentes, alguns casos em particular foram destacados e apresentados nesta tese: o 
caso de um doente com policitémia vera JAK2 exão 12 positivo, apresentando uma nova mutação - 
c.1605G> T (p.Met535Ile) - associada a outra mutação já anteriormente descrita, evidenciando um 
fenótipo clínico atípico; dois doentes com trombocitémia essencial, com suspeita da coexistência rara 
da mutação JAK2 V617F e da translocação BCR-ABL1; e um doente com leucemia mieloide crónica, 
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apresentando uma nova mutação no domínio kinase BCR-ABL1 - c.839T> G (p.Val280Gly) - que 
poderá estar associada a resistência ao imatinib. 
Quanto aos polimorfismos investigados, os nossos resultados revelaram potenciais 
associações entre alguns dos polimorfismos e a susceptibilidade individual para estas doenças, 
sugerindo o potencial envolvimento de polimorfismos do gene CASP9 (Phe136Phe) e dos genes 
XRCC1_399 (Gln399Arg) e MUTYH (Gln335His), após estratificação por patologia para os doentes 
com trombocitémia essencial e quando se tratam de mulheres. Nos doentes JAK2 positivos verificou-
se uma associação com os polimorfismos do gene CASP9 (Phe136Phe) e do gene XRCC1_399 
(Gln399Arg). Nos genes de reparação por excisão de bases, a combinação de alelos também 
demonstrou associação com doença para um haplogrupo específico. 
Em relação à evolução clínica dos doentes sob tratamento, na maioria dos casos com 
hidroxiureia, de acordo com nossos resultados: 17 doentes apresentaram progressão para mielofibrose 
secundária/leucemia mieloide aguda, influenciando a sobrevivência e estando associada à exposição 
a agentes citoredutores. Nestes doentes, houve também evidência global de associação com 
polimorfismos do gene CASP8 (3'UTR) e do gene XRCC1_194 (Arg194Trp), e após estratificação para 
trombocitémia essencial com polimorfismos do gene CASP9 (Arg173His) e dos genes APEX1 
(Asp148Glu) e XRCC1_194 (Arg194Trp); 11 doentes desenvolveram uma neoplasia não mieloide 
primária de novo, evidenciando uma associação global com polimorfismos do gene CASP8 
(Asp270His) e do gene XRCC1_399 (Gln399Arg); 22 doentes apresentaram eventos trombóticos e 
uma associação global com polimorfismos do gene XRCC1_399 (Gln399Arg). 
Os resultados apresentados na presente dissertação ajudaram a caracterizar uma população 
de doentes com neoplasias mieloproliferativas Philadelphia negativas, podendo refletir a realidade 
portuguesa, e revelaram o papel potencial de determinados polimorfismos e outros fatores na 
susceptibilidade para a doença e na evolução clínica dos doentes sob terapêutica, com impacto 
prognóstico. 
Embora sejam necessários estudos mais alargados para confirmar estes resultados, estes 
novos dados podem contribuir para um melhor conhecimento da fisiopatologia e, no futuro, para uma 











  ABSTRACT 
Myeloproliferative neoplasms are classically divided into BCR-ABL1 (Philadelphia 
chromosome) positive chronic myeloid leukemia and BCR-ABL1 negative myeloproliferative 
neoplasms, including polycythemia vera, essential thrombocythemia and primary myelofibrosis. These 
disorders have origin from the malignant transformation of a hematopoietic stem-cell, leading to 
abnormal amplification and proliferation of myeloid lineages. 
The phenotypic diversity of Philadelphia chromosome negative myeloproliferative neoplasms 
results from the combination of somatic mutations already identified and characterized, inherited 
genetic variability, postgenetic regulation, and individual conditioners. According to the literature, 
several genetic polymorphisms have been identified, which may influence the apoptosis mechanisms 
and the DNA repair capacity, compromising genetic transcription and/or cell function, conferring genetic 
predisposition to disease, including myeloproliferative disorders, and conditioning the therapeutic 
response, the clinical outcome and prognosis. 
The present work had the purpose of characterize the Portuguese population according to the 
type of Philadelphia chromosome negative myeloproliferative neoplasm, its prevalence and the 
presence of JAK2 mutation, with special emphasis on some particular patients; investigate the role of 
polymorphisms in genes involved in apoptosis and base excision repair pathways in these disorders 
susceptibility and, along with other risk factors, in survival, clinical outcome and prognosis. 
Case-control studies were carried out in a Caucasian Portuguese sample of 133 patients and 
281 matched control subjects, nine and eight polymorphisms of genes involved in apoptosis and base 
excision repair pathways, respectively, were selected and genotyped using real time polymerase chain 
reaction technique and statistical analysis was performed with SPSS version 22.0.   
The results from this study revealed a pathology distribution of 60.2% of patients with essential 
thrombocythemia, 29.3% with polycythemia vera and 10.5% with primary myelofibrosis, with a discrete 
predominance in females, and a total of 75.0% of patients positive for the presence of the JAK2 V617F 
mutation, with an increased incidence in essential thrombocythemia and a decreased incidence in 
polycythemia vera patients than expected.  
Among the patients, some particular cases were highlighted and presented in this thesis, 
namely the case of a polycythemia vera patient JAK2 exon 12 positive, presenting a novel mutation – 
c.1605G>T (p.Met535Ile) - associated with another mutation previously described, evidencing an 
atypical clinical phenotype; two patients with essential thrombocythemia, with suspicion of the rare 
coexistence of JAK2 V617F mutation and BCR-ABL1 translocation; and a patient with chronic myeloid 
leukemia, presenting a new BCR-ABL1 mutation kinase domain mutation – c.839T>G (p.Val280Gly) – 
which might be associated with resistance to imatinib. 
Concerning the polymorphisms investigated, our results revealed potential associations 
between some polymorphisms and individual susceptibility to these disorders, suggesting the potential 
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involvement of CASP9 (Phe136Phe) gene and XRCC1_399 (Gln399Arg) and MUTYH (Gln335His) 
genes polymorphisms after stratification by pathology diagnosis for essential thrombocythemia patients 
and when they are women.  When patients are JAK2 positive an association with CASP9 (Phe136Phe) 
gene and XRCC1_399 (Gln399Arg) gene polymorphisms was found. In base excision repair genes, 
combination of alleles also demonstrated an association with the disease for one specific haplogroup.  
Regarding the clinical outcome in patients under treatment, the majority of them with 
hydroxyurea, according to our results: 17 patients showed progression to secondary 
myelofibrosis/acute myeloid leukemia, influencing survival and being associated with exposure to 
cytoreductive agents. In these patients, there was also global evidence of association with CASP8 
(3’UTR) gene and XRCC1_194 (Arg194Trp) gene polymorphisms, and after stratification for essential 
thrombocythemia with CASP9 (Arg173His) gene, and APEX1 (Asp148Glu) and XRCC1_194 
(Arg194Trp) genes polymorphisms; 11 patients developed a new primary nonmyeloid neoplasm, 
evidencing a global association with CASP8 (Asp270His) gene and XRCC1_399 (Gln399Arg) gene 
polymorphisms; 22 patients presented thrombotic events and a global association with XRCC1_399 
(Gln399Arg) gene polymorphisms. 
The results shown in the present dissertation helped to characterize a population of 
Philadelphia negative myeloproliferative neoplasms patients that could reflect Portuguese reality, and 
have revealed the potential role of polymorphisms and other factors in disease susceptibility and clinical 
outcome of patients under treatment, with prognostic impact.  
Although larger studies are required to confirm these results, these new data may contribute to 
a best knowledge of the pathophysiology and, in the future, to a more rational and efficient choice of 
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CHAPTER 1: GENERAL INTRODUCTION 
 
1.1 – MYELOPROLIFERATIVE NEOPLASMS: PHILADELPHIA CHROMOSOME 
NEGATIVE DISORDERS 
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic malignancies resulting from the 
transformation of hematopoietic stem cells, leading to abnormal amplification of physiological signal-
transduction pathways and proliferation of one or more myeloid lineages. With regard to MPNs, the 
Word Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues 
includes chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), 
primary myelofibrosis (PMF) (Vardiman, Harris, & Brunning, 2002), chronic neutrophilic leukemia, 
chronic eosinophilic leukemia not otherwise specified and MPNs unclassifiable (Swerdlow et al., 2008). 
In addition to primary (de novo), myelofibrosis can be secondary to PV (post-PV) or ET (post-ET)  
(Tefferi & Barbui, 2017). In the last revision of WHO classification, in 2016, mastocytosis is no longer 
listed under the heading of MPNs (Arber et al., 2016). 
This chapter intends to focus on the insights and give a brief description of Philadelphia 
negative myeloproliferative neoplasms (PN-MPNs; PV, ET and PMF), the group of disorders which was 
the subject of study and whose results will be presented throughout this dissertation. It will be addressed 
to their molecular pathophysiology, clinical manifestations and diagnosis criteria, prognosis and 





In 1951, William Dameshek (1900-1969) was the first to conceptualize these group of disorders, 
highlighting the clinical and morphologic similarities between CML, PV, ET and PMF (Dameshek, 1951). 
He recognized that these disorders are caused by hyperproliferation of multiple hematopoietic lineages 
in the bone marrow that proliferate ‘‘as a unit’’, and he proposed the term “myeloproliferative disorders” 
to indicate that these entities may represent a continuum of related syndromes. Moreover, he also 
proposed that the proliferative activity could be perhaps due ‘‘to a hitherto undiscovered stimulus’’. 
However, the finding that bone marrow and peripheral blood cells from MPNs patients can produce 
erythroid colonies in vitro in the absence of added growth factors indicated the cell autonomous nature 
of these diseases (Skoda, Duek, & Grisouard, 2015). 
But the “story” about MPNs had begun a few years before. Previously in 1845, John Hughes 
Bennett (1812–1875), an English pathologist working in Edinburgh, had described CML, and in 1879, 
 
GENETIC SUSCEPTIBILITY TO MYELOPROLIFERATIVE NEOPLASMS AND THERAPEUTIC EFFICACY  
 4 
a German surgeon, Gustav Heuck (1854–1940), underlined the morphological distinguishing features 
between PMF and CML, namely the presence of bone marrow fibrosis, osteosclerosis, and 
extramedullary hematopoiesis in the former. Some years later in 1892, Louis Henri Vaquez (1860–
1936), a French physician, was the first to describe PV, about a patient with marked erythrocytosis and 
hepatosplenomegaly, and in 1903 William Osler (1849–1919) took another step forward, distinguishing 
PV from both relative polycythemia and secondary polycythemia. The first description of ET is credited 
to Emil Epstein (1875–1951) and Alfred Goedel, two Austrian pathologists, who in 1934 published a 
case report of an “hemorrhagic thrombocythemia” in the absence of marked erythrocytosis.  
In 1960, Peter Nowell (b. 1928) and David Hungerford (1927–1993), two American scientists 
working in Philadelphia, described the association between the Philadelphia (Ph) chromosome and 
CML (Figure 1.1) (Nowell & Hungerford, 1960), in contrast to PN-MPNs (PV, ET and PMF). 
Finally, the establishment of all four classic MPNs as clonal stem cell diseases was achieved 
by Philip Fialkow (1934–1996), an American physician scientist, through his studies developed between 
1967 and 1981, on X chromosome inactivation patterns in women with PV, ET, PMF or CML carrying 
a polymorphic variant of the X-linked glucose-6-phosphate dehydrogenase (G-6-PD) gene (Adamson, 
Fialkow, Murphy, Prchal, & Steinmann, 1976; Fialkow, 1977; Fialkow, Faguet, Jacobson, Vaidya, & 
Murphy, 1981; Tefferi, 2016).  
In 1972, Janet Rowley (1925–2013), an American geneticist, described the Ph chromosome as 
a reciprocal translocation between chromosomes 9 and 22; t(9;22)(q34;q11) and in 1985-6, the BCR-
ABL1 transcript and its P210 fusion protein product were identified, contributing to distinguish CML from 
other MPNs. In 1996, in the era of the Human Genome Project development, these discoveries led 
Nicholas Lydon (b.1957), a British scientist, and Brian Druker (b. 1955), an American physician 
scientist, to the elaboration and therapeutic use of imatinib (a tyrosine kinase inhibitor) in CML (Figure 
1.1) (Tefferi, 2016). 
The discovery of somatic mutations in Janus kinase 2 gene (JAK2), namely exon 14 V617F 
gain-of-function mutation, identified in 2005 by several independent groups of investigators (Baxter et 
al., 2005; James et al., 2005; Kralovics et al., 2005; Levine et al., 2005), in most patients with PV, but 
also with ET or PMF, was one of the major genetic insights into the pathogenesis of the PN-MPNs 
(Figure 1.1). The fact that approximately 50% of ET and PMF patients are JAK2 V617F negative, led 
the investigators to continue to study whether other genes in the JAK-STAT signaling pathway could 
be mutated in these patients. Thus, in 2006, Pikman and colleagues (Pikman et al., 2006) identified the 
mutations of thrombopoietin receptor (TPO-R) in myeloproliferative leukemia virus oncogene (MPL). 
Moreover, only one year later, in 2007, Scott and colleagues identified a set of JAK2 exon 12 mutations 
in JAK2 V617F negative patients with PV (Scott, Tong, et al., 2007). Nevertheless, one of the latest 
discoveries was made by Kralovics in 2013, with the identification of calreticulin (CALR) mutation in 
73% of MPNs patients who do not bear the JAK2 or MPL mutation (Figure 1.1) (Klampfl et al., 2013). 
The discovery of all these mutations, that directly or indirectly activate JAK-STAT pathway, 
contributed to the establishment of the WHO diagnostic criteria and risk stratification in PN-MPNs. 
 
CHAPTER 1: GENERAL INTRODUCTION 
 5 
Mutations other than in these driver genes have also been described in PN-MPNs and have shown to 




Figure 1.1 – Timeline of the elucidation of genomic alterations in myeloproliferative neoplasms.  
Note the significant impact of the Human Genome Project on the elucidation on Ph negative specific genomic 
alterations. In 2008, the WHO has revised its classification of myeloid malignancies and coined the term 




HEMATOPOIESIS AND PN-MPNS EPIDEMIOLOGY 
 
Hematopoiesis (Figure 1.2) is the process by which multipotent bone marrow-based stem cells 
(HSC) differentiate and mature into fully formed blood cells (namely lymphoid, erythroid, 
megakaryocytes and other myeloid cells), in response to external stimulus, such as erythropoietin 
(EPO), thrombopoietin (TPO), granulocyte-macrophage-colony stimulating factor (GM-CSF), other 
stimulating growth factors and several interleukins.  Growth factors initiate signal transduction pathways 
(ex: JAK-STAT pathway), which lead to activation of transcription factors, and elicit different outcomes 
depending on the combination of factors and the cell's stage of differentiation.  
In a healthy adult person, approximately 1011–1012 new blood cells are produced daily in order 
to maintain steady state levels in the peripheral circulation. Besides bone marrow, in some cases and 
if necessary, the liver, thymus, and spleen may resume their hematopoietic function, if necessary, which 
is called extramedullary hematopoiesis, causing these organs to increase in size substantially.  
The PN-MPNs are characterized by the clonal proliferation of one or more myeloid cell lineages 
(erythrocytic, granulocytic or megakaryocytic) (Figure 1.2), without altering the hematopoietic stem-cell 
hierarchy, predominantly in the bone marrow and involving JAK-STAT pathway (discussed below), in 
some cases associated with the presence of extramedullary hematopoiesis. There is evidence of a 
normal and effective maturation, resulting in peripheral blood increased erythrocytes, granulocytes and 
platelets  counts (Passamonti, Mora, & Maffioli, 2016).  
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Figure 1.2 – Overview of hematopoiesis and affected myeloid cell lineages in PN-MPNs. 
The hematopoietic lineages begin at a pluripotent hematopoietic stem cell (HSC). Myeloid differentiation occurs 
through the common myeloid progenitor, differentiating into megakaryocyte, red blood cell, mast cell, or 
granulocyte-monocyte progenitor, which in turn differentiate into a basophil, neutrophil, eosinophil, or monocyte 
followed by macrophage. Differentiation in the lymphocytic pathway (not involved in PN-MPNs) proceeds through 
the common lymphoid progenitor, ultimately ending as a B cell and plasma cell, T cell, or natural killer cell. 
MPL, EPO-R and G-CSFR - Receptors of bone marrow progenitor cells (Adapted from http://oerpub.github.io). 
 
 
Among the different PN-MPNs entities there is a frequent overlap of clinical, laboratory and 
morphological data. Leukocytosis with neutrophilia, thrombocytosis, excessive megakaryocytic 
proliferation, myelofibrosis, splenomegaly and hepatomegaly can occur in any of these diseases. 
Despite insidious clinical onset, all PN-MPNs are at risk of clonal evolution, with disease progression 
that may end in medullary failure (myelofibrosis or ineffective hematopoiesis) or transformation into 
acute leukemia. These aspects will be further explored below in this section. 
PN-MPNs are considered as rare disorders, because their combined incidence is lower than 6 
per 100 000 individuals per year (Rumi & Cazzola, 2017). 
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Among the existent registries in European Union, the PN-MPNs have an annual incidence rate 
per 100 000 individuals per year ranging from 0.4-2.8 (while the literature estimated 0.68-2.6) for PV, 
from 0.38-1.7 for ET (in the literature 0.6-2.5) and from 0.1-1.0 for PMF, respectively (Moulard et al., 
2014; Titmarsh et al., 2014).    
There are few European studies reported on the MPNs' prevalence (Moulard et al., 2014). 
However, according to American data published in 2014, the prevalence per 100 000 individuals of PV 
(44-57) and ET (38-57) was much higher than that of MF (4-6) or subgroups with MF features (post-PV 
MF = 0.3-0.7; post-ET MF = 0.5-1.1) (Mehta, Wang, Iqbal, & Mesa, 2014). 
These group of disorders occur in middle- or advanced-age adults, with a medium age of 
diagnosis of 65-67 years for PV, 65-70 years for ET and 67-70 years for PMF (Srour et al., 2016), 
although it can be diagnosed in younger individuals, particularly if there is a familial predisposition 
(Bellanné-Chantelot et al., 2006).  
There are reports in the literature indicating that ET is more common in women (particularly at 
younger ages) and PV more common in men, while in PMF both sexes are nearly equally affected (Bai 
et al., 2008; Passamonti et al., 2008; Swerdlow et al., 2008). 
As demonstrated by European and international studies (Hultcrantz et al., 2012; Tefferi, 
Guglielmelli, et al., 2014), the distinction of MPNs in three nosological entities has a relevant prognostic 
significance. From the various published reports, generally PN-MPNs patients have a reduced life 
expectancy compared with general population, with PMF having the lowest overall survival (5.7 years), 
followed by PV with 15 years survival in 65% of cases, and ET with an overall survival of more than 18-
20 years (Rumi & Cazzola, 2017; Tefferi, 2008a). As will be discussed below, it was also reported that 
mortality in PN-MPNs patients is generally attributed to disease progression to other hematologic 
malignancies (the most common being acute myeloid leukemia (AML) and myelodysplastic syndromes 
(MDS)), bacterial infections and cardio- and cerebrovascular diseases, especially in younger patients 
(Hultcrantz et al., 2015). Fortunately, mortality due to these complications has been decreasing in the 
last few years (Rumi & Cazzola, 2017). 
In Portugal epidemiological data is very scarce, however several efforts have been made in the 
last years in order to organize a national registry on these disorders and develop consensus meetings 
where several related aspects can be debated, such as diagnostic classification, high-risk mutations 
and treatment strategies. One of the achieved advances respects to the development and validation of 
a scale of evaluation of symptomatic load (MPN10) designed specifically for these patients, in 
Portuguese language, based on international ones already existing. The sequential use in time of these 
scales is an useful instrument of symptom evaluation in clinical practice, may give us a perspective of 
disease evolution and treatment response, in order to a standardize criteria for multicentric studies. 
In Chapters 3 and 9 of this dissertation, will be presented the results obtained from the study 
of a group of Portuguese patients, which were characterized according to the type of PN-MPN, general 
features, prevalence of JAK2 mutation, clinical outcome and therapy management. 
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1.1.1 – MOLECULAR PATHOPHYSIOLOGY 
Until 2005 little was known about the etiology of PN-MPNs, but the discovery of JAK2 V617F 
mutation, which turned out to be the most important and most frequently recurring somatic mutation in 
PN-MPNs, was crucial and revolutionized the understanding of these disorders.  
After JAK2 V617F discovery in the majority of PN-MPNs patients, there may have been an 
assumption of genetic uniformity. However, major genetic insights into the pathogenesis of the PN-
MPNs were achieved with the identification of other driver mutations, such as JAK2 exon 12, MPL and 
CALR mutations, which contributed to a better clarification of the pathophysiology of these disorders, 
their diagnostic tools and therapeutic management (Baxter et al., 2005; James et al., 2005; Kralovics 
et al., 2005; Levine et al., 2005; Scott, Tong, et al., 2007; Tefferi, 2016). It soon became clear that this 
group of diseases was far more genetically heterogeneous and complex than CML. In the majority of 
PN-MPNs cases CALR, MPL and JAK2 mutations are mutually exclusive, however rare exceptions can 
occur (Kang et al., 2016; Spivak, 2017). 
The present section is a review of the mutations more commonly found in PN-MPNs (Figure 
1.3). A particularly interesting note is that the majority of those mutations fall into one of two categories 
- activation of the JAK-STAT pathway (JAK2 V617F, JAK2 exon 12, MPL, LNK and probably CALR) or 
aberrant epigenetic modification (TET2, ASXL1, and EZH2) (Tefferi & Pardanani, 2011). A combination 
of mutations in these genes and environmental factors are likely the determining factors of the 
development of each one of these disorders.  
 
 
PN-MPNs DRIVER MYELOID GENES 
 
The presence of somatic mutations in the three driver genes, namely JAK2, MPL and CALR, 
represent a major diagnostic criteria, in combination with clinical-hematological and morphological 
abnormal features (Rumi & Cazzola, 2017). 
Variation frequency of JAK2 V617F and exon 12, MPL W515L/K and CALR mutations is 
represented in Figures 1.3 and 1.4. 
 
 
JAK2 V617F MUTATION 
JAK2 gene, located at chromosome 9 and first identified in 1993, is a member of the Janus 
kinase family and the most common MPN driver gene. As will be discussed below in this Chapter, JAK2 
serves as the cognate tyrosine kinase for the EPO and TPO receptors and can also be used by the G-
CSF receptor, all of which lack an intrinsic kinase domain (Spivak, 2017; Tefferi, 2016). 
 
 




Figure 1.3 – Frequency, distribution and pathogenetic relevance of acquired gene mutations in 
hematologic malignancies. 
Frequency represented by red portions of the horizontal bars. ALL-acute lymphocytic leukemia; AML-acute myeloid 
leukemia; BP-blastic phase; CML-chronic myeloid leukemia; CNL-chronic neutrophilic leukemia; ET-essential 
thrombocythemia; MDS-myelodysplastic syndromes; MPN-myeloproliferative neoplasms; PMF-primary 
myelofibrosis; PV-polycythemia vera; RARS-T-refractory anemia with ring sideroblasts and thrombocytosis (WHO 
2016: MDS-RS - myelodysplastic syndrome with ring sideroblasts); sAML-secondary acute myeloid leukemia. 
(Adapted from (Barbui et al., 2012; Koopmans, Schouten, & van Marion, 2015; Rumi & Cazzola, 2017; Skoda et 




JAK2 V617F was the first driver mutation to be described in 2005 (Baxter et al., 2005; James 
et al., 2005; Kralovics et al., 2005; Levine et al., 2005), and is the most commonly involved in PN-MPNs 
pathogenesis, with the highest frequency (up to 95%) in PV, and 50–60% in ET and PMF patients 
(Figures 1.3 and 1.4) (Cazzola & Kralovics, 2014; Hinds et al., 2016; Levine, 2009; Meyer & Levine, 
2014; Oh & Gotlib, 2010; Skoda et al., 2015; Tefferi, 2016; Tefferi & Pardanani, 2015).  
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Figure 1.4 – Variation frequency of driver and other mutations in PN-MPNs. 
(Langabeer et al., 2015; Nangalia & Green, 2014; Rumi & Cazzola, 2017). 
 
 
V617F consists of a gain-of-function missense mutation with a G to T (guanine to thymidine) 
substitution at nucleotide 1849, in exon 14 of the JAK2 gene, resulting in the substitution of valine with 
phenylalanine at codon 617 in the inhibitory JH2 domain (Figure 1.5). In humans, JAK2 V617F occurs 
at the stem cell level and is present in hematopoietic stem cells progenitors from affected individuals, 
but not usually in the germline, suggesting that this mutation is acquired as a somatic disease allele in 
the hematopoietic compartment (Tefferi, 2008b). It is believed to be myeloid lineage specific because 
it is present in erythroid and granulocyte-macrophage progenitors. However, some reports have 
suggested JAK2 V617F clonal involvement of B (Ishii, Bruno, Hoffman, & Xu, 2006), T (Ishii et al., 
2006), and NK lymphocytes (Bellanné-Chantelot et al., 2006), also confirming the stem cell nature of 
JAK2 V617F MPN's (Tefferi, 2008b). 
Lower frequencies of V617F mutation occur in PN-CML, chronic myelomonocytic leukemia, 
megakaryocytic AML and juvenile myelomonocytic leukaemia. Other mutations in the JAK2 
pseudokinase domain (including point mutations involving R683) have been detected in about 20% of 
Down Syndrome-associated and other acute lymphoblastic leukaemia and AML. A number of JAK2 
fusion proteins lead to activation of JAK kinase activity and have also been associated with myeloid 
and lymphoid leukemia or atypical CML. They include the TEL-JAK2, PCM1-JAK2 and BCR-JAK2 
fusion proteins (Babon, Lucet, Murphy, Nicola, & Varghese, 2014; Meyer & Levine, 2014). 
Although the prevalence of JAK2 V617F mutation differs among PN-MPNs, one of the most 
challenging aspects of the study of these disorders still is the explanation of phenotypic heterogeneity 
and mechanism of progression of the PN-MPNs (Hinds et al., 2016).   
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Figure 1.5 – Schematic representation of JAK2 gene and mutation hot spots. 
Representation of mutations: red triangle for V617F, black triangles for other SNP mutations, and blue triangles for 
insertions/deletions. FERM, four-point-one, ezrin, radixin, moesin domain; JH1, kinase domain; JH2, pseudokinase 
domain; SH2-like, SH2-like domain (Adapted from (Gong et al., 2013). 
 
 
It is known that JAK2 V617F mutation is present in myeloblasts, granulocytes, erythroblasts 
and in all EPO-independent erythroid colonies, affecting the inhibitory function of the pseudokinase JH2 
domain of JAK2 gene. The JH2 domain is believed to be auto-inhibitory and valine 617 plays an 
important role in JAK2 kinase auto-inhibition (Tefferi, 2008b). When V617F mutation occurs, the result 
is an increased activity in myeloid progenitor cells, which leads to proliferation and excessive production 
of mature cells (Figure 1.6) (Anand et al., 2011; Chen & Mullally, 2014; Ebid, Ghareeb, Salaheldin, & 
Kamel, 2015; Green & Llambi, 2015; Steensma et al., 2006).  
The receptors of bone marrow progenitor cells are hypersensitive to EPO (stimulates 
erythroblasts), TPO (stimulates proliferation and differentiation of megakaryocytes), stem cell factor 
(SCF, induces proliferation and selfrenewal of multipotent hematopoietic progenitors), granulocyte 
stimulating factor (GSF, stimulates proliferation and differentiation of granulocytes) and interleukins. 
The hypersensitivity to these cytokines results in monoclonal stimulation of the erythropoiesis, 
megakaryopoiesis and granulopoiesis.  
JAK2 V617F mutation activates signaling through the three main homodimeric receptors EPO-
R, MPL, and G-CSFR, which are involved in erythrocytosis, thrombocytosis, and neutrophilia, 
respectively (Vainchenker & Kralovics, 2017). In addition, expression of JAK2 V617F results in 
constitutive activation of downstream signaling pathways including the JAK-STAT, PI3K/AKT and 
MAPK/ERK pathways (discussed below in this section) (Baxter et al., 2005; James et al., 2005; 
Kralovics et al., 2005; Levine et al., 2005). However, studies have shown that expression of JAK2 
V617F results in transformation of Ba/F3 cells, characterized by IL-3 independent growth, unlike wild-
type JAK2 (James et al., 2005). Due to JAK2 V617F mutation and other mutations, hematopoietic 
progenitor cells can proliferate without the presence or induction by cytokines, resulting in factor 
independent growth of the erythroid cell line and activation of signal transduction (Tefferi, 2008b), 
mostly in PV homozygous cases. Nevertheless, it is essential the presence of receptors (Ebid et al., 
2015; Michiels, 2005). 
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Figure 1.6 – Schematic representation of JAK2 V617F positive PN-MPNs. 
The mutation JAK2 V617F arises in HSC and results in clonal proliferation of terminally mature myeloid cells. This 
mutation is found in three clinically distinct MPNS (ET, PV and PMF), that are characterized by the hyper 
proliferation of platelets, red blood cells/neutrophils and neutrophils/megakaryocytes, respectively. However, a 
small proportion of ET may overlap PV phenotype depicting the fruste form of PV and PV can evolve into 
myelofibrosis by passing through a spent phase featuring some symptoms of MF. Of note, PV is also characterized 
by hyperproliferation of granulocytes and platelets in contrast to erythrocytosis that is characterized by the sole 
hyperproliferation of erythroid cells. JAK2 V617F heterozygosity is associated with ET and homozygosity due to 
chromosome 9 uniparental disomy (9p UPD) is associated with PV. JAK2 V617F allele burden increases across 
the spectrum of PN-MPNs, lowest in ET and highest in MF. These disorders form a continuum where ET and PV 
depicts the chronic phase of disease and accelerated phase may encompass the transformation of ET and PV into 
myelofibrosis along with other manifestations such as increasing white blood cells, blasts and neutropenia and 
thrombocytopenia (Adapted from (Hasan et al., 2013). 
 
 
JAK2 V617F is a somatically acquired mutation and a subset of patients with PV are 
homozygous for the JAK2 V617F allele as a result of mitotic recombination and duplication of the mutant 
allele, leading to uniparental disomy (UPD) (Figure 1.6). Uniparental disomy of chromosomal locus 
9p24, including JAK2, had previously been noted in PV, before identification of the JAK2 V617F allele 
(Tefferi, 2008b). JAK2 V617F mutation occurs in a homozygous state in 25% to 30% of patients with 
PV and 2% to 4% with ET (Tefferi, 2008b; Vannucchi et al., 2007). These observations suggest that 
mitotic recombination, which leads to JAK2 V617F homozygosity, is more likely to occur in PV patients 
with mutation in exon 14 of the JAK2 gene than in those with exon 12 mutations (Pietra et al., 2008), 
and is an early genetic event in the development of PV, but not ET (Tefferi, 2008b). Although JAK2 
V617F homozygous subclones can be detected both in PV and ET patients, expansion of a dominant 
homozygous subclone is almost exclusive in PV patients (Rumi & Cazzola, 2017). In the heterozygous 
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state, JAK2 V617F–bearing receptors are still responsive to growth factors. Only with JAK2 V617F 
homozygosity, do these receptors become autonomous with respect to growth factor (Spivak, 2017). 
Several published data have shown the contribution and influence of JAK2 V617F mutation 
allelic burden,  in the definition of phenotype and prognostic impact in PN-MPNs (Larsen, Pallisgaard, 
Møller, & Hasselbalch, 2007; C. Nielsen, Bojesen, Nordestgaard, Kofoed, & Birgens, 2014). JAK2 
V617F allelic burden corresponds to the ratio between mutant and wild type JAK2 in hematopoietic 
cells and is on the basis of a stronger activation of intracellular signaling pathways (Vannucchi, Pieri, & 
Guglielmelli, 2011). Between MPNs patients there is a variability in the number of cells carrying the 
JAK2 V617F mutation and there is a variability in the alleles that carry the mutation.  
It is recognized that the allele burden tends to be higher in PV (due to the higher number of 
homozygous cases) and PMF, with defined hematological and clinical markers indicative of a more 
aggressive phenotype (Vannucchi et al., 2011), whereas a lower allele burden is generally observed in 
ET patients (Figure 1.6) (Chen & Mullally, 2014; Duletić et al., 2012; Ha, Kim, Jung, Jung, & Chung, 
2012; Hinds et al., 2016; Larsen et al., 2007). Indeed, some ET patients with increasing allele burden 
transform over time to PV or PMF. Importantly, ET patients with the mutation have a “PV-like” phenotype 
compared to ET patients without this mutation.  However, patients carrying JAK2 V617F mutation do 
not have a higher risk of developing post-PV and post-ET myelofibrosis,  compared to patients without 
the mutation (Koopmans et al., 2015).  
Another possible explanation concerns the concept of a ‘pre-JAK2’ phase in which additional 
somatic mutations or inherited predisposing alleles present before the mutation are responsible for the 
clonal hematopoiesis, determine the phenotype, influence the risk of progression to AML, and might 
even be responsible for generating the mutation or act synergistically (Koopmans et al., 2015; Skoda 
et al., 2015). In fact, although JAK2 V617F mutation is central to the pathogenesis of PV, ET and PMF, 
the presence of the same allele in three clinically distinct MPN's suggests that there might be additional 
inherited or acquired genetic predisposition. Indeed, a familial tendency has been reported in 72 
families, which is consistent with an inherited genetic predisposition to MPN (Pardanani, Lasho, 
McClure, Lacy, & Tefferi, 2006).  
 On the other hand, mutations in epigenetic regulators, transcription factors, and signaling 
components modify the course of the disease and can contribute to disease initiation and/or progression 
(Skoda et al., 2015). Some studies performed in mice, conducted to the consideration of the ‘host 
genetic factors’, which act as modifiers of the phenotype in combination with the mutation, for instance, 
singe nucleotide polymorphisms (SNPs) (focused below in this section). Even gender could be an 
independent modifier, with women having a lower allele burden than men (Koopmans et al., 2015). 
Also, the coexistence of independent JAK2-mutant and JAK2 wild-type clonal expansions in 
the same patient can be an explanation. It is observed that JAK2 positive AML patients are preceded 
by transformation to myelofibrosis during their disease course, in contrast to JAK2 wild-type AML, which 
is preceded by chronic-phase ET and PV patients (Koopmans et al., 2015).  
JAK2 V617F mutation, along with other driver mutations connected with clonal expansion of 
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hematopoietic cells, might also represent a feature of the aging hematopoietic system in individuals 
without a malignant disease (Jaiswal et al., 2014; C. Nielsen, Birgens, Nordestgaard, & Bojesen, 2013). 
There is increasing evidence that JAK2 V617F is relatively frequent in the aging healthy population and 
is presently estimated to be 0.5% (Vainchenker & Kralovics, 2017). This share of the population usually 
presents higher erythrocyte, platelet and leucocyte counts. Moreover, it has been observed that 
individuals without malignant disease but who are positive to the JAK2 V617F somatic mutation were 
44/28 risk fold more likely to develop an hematological cancer, since aging is generally associated with 
a deregulation of hematopoietic stem cells, which lose their function and become myeloid-biased and 
less quiescent as a consequence of intrinsic and environmental changes, with JAK2 V617F 
hematopoietic stem cells having higher competitive properties in this context (C. Nielsen et al., 2013; 
Vainchenker & Kralovics, 2017). 
Although there is no gold standard and the choice of methodology is dependent on the 
application, quantitative real-time PCR is a useful method for detecting V617F mutation in JAK2 gene 
(Bench, Baxter, & Green, 2013). 
The description of the developed work within the scope of this dissertation, begins precisely in 
Chapter 3, were the study carried out for JAK2 V617F evaluation is discussed. Moreover, in Chapter 5 
it is reported the case of two ET patients included in our study population, bearing JAK2 V617F 
mutation, with the suspicion of a very rare association with BCR-ABL translocation. 
 
 
JAK2 EXON 12 MUTATION 
 
A small proportion of patients with PV are JAK2 V617F negative when tested by sensitive allele-
specific assays (Tefferi, 2008b), which motivated a search for additional JAK2 mutations. Thus, in 2007, 
a set of JAK2 exon 12 mutations were described by Scott and colleagues, in JAK2 V617F negative 
patients with PV (Scott, Tong, et al., 2007). 
Unlike V617F where only a single codon is affected, exon 12 frameshift mutations comprise 
more than forty different small deletions/duplications and substitutions of one or more amino acids  
between phenylalanines F533 and F547 (ex: lysine for leucine at codon 539 - K539L), which are located 
in a linker between the JH2 pseudokinase and the SH2 domains (Figure 1.5) (Vorechovsky, Jones, & 
Cross, 2013). 
From literature review, almost the totality of the patients diagnosed with PV negative for JAK2 
V617F mutation are exon 12 positive (95% vs 2-4%, respectively; Figures 1.3 and 1.4) (Arber et al., 
2016; Butcher et al., 2008; C. H. Park et al., 2016; Passamonti, Rumi, et al., 2010; Rumi et al., 2014; 
Scott, 2011; Scott, Beer, Bench, Erber, & Green, 2007; Scott, Tong, et al., 2007). Some studies have 
reported that the Chinese PV patients have a relatively lower JAK2 V617F mutation frequency (82%), 
while the mutations in JAK2 exon 12 are much more pervasive (13%), when compared to Westerns, 
and other East Asians (C. H. Park et al., 2016; Z. Wu et al., 2014). Unlike JAK2 V617F, which can be 
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detected in any of the PN-MPNs, JAK2 exon 12 mutations are almost exclusive of JAK2 V617F negative 
PV patients (Tefferi, 2008b). 
PV patients who present JAK2 exon 12 mutations, unlike those who are V617F positive, are 
not commonly homozygous (Godfrey et al., 2016; Scott, 2011; Scott, Tong, et al., 2007; Spivak, 2017). 
However, just like JAK2 V617F mutation, also exon 12 mutant alleles induce cytokine-
independent/hypersensitive proliferation in EPO receptor (EPO-R) expressing cell lines and constitutive 
activation of JAK-STAT signaling (Tefferi, 2008b).  
There are also reports of the coexistance of JAK2 V617F and JAK2 exon 12 mutations as two 
separate clones (Passamonti et al., 2011; Spivak, 2017). 
The JAK2 exon 12 mutations contribute primarily to erythroid myeloproliferation, associated 
with increasing levels of phosphorylated JAK2, STAT5 and Erk1/2, compared to patients with wild type 
JAK2, and even higher activated JAK2 and Erk1/2 levels compared to patients with the JAK2 V617F 
mutation (Godfrey et al., 2016; Koopmans et al., 2015; Scott, Tong, et al., 2007).  
PV patients with the JAK2 exon 12 mutations are usually younger than those with the JAK2 
V617F mutation, and have a phenotype usually more benign than that of JAK2V617F, usually without 
panmyelosis (Arber et al., 2016), with normal leukocyte and platelet counts (Koopmans et al., 2015; 
Spivak, 2017). However, there are exceptions as will be demonstrated in the clinical case presented in 
Chapter 4. 
PN-MPNs JAK2 exon 12 positive patients appear to be associated with a distinct syndrome, 
specific to patients with higher hemoglobin concentrations, without concomitant leukocytosis or 
thrombocytosis (or minimal thrombocytosis), and isolated bone marrow erythroid hyperplasia (Godfrey 
et al., 2016), independently of the mutational variant (Godfrey et al., 2016; Passamonti et al., 2011). 
The fact that exon 12 mutations are more frequently associated with erythrocytosis is compatible with 
their absence in ET, but possible presence in PMF or AML secondary to PV (Scott, 2011). 
However, despite the phenotypical difference, the clinical course and outcome seems similar 
between JAK2 V617F and JAK2 exon 12 positive patients, with similar incidences of thrombosis, 
myelofibrosis, leukemia and death (Passamonti et al., 2011). 
Although there is no gold standard and the choice of methodology is dependent on the 
application, quantitative real-time PCR and high resolution melt-curve analysis are useful methods for 
detecting this type of mutation in JAK2 gene (Bench et al., 2013). 
In Chapter 4 of this dissertation it is presented the interesting case of the only known JAK2 
exon 12 positive patient included in the studied population, presenting a novel mutation – c. 1605G>T 
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MYELOPROLIFERATIVE LEUKEMIA ONCOGENE (MPL) 
 
Approximately 50-60% of ET and PMF patients are JAK2 V617F negative. This led Pikman and 
colleagues (Pikman et al., 2006), one year after the discovery of the JAK2 V617F mutation, to study 
whether other genes in the JAK-STAT signaling pathway might be mutated in JAK2 V617F negative ET 
and PMF patients. They described mutations of the myeloproliferative leukemia oncogene (MPL), 
located at chromosome 1p34, which encodes for TPO-R, and is a key factor for growth and survival of 
megakaryocytes. The two MPL W515L exon 10 missense mutations consist in a G (glycin) to T (treonin) 
transition at nucleotide 1544, resulting in a switch from tryptophan to leucine or lysine or, less frequently, 
to arginine or alanine at amino acid 515 (MPL W515L/K or W515R/A) in the MPL juxtamembrane 





Figure 1.7 – Schematic representation of MPL gene and mutation hot spots. 
Representation of mutations: red triangles for W515L and W515K, and black triangles for other SNP variant 
mutations. CP, cytoplasmic domain; DCR-NRD, distal cytokine receptor domain-negative regulatory domain; PCR-
LBR, proximal cytokine receptor domain-ligand binding region; TM, transmembrane domain (Adapted from (Gong 
et al., 2013). 
 
 
MPL mutational frequency in MPNs is substantially lower (<10%) than the other driver 
mutations (Figures 1.3 and 1.4) (Tefferi, 2008b). With rare exceptions, MPL mutations are absent in PV 
and other myeloid malignancies (Pardanani et al., 2006), being found in approximately 15% of JAK2 
V617F negative MPNs, with a frequency of 3–4% in ET, and 6–7% in PMF patients (Figures 1.3 and 
1.4) (Langabeer et al., 2015; Tefferi, 2016). 
These acquired gain of function mutations are stem cell-derived events, which constitutively 
force a change in the TPO-R activating JAK2, STAT3, STAT5, Erk and Akt pathway in the absence of 
TPO binding. Like JAK2 and CALR mutations, however, MPL mutations require a hematopoietic growth 
factor, in this case TPO, for complete kinase activation in the heterozygous state (Spivak, 2017).  
Overall, compromised MPL function due to incomplete glycosylation and impaired MPL cell-
surface expression may have a more important role in the pathophysiology of myeloproliferative 
neoplasms than any MPL mutation. JAK2 V617F impairs MPL maturation, increasing the proportion of 
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immature receptors in the plasma membrane, reduces MPL recycling, and increases its degradation. 
Impaired MPL cell-surface expression, which is also a feature of CALR and MPL mutations, results in 
elevated plasma TPO levels, as a result of reduced clearance of TPO from the plasma by 
megakaryocytes and platelets, and may also be involved in the emigration of involved hematopoietic 
stem cells from their marrow niches (Spivak, 2017). 
Somatic MPL mutations and germline single-nucleotide variants are not mutually exclusive of 
JAK2 V617F, though they are not in the same clone (Spivak, 2017). 
Patients with MPL exon 10 mutations have a distinct clinical phenotype tending to have lower 
hemoglobin levels, when compared to JAK2 V617F positive MPNs patients (Koopmans et al., 2015; 
Langabeer et al., 2015). ET patients with an MPL mutation are of older age, and are also reported to 
have higher platelet counts, isolated megakaryocytic proliferation and higher serum erythropoietin 
levels compared to JAK2 V617F positive ET patients. MPL mutated PMF patients are also of older age 
with lower hemoglobin levels.  
Compared to JAK2 V617F mutations, there seems to be no prognostic difference with respect 
to thrombosis, hemorrhage, myelofibrotic (except in ET patients) and leukemic transformation or 
survival. Patients carrying the W515K mutation have higher allelic burdens than those with the W515L 
allele (that may be in the range of 3–15%), suggesting a functional difference between these variants 
(Langabeer et al., 2015). The mutant allele burden is often greater than 50% and homozygosity has 
been described, suggesting biallelic mutation or loss of heterozygosity (LOH).  
 
 
CALRETICULIN (CALR) MUTATION 
 
The second most common and most recent driver gene to be described in MPNs, by Kralovics 
in December 2013, was calreticulin (CALR) (Klampfl et al., 2013; Tefferi, 2016).  
CALR is a multi-functional highly conserved Ca binding protein chaperone, with pleiotropic roles 
related to its distribution in the endosplasmic reticulum (ER), cytosol, and on the cell surface. It is also 
involved in glycoprotein folding and in cellular functions such as proliferation, phagocytosis, and 
apoptosis (Spivak, 2017). 
To date, more than 50 different CALR mutations have been identified, which often consist of 
exon 9 frameshift mutations (chromosome 19) with somatic insertions or deletions, resulting in one 
base pair reading frameshift, an altered C-terminal that is missing the KDEL (lysine, aspartic acid, 
glutamic acid and leucine) ER retention motif and is positively rather than negatively charged, and Ca2+ 
impaired function. These mutations substantially alter CALR cellular distribution because mutant CALR 
is able to bind MPL through the receptor’s extracellular domain and chaperone it to the plasma 
membrane. The mutant, positively charged CALR C terminal domain is obligatory for both MPL binding 
and cellular transformation, but how MPL JAK2 signaling is activated by mutant CALR is unknown. As 
is the case with JAK2 and MPL mutations, the proportion of immature MPL in the cell is increased. Like 
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receptors containing JAK2 V617F, MPL bound by mutant CALR still requires growth factor stimulation 
for complete JAK2 activation in the heterozygous state (Spivak, 2017; Vainchenker & Kralovics, 2017). 
The CALR mutants mainly activate MPL and at a low level the G-CSFR but not the EPOR, explaining 
the thrombocytosis associated with these mutants (Vainchenker & Kralovics, 2017). 
With rare exceptions, CALR (and MPL) mutations are absent in PV. Somatic CALR mutations 
have been identified in 20–25% of ET and PMF patients (Figures 1.3 and 1.4) (Klampfl et al., 2013; 
Nangalia et al., 2013; Skoda et al., 2015; Tefferi, 2016).  
About 80-85% of CALR mutated patients harbor one of two mutation variants: type 1, a 52-bp 
deletion (p.L367fs*46) or type 2, a 5-bp TTGTC insertion (p.K385fs*47). Type 1 mutations are more 
common in PMF, whereas type 1 and type 2 occur with similar frequency in ET (Spivak, 2017; Tefferi, 
2016). CALR variants that are neither type 1 nor type 2 are operationally classified into “type 1-like” and 
“type 2-like” variants, based on their structural similarities to each type, which is in turn based on alpha-
helix content of the mutant C-terminus (Tefferi, 2016). 
 CALR mutations are occasionally homozygous as a result of chromosome 19 UPD, usually 
with type 2 mutations. They are not mutually exclusive of JAK2 V617F, and can be detected in PV in 
rare cases (Spivak, 2017). 
Whereas JAK2 and MPL mutations are believed to directly activate JAK-STAT, CALR 
mutations might do the same indirectly in megakaryocytic and granulocytic precursor cells (Klampfl et 
al., 2013), with aberrant and preferential expansion for the megakaryocyte lineage. How these changes 
result in JAK-STAT or other pathway activation is currently being investigated. Moreover, some mouse 
models suggest a primary effect on platelet production (Tefferi, 2016).  
In some but not all studies, the type 1 CALR mutation appeared to be associated with a survival 
advantage as compared with JAK2 V617F and MPL mutations, but the three mutations did not differ 
with respect to leukemic transformation (Spivak, 2017). 
In ET, type 2 CALR mutation is associated with significantly higher platelet count and a higher 
tendency to thrombotic events, compared to patients with type 1 CALR mutations (Kang et al., 2016; 
Spivak, 2017). In PMF, it is associated with higher risk category, circulating blast percentage, leukocyte 
count, and inferior survival (Tefferi, 2016).  
Compared with ET patients bearing JAK2 or MPL mutations, CALR mutated ET patients are 
more commonly male, and exhibit lower white blood cell and hemoglobin levels, higher platelet counts 
and better clinical outcome, with a lower risk of thrombosis and no progression to PV. However, there 
is no meaningful difference in the rate of transformation to pos-ET MF, nor in overall survival (Rumi et 
al., 2014; Vannucchi et al., 2014).  
In PMF, carrying a CALR mutation is associated with better survival compared to patients with 
JAK2 or MPL mutations. The prognostic benefit of CALR mutations may be limited to type 1 or type 1–
like CALR variants (Tefferi & Vannucchi, 2017); patients with type 2 or type 2–like CALR variants exhibit 
comparably worse survival, which is comparable with that of PMF patients with JAK2 V617F mutation 
(Rotunno et al., 2014). In PMF, cumulative incidence of thrombosis at 10 years was 11,0% in CALR 
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mutated vs 21,0% in JAK2 mutated patients (Klampfl et al., 2013; Rotunno et al., 2014; Rumi et al., 
2014). 
While CALR is a clonal marker that can provide diagnostic clarity in cases of ambiguous 
thrombocytosis, it does not have a bearing on general therapeutic decisions in established cases of ET 
or PMF (discussed below). For example, CALR mutation does not affect the International Prognostic 
Score for predicting the risk of thrombosis in ET (Tefferi, Lasho, et al., 2014). Moreover, PMF patients 
with mutant CALR exhibit responsiveness to JAK inhibitor therapy, even with unmutated JAK2 (Tefferi, 
Guglielmelli, et al., 2014). Nevertheless, the prognostic impact of mutated CALR needs to be weighed 
in the context of dynamic genetic-based scoring systems that layer additional prognostic information, 
such as karyotype and other molecular abnormalities (especially poor-risk mutations in ASXL1, EZH2, 
SRSF2, IDH 1/2), on top of the clinical and laboratory variables (DIPSS-PLUS prognostic score). Such 
refined prognostic schemes are particularly relevant to decision making about hematopoietic stem cell 
transplantation, mostly in PMF patients. 
In the following subsection it will be discussed how the cytokine receptor/JAK2 pathway is 
activated and their downstream effectors. 
 
 
JAK-STAT SIGNALLING PATHWAY 
 
Not the least, the cellular and molecular mechanisms involved in the pathophysiology of PN-
MPNs have not yet been fully clarified (Beer et al., 2010; Björkholm, Hultcrantz, & Derolf, 2014; Bolufer 
et al., 2006; Campregher, Santos, Perini, & Hamerschlak, 2012; Delhommeau, Jeziorowska, Marzac, 
& Casadevall, 2010; Hinds et al., 2016; Kilpivaara & Levine, 2008; Rice et al., 2011; Rueff & Rodrigues, 
2016). However, in PN-MPNs patients, hyperactive JAK/STAT signaling pathway appears to be a 
constant, even in the presence of CALR mutations and the so-called ‘‘triple-negative’’ MPNs 
(nonmutated JAK2, CALR, and MPL), where the driver gene mutation is still unknown (Reuther, 2016; 
Skoda et al., 2015). 
Due to their essential roles as intracellular signaling effectors of cytokine receptor activation, 
the Janus Kinase (JAK) family of tyrosine kinases have aroused much interest since their discovery 
more than 20 years ago (Babon et al., 2014).  
This family comprises four members, JAK1, JAK2, JAK3 and TYK2, originally named ‘just 
another kinase’.  They owe their name due to the homology of kinase (JH1) and pseudokinase (JH2) 
symmetrical domains with Janus, the Roman god of two faces (Figure 1.8) (Becerra-Díaz, Valderrama-
Carvajal, & Terrazas, 2011; McLornan, Percy, & McMullin, 2006). The first JAK identified was TYK2 by 
Krolewski in 1990, using libraries of complementary DNA from human T lymphocytes, while JAK1, JAK2 
and JAK3 where identified through conserved motif clonation of the catalytic domain (Becerra-Díaz et 
al., 2011).  They comprise seven homologous JH domains organized into four regions; kinase (JH1), 
pseudo-kinase (JH2), FERM (four-point-one, ezrin, radixin, moesin; includes the N-terminal JH7, JH6, 
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JH5 and part of JH4) and SH2-like (JH3 and part of JH4). The carboxy-terminal portion of these 
molecules includes the distinctive kinase domain (JH1) which is catalytically active and the catalytically 
inactive pseudo kinase domain (JH2) which is felt to regulate the activity of JH1. The other amino-
terminal JH domains, JH3-JH7, mediate association with receptors. In humans, JAK1 is located on 
chromosome 1p31.3, JAK2 on 9p24, JAK3 on 19p13.1 and TYK2 on 19p13.2 (Tefferi, 2016). 
JAK proteins interact with different intracellular domains of cytokine receptors and are present 
in a variety of cell subtypes. Expression is ubiquitous for JAK1, JAK2 and TYK2 but restricted to 
hematopoietic cells for JAK3 (Tefferi, 2016).  
Furthermore, a seven-member family of transcription factors named Signal Transducers and 
Activators of Transcription (STAT) (Figure 1.8) are also involved in many cytokine signaling pathways. 
In 1994, Darnell and colleagues identified the first two members of the family, STAT1 and 2, by 
purification of factors linked to interferon (IFN) stimulated genes, and  the other family members were 
described subsequently (Becerra-Díaz et al., 2011). These proteins act as transcriptional factors when 
they form homo- and heterodimers among them, by phosphorylation at tyrosine residues in their SH2 
domain, induced by upstream JAK proteins, activating different genes and regulating downstream the 





Figure 1.8 – JAK and STAT protein structures. 
JAK proteins are composed of seven regions (JH1-JH7), in which JH1 domain has kinase activity and JH2 domain 
is homologous to JH1 but associated with regulatory functions, without the residues required for kinase activity 
(pseudokinase domain). STAT proteins are transcription factors constituted by five conserved domains (Adapted 
from Becerra-Díaz et al., 2011).  
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The Janus kinase/signal transducers and activators for transcription (JAK/STAT) pathway 
regulate a large plethora of biological processes including cell proliferation, differentiation, cell migration 
and apoptosis (Becerra-Díaz et al., 2011).  
All of these proteins are constitutively present in the cytoplasm without previous stimuli, but can 
be quickly activated from the cellular membrane to the nucleus, by the binding of cytokines, growth 
factors or hormones on cell surface receptors (Table 1.1) (Becerra-Díaz et al., 2011).  
 
 
Table 1.1 – Cytokine and factors stimuli for JAK and STAT families activation. 





Typically, JAK kinases function through their interaction with cytokine receptors that lack 
intrinsic kinase activity. 
As illustrated in Figure 1.9, with the example of JAK2, cytokines initiate signaling when occurs 
ligand binding (ex: EPO, TPO) to the appropriate cytokine receptor (type 1 or type 2 cytokine receptors; 
ex: EPO-R, MPL), which results in juxtaposition of JAKs and bind to their specific cell surface receptors, 
inducing several important conformational changes mainly oligomerization or multimerization of their 
receptors.  Follows JAKs recruitment to the cytoplasmatic domain of the cytokine receptor and 
phosphorylation of a tyrosine residue in the receptor, creating a docking site for the recruitment and 
activation of cytoplasmic signal transducers and activators of transcription (STATs; STAT3 and STAT5 
in the case of JAK2), through their SH2 domain. While STAT proteins are attached to the cytokine 
receptor, JAK2 proteins undergo autophosphorylation at a tyrosine residue, detaching the STAT protein 
from the cytokine receptor so that the STATs form homo- and heterodimers through their SH2 domain, 
that will translocate to the nucleus. There they bind to the promoter region of genes via specific DNA 
binding domains to promote gene transcription.  
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The net result of STAT3 and STAT5 activation is apoptosis inhibition and a proliferative activity 
(Koopmans et al., 2015), playing an important role in growth factor induced myeloid differentiation. 
STAT3 regulates cell growth through regulation of cyclins promoting cell-cycle progression, as cyclin 
D1, and induces Bcl-2, resulting in an anti-apoptotic signal. May promote cellular differentiation by 
upregulating the expression and enhancing the transcriptional activity of CCAAT/enhancer binding 
protein alpha (C/EBPα), a key transcription factor that drives myeloid differentiation (Numata et al., 
2005). STAT3 was also shown to play an important role in megakaryopoiesis, mainly through the 




Figure 1.9 – Overview of molecular JAK signaling and regulation (ex: JAK2) and acquired genetic 
alterations involved in activation of components of JAK/STAT pathway.  
In the absence of ligand, JAK2 molecules bind to cytokine receptor (EPO-R) as an in active dimer. Ligand (EPO) 
binding to cytokine receptor induces the conformational change in the receptor resulting in auto and trans 
phosphorylation on JAK2 and cytokine receptor. Once activated, cytokine receptor then recruits and 
phosphorylates several signal transmitter molecules that lead to signaling through signal transducers and activators 
(STAT), phosphatidylinositol-3 kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways. JAK2 
signaling is regulated by dephosphorylation (SHP-1), by competing for STAT binding (PIAS or SOCS), cytokine 
receptor ubiquitination (c-CBL) and JAK2 inactivation (LNK) (Adapted from (Babon et al., 2014; Becerra-Díaz et 
al., 2011; Levine, Pardanani, Tefferi, & Gilliland , 2007; Meyer & Levine, 2014). 
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Successful differentiation of neutrophils, induced by G-CSF, is perturbed by expression of a 
dominant negative form of STAT5. It has been suggested that STAT5 may be responsible for promoting 
the survival of myeloid progenitors via transcriptional upregulation of the anti-apoptotic protein BclxL 
and Pim kinase, inhibiting apoptosis of megakaryocytes, and mediates cell growth through induction of 
cyclin D1, thereby allowing myeloid differentiation to proceed (Kieslinger et al., 2000).  
EPO is secreted by interstitial kidney cells in response to reduction in blood oxygen 
concentration, transported to the bone marrow where it binds its receptor, EPO-R, and transmits an 
intercellular signal through a receptor conformational change, which stimulates an increased production 
of red blood cells (Jacobson, Goldwasser, Fried, & Plzak, 1957; Maxwell, Lappin, Johnston, Bridges, & 
McGeown, 1990; Remy, Wilson, & Michnick, 1999). The JAK2 FERM domain constitutively binds the 
EPO-R. EPO-induced EPO-R conformational change facilitates cross-phosphorylation and activation 
of the JAK2 proteins (Witthuhn et al., 1993). 
The amino-terminal extracellular TPO-R domain has a similar structure to EPO-R, which is 
critical in ligand binding, resulting in a significant overlap between EPO and TPO stimulated pathways.  
As in EPO signaling, TPO stimulation causes the JAK2-dependent phosphorylation of STAT3 and 
STAT5, activation of the MAP kinase pathway, activation of the PI3K / Akt survival pathway indirectly, 
and can induce transcription of the pro-survival factor BclxL through STAT5- and PI3K-dependent 
pathways, promoting megakaryocyte differentiation. Overall, discovery of STAT, MAP kinase, and PI3K 
pathway stimulation downstream of the TPO-R gave a framework to understand the considerable 
overlap in phenotypic response to TPO and EPO (Kralovics et al., 2003; Li et al., 1994). 
JAK2 also serves as an endoplasmic reticulum chaperone for the EPO and TPO receptors, 
transporting them to the cell surface, and increases the total number of TPO receptors by stabilizing 
the mature form of the receptor, enhancing receptor recycling, and preventing receptor degradation 
(Spivak, 2017). On the other hand, nuclear JAK2 is involved in epigenetic modifications ((Babon et al., 
2014; Becerra-Díaz et al., 2011; Levine et al., 2007; Meyer & Levine, 2014).  
The JAK/STAT pathway is tightly regulated and inhibited at multiple levels by several protein 
families - tyrosine phosphatases, suppressors of cytokine signaling (SOCS) and protein inhibitors of 
activated STATs (Figure 1.9) (Tefferi, 2016): 
1) Suppressors of cytokine signaling proteins (SOCS), most notably SOCS1 and SOCS3, and 
CBL interact with activated JAKs and phosphorylated receptors or mark JAK for proteasomal 
degradation. CIS, SOCS1, SOCS2 and SOCS3 are members of the SOCS protein family. The synthesis 
of SOCS is induced by activated STATs resulting in a negative feedback loop, through interaction with 
activated JAKs and consequent inhibition of STAT recruitment to the binding sites (Espert, Dusanter, 
Fourt, & Chelbi Alix, 2005; Rawlings,  Rosler, & Harrison, 2004); 
2) Hematopoietic cells express SHP1. SHP1 belongs to the family of phosphotyrosine 
phosphatases (PTP); PTP dephosphorylates activated JAKs, STATs and cytokine receptors (Valentino 
& Pierre, 2006); 
3) Protein inhibitors of activated STATs (PIAS), interact with activated STATs, inhibit their 
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dimerization and prevent their binding to target DNA (Meyer & Levine, 2014); 
4) LNK sequesters JAK2 by direct binding (Meyer & Levine, 2014). 
Mutations in all four JAKs have been associated with human diseases. Inherited mutated JAK 
alleles lead to inactivated JAK3 and TYK2 in human immune deficiency syndrome, while somatic 
mutations in JAK1, JAK2 and JAK3 result in constitutively active kinases in myeloproliferative diseases 
and leukemia/lymphomas (Babon et al., 2014; Meyer & Levine, 2014).  
A qualitative difference in the signaling state of STAT proteins has been described in MPN. ET 
progenitors have high phosphorylation levels of STAT1 and STAT5, whereas PV progenitors have only 
phosphorylated STAT5. The reasons behind this and other phenotypic differences are unclear, but are 
potentially the result of a complex interplay between acquired and/or inherited variation, and possibly 
environmental exposure, all unique to each MPN patient (Jones & Cross, 2013). 
The most frequent mutation, JAK2 V617F, activates the three main myeloid cytokine receptors 
(EPO-R, G-CSFR and MPL) whereas CALR or MPL mutants are restricted to MPL activation, explaining 
why JAK2 V617F is associated with PV, ET and PMF, whereas CALR and MPL mutants are found in 
ET and PMF (Vainchenker & Kralovics, 2017).  
The JAK2 V617F mutation also activates the MAPK and phosphatidylinositol-3-kinase (PI3K)-
Akt pathway (Figure 1.9), by interacting with p85, a regulatory subunit of PI3K, promoting proliferation 
and survival. Activated PI3K activates Akt, which in turn activates mammalian target of rapamycine 
(mTor) on Ser2448 which directly phosphorylates ribosomal p70S6Kinase (p70S6k). p70S6K and mTor 
are involved in angiogenesis by activation of vascular endothelial growth factor (VEGF) (Koopmans et 
al., 2015; Meyer & Levine, 2014). It is known that this pathway is commonly activated in leukemia and 
lymphoma and is involved in inhibiting apoptosis in normal human erythroblasts. The PI3K/Akt pathway 
also induces the phosphorylation of BAD, a pro-apoptotic member of the Bcl2 family, via phosphorylated 
Akt (pAkt) and p70S6k, inhibiting BAD function and resulting in inhibition of apoptosis. BclxL is also 
activated by this pathway, resulting in inhibition of megakaryocyte apoptosis (Koopmans et al., 2015). 
On the other hand, it was also demonstrated in PV patients an increased activation of Ras-Erk 
signalling pathway (Figure 1.9). Ras is activated and activates Raf-1, which mediates the activation of 
MEK, which in turn activates extracellular signal-regulated kinase (Erk), one of members of the MAPK 
families. The result of Erk phosphorylation is the inhibition of apoptosis, by blocking the function of BAD 
and activation of Bcl2. Therefore, the activation of the Erk pathway is suggested to be one of the 
mechanisms responsible for the hypercellularity seen in the bone marrow of MPNs patients, also 
possibly secondary to the JAK2 V617F mutation (Koopmans et al., 2015). Due to the inactivation of the 
pro-apoptotic factor BAD and activation of BclxL, Akt together with JAK2 V617F mutation suppresses 
apoptosis and promotes cell survival, up-regulating megakaryocytes and erythropoiesis (Koopmans et 
al., 2015). 
In contrast to its effect on the EPO receptor, JAK2 V617F appears to increase the quantity of 
immature MPL while increasing MPL degradation through ubiquitination and reducing its cell-surface 
expression (Spivak, 2017). 
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Recently, at the beginning of 2017, Yao et al. demonstrated that activation of JAK2 mutants 
can differentially couple to selective cytokine receptors and change the signaling repertoire, revealing 
the molecular basis for phenotypic differences elicited by JAK2 V617F or mutations in exon 12. On the 
basis of these findings, receptor-JAK2 interactions could represent new targets of lineage-specific 
therapeutic approaches against MPN, which may be applicable to other cancers with aberrant JAK-
STAT signaling (Yao et al., 2017). 
Recent data indicate that the JAK2V617F allele might escape negative feedback by SOCS3 
(Meyer & Levine, 2014). 
 
 
NON-MPN-DRIVER MYELOID GENES 
 
Pathogenic mutations have been identified in more than 90% of patients with PN-MPNs, 50 to 
60% of them having only a driver mutation (JAK2 V617F, CALR, MPL, or in rare cases, LNK) (Figure 
1.4) (Spivak, 2017). However, about 10–15% of patients who meet the WHO criteria mostly for PMF or 
ET, do not express any one of the three mutations and are referred to as being “triple-negative” 
(nonmutated JAK2, CALR, and MPL), carrying a poor prognosis and a high rate of disease progression 
and leukemic transformation (Delhommeau et al., 2010; Nangalia et al., 2013; Rumi & Cazzola, 2017; 
Rumi et al., 2014; Tefferi & Pardanani, 2015).  
It is known that the different driver mutations involved in the pathogenesis of MPNs can lead to 
different clinical effects and that a single mutation may be associated with distinct phenotypes and 
clinical outcomes (Rumi & Cazzola, 2017). Moreover, none of the driver JAK2 V617F, MPL W515L/K, 
or CALR mutations is specific of a particular MPN subtype, and cannot fully explain the phenotypic 
heterogeneity of PN-MPNs, nor the susceptibility of progression to MF, AML or MDS (Hinds et al., 
2016).  
More than a decade on from the original description of JAK2 V617F, attributing the PN-MPNs 
phenotype only to constitutive activation of JAK2, is to over simplify the complex molecular interactions 
that regulate the JAK/STAT pathway. Although the pathogenic mechanism of PN-MPNs is not 
completely clarified, it is well known that, in addition to the “phenotypic driver mutations” referred above, 
there are other somatic mutations directly associated with hyperproliferation of hematopoietic cells, that 
could be involved in these disorders (Figures 1.3 and 1.4). This can occur due to different variants within 
the same gene or between variants in different genes. The latter must be considered, as the number of 
passenger mutations in a tumor may modulate the effect of driver mutations, thus acting as putative 
modifier genes (Rueff & Rodrigues, 2016). 
Along with the recent description of the CALR mutation, differences in the epigenetic landscape 
have been hypothesized to be a key component, and additional  mutations in genes involved in 
epigenetic regulation, splicing, signal transduction and tumor-suppression have been investigated 
(McPherson, McMullin, & Mills, 2017; Spivak, 2017; Vainchenker & Kralovics, 2017). 
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Epimutations  are included in different categories and constitute epigenetic regulators (DNA 
methylation: TET2, IDH1, IDH2, DNMT3A; histone methylation: EZH2, ASXL1), transcription factors 
(tumor suppressor: TP53; IKZF1, NF-E2, CUX1, ETV6, RUNX1), RNA splicing (SRSF2, U2AF1, 
SF3B1) or signaling molecules (CBL, NF1, LNK) (Figure 1.10) (Spivak, 2017; Tefferi, 2016; 
Vainchenker & Kralovics, 2017). Mutations that can silence tumor suppressor genes must be taken into 
account (Rueff & Rodrigues, 2016), which highlights the concept that, probably more important than 
the genes, are their levels of expression. 
 
 
Figure 1.10 – Epigenetic regulators. 
Some of these genes are involved in leukemic transformation (ex: NRAS, TP53, RUNX1) (Adapted from 
(Vainchenker & Kralovics, 2017). 
 
 
The pathogenic role of these other mutations is incompletely understood and might include 
cooperation with the driver mutations in defining phenotype and facilitating disease progression (Tefferi, 
2016; Vainchenker & Kralovics, 2017).  
Usually, they are detected in patients with a very different phenotype and disease evolution 
profile, with variable frequencies (Figure 1.3), appearing that their presence alone is not sufficient to 
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cause, nor explain the clinical presentation and complications observed in those PN-MPNs patients 
(Hermouet, Bigot-Corbel, & Gardie, 2015).  
Epimutations occurrence may chronologically precede or follow the acquisition of driver 
mutations. Identification of this great number of mutations in PN-MPNs patients suggests that they are 
primarily background mutations, several of them involved in the same pathways and in the same “stage” 
of the disease (Table 1.2). On the other hand, many of them are sequentially acquired in cells that 
already bear a mutation in one of the phenotypic driver genes, most frequently JAK2 V617F, and are 




Table 1.2 – Frequencies of gene mutations co-occurrence in the chronic phase of PN-MPNs, according 
to phenotype and driver mutation. 


























TET2 ++/+++ NA NA ++ NA NA NA +++ + + ? 
DNMT3A ++ NA NA ++ NA + NA ++ - NA - 
IDH1/2 + NA NA -/+ NA NA NA + +/++ - ++ 
Histone methylation 





EZH2 + NA NA -/+ + NA NA +/++ ++ +++ ++ 
SUZ12 + NA NA - NA NA NA + NA NA - 
Spliceosome 
U2AF1 - NA NA - NA NA NA +++/ 
++++ 
-/+ ++++ ++ 
SRSF2 - NA NA - NA NA NA +++ + +++ ++++ 
SF3B1 ++/+++ NA NA - NA NA NA +/++ -/+ ++ +++ 
ZRSR2 - NA NA - NA NA NA + NA NA - 
Tumor suppressors 
TP53 ++ NA NA ++ NA NA NA ++ NA NA - 
Transcription factors 
NF-E2 + NA NA ? NA NA NA ? ? ? NA 
Activated signaling 
NRAS/KRAS + NA NA - NA NA NA ++ NA NA - 
CBL + NA NA + NA NA NA ++ NA NA ? 
NF1 + NA NA - NA NA NA + NA NA - 
SH2B3(LNK) ? NA NA ? NA NA ? ? NA NA NA 
-: 0%; +: <5%; ++: 5-9%; +++: 10-19%; ++++: ≥20%; NA: not available; ?: Unknown 
 
Some mutations are involved in early phase of disease initiation MPNs (TET2, DNMT3A, 
IDH1/2, ASXL1, EZH2), in chronic phase (TET2, DNMT3A, IDH1/2, ASXL1, EZH2, U2AF1, SRSF2, 
SF3B1) and some in disease progression (TET2, IDH1/2, EZH2, ASXL1, SRSF2, LNK; progression to 
leukemia – CBL, NRAS, NF1, FLT3, TP53, RUNX1) (Table 1.2 and Figure 1.3) (McPherson et al., 2017; 
Spivak, 2017; Vainchenker & Kralovics, 2017). Other mutations may be associated with phenotypic 
change (ex: SF3B1 and U2AF1 related to anemia) (Vainchenker & Kralovics, 2017). 
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In addition, some of these mutations are not mutually exclusive, making the hierarchy complex 
and unpredictable. This makes it more difficult to predict MPN patient outcomes at a single time-point 
(McPherson et al., 2017). 
Ten-Eleven-Translocation2 (TET2) mutations have been implicated in several myeloid 
disorders (Figures 1.3 and 1.10), consisting in a group of frameshift, nonsense, and missense mutations 
that may induce DNA hypermethylation, resulting in gene silencing and impaired myelopoiesis (Tefferi 
& Pardanani, 2011). The role of TET2 mutations in disease progression varies according to disease, 
appearing not to be a prognostic indicator in PN-MPNs in general (Jankowska et al., 2009; Tefferi et 
al., 2009).  
Represented in Figure 1.10, additional mutations in other epigenetic modifiers are Sex Comb-
Like1 (ASXL 1), Isocitrate Dehydrogenase 1/2 (IDH1/IDH2) and Enhancer of Zeste Homolog 2 (EZH2) 
and DNA cytosine methyltransferase 3a (DNMT3A) mutations, which influence the regulation of 
transcription involving DNA and histone modifications. These mutations are predominantly found in 
PMF patients and blast phase MPNs patients (Figure 1.3), suggesting that they occur late in disease 
progression or collaborate with mutations in other genes, and are associated with poor survival in PN-
MPNs patients. 
By a higher frequency of some mutations in myelofibrosis patients (PMF and post-ET/PV MF) 
they might predict disease progression to myelofibrosis in PV and ET patients (ex: ASXL1). Other 
mutations are found in higher frequency in AML patients preceded by a MPN (LNK, DNMT3A) 
(Koopmans et al., 2015). IDH1 and IDH2 mutations are associated with higher risk of de novo leukemia 
(Guglielmelli et al., 2014). 
In PMF, several mutations were also associated with shortened leukemia-free survival, namely 
ASXL1, SRSF2, EZH2, IDH1/2, and U2AF1. CALR mutations favorably affected survival, independently 
of both number of mutations and IPSS/DIPSS-plus. The 'number' of detrimental mutations provides 
added value in the combined molecular and clinical prognostication of PMF (Guglielmelli et al., 2014). 
In addition, TP53, IDH2, SRSF2, and SH2B3 mutations have been reported to be over-
represented in blast phase MPNs, suggesting their relevance in disease progression. Most noteworthy 
in this regard is TP53 loss, which is believed to make JAK2-mutated patients vulnerable to leukemic 
transformation (Tefferi, 2016). 
They are also frequently found in other hematologic malignancies, such as MDS and de novo 
acute leukemia (Figure 1.3)  (Skoda et al., 2015). An example are the LNK mutations, also found in 
other myeloid malignancies and therefore not specific for PN-MPNs (low frequency, but 10% in 
leukemic transformation), that result in neutralization of the inhibition of JAK2 V617F and MPL activity 
induced by wildtype LNK via the TPO-R (Koopmans et al., 2015). 
According to WHO classification criteria, in the absence of any of the three driver mutations, 
the patients should be tested for the presence of the most frequent accompanying mutations, in order 
to establish clonality (Arber et al., 2016; Rumi & Cazzola, 2017).  
The majority of MPN patients do not have cytogenetic abnormalities and cytogenetic 
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assessment is not part of routine work-up. Cytogenetic abnormalities are found in 43%, 15%, and 7% 
of patients with PMF, PV and ET, respectively (Gangat et al., 2008; Gangat et al., 2009; Hussein et al., 
2009; Tefferi & Vannucchi, 2017). The most recurrent is gain of part or all of chromosome 9 in PV, and 
this is associated with a copy number gain of JAK2 V617F mutation. Gain of chromosome 8, partial 
trisomy for 1q, and interstitial deletions of 13q and 20q have also been recorded in all MPNs subtypes. 
Many of these are seen in other hematological malignancies, most frequently in MDS, but abnormalities 
+9 and 13q are relatively specific to MPNs (Tefferi, 2012). 
Acquired UPD 1p, 4q 7q, 9p, and 11q is usually associated with homozygosity for mutations in 
MPL, TET2, EZH2, JAK2 and CBL, respectively (Jones & Cross, 2013). 
Prognostic significance has been described for cytogenetic abnormalities in PMF, but not in PV 
or ET patients (Bittencourt et al., 2012; Guglielmelli et al., 2014; Hussein et al., 2009).  
Genetic variation across the genome and single nucleotide polymorphisms (SNPs), 
including JAK2, CALR, MPL and other genes, have also been investigated, through genomewide 
association studies (GWAS) for their association with disease susceptibility, phenotype definition and 
disease progression, additionally to sex and age  (Batar, Guven, Baris, Celkan, & Yildiz, 2009; Bolufer 
et al., 2006; Bănescu et al., 2014; da Silva Silveira et al., 2009; Hernández-Boluda et al., 2012; Jiang, 
Zhang, Yang, & Wang, 2009; Jones & Cross, 2013; Joshi, Korgaonkar, Shanmukhaiah, & Vundinti, 
2015; Pakakasama et al., 2007; Pardanani, Fridley, Lasho, Gilliland, & Tefferi, 2008; Seedhouse et al., 
2002). A predisposing haplotype (46/1) in the JAK2 locus has been described (Jones et al., 2009; 
Olcaydu et al., 2009), Another example is a single-nucleotide variant in TERT, which is associated with 
all three PN-MPNs, most significantly with their familial forms, having an additive effect on susceptibility 
to these disorders and in predisposition to the co-occurrence of solid tumors in these patients (Spivak, 
2017). 
On the other hand, these genetic predispositions may explain the co-occurrence of stem-cell 
clones harboring JAK2, MPL, or CALR  mutations in the same person (Spivak, 2017). 
In addition to the above mentioned genetic changes, familial aggregation of MPNs has been 
described with a 5-7 fold increased risk in first-degree relatives (Landgren et al., 2008). In a study 
developed by Landgren et al, no anticipation was seen; however, Rumi et al have observed a lower 
median age in second-generation compared to first-generation MPNs patients in their family studies 
(Rumi et al., 2007; Rumi et al., 2008). More recently, a number of germline JAK2 or MPL mutations 
associated with familial syndromes characterized by a thrombocytosis phenotype have been identified 
(Skoda et al., 2015; Spivak, 2017). 
In this dissertation (Chapters 7, 8 and 9) will be presented the results obtained from the 
application of case-control studies to a Portuguese population of PN-MPNs, for the investigation of 
caspases and base excision repair pathway polymorphisms association with genetic susceptibility for 
disease and their impact on disease progression in patients under treatment.  
Besides these molecular aberrations, other mechanisms are believed to be involved in the 
pathogenic mechanism initiating PN-MPNs disease. Bone marrow mutant and non-mutant cells, 
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including stem cells, megakaryocytes and myeloid cells, as well as nonhematopoietic cells such as 
mesenchymal stromal cells, can produce aberrant cytokines, activating signaling pathways. Moreover, 
STAT3 and NF-κβ signaling have been found to regulate cytokine transcription in other diseases. This 
is the reason why unmutated JAK patients are also capable of clinically respond on JAK inhibitory 
therapy, since JAK inhibitors and also STAT3 deletion can modulate cytokine expression (Koopmans 
et al., 2015; Vainchenker & Kralovics, 2017).  
On the other hand, the inflammatory cytokines might also be involved in extramedullary 
hematopoiesis by favoring colonization of JAK2 V617F hematopoietic stem cells and progenitors in the 
spleen (Vainchenker & Kralovics, 2017). 
 
1.1.2 – DIAGNOSIS, PROGNOSIS AND PREDICTIVE FACTORS 
PN-MPNs DIAGNOSIS 
 
Although defined as distinct disorders, PN-MPNs share some phenotypic characteristics 
among themselves, as well as with other myeloid neoplasms and even benign hematopoietic disorders. 
In addition to phenotypic mimicry, each type of PN-MPNs is capable of evolve into another type and 
transform to an aggressive form of bone marrow failure or acute leukemia, which makes diagnosis, risk 
assessment, and therapeutic decisions very difficult (Spivak, 2017). 
Current diagnosis is based on WHO-criteria and, since the earlier classifications, involves a 
composite assessment of clinical manifestations, laboratory abnormalities, peripheral blood smear 
characteristics, bone marrow morphology and molecular and cytogenetic features (Table 1.3) (Arber et 
al., 2016; Swerdlow et al., 2008).  
In the most recent revision (Arber et al., 2016), WHO classification was modified to incorporate 
the recent advances in the molecular characterization of these diseases, in which these clonal markers 
are considered as one of several major criteria in the diagnosis of PV, ET and PMF. Proof of clonality 
and diagnostic and prognosis determination were provided by the discovery of novel molecular findings, 
such as CALR mutation, in addition to JAK2 and MPL mutations (Arber et al., 2016). Driver mutations 
were effectively integrated into the WHO diagnostic criteria (Table 1.3) used to distinguish MPNs from 
secondary/reactive erythrocytosis or thrombocytosis. Additional differential diagnosis includes chronic  
myeloid leukemia, chronic neutrophilic leukemia, chronic myelomonocytic leukemia, myelodysplastic 
syndromes and acute myeloid leukemia (Arber et al., 2016). 
Globally, the establishment of the molecular mutational profiles of MPNs patients is of major 
importance in the classification of MPNs subtypes and determination of prognosis, influencing 
therapeutic decisions (Skoda et al., 2015).  Figure 1.11 represents a practical algorithm for the diagnosis 
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of PN-MPNs, specially based on the screening for the three driver mutations, JAK2, CALR, and MPL 
(Langabeer et al., 2015). 
Current WHO guidelines do not recommend further testing once JAK2 V617F mutation is 
detected in PN-MPNs. However, Nussenzveig et al. have recently published data that indicate that 
quantification of JAK2 V617F allele burden may be clinically relevant in PN-MPNs and that in those with 
low allelic burden additional testing for JAK2 exon-12 and MPL exon-10 mutation should be pursued 
(Nussenzveig et al., 2016). 
 
 
Table 1.3 –  WHO classification criteria for PN-MPNs diagnosis. 














Both major criteria and one minor criterion or the 
presence of the first major criterion together with two 
minor criteria 
All three major criteria, or the first two major criteria and 
the minor criterion* 
 
Major criteria 
1. Hemoglobin > 18.5 g/dL in men, 16.5 g/dL in women or 
other evidence of increased red cell volume 
2. Presence of JAK2 V617F or other functionally similar 




1. Hemoglobin > 16.5 g/dL in men, 16.0 g/dL in women 
or, hematocrit > 49% in men, > 48% in women or, 
increased red cell mass (RCM, > 25% above mean 
normal predicted value) 
2. BM biopsy showing hypercellularity for age with 
trilineage growth (panmyelosis) including prominent 
erythroid, granulocytic, and megakaryocytic 
proliferation with pleomorphic, mature megakaryocytes 
(differences in size) 





1. BM biopsy showing hypercellularity for age with 
trilineage growth (panmyelosis) with prominent 
erythroid, granulocytic and megakaryocytic proliferation 
2. Serum erythropoietin level below the reference range 
for normal 


























All four criteria All four major criteria or the first three major criteria and 
the minor criterion 
 
 
1. Sustained platelet count ≥ 450x109/L 
2. BM biopsy specimen showing proliferation mainly of 
the megakaryocytic lineage with increased number of 
enlarged, mature megakaryocytes. No significant 
increase or left-shift of neuthrophil granulopoiesis or 
erythropoiesis 
3. Not meeting WHO criteria of Polycythemia vera, 
primary myelofibrosis, BCR-ABL1 positive chronic 
myelogenous leukemia or myelodysplastic syndrome 
or other myeloid neoplasm 
4. Demonstration of JAK2 V617F or other clonal marker, 




1. Platelet count ≥ 450x109/L 
2. BM biopsy showing proliferation mainly in the 
megakaryocyte lineage with increased numbers of 
enlarged mature megakaryocytes with hyperlobulated 
nuclei. No significant increase or left shift in neuthrophil 
granulopoiesis or erythropoiesis and very rarely minor 
(grade 1) increase in reticulin fibers 
3. Not meeting WHO criteria for BCR-ABL1+ CML, PV, 
PMF, myelodysplastic syndromes, or other myeloid 
neoplasms 



























All three major criteria and two minor criteria  All three major criteria, and at least one minor criterion, 




1. Presence of megakaryocytic proliferation and atypia, 
usually accompanied by either reticulin and/or collagen 
fibrosis, or in the absence of significant reticulin 
fibrosis, the megakaryocyte changes must be 
accompanied by an increased bone marrow cellularity, 
characterized by granulocytic proliferation and often 
decreased erythropoiesis (i.e. prefibrotic cellular-phase 
disease)  
2. Not meeting WHO criteria for polycythemia vera, BCR-
ABL1+ CML, myelodysplastic syndrome, or other 
myeloid neoplasms 
3. Demonstration of JAK2 V617F or other clonal marker 
(e.g. MPL W515K/L), or in the absence of a clonal 
marker, no evidence that the bone marrow fibrosis or 
the changes are secondary to infection, autoimmune 
disorder or other chronic inflammatory condition, hairy 
cell leukemia or other lymphoid neoplasm, metastatic 






1. Presence of megakaryocytic proliferation and atypia, 
without reticulin fibrosis > grades 1, accompanied by 
increased age-adjusted bone marrow cellularity, 
granulocytic proliferation, and often decreased 
erythropoiesis 
2. Not meeting WHO criteria for ET, PV, BCR-ABL1+ 
CML, myelodysplastic syndromes, or other myeloid 
neoplasms 
3. Presence of JAK2, CALR, or MPL mutation or in the 
absence of these mutations, presence of another 
clonal marker, or absence of minor reactive BM 
reticulin fibrosis (minor reticulin fibrosis secondary to 
infection, autoimmune disorder, or other chronic 
inflammatory conditions, hairy cell leukemia or other 




1. Presence of megakaryocytic proliferation and atypia, 
accompanied by either reticulin and/or collagen fibrosis 
grades 2 or 3 
2. Not meeting WHO criteria for ET, PV, BCR-ABL1+ 
CML, myelodysplastic syndromes, or other myeloid 
neoplasms 
4. Presence of JAK2, CALR, or MPL mutation or in the 
absence of these mutations, presence of another 
clonal marker, or absence of minor reactive BM 
reticulin fibrosis (minor reticulin fibrosis secondary to 
infection, autoimmune disorder, or other chronic 
inflammatory conditions, hairy cell leukemia or other 












1. Anemia not attributed to a comorbid condition 
2. Leucocytosis (WBC count ≥ 11x109/L) 
3. Palpable splenomegaly 
4. LDH increased to above upper normal limit of 
institutional reference range 
 
Overt PMF 
1. Anemia not attributed to a comorbid condition 
2. Leucocytosis (WBC count ≥ 11x109/L) 
3. Palpable splenomegaly 
4. LDH increased to above upper normal limit of 
institutional reference range 
5. Leukoerythroblastosis 
 
* PV: Criterion number 2 (BM biopsy) may not be required in cases with sustained absolute erythrocytosis: hemoglobin levels 
>18.5 g/dL in men (hematocrit, 55.5%) or >16.5 g/dL in women (hematocrit, 49.5%) if major criterion 3 and the minor criterion  
are present. However, initial myelofibrosis (present in up to 20% of patients) can only be detected by performing a BM biopsy; 
this finding may predict a more rapid progression to overt myelofibrosis (post-PV myelofibrosis). 
** PMF: In the absence of any of the 3 major clonal mutations, the search for the most frequent accompanying mutations (ex: 
ASXL1, EZH2, TET2, IDH1/IDH2, SRSF2, SF3B1) are of help in determining the clonal nature of the disease.  
See Table 1.5 for myelofibrosis grading definition; BM – Bone marrow. 
 
 
Establishing PN-MPNs diagnosis is of immediate clinical importance with selection, 
implementation and the continual evaluation of the appropriate laboratory methodology to achieve this  
goal, whilst many of these mutations appear to have also prognostic implications. The advantages and  
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limitations of these approaches in identifying and quantitating the common PN-MPNs-associated 
mutations are considered with particular regard to their clinical utility.  
 
 
Figure 1.11 – Practical workflow for the diagnosis of PN-MPNs.  
(Adapted from (Tefferi & Barbui, 2017). 
 
 
The evolution of molecular diagnostic applications and platforms has occurred in parallel with 
the discovery of PN-MPNs-associated mutations. Quantitative , real-time, allele specific PCR (AS-
qPCR) assays have been widely adopted in the study of JAK2 V617F mutation and other associated 
mutations, including quantification of mutant allele burden (Langabeer et al., 2015). Probably, emerging 
technologies such as next-generation sequencing (NGS) and digital PCR will in the future play an 
increasing role and improve the molecular diagnosis of PN-MPNs (Langabeer et al., 2015). Most 
recently, whole exome sequencing revealed the presence of somatic or germline MPL or JAK2 variants 
in 3 of 8 triple-negative patients with MPNs and subsequent MPL/JAK2 entire codon sequencing among 
62 ET and 49 PMF triple-negative cases revealed novel somatic or germline MPL variants in 5 of 62 
cases and JAK2 variants in 5 of 57 cases (Tefferi, 2016). 
In routine practice, clonality is usually determined by the presence of an acquired mutation or 
cytogenetic abnormality, however additional clinical, laboratory and morphological information play an 
important role in the diagnosis and distinction of each specific subtype (Cross, 2011; Duletić et al., 
2012; Tefferi & Pardanani, 2015). 
An accurate boné marrow cytological/histological exam is fundamental for a well defined 
diagnosis and prognosis prediction in PN-MPNs, highlighting the importance of establishing 
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standardized morphologic criteria in this group of disorders, enhancing interobserver reproducibility and 
consensus of morphologic diagnosis, which was reported to range from 76% to 88% among several 
studies performed (Arber et al., 2016). 
The inclusion of bone marrow morphology as a major criterion for the 2016 WHO classification 
(Table 1.3) has allowed lowering of the threshold hemoglobin level for the diagnosis of PV from 18.5 
g/dL in men and 16.5 g/dL in women to a hemoglobin level of 16.5 g/dL in men and 16 g/dL for women 
(or a hematocrit level of 49% in men and 48% in women), reducing the risk of underdiagnose of PV 
patients when using the previous WHO 2008 classification hemoglobin levels (Arber et al., 2016). 
Hematocrit and qualitative JAK2 V617F mutation allowed a reliable diagnosis of PV, but the 
incorporation of EPO and/or JAK2 V617F mutant load did not improve the diagnostic accuracy 
(Ancochea et al., 2014). On the other hand, histologic evidence of the absence of reticulin fibrosis at 
disease onset, along with other features, allowed to differentiate between the patients with ET and those 
with masked PV or prefibrotic/early PMF, having prognostic implications (Tefferi & Pardanani, 2015). 
The minor clinical criteria in prefibrotic PMF were also well defined, having a major impact on accurate 
diagnosis and prognosis (Table 1.3)  (Arber et al., 2016). 
Characterization and classification of PN-MPNs is based on which myeloid cell lineage 
(erythrocytic, granulocytic or megakaryocytic) is predominantly expanded in the peripheral blood, 
depending on the type of driver and additional mutations acquired , resulting in very different phenotypic 
readouts (Figure 1.12) (Tefferi, 2016). As mencioned above, regarding the influence that the order of 
mutation acquisition might have in clinical phenotype definition, the opinions are divergent (Spivak, 





Figure 1.12 – Spectrum of PN-MPNs phenotypes associated with JAK2 and MPL lesions.  




Table 1.4 is a summary of most prominent clinical, morphological and molecular features of 
each one of classical PN-MPNs. 
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Table 1.4 – Classical PN-MPNs clinical, morphological and molecular features. 
(Adapted from (Rumi & Cazzola, 2017). 
 
















Erythrocytosis frequently combined with thrombocytosis 
and/or leukocytosis (that is, polycythemia) and typically 
associated with suppressed endogenous erythropoietin 
production.  
 




• JAK2 V617F in about 96% of patients 
• JAK2 exon 12 mutations in about 4% of patient (isolated 
erythrocytosis in most of these patients) 























Bone marrow: normocellular bone marrow with 
proliferation of enlarged megakaryocytes 
 
• JAK2 V617F in 60-65% of patients 
• CALR exon 9 indels in 20-25% of patients 
• MPL exon 10 mutations* in about 4-5% of patients 
• Noncanonical MPL mutations* in 1% of patients 
• About 10% of patients do not carry any of the above somatic 



















• Various abnormalities of peripheral blood 
• Bone marrow: granulocytic and megakaryocytic 
proliferation, with lack of reticulin fibrosis 
 
Overt PMF 
• Various abnormalities of peripheral blood 
• Bone marrow: megakaryocytic proliferation with atypia, 
accompanied by either reticulin and/or collagen fibrosis 
grades 2/3.  
• Abnormal stem cell trafficking with myeloid metaplasia 
(extramedullary hematopoiesis in the liver and/ or the 
spleen) 
 
• JAK2 V617F in 60-65% of patients 
• CALR exon 9 indels in 25-30% of patients 
• MPL exon 10 mutations* in about 4-5% of patients 
• Noncanonical MPL mutations* in 1% of patients 
• About 5-10% of patients do not carry any of the above 
somatic mutations (the so-called triple-negative cases) 
*Canonical MPL exon 10 mutations include W515L/K/A/R, S505N/C, and V501A (transmembrane domain of MPL); noncanonical 
MPL mutations (outside exon 10) include T119I, S204F/P, E230G, Y252H (extracellular domain) and Y591D/N (intracellular 
domain) AML, acute myeloid leukemia. 
 
Although these diseases are defined as distinct entities, they have similar biological features, 
as already mentioned. They share a common stem cell-derived clonal origin, arising from a primitive 
bone marrow progenitor cell, with myeloproliferation leading to an excess of abnormal cells in peripheral 
blood, and together with extramedullary hematopoiesis often causing splenomegaly and hepatomegaly 
(Figure 1.13) (Passamonti et al., 2016).  
The major presenting symptoms of PN-MPNs are related to hypertension or other 
cardiovascular abnormalities, however approximately half of all PN-MPNs patients are reported to be 
asymptomatic at diagnosis (Jones & Cross, 2013).  
The most common PN-MPN, PV, is the ultimate phenotypic consequence of JAK2 gene 
mutations and, in rare cases, CALR or LNK mutations. It is clinically characterized by excessive 
production of erythrocytes, independent of the mechanisms that normally regulate erythropoiesis (with 
subnormal EPO levels), granulocytes and megakaryocytes as well, increased red cell mass (increased 
hemoglobin or hematocrit) and extramedullary hematopoiesis, leading to splenomegaly, and 
thrombohemorrhagic complications (Figure 1.13 and Table 1.4) (Arber et al., 2016; Jones & Cross, 
2013; Rumi & Cazzola, 2017; Swerdlow et al., 2008; Tefferi & Vardiman, 2008).  PV symptoms include 
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headache, dizziness, paraesthesias, visual disturbance, pruritus (due to activated basophils), gouty 
arthritis, and when patients become overtly polycythemic they can have plethora and enlarged spleen 
and liver (Swerdlow et al., 2008). In about 20% of cases it is reported a venous or arterial thrombotic 
event, such as deep vein thrombosis, myocardial ischemia or stroke, which could be the first symptom. 
As it will be discussed later, in some patients it occurs transformation to bone marrow failure, 




Figure 1.13 – Clinical presentation in classic PN-MPNs. 
Clinical features are shared over the spectrum of PN-MPNs. Grey bars represent the proportion of specific found 
overlapping in ET, PV and PMF. Leukocytosis often present in PV and PMF patients and cytopenia of some PMF 
patients is not represented (Adapted from (Kiladjian et al., 2012). 
 
 
PV can be divided in a prodromal pre-polycythemic phase (with a borderline or mild 
erythrocytosis associated with thrombocytosis, mimetizing ET, and low EPO levels), followed by a 
polycythemic phase (with significant erythrocytosis, palpable splenomegaly in nearly 70% and 
hepatomegaly in 40% of cases) and a post-polycythemic myelofibrosis phase (post-PV MF; with 
cytopenias, including anemia associated with ineffective hematopoiesis, medullary fibrosis, 
extramedullary hematopoiesis and hypersplenism). Blood count show increase of hemoglobin, normal 
erythrocytes and hematocrit levels, but microcytosis and hypochromia due to iron deficiency may occur 
with lower hemoglobin and hematocrit values. Leukocytosis with neuthrophilia is frequent (up to 
20x109/L), with absolute neutrophilia in about 2/3 of patients and frequent basophilia (<3%). Occasional 
immature granulocytes may be present in the overt polycythemic phase, but blasts are not usually 
observed. Thrombocytosis is also frequent, occurring in about 50% of patients at the time of diagnosis, 
with more than 1000x109/L in 10% of cases (Swerdlow et al., 2008). 
Both in the pre-polycythemic and polycythemic phases of PV, the major features observed in 
the peripheral blood and bone marrow result from the effective proliferation of erythroid, granulocytic 
and megakaryocytic lineages (panmyelosis) (Table 1.4). Bone marrow usually reveal accentuated 
hypercellularity, especially in the subcortical space (an area which is normally hypocellular), with 
hyperplasia of the three hematopoietic strains (particularly the erythroid and megakaryocytic), although 
less prominent in the pre-polycythemic than in the overt polycythemic phase. Erythropoiesis and 
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granulopoiesis are morphologically normal, but megakaryocytic morphology is abnormal, with 
megakaryocytes evidencing a significant pleomorphism, varying from small and hypolobate to large 
and hyperlobulated, with increased mean size and lobulation (Figure 1.14). Megakaryocytes tend to 
form loose clusters or to lie close to bone trabeculae, and reticulin fibre network is normal in about 80% 
of patients. Generally, iron deposits are absent. 
 
 
Figure 1.14 –  Bone marrow morphologic and histologic aspects from a PV patient. 
Bone marrow aspirate A) to C) and biopsy D) to H) showing trilinear hyperplasia and pleomorphic mature 
megakaryocytes.  
A) x10, B) x40 and C) x100, May-Grünwald-Giemsa stain; D) x40, E) x100, F) x200 and G) x200, Hematoxylin 
eosin stain; H) x200, Giemsa stain. 
Bone marrow aspirate slides were obtained and scored by the author; biopsy images were courtesy of Pathology 
Department of CHLO. 
 
 
PV differential diagnosis includes other PN-MPNs (ET, pre-fibrotic PMF), relative 
hemoconcentration, secondary polycythemia to tissue hypoxia (ex: heart or lung disease, 
hemoglobinopathies with increased affinity for oxygen, carbon monoxide intoxication, acute smoking 
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habits) and polycythemia due to non-physiological EPO production (ex: anabolics, tumors, benign 
nephropathies). 
ET is caused by JAK2 V617F, CALR, or MPL mutations and infrequently by germline single-
nucleotide variants. It involves primarily the megakaryocytic lineage and is characterized by an 
excessive production of platelets (thrombocytosis), with increased numbers of large, mature 
megakaryocytes in the bone marrow and thrombohemorrhagic complications (Table 1.4) (Arber et al., 
2016; Jones & Cross, 2013; Rumi & Cazzola, 2017; Swerdlow et al., 2008; Tefferi & Vardiman, 2008). 
Bone marrow and peripheral blood are the main sites of involvement, whereas the spleen is a 
sequestration site for platelets, but does not evidence significant extramedullary hematopoiesis 
(Swerdlow et al., 2008). 
ET is generally an indolent disease, characterized by long symptom free intervals. More than 
half of the patients are asymptomatic at diagnosis and the remainder present clinical signs related to 
thrombotic and hemorrhagic events. Occlusion of microvasculature may lead to transient ischemic 
attacks, digital ischemia with paresthesias and gangrene, but major arteries and veins may also be 
affected, causing splenic or hepatic vein thrombosis (Swerdlow et al., 2008).  Bleeding occurs most 
frequently at mucosal surfaces from gastrointestinal and upper respiratory tracts (Swerdlow et al., 
2008). At diagnosis, mild splenomegaly is present in about 50% and hepatomegaly in 15-20% of ET 
patients (Swerdlow et al., 2008). Some cases evidence disease transformation to bone marrow failure, 
myelofibrosis, and acute leukemia. ET is a diagnosis of exclusion because the TPO-R, MPL, is the only 
hematopoietic growth factor receptor expressed by hematopoietic stem cells, and isolated 
thrombocytosis may be the first manifestation of PV or PMF (Spivak, 2017). 
Peripheral blood smear shows marked thrombocytosis, platelet anisocytosis, giant platelets, 
sometimes hypogranulous, fragments of megakaryocytes or small nuclei of megakaryocytes (Figure 
1.15). Leukocytes and differential counts are normal or borderline leukocytosis, and mild myelemia may 
occur (<5% of cases), with absent or minimal basophilia. Hypochromia and microcytosis due to iron 
deficiency may be present if there is recurrent hemorrhage, and about 50% of cases present mild 
splenomegaly at the time of diagnosis (Swerdlow et al., 2008).  
Bone marrow is generally, normocellular or, moderately, hypercellular, megakaryocytes are 
present in increased numbers, and granulopoiesis and erythropoiesis are no more than slightly 
increased (Table 1.4). Usually there is abnormal megakaryocytic morphology, revealing 
megakaryocytes with increased mean size and lobulation, mainly large megakaryocytes to giants, 
displaying abundant, mature cytoplasm, and deeply lobulated/hyperlobated (stag-horn like), but less 
pleomorphic than in PV (and in the hypercellular phase of primary myelofibrosis), with no increase of 
small megakaryocytes number (Figures 1.15 and 1.16). Iron stores are present in 40-70% of patients 
at diagnosis (Swerdlow et al., 2008).  
The megakaryocytes are usually distributed throughout the bone marrow, but may occur in 
loose clusters. The reticulin network is normal or only minimally increased (Swerdlow et al., 2008). 
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Figure 1.15 – Peripheral blood smear and bone marrow morphologic aspects from an ET patient. 
A) Peripheral blood smear showing marked thrombocytosis with platelets anisocytosis and small nuclei of 
megakaryocytes; B) to D) Bone marrow aspirate showing megakaryocytic hyperplasia and enlarged/giant 
megakaryocytes with hyperlobulated nuclei, and no abnormalities of the myeloid and erythroid series. 
A) x40 and image magnification, Wright stain; B) x10, C) x40 and D) x100, May-Grünwald-Giemsa stain.  




Bone marrow morphological findings are essential to distinguish ET from other conditions 
associated with thrombocytosis. If granulocytic and erythroid proliferation is present should prompt 
concern for prodromal stage of PV. When granulocytic proliferation is associated with bizarre or atypical 
megakaryocytes should raise consideration of pre-fibrotic stage of PMF. On the other hand, significant 
dyserythropoiesis or dysgranulopoiesis raises the suspicion of MDS (isolated del(5q), MDS with ring 
syderoblasts). Megakaryocitic morphology is essential in distinction between ET and MDS, 
chromosomal abnormalities and CML (Swerdlow et al., 2008). Other differential diagnosis includes 
reactive thrombocytosis (infectious, inflammatory, malignant neoplasms, surgery and trauma) and 
acute leukemia (associated with cytogenetic abnormalities involving the 3q21 and 3q26 regions).  
On the other hand, bone marrow fibrosis is the hallmark of PMF, the least common and most 
aggressive MPN, resulting in a variable count of myeloid series cells, with a proliferation of 
predominantly megakaryocytes and granulocytes, associated with extramedullary hematopoiesis and 
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hepatosplenomegaly (Table 1.4) (Arber et al., 2016; Jones & Cross, 2013; Rumi & Cazzola, 2017; 




Figure 1.16 – Bone marrow histological aspects from an ET patient. 
Bone marrow biopsy shows a normocellular in A) and a hypercellular marrow in B) and D) with megakaryocytic 
and granulocytic hyperplasia; C) immunohistochemical CD61 marker for megakaryocytes. 
A) x40 and B) x200, Hematoxylin eosin stain; C) x100, Immunohistochemical CD61 marker; D) x200, Giemsa stain. 
Images were courtesy of Pathology Department of CHLO. 
 
 
There is a stepwise evolution from an early pre-fibrotic phase, in which there is an hypercellular 
bone marrow with absent or minimal reticulin fibrosis, followed by disease progression with 
accumulation of fibrous tissue, to a fibrotic phase with marked reticulin or collagen fibrosis in the bone 
marrow and often osteosclerosis, and transformation to acute leukemia (Swerdlow et al., 2008). 
PMF morphological and clinical data vary considerably at the time of diagnosis, depending on 
whether the patient is in the pre-fibrotic or fibrotic stage. Up to 30-40% of patients are asymptomatic at 
the time of diagnosis and the disease is suspected due to splenomegaly, anemia, leukocytosis and / or 
thrombocytosis, or less often due to unexplained leukoerythroblastosis or an increased lactate 
dehydrogenase. Constitutional symptoms, due to inflammatory cytokine production, such as fatigue, 
dyspnea, weight loss, night sweats, low-grade fever, bleeding episodes, gouty arthritis and 
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hyperuricemia may be present. Splenomegaly is present nearly in 90% of patients and may be severe, 
whereas about 50% have hepatomegaly (Swerdlow et al., 2008). 
Peripheral blood and bone marrow are always involved (Table 1.4). Blood count usually shows 
evidence of normocytic normochromic anemia <10 g/dL in 60% of patients, initial leukocytosis with 
neuthrophilia (up to 50 to 100x109/L) with moderate myelemia (10 to 15%), some blasts (1 to 5%), 
anisopoikilocytosis with “teardrop” cells or dacrocytes and nucleated red blood cells (5 to 10/100 
leukocytes) (Figure 1.17). This disease may be initially more proliferative with leukocytosis and then 
progressively cytopenic (ineffective granulopoiesis and splenomegaly). Platelets are present in varying 
numbers, from mild to moderate thrombocytopenia (in about 1/3 of patients at diagnosis) to 
thrombocytosis (in about 40% of patients, sometimes higher than 1000x109/L, which may be the only 
change observed in the pre-fibrotic phase, simulating ET). Pancytopenia may occur in 10% of patients 
(Swerdlow et al., 2008). 
Bone marrow can evidence different stages of the disease (Figure 1.17 and Tables 1.4 and 
1.5). In the prefibrotic phase (fibrosis grade 0 and 1) there is normal or slightly increased reticulin, 
absence of collagen, and vascular proliferation, associated with hypercelularity due to increased 
granulopoiesis, presence of  markedly atypical megakaryocytes, including with abnormal patterns of 
chromatin clumping, cloud-like or balloon-like nuclei, hyperchromatic and increased nude nuclei, 
organized in dense aggregates, some adjacent to bone trabeculae or vascular sinuses, and reduced 
erythropoiesis. In fibrotic phase (fibrosis grade 2 and 3) the presence of markedly increased reticulin, 
collagen, sometimes with osteosclerosis, results in a cellularity focally increased, normal or 
hypocellular, with megakaryocytes often increased, in which large dense aggregates of atypical 
megakaryocytes may persist, often within dilated vascular sinuses, with increased proportion of small 
megakaryocytes and prominence of hyperchromatic nuclei. 
PMF differential diagnosis includes other MPNs (CML, ET, PV), other hematological diseases 
(hairy cell leukemia, some lymphomas, MDS with myelofibrosis, systemic mastocytosis), autoimmune 
myelofibrosis, solid tumors with spinal metastases and disseminated tuberculosis. 
Irrespective of clinical diagnosis, several authors have pointed that homozygous JAK2 V617F 
mutation is more symptomatic and is generally associated with older age, higher hemoglobin level and 
hematocrit value, leukocytosis, lower platelet count, larger spleen volume, increased risk of thrombosis 
(in ET) and cardiovascular events, and more frequent fibrotic transformation in both PV and ET (Tefferi, 
2016; Tefferi & Vardiman, 2008; Vannucchi et al., 2007), also  evidenced in Medline- and Embase-
guided meta-analyses (Dahabreh et al., 2009; Lussana et al., 2009).  
Compared to PV patients with JAK2 V617F mutation, patients with exon 12 mutations (and also 
in mouse models), do not usually present panmyelosis (Arber et al., 2016; Rumi & Cazzola, 2017). 
JAK2 exon 12 positive patients appear to be associated with a distinct syndrome, mainly characterized 
by  isolated marked erythrocytosis, with higher hemoglobin concentrations, lower white cells and 
platelets counts (minimal thrombocytosis), and isolated bone marrow erythroid hyperplasia (Godfrey et 
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Figure 1.17 – Peripheral blood smear morphological and bone marrow histological aspects from a PMF 
patient. 
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A) Peripheral blood smear showing many “teardrop” cells or dacrocytes and a red nucleated cell; Bone marrow 
biopsy showing a pack marrow in B) and C), with a group of megakaryocytes with morphological atypia in D) and 
F); E) Irregular thickening of bone trabeculae and marked fibrosis of collagen; G) Fibrotic phase with marked 
collagen fibrosis with reduction of all hematopoietic cells; H) Fibrotic phase with grade 3 reticulin fibrosis. 
A) x100, Wright stain; B) x40, C) x100, D) x400, E) x100, F) x400 and G) x100, Hematoxylin eosin stain; H) x400, 
Reticulin stain. 
Periphearl blood smear slide was obtained and scored by the author; bone marrow biopsy images were courtesy 




Table 1.5 – Myelofibrosis grading. 
 (Arber et al., 2016). 
 
Semiquantitative grading of BM fibrosis*  
MF – 0 Scattered linear reticulin with no intersections (crossovers), corresponding to normal BM  
MF – 1 Loose network of reticulin with many intersections, especially in perivascular areas 
MF – 2** 
Diffuse and dense increase in reticulin with extensive intersections, ocasionally with focal bundles 
of thick fibers mostly consistent with collagen, and/or focal osteosclerosis 
MF – 3** 
Diffuse and dense increase in reticulin with extensive intersections and coarse bundles of thick 
fibers consistent with collagen, usually associated with osteosclerosis 
* With minor modifications concerning collagen and osteosclerosis; Fiber density should be assessed only in hematopoietic areas 
** Additional trichrome stain is recommended 
BM – Bone marrow 
 
According to literature, even though JAK2 exon 12 mutations are mostly associated with 
erythrocytosis, up to 25% percent of patients present with elevated counts of other lineages (Scott, 
2011). The basis for this different phenotype is not completely known (J. Li et al., 2014). Scott et al 
suggested that genetic factors might be involved, such as the nature of the mutation or other additional 
MPN-associated mutations (Scott, 2011). An enhanced STAT1 activation might cause superior 
megakaryopoiesis and, therefore, possibly be a contributing factor to the understanding of the small 
share of PV patients with exon 12 mutation who behave differently. On the other hand, the absence of 
thrombocytosis in the majority of patients may be related to STAT1-independent mechanisms that might 
cause, for instance, increase platelet destruction (Godfrey et al., 2016). The fact that exon 12 mutations 
are more frequently associated with erythrocytosis is compatible with their absence in ET, but possible 
presence in PMF or AML secondary to PV (Scott, 2011). 
Mutant CALR in ET is associated with younger age, male sex, higher platelet count, lower 
hemoglobin level and lower leukocyte count and, in PMF, with younger age, higher platelet count and 
lower frequencies of anemia, leukocytosis, and spliceosome mutations (Tefferi, 2016). Type 2 CALR 
mutation in ET patients is associated with significantly higher platelet count and, in PMF, with higher 
circulating blast percentage and leukocyte count (Tefferi, 2016).  
Myeloproliferative disease burden in each of the JAK2, CALR and MPL mutant PN-MPNs is 
best reflected by the degree of anemia, splenomegaly, mutation allele burden, bone marrow cellularity 
and myelofibrosis degree (Jan Jacques et al., 2016). 
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PROGNOSIS AND PREDICTIVE FACTORS  
 
Although there has been a clear improvement in survival in the last years, globally, PN-MPNs 
patients have a reduced life expectancy, compared with the general population, due to several causes, 
such as other hematologic malignancies, bacterial infections, cardiovascular and cerebrovascular 
diseases (Rumi & Cazzola, 2017).  
In a study recently published by the Italian collaborative group of Mayo Clinic, involving 826 
patients, the median survival for ET was 20 years, for PV 14 years and 6 years for PMF, with an average 
increase of ten years in each disorder for patients younger than 60 years old. The study also revealed 
an inferior life expectancy in ET patients, when compared to age and sex-matched individuals (Rumi & 
Cazzola, 2017; Tefferi, 2016; Tefferi & Vannucchi, 2017). 
Clinical course and disease progression depend on the contribution of several risk factors, 
influencing survival (Table 1.6) (Arber et al., 2016; Jones & Cross, 2013; Mesa et al., 2016; Rumi & 
Cazzola, 2017; Tefferi, 2016).  
Age is the most important determinant of survival with the corresponding median of 33, 24, and 
15 years in patients younger than 60 years.  
Genetic information is the second most important prognostic tool and includes karyotype, driver 
mutational status, and presence of specific other mutations, which used in combination may enhance 
genetic risk stratification. Globally, karyotype has been shown to have prognostic relevance in PV 
(abnormal vs normal) and PMF (unfavorable vs favorable abnormalities). Driver mutations are 
prognostically most relevant in PMF (type 1/type 1-like CALR has been associated with superior 
survival) (Tefferi & Vannucchi, 2017). 
 
 
Table 1.6 – Classical PN-MPNs conventional and molecular risk factors influencing clinical outcome 
and affecting prognosis. 
(Adapted from (Rumi & Cazzola, 2017; Tefferi, 2016). 
 
 Relationships between genotype, phenotype, 
and clinical outcome 















• PV patients are at increased risk of thrombosis 
• PV may progress to myelofibrosis and less commonly to 




• previous thrombosis 
• age ≥ 60 years 
• JAK2 V617F mutation 
• blood hyperviscosity 
 
Myelofibrotic transformation: 
• JAK2 V617F mutant allele burden >50% 
• co-operating mutations in myeloid genes 
 
Leukemic transformation: 
• age ≥ 60 years 
• leukocytosis 
• co-operating mutations in myeloid genes 
 
Survival: 
• previous thrombosis 
• leukocytosis 
• co-operating mutations in myeloid genes 
 
 























• ET involves increased risk of thrombosis and bleeding, 
and may progress to more aggressive myeloid neoplasms 
• JAK2 V617F-mutant ET involves a high risk of thrombosis, 
and may progress to PV or myelofibrosis 
• CALR-mutant ET involves lower risk of thrombosis and 
higher risk of progression to myelofibrosis 
• Triple-negative ET is an indolent disease with low 
incidence of vascular events 
 
Thrombosis: 
• previous thrombosis 
• age ≥ 60 years 
• JAK2 V617F mutation 
 
Bleeding: 
• previous major bleeding 
• high PLT count (≥1500 x 109/L) 
 
Polycythemic transformation: 
• JAK2 V617F mutation 
 
Myelofibrotic transformation: 
• age ≥ 60 years 
• anemia 
• CALR mutation 
• co-operating mutations in myeloid genes 
 
Leukemic transformation: 
• previous thrombosis 
• extreme thrombocytosis (PLT count >1000x109/L) 
• co-operating mutations in myeloid genes 
 
Survival: 
• previous thrombosis 
• leukocytosis 


















• PMF is associated with the greatest symptom burden and 
the worst prognosis within MPNs, with a variable risk of 
progression to AML 
• CALR-mutant PMF is associated with longer survival 
compared with other genotypes 
• JAK2 V617F- and MPL-mutant PMF have worse 
prognosis than CALR-mutant PMF 
• Triple-negative PMF is an aggressive myeloid neoplasm 
characterized by prominent myelodysplastic features and 
high risk of leukemic evolution 
 
 
Survival & leukemic transformation: 
• age >65 years 
• presence of constitutional symptoms 
• anemia (Hb <10 g/dL) 
• leukocytosis (WBC count >25 x 109/L) 
• thrombocytopenia (PLT <100 x 109/L) 
• circulating blasts (≥1%) 
• degree of bone marrow fibrosis 
• unfavorable karyotype 
• driver mutation (triple negative vs JAK2/MPL vs CALR 
mutation) 
• co-operating mutations in myeloid genes 
 
AML – Acute myeloid leukemia; Hb – Hemoglobin; WBC – White blood cells; PLT – Platelets count 
 
 
PN-MPNs have high morbidity and mortality with thrombohemorrhagic complications (the most 
frequent), and risk of progression (Figure 1.18).  Signs of progression of these diseases include genetic 
evolution, increased splenomegaly, increased or decreased cell counts, myelofibrosis/myelodysplasia, 
10 to 19% of blasts in the peripheral blood or bone marrow (accelerated phase) and finally presence of 
more than 20% blasts in peripheral blood or bone marrow (blast phase). 
 
 
Figure 1.18 – Clinical course in classic PN-MPNs. 
Complications are shared over the spectrum of PN-MPNs. Grey bars represent the proportion of specific 
complications found overlapping in ET, PV and PMF (Adapted from (Kiladjian et al., 2012). 
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ET can phenotypically develop into PV (Passamonti et al., 2008) and both PV and ET can 
progress to secondary MF. PV, ET, and PMF can at any time transform to AML, in occasions preceded 
by a phase of myelofibrosis or MDS (Figure 1.19) (Swerdlow et al., 2008). 
 
 
Figure 1.19 – Disease course and complications associated with PN-MPNs. 
Around 95% of PV and 50-60% of ET and PMF patients harbor JAK2 V617F mutation. In the natural course of 
disease progression ET may evolve into PV and PV into secondary myelofibrosis and all three of them can directly 
transform into AML. Value on each flash represents the approximate percentage of each type of progression 
(Adapted from (Swerdlow et al., 2008). 
 
 
Patients with PN-MPNs have a high risk of both arterial and venous thromboembolic 
complications. The largest epidemiologic study in PV, the European Collaboration on Low-dose Aspirin 
(ECLAP), revealed that about 41% of all deaths in PN-MPNs (1.5 deaths per 100 persons per year) 
were due to cardiovascular complications.  
In PV, 11-39% of patients present with a major thrombosis and around 20% develop thrombosis 
during follow-up (De Stefano et al., 2008; Papadakis, Hoffman, & Brenner, 2010). The cumulative rate 
of nonfatal thrombosis in PV was 3.8 events per 100 persons per year, without a significant difference 
between arterial and venous events (Barbui, Finazzi, & Falanga, 2013). 
In patients with ET, the frequency of thromboembolic events in different studies ranges from 
10% to 30% at diagnosis and between 8% and 31% during follow-up (Carobbio et al., 2007) and the 
rate of fatal and nonfatal thrombotic events ranged from 2% to 4% patient-years, with a predominance 
of arterial events (Barbui et al., 2013), whose risk is higher in patients with JAK2 or MPL mutations 
(Tefferi & Vannucchi, 2017) 
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PMF seems less susceptible for thrombotic events as the overall cumulative rate of 
cardiovascular death and nonfatal thrombotic complications was 2.23 events per 100 persons per year 
(Andıç et al., 2016; Barbui et al., 2010; Barbui et al., 2013).  
The pathogenesis of thrombosis in PN-MPNs patients is complex, involving clinical factors such 
as age, previous history of thrombotic events, obesity, hypertension, and hyperlipemia, as well 
increased blood cell counts (ie, leukocytosis, erythrocytosis, and thrombocytosis) (Barbui et al., 2013). 
The most important risk factor for future arterial and venous thrombosis in MPNs is previous history of 
arterial or venous thrombosis, respectively (Tefferi, 2016). High hematocrit, leukocytosis and JAK2 
mutation are shown to be additional risk factors (Table 1.6). The influence of the JAK2 V617F mutational 
status and allele burden on the thrombotic risk has been evaluated and established in several studies 
among PN-MPNs, however  regarding the presence of MPL mutation, the published results are 
discrepant (Barbui et al., 2013). Older (age >60 years) patients are no longer considered “high risk,” 
unless they have a history of thrombosis or are JAK2-mutated (Table 1.6) (Barbui et al., 2013; Tefferi, 
2016). 
It was reported that PV patients with a white blood cell count >15 × 109/L, had a significant 70% 
increase of myocardial infarction, when compared with those with a WBC count <15 × 109/L.  It was 
also demonstrated that an increased baseline leukocyte count was an independent risk factor for both 
thrombosis and inferior survival in ET patients and an elevated WBC count developing during follow-up 
was also correlated with major thrombosis (Barbui et al., 2013; Carobbio et al., 2007; De Stefano et al., 
2010; Papadakis et al., 2010). However, in the ECLAP study, neither the currently proposed therapeutic 
target of 400 × 109/L, nor any of the other platelet-count thresholds evaluated predicted a higher risk of 
thrombosis (Barbui et al., 2013).  
Conventional risk factors for atherosclerosis, including hypertension, hyperlipidemia, diabetes, 
and smoking, have been assessed in multivariable analysis in PN-MPNS with variable results (Barbui 
et al., 2013). 
Besides clinical factors, the pathogenesis of thrombosis in PN-MPNs involves a number of 
complex cellular and molecular mechanisms, as illustrated in Figure 1.20. Clonal proliferation of 
hematopoietic stem cells induces both quantitative and qualitative changes in blood cells, resulting in 
cellular activation and expression by the blood cells themselves (ie, erythrocytes, platelets, and 
leukocytes) of procoagulant and proteolytic properties, secretion of inflammatory cytokines, and 
expression of adhesion molecules. At the same time, in response to inflammatory cytokines, 
hyperviscosity, and leukocyte-derived proteases (ie, elastase, cathepsin-G, and myeloperoxidase), 
there are  prothrombotic changes occurring in the normal vascular endothelium, with the upregulation 
of endothelial adhesion receptors, which favors the attachment of platelets, erythrocytes, and 
leukocytes to the vascular wall, with subsequent localization of clotting reactions and fibrin deposition 
(Barbui et al., 2013). Once activated, neutrophils can release proteolytic enzymes and reactive oxygen 
species capable of activate or damage platelets and endothelial cells and impair some coagulation 
proteins. Activated platelets express P-selectin and tissue factor and release membrane fragments, 
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which have procoagulant properties. The increased expression of CD11b on the neutrophil surface 
allows the adhesion of neutrophils to endothelial cells and platelets and the assembly of coagulation 
proteases on the neutrophil surface. In addition, biochemical changes in the cell membrane and content 
of erythrocytes may impair blood flow also through the formation of aggregates, which induce platelet 




Figure 1.20 – Mechanisms involved in the pathogenesis of thrombosis in PN-MPNs. 
(Adapted from (Barbui et al., 2013). 
 
 
Moreover, PN-MPNs patients present a hypercoagulable background state, not only for the 
increased levels of circulating procoagulant microparticles, but also due to the presence of an acquired 
activated protein C resistance, result of Protein S cleavage (Barbui et al., 2013). 
On the other hand, the risk of major bleeding is elevated in MPN patients, although bleeding 
complications are not as common as thromboembolic complications (Finazzi et al., 2012). Unprovoked 
hemorrhage is uncommon (Spivak, 2017). 
The cumulative incidence of bleeding in PV and ET is around 5-6% and in PMF is about 12% 
(Finazzi et al., 2012; Papadakis et al., 2010). 
Risk factors for bleeding are history of previous bleeding event, thrombocytopenia, and the use 
of aspirin and vitamin K antagonists (Table 1.6) (Finazzi et al., 2012). A higher risk of bleeding has also 
been noted in patients treated with a combination of aspirin and anagrelide (C. N. Harrison et al., 2005). 
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Extreme thrombocytosis (platelets count over 1000 or 1500x109/L) was found to be related with a lower 
risk of thrombosis but increased risk of hemorrhagic complications, because of associated acquired von 
Willebrand syndrome, as a result of platelet proteolysis of high-molecular weight von Willebrand 
multimers (Andıç et al., 2016; Campbell et al., 2012; Michiels et al., 2006; Spivak, 2017; Tefferi, 2016). 
The most common pattern of disease progression is overt reticulin and collagen fibrosis of the 
bone marrow (see Table 1.5 above).  
The range of reported frequencies for fibrotic transformation for PV is 4.9-6% at 10 years and 
6-14% at 15 years and for ET is 0.8-4.9% at 10 years and 4-11% at 15 years, according to recent 
updates (Figure 1.19) (Cerquozzi & Tefferi, 2015; Swerdlow et al., 2008).   
Risk factors for fibrotic transformation in PV include JAK2 V617F allele burden of >50%; in ET 
include advanced age and anemia, with the presence of JAK2 V617F being associated with a lower 
risk of fibrotic transformation and CALR with a  higher risk (Table 1.6) (Tefferi, 2016).  Moreover, MPL-
mutated patients might be at risk for accelerated fibrotic progression (Tefferi & Vannucchi, 2017).  
Recent published works have reported that genomic abnormalities are present in 
megakaryocytes in MPNs and that these appear to be associated with progression to bone marrow 
fibrosis (Guo et al., 2017; Vainchenker & Kralovics, 2017). 
In addition to WHO classification, the International Working Group for MPN Research and 
Treatment (IWG-MRT) criteria are used for diagnoses of post-PV and post-ET myelofibrosis (Table 1.7) 
(Tefferi & Pardanani, 2015). 
During post-PV and post-ET myelofibrosis installation, erythropoiesis progressively decreases, 
peripheral blood smear evidences a leucoerythroblastic reaction and poikilocytosis with “teardrop” 
shaped erythrocytes, and the spleen further enlarges, due to extramedullary erythropoiesis (Table 1.7). 
Bone marrow hypocellular specimens are common, with a decrease of erythropoiesis and 
granulopoiesis, and clusters of megakaryocytes bearing very dysmorphic nuclei are prominent 
(Swerdlow et al., 2008). 
PMF may show progressive aggravation of myelofibrosis (Table 1.5) and evolve with infectious 
and hemorrhagic complications resulting from pancytopenia, thrombosis, hepatosplenomegaly 
(aggravation of pancytopenia, portal hypertension, heart failure, digestive compression), post-
transfusion hemochromatosis and progression to AML in 15% of cases. Development of myelofibrosis 
in PMF is related to disease progression and is not significantly influenced by treatment options other 
than allogeneic stem-cell transplantation (Swerdlow et al., 2008). 
Although the clinical characteristics of post-PV and post-ET myelofibrosis patients are not 
substantially different from those with PMF, their outcomes differ and prognostic scoring systems for 
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Table 1.7 – International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) 
recommended criteria for post-PV and post-ET myelofibrosis. 

















Required criteria: Additional criteria (two are required): 
 
1. Documentation of a previous diagnosis of PV as 
defined by the WHO criteria 
2. BM fibrosis grade 2–3 (on 0–3 scale) or grade 3–4 (on 
0–4 scale) (see footnote for details) 
 
1. Anemia or sustained loss of requirement for 
phlebotomy in the absence of cytoreductive therapy 
2. A leukoerythroblastic peripheral blood picture 
3. Increasing splenomegaly defined as either an increase 
in palpable splenomegaly of ≥ 5 cm (distance of the tip 
of the spleen from the left costal margin) or the 
appearance of a newly palpable splenomegaly 
4. Development of ≥1 of three constitutional symptoms: 
>10% weight loss in 6 months, night sweats, 


















Required criteria: Additional criteria (two are required): 
 
1. Documentation of a previous diagnosis of ET as 
defined by the WHO criteria 
2. BM fibrosis grade 2–3 (on 0–3 scale) or grade 3–4 (on 
0–4 scale) (see footnote for details) 
 
1. Anemia and a ≥ 2 g/dL decrease from baseline 
hemoglobin level 
2. A leukoerythroblastic peripheral blood picture 
3. Increasing splenomegaly defined as either an increase 
in palpable splenomegaly of ≥ 5 cm (distance of the tip 
of the spleen from the left costal margin) or the 
appearance of a newly palpable splenomegaly 
4. Increased lactate dehydrogenase 
5. Development of ≥ 1 of three constitutional symptoms: 
>10% weight loss in 6 months, night sweats, 
unexplained fever (>37.5ºC) 
 
See Table 1.5 for myelofibrosis grading definition; BM – Bone marrow 
 
 
In PN-MPNs, although the cells mature relatively normally, there is potential for further evolution 
of the neoplastic clone, which may result, besides bone marrow failure, in transformation to accelerated 
phase and/or myelodysplasia (with more than 10% blasts in peripheral blood or bone marrow or 
significant myelodysplasia) or transformation to AML if blasts are higher than 20%. The risk of 
transformation to AML or MDS in ET and PV is associated with a bad prognosis, and has been reported 
to occur in 0.7-3% and 2.3-14.4% of patients, respectively, 10 years following the initial diagnosis, and 
increases with time after diagnosis (2.1-5.3% and 5.5-18.7%, respectively, at 15 years) (Figure 1.19) 
(Cerquozzi & Tefferi, 2015; Rampal et al., 2014; Swerdlow et al., 2008). The reported frequency of AML 
in PMF is highest and ranges from 5 to 30% (Figure 1.19) (Swerdlow et al., 2008).  
According to IWG-MRT, risk factors for leukemic transformation in PV include older age, 
leukocytosis and abnormal karyotype, in ET include thrombosis and extreme thrombocytosis (platelets 
>1000x109/L) and in PMF they include some of the above outlined clinical and genetic risk factors such 
as age, constitutional symptoms, hemoglobin levels, leukocytes/platelets count, circulating blasts, red 
blood cells transfusion need and karyotype (Table 1.6)  (Tefferi, 2016). In addition, several mutations 
have been associated with leukemic transformation, namely ASXL1, SRSF2, EZH2, IDH1/2, IKZF1, 
TP53, NF1, RUNX1, NRAS, SRSF2, and DNMT3A (Abdel-Wahab et al., 2010; Vainchenker & 
Kralovics, 2017). Prognostic significance has been described for cytogenetic abnormalities in PMF, but 
not in PV and ET patients (Bittencourt et al., 2012; Guglielmelli et al., 2014; Hussein et al., 2009). 
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On the other hand, JAK2 V617F has not been correlated to an increased risk of transformation 
to AML, nevertheless, patients JAK2 V617F positive at MPN diagnosis can transform to JAK2 V617F 
negative AML (Theocharides et al., 2007).  AML secondary to MPNs is often characterized by a more 
complex karyotype compared to de novo AML, indicating a worse prognosis (Milosevic et al., 2012). 
The risk of transformation seems to increase following certain types of cytotoxic therapy 
(Swerdlow et al., 2008), increasing the incidence to 20% (Spivak, 2017). In a small subset of patients, 
it was evidenced that the presence of inherited DNA mutations involved in repair pathways are 
associated  with the development of therapy related AML/MDS (McNerney et al., 2017). Moreover, 
abnormal function of the bone marrow niche, previously or following treatment, may induce lesions in 
the local microenvironment, favoring the expansion of preleukemic clones (McNerney et al., 2017). 
However, there are no conclusive randomized studies on treatment and AML transformation in patients 
with PN-MPNs, due the late-appearing and rare events in a long-term disease course, and reluctance 
to randomly assign patients to receive potentially leukemogenic therapies.  
JAK2 V617F mutational status may have prognostic significance in PV, ET and PMF (Tefferi, 
2008b). In PV, despite the phenotypic differences, the clinical course seems similar between JAK2 
V617F and JAK2 exon 12 positive patients, with similar incidences of thrombosis, myelofibrosis, 
leukemia and death (Passamonti et al., 2011). JAK2/CALR mutational status did not affect survival in 
ET (Tefferi, 2016). In PMF and ET, triple-negative patients appear to have a less favorable prognosis 
than patients with a driver mutation (JAK2, CALR, or MPL), whereas patients with CALR mutations tend 
to have a better prognosis than patients with JAK2 or MPL mutations. Type 2 CALR mutation in PMF 
patients is associated with higher risk category, and inferior survival (Tefferi, 2016). Most noteworthy is 
the survival advantage shown by PMF patients with type 1 or type 1-like CALR variants, compared to 
all other genotypes (Table 1.6) (Tefferi, 2016). ASXL1 and SRSF2 mutations have been associated 
with inferior overall, leukemia-free, or fibrosis-free survival in both PV and PMF, and a recent targeted 
sequencing study has identified additional other adverse mutations in both these disorders, as well as 
in ET (Tefferi & Vannucchi, 2017). 
Another important concern refers to the increased risk of development of new 
nonhematological and nonmyeloid neoplasms in MPNs, with an incidence ratio of 1.2-1.4 and 3.4, 
respectively, compared to the general population (Hernández-Boluda et al., 2012). There is evidence 
that this risk is higher when JAK2 V617F mutation is present and other patient related factors may be 
also involved. However, the association with cytoreductive therapy is controversial. It has been 
hypothesized that ET patients have the intrinsic potential to evolve into malignant diseases, because of 
the presence of an impaired “tumor immune surveillance,” persistent inflammatory state, accumulation 
of reactive oxygen species, and favorable role of platelets to promote cellular growth, angiogenesis, 
and metastasis (Santoro et al., 2017). 
In Chapter 9 of this dissertation will be presented part of the developed work, which was 
dedicated to the evaluation of clinical outcome of the patients under treatment with hydroxyurea 
included in the studied population, in terms of the presence of thrombotic events, occurrence of new 
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nonmyeloid neoplasms and progression to myelofibrosis or AML transformation, and their relation with 
caspases and BER polymorphisms. 
 
1.1.3 – RISK STRATIFICATION, THERAPY MANAGEMENT AND RESPONSE 
EVALUATION 
 
PN-MPNs RISK STRATIFICATION 
  
Over the last 50 years, Louis Wasserman from the Unites States and Tiziano Barbui from Italy 
developed a crucial work and skillfully organized a number of important clinical trials, whose results 
constituted the basis for the creation of international prognostic systems and current treatment 
algorithms in PN-MPNs (Tefferi, 2016).  
The therapeutic strategy to be adopted in each disorder is decided according to the stratification 
of risk for each patient, using the prognostic models and risk criteria described in Table 1.8. For each 
one of PN-MPNs different prognostic models were developed, which were subsequently upgraded in 
the recent years, based on the risk factors previously mentioned in Table 1.6, known to influence 
disease progression.  
As shown in Table 1.8, in the case of PV and ET patients risk stratification is based on IPSS 
and IPSET scores, respectively, depending on the age, JAK2 mutation status, leukocytes/platelets 
count and previous history of thrombotic events  (Rumi & Cazzola, 2017; Tefferi, 2016). For PMF, risk 
stratification depends on DIPSS-plus score (including previously mentioned risk factors such as age, 
constitutional symptoms, hemoglobin levels, leukocytes/platelets count and circulating blasts, in 
addition to red blood cells transfusion need and karyotype), molecular status for CALR and ASXL1 or 
other high risk mutations (IDH1/2, EZH2, SRSF2), and increased serum IL-8, IL-2R or serum free light 
chain levels (Rumi & Cazzola, 2017; Tefferi, 2016). 
 
 
Table 1.8 – Prognostic models and risk stratification for PN-MPNs patients. 
(Adapted from (Rumi & Cazzola, 2017). 
 















Conventional thrombosis score (European LeukemiaNet recommendations) (Barbui et al., 2011) 
 
At least 1 of the following risk factors: 
• Age ≥60 y 
• Previous thrombosis 
 
 
Low risk: age <60 y AND no history of thrombosis, that is, no risk factors 
High risk: age ≥60 y AND/OR history of thrombosis, that is, at least 1 risk factor 
 
Low-risk patients are given low-dose aspirin and undergo regular phlebotomy to 
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IPSS for overall survival in PV (Tefferi, Rumi, et al., 2013) 
 
Risk factors (weight): 
• Age ≥67 y (5 point) 
• Age 57-66 y (2 points) 
• WBC count ≥15 x 109/L (1 point) 
• Previous venous thrombosis (1 point) 
 
 
Low risk: 0 (median survival, 28 y) 
Intermediate risk: 1-2 points (median survival, 19 y) 





















Conventional score for prediction of vascular complications (European LeukemiaNet recommendations) (Barbui et 
al., 2011) 
 
At least 1 of the following risk factors: 
• Age ≥60 y 
• Previous thrombosis or major bleeding 
• PLT count ≥1500 x 109/L 
 
Low risk: age <60 y AND no history of thrombosis or major bleeding AND PLT 
count <1500 x 109/L, that is, none of the 3 major risk factors 
High risk: age ≥60 y AND/OR history of thrombosis or major bleeding AND/OR 
PLT count ≥1500 x 109/L, that is, at least 1 of the 3 major risk factors 
 
While low-risk patients are just followed (observation alone) or given low-dose 
aspirin, high-risk patients are given a cytoreductive treatment plus low-dose 
aspirin 
 
IPSET-thrombosis (International Prognostic Score for ET: estimates the risk of thrombosis) (Barbui et al., 2012) 
 
Risk factors (weight): 
• Age ≥60 y (1 point) 
• Previous thrombosis (2 points) 
• Cardiovascular risk factors* (1 point) 
• JAK2 V617F mutation (2 points) 
 
*Cardiovascular risk factors include hypertension, 
diabetes, and active tobacco use 
 
 
Low risk: 0-1 point (probability of thrombotic events: 1.03% of patients/year) 
Intermediate risk: 2 points (2.35% of patients/year) 
High risk: ≥3 points (3.56% of patients/year) 
 
Potential therapeutic implications: (1) observation alone may be adequate in 
patients with no risk factors; (2) low-dose aspirin should be used in all patients 
with JAK2 V617F and/or cardiovascular risk factors; (3) older patients (≥60 y) 
without additional risk factors may not need a cytoreductive treatment; (4) 
conversely, a cytoreductive treatment may be considered in younger patients 
(<60 y) with JAK2-mutant ET and concomitant cardiovascular risk factors, even 
in the absence of previous thrombosis 
 
IPSET (International Prognostic Score for ET: predicts survival) (Barbui et al., 2015) 
 
Risk factors (weight): 
• Age ≥60 y (2 points) 
• Previous thrombosis (1 point) 
• WBC count >11 x 109/L (1 point) 
 
 
Low risk: 0 (median survival not reached) 
Intermediate risk: 1-2 points (median survival, 24.5 y) 
















IPSS (Cervantes et al., 2009)                                      
 
Risk factors (weight): 
• Age >65 y (1 point) 
• Constitutional symptoms (1 point) 
• Hb <10 g/dL (1 point) 
• WBC count >25 x 109/L (1 point) 
• Circulating blasts ≥1% (1 point) 
 
 
Low risk: 0 (median survival, 11.3 y) 
Intermediate-1 risk: 1 point (7.9 y) 
Intermediate-2 risk: 2 points (4.0 y) 
High risk: ≥3 points (2.3 y) 
 
IPSS estimates survival at the time of diagnosis 
DIPSS (Passamonti, Cervantes, et al., 2010) 
 
Risk factors (weight): 
• Age >65 y (1 point) 
• Constitutional symptoms (1 point 
• Hb <10 g/dL (2 points) 
• WBC count >25 x 109/L (1 point) 
• Circulating blasts ≥1% (1 point) 
 
 
Low risk: 0 (median survival, >20 y) 
Intermediate-1 risk: 1-2 points (14.2 y) 
Intermediate-2 risk: 3-4 points (4.0 y) 
High risk: 5-6 points (1.5 y) 
 
DIPSS can be applied anytime during clinical course 
 
DIPSS-plus (Gangat et al., 2011)                       
 
Risk factors (weight): 
• DIPSS score (DIPPS low=0, 
DIPPS int-1=1 point, DIPPS 
int-2=2 points, DIPSS high=3 points) 
• RBC transfusion need (1 point) 
• PLT count <100 x 109/L (1 point) 






Low risk: 0 (median survival, 15 y) 
Intermediate-1 risk: 1 point (6.6 y) 
Intermediate-2 risk: 2-3 points (2.9 y) 
High risk: 4-6 points (1.3 y) 
 
DIPSS-plus can be applied anytime during clinical course 
Hb – hemoglobin; PLT – platelets; RBC – red blood cells; WBC – white blood cells;  
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DIPSS –  Dynamic International Prognostic Scoring System; IPSET – International Prognostic System for ET; IPSS 
– International Prognostic Scoring System. 
 
 
In a recent international study involving PMF patients, it was reported that CALR1ASXL12 
patients had the longest survival (median 10.4 years) and CALR2ASXL11 patients the shortest (median 
2.3 years). CALR1ASXL11 and CALR2ASXL12 patients had similar survival, grouped together in an 
intermediate risk category (median survival 5.8 years) (Tefferi, 2016). 
Regarding post-PV/ET MF, in a very recent article Tefferi et al. provided evidence to support 
the use of IPSS/DIPSS/DIPSS-plus, thus maintaining familiarity and uniformity, until a molecularly more 
robust system is developed (Tefferi et al., 2017). In patients with secondary myelofibrosis, only SRSF2  
is associated with shortened survival (Spivak, 2017). 
 
 
THERAPY MANAGEMENT AND RESPONSE EVALUATION 
  
Cure is the ultimate objective of cancer therapy. However, current available drug therapy in PV, 
ET, or PMF does not have curative power and chronicity is the hallmark of PN-MPNs. Globally, the 
main goal in PN-MPNs therapy consists in prevention of thrombotic events, occurrence of other 
nonmyeloid neoplasms and fibrotic or AML transformation. Thus, strategies for accurate risk 
assessment are essential to maximize therapeutic benefits, with the minimal possible iatrogenic harm, 
and prolong life.  
Accordingly, treatment indications in PV and ET are directed towards alleviation of symptoms 
and prevention of complications, such as thrombosis and/or bleeding events (Figure 1.21) (Tefferi, 
2016), to which is necessary to lower hematocrit below 45% and correct leukocytosis, respectively, 
since thrombosis probability in ET patients under treatment is not influenced by platelet count (more 
related with bleeding) (Rumi & Cazzola, 2017). 
On the other hand, in PMF the principal aim is symptomatic control (ameliorating anemia, 
reducing splenomegaly and improving systemic symptoms), with the possibility of cure limited to 
patients undergoing allogeneic stem cell transplant (discussed below) (Tefferi, 2016). 
Treatment of PV and the other MPNs have included skeletal radiation therapy (1917), 
acetylphenylhydrazine (1918), potassium arsenite (1933), lead acetate (1942), nitrogen mustard 
(1950), triethylene melamine (1952), pyrimethamine (1954), 6-mercaptopurine (1962), uracil mustard 
(1964), chlorambucil (1965) and dapsone (1966). P32 was introduced in 1940, busulfan 1958, 
pipobroman 1962, hydroxyurea and melphalan in the 1970s and interferon-α in the 1980s (Tefferi, 
2008c). 
Phlebotomy prescription, indicated in all patients with PV, has been used since the disease 
was first described (Tefferi, 2008c). Is the recommended main tool to control hematocrit levels below 
45% reducing a the rate of major thrombosis and dead from cardiovascular causes as it was 
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demonstrated in the Cytoreductive Therapy in PV study (Vannucchi, 2015), with a significant 
improvement in patients medial survival (<2years increased to >14 years) (Tefferi, 2016). One of the 
most concerning side effects of phlebotomies is iron deficiency and its complications (Vannucchi, 2015). 
Patients with PV or ET whose thrombohemorragic risk is high enough, might require treatment with 
aspirin and/or cytoreductive drugs such as hydroxyurea, for lowering that risk and symptomatic control, 
but subject to short- and long-term side effects of these drugs (Figure 1.21) (Tefferi, 2016). 
 
 
Figure 1.21 – Contemporary treatment flow-chart in ET and PV.  
(Adapted from (Tefferi, 2016). 
 
 
The use of acetylsalicylic acid  therapy in PV is supported by controlled evidence in the 
ECLAP (European Collaboration study on Low-dose Aspirin in Polycythemia) study (Barbui et al., 
2013; Tefferi, 2016). Since then, low-dose aspirin is standard treatment in PV and also many patients 
with ET and PMF (Landolfi et al., 2004). In ET it has been suggested that antiplatelet therapy reduces 
the incidence of venous thrombosis in JAK2 positive patients and the rate of arterial thrombosis in 
patients with associated cardiovascular risk factors (Barbui et al., 2013; Tefferi, 2016). Current 
treatment should not primarily aim at lowering the platelet count for thrombosis prevention. However, 
platelet-lowering drugs should be considered at platelet counts >1500 × 109/L to reduce the risk of 
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bleeding (Barbui et al., 2013), but with serious caution. In regard to bleeding, the annual incidence of 
major hemorrhages attributed to aspirin in PV and ET patients ranges between 0.3% and 0.8%, and 
this rate is higher in ET patients presenting with prefibrotic myelofibrosis (1.39% patient-years) (Barbui 
et al., 2013). 
Regarding cytoreductive therapy in PN-MPNs, it is recommended for those patients with 
persistent or progressive hematologic abnormalities, splenomegaly or other symptoms, at high risk for 
thrombosis, or for PV patients who cannot undergo phlebotomy or who require them frequently 
(Vannucchi, 2015). In addition, an expert consensus conference indicated that another aim of 
cytoreduction in ET and PV should be to keep the leucocytes count within the normal range (Barbui et 
al., 2013). There is controlled evidence of value for chlorambucil or radiophosphorus in PV, and 
hydroxyurea in high risk ET. However, the use of chlorambucil and radiophosphorus was complicated 
by shortened survival because of the increased leukemogenicity of these drugs, as it was demonstrated 
in a trial developed by the Polycythemia Vera Study Group (1967-1997), compared to patients treated 
with phlebotomy alone (Berk et al., 1981). Pipobroman, another myelosuppressive drug used in Europe, 
was also recently implicated as being leukemogenic in PV patients (Tefferi, 2016).  
Therefore, while the anti-thrombotic value of cytoreductive therapy in high risk PV and ET is 
well recognized, the only drug with adequate evidence of efficacy and safety, in this regard, is 
hydroxyurea (HU), also called hydroxycarbamide, which is currently the first-line drug of choice in 
intermediate and high risk PV or ET patients (Barbui et al., 2013; Tefferi, 2016).  
HU (Figure 1.22) is an antimetabolite/cytotoxic non-alkylating antineoplastic and antiviral agent, 
capable of inhibiting DNA-synthesis and cell growth, that has been used for a variety of conditions in 
hematology, oncology, infectious disease and dermatology. It was first synthesized over a century ago 
in 1869, but it was not until ~60 years later in 1928 that the biological effects of this simple antimetabolite 
compound on blood cells in rabbits were reported. In the 1960s, a large-scale drug screen revealed its 
anti-tumor potential. Subsequent studies showed that it could be used to treat several types of solid 
tumors and myeloproliferative disorders (Tefferi, 2016). It is metabolized in liver (to CO2 and urea), with 
a half-life of 2-4 hours is being excreted by kidney and lung. This drug is a ribonucleotide reductase 
inhibitor, blocking the synthesis of DNA and arresting cells in the S phase of the cell cycle, characterized 
by an easy reversibility of its action. HU has been shown to induce chromosome damage in various 
organisms and also cytotoxic effects depending on the concentration used, duration of exposure, and 
sensitivity of the cell lines used in the studies. HU can also cross the placenta, being teratogenic. Thus, 
the DNA damage, such as the strand breaks caused by inhibition of DNA synthesis, is generally 
believed to be responsible for its cytotoxicity, anti‐neoplastic activity and teratogenic effects. However, 
the reversible effect of HU on DNA replication suggests that it is a cytostatic agent, and, in addition to 
the DNA damage, its cytotoxic effects may involve a more complex mechanism (Singh & Xu, 2016).  
HU is the most commonly used first-line cytoreductive agent because of its proven efficiency, 
especially in reducing thrombotic risk (Cortelazzo et al., 1995). In patients with high risk ET, it was 
associated with a lower risk of arterial thrombosis and progression to myelofibrosis, but a higher risk of 
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venous thrombosis compared to anagrelide (discussed below) (C. N. Harrison et al., 2005). 





Figure 1.22 – Hydroxyurea (HU) molecule and its cellular effects. 
HU inhibits its primary cellular target ribonucleotide reductase (RNR), which decreases the deoxyribonucleotide 
triphosphate (dNTP) levels and slows the movement of DNA polymerases at the forks (red cross). Slowed forks 
activate the DNA replication checkpoint, which in turn stimulates RNR to increase the dNTP production for DNA 
synthesis and fork recovery. Activated checkpoint can also suppress mitosis to prevent aberrant cell division (not 
shown). Without a functional checkpoint, slowed forks collapse and thus generate DNA damage, which leads to 
cell inviability. Recent studies suggest that, in addition to RNR, HU may have a secondary target(s) (red question 
mark) such as metal enzymes and matrix proteases, that are suppressed and may arrest the cells in cytokinesis 
or generate oxidative stress, which also leads to cell lethality (Adapted from (Singh & Xu, 2016). 
 
 
HU is recommended to be used with caution in young patients, regarding the data reported by 
Kiladjian et al., showing a risk increment of leukemia in long-term usage (Andıç et al., 2016). However, 
this effect was not supported by other authors (I. Nielsen & Hasselbalch, 2003). 
Some patients have important side effects or an inadequate response to the drug, being 
classified according to the European LeukemiaNet (ELN) criteria as having intolerance or resistance to 
HU (Barosi et al., 2013), associated with shorter survival (Vannucchi, 2015). In those patients, data 
from non-controlled studies support the use of interferon-alpha or busulfan as second-line drugs of 
choice. There is adequate long-term safety information on these drugs, which have both been shown 
to significantly reduce JAK2 V617F mutant allele burden in ET and PV and CALR in ET patients and 
result in hematologic and complete molecular responses (in 20% of PV patients), although the effect of 
such biologic activity on risk of thrombosis or survival is unknown (Rumi & Cazzola, 2017; Tefferi, 2016). 
Moreover, interferon-alpha showed to reduce bone marrow fibrosis in early stages of PMF (Kiladjian et 
al., 2008; Silver, Vandris, & Goldman, 2011). However, interferon-alpha is the least commonly used 
agent in all PN-MPNs groups, probably because of its parenteral usage and poor tolerability 
(immunosuppression, myelotoxicity, and neurotoxicity) (Andıç et al., 2016; Kiladjian et al., 2008; Spivak, 
2017). Moreover, it is well known that alkylating agents (given alone or in combination/sequentially) 
increase the risk of transformation into AML (Santoro et al., 2017; Vannucchi, 2015).  
In the ANAHYDRET study, it was shown that anagrelide was as effective as HU in PN-MPNs 
treatment (Gisslinger et al., 2013). Anagrelide is effective in reducing platelet counts in ET and PV 
 
GENETIC SUSCEPTIBILITY TO MYELOPROLIFERATIVE NEOPLASMS AND THERAPEUTIC EFFICACY  
 58 
patients who are resistant or intolerant to HU. The platelet-lowering effect of anagrelide results from 
impaired megakaryocyte maturation and reduced proplatelet formation, both of which are deregulated 
in ET, although the basis for this effect remains unclear (Espasandin et al., 2015). In high risk ET, 
ANAHYDRET study showed no difference in the risk of arterial or venous thrombosis or bleeding 
(Gisslinger et al., 2013). Secondary leukemia has not been reported with anagrelide treatment yet 
(Andıç et al., 2016), but its use in high risk ET was associated with increased risk of post-ET MF (Tefferi, 
2016). 
The discovery of the JAK2 mutations and their relation with the subsequent activation of the 
JAK-STAT pathway was crucial to the understanding of the pathogenesis of PV, ET and PMF. This 
knowledge has led to the development of small molecular JAK inhibitors to target autoimmune 
disease/immunosuppression (anti-JAK1, JAK3) and MPNs and leukemia/lymphoma (anti-JAK2, JAK1), 
which have been tested in several clinical trials, suggesting an overall reduction in JAK-STAT signaling 
and pro-inflammatory cytokines (Pardanani et al., 2007; Lasho et al., 2008; Pardanani, 2008). About 
ten compounds were studied for MPNs, rheumatoid arthritis, psoriasis and inflammatory bowel disease, 
all of them targeting the ATP-binding site of JAKs and so none is absolutely specific for any JAK (Tefferi, 
2008a). Nevertheless, ruxolitinib (a JAK1, JAK2 inhibitor, trade name Jakavi®) has been approved by 
the Food and Drug Administration (FDA) in November 2011, for use in myelofibrosis and tofacitinib (a 
JAK1, JAK3 inhibitor) has been approved for use in rheumatoid arthritis. The first two randomized 
controlled trials (Comfort I and II) on the effect of the JAK2 inhibitor ruxolitinib vs placebo and vs best 
available therapy in intermediate-2 and high risk PMF showed a decrease in spleen size and symptom 
burden in the experimental arm of both studies and in Comfort I, a survival benefit was observed in the 
ruxolitinib arm compared to patients on placebo (C. Harrison et al., 2012; Verstovsek et al., 2012). 
The treatment options of PMF patients are currently limited (Figure 1.23), giving JAK2 inhibitors 
immediate clinical value in the management of symptoms. PMF patients may benefit from JAK2 
inhibition through directly modulating the pro-growth signals of the JAK-STAT pathway, suppression of 
hematopoietic progenitor cell proliferation, and from downregulating specific pro-inflammatory cytokines 
produced by the affected clone (Spivak, 2017; Tefferi & Pardanani, 2011). 
Ruxolitinib treatment substantially alleviates symptomatic splenomegaly and constitutional 
symptoms and improve quality of life in a significant proportion of patients with primary or post-PV/ET 
myelofibrosis (Tefferi, 2008a). Surprisingly, treatment with ruxolitinib is also effective in patients without 
mutated JAK2, suggesting that other, still unknown, underlying mechanism(s) are responsible for the 
increased JAK/STAT pathway activity in PN-MPNs patients. On the other hand, there is not convincing 
evidence of reduction in mutated allele burden or progression to AML (Tefferi, 2016).  
Ruxolitinib is capable of induce complete molecular response in PMF and recently was also 
approved for use in HU-intolerant/resistant PV and ET , based on its ability to alleviate constitutional 
symptoms and reduce spleen size (C. N. Harrison et al., 2017; Rumi & Cazzola, 2017; Vannucchi, 
2015; Verstovsek et al., 2017). However, the drug has not been shown to modify the natural history of 
PV and is associated with significant short and long term side effects that make its utility questionable 
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and not recommended for use in PV, in the absence of refractory symptomatic splenomegaly or 
intractable pruritus that fail to respond to HU, busulfan or interferon alfa (Tefferi, 2016).  
Whether the presence of additional mutations impairs the effectiveness of ruxolitinib is disputed 
(Spivak, 2017). 
Other promising JAK inhibitors investigational drugs for PMF, under study in different phases 
of clinical trials, include fedratinib, momelotinib, and pacritinib (Tefferi, 2016), but they have so far not 
shown disease-modifying activity, including reversal of bone marrow fibrosis or induction of complete 
or partial remissions (Tefferi, 2016). 
 
 
Figure 1.23 – Contemporary treatment flow-chart in myelofibrosis. 




The side effects of JAK inhibitors include thrombocytopenia, anemia and neutropenia and 
gastro-intestinal symptoms, such as diarrhoea, nausea and vomiting. Further, a withdrawal syndrome 
has been reported during discontinuation of ruxolitinib, characterized by acute relapse of disease 
symptoms, accelerated splenomegaly and worsening of cytopenias, requiring a balance for each 
individual patient with enough benefit and the least side effects (Tefferi, 2016).  
In terms of treatment, the limitation of JAK inhibitors to disease palliation is now well recognized 
and there is a dire need for disease-modifying drugs. In this regard, two papers on the telomerase 
inhibitor imetelstat were recently published in the New England Journal of Hematology and showed a 
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potential disease modifying activity through the induction of clinical, histological and molecular 
remissions in both ET and PMF. Severe myelosuppression and mostly reversible low grade 
abnormalities in liver function tests were the two main side effects of treatment with imetelstat (Tefferi, 
2016). Other therapies that are currently being tested primarily in PMF include immunomodulators, 
histone deacetylase inhibitors, inhibitors interfering with epigenetic mechanisms and signaling 
pathways (Bose & Verstovsek, 2017). Ongoing work will answer whether the use of these epigenetic 
therapies as alterative pathways in combination with JAK inhibitors may be more effective than single 
agent treatment (McPherson et al., 2017). 
Despite some controversies, current drug therapy for PMF is not curative and is unlikely to 
prolong survival, with allogeneic stem cell transplant, introduced during the 1970s and 80s, being the 
only treatment modality capable of achieving those aims. Therefore, it is recommended in either DIPSS-
plus intermediate-2 and high risk (ie, presence of at least three of the eight DIPSS-plus risk factors) or 
molecularly high risk disease (absence of type 1/type 1-like CALR mutation and presence of ASXL1 or 
related high risk mutation) (Figure 1.23) (Tefferi, 2016). However, it is associated with a substantial 
transplantation-related mortality (Abelsson et al., 2012; Ballen et al., 2010). 
There is no evidence to support the value of specific therapy in asymptomatic patients with 
DIPSS-plus low or intermediate-1 risk disease, however, such patients might require therapy. First-line 
drugs of choice in such patients are HU for symptomatic splenomegaly, androgens preparations, 
prednisone, danazol, thalidomide/prednisone or lenalidomide/prednisone and transfusions for 
symptomatic anemia, splenectomy (or splenic radiotherapy for nonsurgical candidates) in cases of 
splenomegaly resistant to conventional drug therapy, field radiotherapy for non hepatosplenic 
extramedullary hematopoiesis and associated pulmonary hypertension and ruxolitinib (and analgesics) 
for severe constitutional symptoms and bone pain that are resistant to HU therapy (Tefferi, 2016). 
Recommendations for assessing therapeutic response, morphologic remission, improvement 
of associated symptomatic burden and to facilitate the development of new and more effective drugs 
for PN-MPNs have been recently revised by the European Leukemia Net (ELN) and the International 
Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) groups, based on 
several studies that are ongoing (Barosi et al., 2013; Miller et al., 2017; Rumi & Cazzola, 2017; Tefferi, 
Cervantes, et al., 2013). In PV and ET, definitions of complete and partial remission incorporate clinical, 
hematological, and histological response assessments, including a standardized symptom evaluation 
and considering absence of vascular events and signs of disease progression (Barosi et al., 2013). In 
PMF the current criteria include stricter definitions of red cell transfusion dependency and independency 
and consideration of the Myeloproliferative Neoplasm Symptom Assessment Form as a tool to quantify 
meaningful changes in disease-related symptoms. These are organized in six response categories, 
namely complete remission and partial remission, corresponding to treatment effects that are consistent 
with disease modification, whereas drug-induced improvements in symptomatic burden are considered 
as clinical improvement, anemia response, spleen response, or symptoms response. Additional criteria 
are provided for progressive disease, stable disease, and relapse. To evaluate therapy response, there 
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are also included recommendations for assessing cytogenetic and molecular remissions, not required 
for complete remission assignment (Tefferi, Cervantes, et al., 2013). It is necessary to test for the driver 
mutations, but also for the other possible concomitant mutations (Rumi & Cazzola, 2017).  
Despite what was referred above and all the advances that have been achieved in the last few 
years, many unanswered questions remain. It is essential to well characterize PN-MPNs patients in 
terms of clinical phenotype and clinical outcome, and to proceed with investigation on molecular 
mechanisms involved, and their complex interactions, in order to a better clarification of the 
pathophysiology  of these diseases. This may allow the identification, in advance, of subgroups of 
patients  with a specified potencial therapeutic response, and at the same time make possible the 
elaboration of therapeutic strategies against new targets, more directed and efficient. These aspects 
represented one of the motivations for the elaboration of this thesis, as will be detailed below in Chapter 
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1.2 – INDIVUDUAL SUSCEPTIBILITY: GENETIC POLYMORPHISMS AND 
ASSOCIATION STUDIES 
Genetic variability has been for a long time recognized as a determinant modulator factor for 
susceptibility and development of disease, including cancer. It is based on the existence of DNA 
polymorphic variations that occur in the population, estimated between 106-107, including repetitions, 
deletions, insertions/duplications, indels, complex rearrangements and single nucleotide 
polymorphisms. These variations are distinct from mutations, which are associated to disease with a 
hereditary pattern of transmission, more frequently observed in the population (mutations > 1% vs 
polymorphisms <1%) (Tabor, Risch, & Myers, 2002).  
The most common polymorphisms are single nucleotide polymorphisms (SNPs) distributed 
throughout the genome, in exons, introns, intergenic regions and promoter regions. Thus, a SNP 
located in the coding region may directly affect a particular protein by substitution of an amino acid, a 
SNP located in intron-exon boundary can influence the process of splicing, while a SNP located in the 
promoter region may influence the expression of a gene. The vast majority of cases have two alleles, 
representing a substitution of a base to another.  For an individual SNP, one allele is designated as the 
most common or wild type, and the other as the least common or variant, based on the frequency 
observed in the general population (Crawford & Nickerson, 2005). 
Several SNPs have been identified, that may influence the normal gene “function” and, in turn, 
confer genetic predisposition to disease and determine therapeutic response. 
Although the individual effects of SNPs generally don’t have consequence, the genetic effect 
of combinations of relevant functional SNPs may additionally and synergistically contribute to the 
increased risk of cancer (Ponder, 2001). 
The specific combination of SNPs functional alleles that are in alignment on one of the two 
homologous chromosomes and are inherited in blocks is called haplotype (Crawford & Nickerson, 
2005).   
An individual is said to be homozygous at a given SNP locus if the two observed alleles are 
the same. Heterozygosity, on the other hand, refers to the presence of more than one allele at a given 
site. The term loss of heterozygosity (LOH), commonly used in the context of oncology, refers 
specifically to the loss of function of an allele, when a second allele is already inactive, through 
inheritance of the heterozygous genotype.  
The minor allele frequency (MAF), also referred to as the variant allele frequency, refers to 
the frequency of the less common allele at a variable site. 
Linkage disequilibrium (LD) measures the correlation between SNP alleles at sites in the 
same region of the genome, allowing to correlate short regions of the genome, with no need of 
genotyping all the possible allelic variants to detect an association between de different SNPs involved 
in a specific disorder, which means that knowledge of the genotype of one SNP predicts the genotype 
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of another SNP if the association between them exists (Crawford & Nickerson, 2005; Lewis & Knight, 
2012). 
Until some time ago the methodologies available for association studies allowed only the 
individual evaluation of a small number of polymorphisms, being an important tool in the detection of 
low penetrance alleles (Easton et al., 2007). However, advances in genotyping and sequencing 
technologies, coupled with the development of sophisticated statistical methods, have provided 
investigators novel opportunities to define the role of sequence variation and increase the predictability 
in the development of common human diseases.  
Due to the completion of human HapMap project (The International HapMap Consortium, 
2003),  and others such as SeattleSNP Variation Discovery Resource and SNP500 Project (Packer et 
al., 2006) and after the great development of high-throughput sequencing/genotyping methodologies in 
the last few years, the availability of an increasing amount of SNPs data and the discovery of novel 
genetic variants has increased the potential of human genetic association studies to identify in a 
genome-wide scale (genome-wide association studies - GWAS, also known as whole genome 
association study – WGAS) common, but also rare, variants underlying complex diseases such as 
cancer, including myeloproliferative disorders (Huh et al., 2010; Jouni et al., 2013; D. H. Kim et al., 
2011; Merker et al., 2013; Stadler, Gallagher, Thom, & Offit, 2010; Stadler, Thom, et al., 2010; Stadler, 
Vijai, et al., 2010; Van Bergen et al., 2010; Wray, Goddard, & Visscher, 2007).  
GWA studies compare the DNA of participants having varying phenotypes for a particular trait 
or disease and the resulting significant genetic association may be interpreted as either (1) direct 
association, in which the genotyped SNP is the true and direct causal variant conferring disease 
susceptibility; (2) indirect association, in which the genotyped SNP is in linkage disequilibrium (LD) with 
the true causal variant (Lewis & Knight, 2012). 
In these processes, statistical and computational methods play key roles, among which 
information-based association tests have gained large popularity (C. Wu, Li, & Cui, 2012).  
The first successful GWAS was published in 2005. It investigated patients with age-related 
macular degeneration and found two SNPs with significantly altered allele frequency compared to 
healthy controls. As of 2007, hundreds or thousands of individuals were tested in a typical GWA study, 
over 3,000 human GWA studies have examined over 1,800 diseases and traits, and thousands of SNPs 
associations have been found (C. Wu et al., 2012). 
Two strategies can be used when based in detection of SNPs. One based on the study of SNPs 
in genes putatively or known to be associated with the disease – the candidate gene approach, and 
as in the case of GWAS an agnostic one, whose conclusions rely on the statistical significance of the 
whole genome associations, in spite of the putatively (if any) role of the gene(s) on which the significant 
SNPs were found.  
At the forefront of these investigations is the use of dense maps of SNPs and the haplotypes 
derived from these polymorphisms, which are the principal focus on case-control association studies, 
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contributing to the identification of candidate genes associated with increased risk for cancer and other 
diseases development (Crawford & Nickerson, 2005; Syvänen, 2001; C. Wu et al., 2012). 
Therefore, the genetic association studies constitute a major tool to test for the eventual 
association between a disease status and the genetic variation in a series of  individuals, in order to 
identify candidate genes or genome regions that contribute to that specific disease (Lewis & Knight, 
2012). These studies allow to identify genes conferring susceptibility to complex disorders, including 
neoplasms, to which environmental factors  also contribute to susceptibility risk (Lewis & Knight, 2012). 
When a SNP allele or genotype is present at a higher frequency  in a group of individuals 
affected with a disease, this can be interpreted as meaning that the tested variant can be involved in 
increasing the risk for a specific disease (Lewis & Knight, 2012). Generally, multiple SNPs within a 
single gene are evaluated. Thus, polymorphic genotype frequencies are compared between groups 
with different phenotypes. The objective is to study which polymorphisms may be related to disease 
risk or which are in linkage disequilibrium with the causative variants (because recombination tends to 
occur in hot spots, making neighboring polymorphisms possibly related) (Easton et al., 2007).  
Most SNPs do not occur in the coding regions of the genes, thus not translating into an amino 
acid change in the protein. Although SNPs located at non coding regions may be also relevant, the few 
non-synonymous SNPs (occurring in the coding regions and translating into an amino acid change) are 
the subject of investigation because a change in an amino acid is presumed to lead to altered protein 
function (Crawford & Nickerson, 2005). 
In association studies SNPs are the most common tested markers, but other factors can also 
be tested, as microsatellite markers, insertion/deletions, variable-number tandem repeats (VNTRs), and 
copy-number variants (CNVs) (Lewis & Knight, 2012). 
Despite associations with polymorphisms in candidate genes have already been confirmed and 
reinforced by meta-analysis studies in many different diseases, such as diabetes, cardiovascular and 
autoimmune disorders (Berndt et al., 2016; Lohmueller, Pearce, Pike, Lander, & Hirschhorn, 2003), 
they have been identified many other novel associations in genes that until the moment were not 
considered as strong enough candidates for the disease under test. A modest increase in risk implies 
that large well-designed and analyzed studies are required to detect and confirm signals for association, 
leading to the need of improvement of SNP data analysis methodologies (Lewis & Knight, 2012; C. Wu 
et al., 2012) . 
The case–control study is the simplest study design used to test for association, in which a 
series of cases affected by the disease of interest are collected together with a series of control 
individuals that can be selected by different methods: the use of either a series of individuals who have 
been screened as negative for presence of the disease or randomly ascertained from the population, 
with unknown disease status, or a group of individuals with different phenotypes for a particular trait. 
This approach is known as phenotype-first, in which the participants are classified first by their clinical 
manifestation(s), as opposed to genotype-first (Lewis & Knight, 2012). The specific phenotype used for 
the cases selection may define the exact hypothesis to be tested, and the application of strict and 
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rigorous clinical criteria is necessary to ensure a homogeneous set of cases.  
Both last control sets form a valid test for association, and have similar power for a rare disease 
analysis. But when is necessary to evaluate a more common disease, a study with screened unaffected 
controls will have higher power to detect association compared with a study using population-based 
controls, and the increase in power is notable for diseases with high prevalence. For some diseases, 
screening controls for the presence or absence of the disease may be difficult, and using a larger 
sample of unscreened controls may be more efficient (Lewis & Knight, 2012). 
A sample of DNA is obtained from each person, from which millions of genetic variants are read 
using SNP arrays. If one type of the variant (one allele) is more frequent in people with the disease, the 
variant is said to be associated with the disease. The associated SNPs are then considered to mark a 
region of the human genome that may influence the risk of disease (Lewis & Knight, 2012). 
Other approaches to genetic association studies include family-based association studies and 
quantitative trait locus studies. 
In conclusion, by association studies carried out, it seems to exist clear evidence that SNPs 
may confer some significant risk increase in the development of the disease. However, the information 
obtained in risk analysis can be an asset into a preventive or therapeutic approach to the disease, 
although this may not be well established in all the situations (Tempfer, Hefler, Schneeberger, & Huber, 
2006). 
Part of the work developed and presented in this dissertation was based on case-control 
association studies. The obtained information came once again to demonstrate the usefulness and 
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1.3  – CASPASES AND APOPTOSIS 
The term "apoptosis" is derived from the Greek words "απο" and "πτωσιζ" meaning "dropping 
off", regarding to the falling of leaves from trees in autumn.  Since the description of apoptosis or 
programmed cell death process in the 1970’ by Kerr et al. (Kerr, Wyllie, & Currie, 1972), who linked this 
mechanism to the elimination of potentially malignant cells, hyperplasia and tumor progression, it 
remains one of the most challenging investigated processes in biologic research (Wong, 2011). 
Apoptosis is critically important during various developmental processes and its role in normal 
physiology is as significant as that of its complementary counterpart, mitosis. It is estimated that to 
maintain homeostasis in the adult human body, around 10 billion cells are made each day just to 
balance those dying by apoptosis. And that number can increase significantly when there is increased 
apoptosis during normal development and aging or during disease (Elmore, 2007). 
In contrast to necrosis, apoptosis is a highly selective process, generally characterized by 
distinct morphological characteristics (Table 1.9) and energy-dependent biochemical mechanisms, in 
which a cell pursues its live course until the moment that certain stimuli induce death (Elmore, 2007).  It 
constitutes a vital component of various cellular mechanisms, including normal cell turnover, proper 
development and functioning of the immune system and central nervous system, hormone-dependent 
atrophy, embryonic development, tissue homeostasis, chemical-induced cell death and removal of 
damaged cells, which are involved and condition both physiological and pathological states, such as 
inflammation and cancer (Elmore, 2007; Wong, 2011).  
 
Table 1.9 – Morphological features of apoptosis and necrosis. 
(Adapted from (Elmore, 2007). 
 
Apoptosis Necrosis 
Single or small clusters of cells Several, often contiguous cells 
Cell shrinkage and convolution Cell swelling 
Pyknosis and karyorrhexis Karyolysis, pyknosis, and karyorrhexis 
Intact cell membrane Disrupted cell membrane 
Cytoplasm retained in apoptotic bodies Cytoplasm released 
No inflammation Inflammation usually present 
 
 
Modifications in apoptotic genes caused by mutations or epigenetic modeling of gene 
expression and disruption of apoptosis mechanisms have been identified as a cause of the onset of 
some diseases, such as cancer, AIDS and other immune disorders, cardiovascular diseases, including 
stroke and other ischemic processes, other inflammatory disorders and neurodegenerative diseases 
(such as Alzheimer and Parkinson diseases) (S. G. Cho & Choi, 2002; Elmore, 2007).  
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Cancer is the result of successive genetic changes, during which a normal cell is transformed 
into a malignant one, associated to a loss of balance between cell division and cell death, with 
persistence of the malignant cells. Thus, cell growth is the result not only of uncontrolled proliferation 
but also of reduced cell death. Proteins that signal cell errors or aberrant growth signals arrest the cell 
cycle so that these errors can be repaired, or alternatively, for apoptosis to be induced. Malfunction in 
this system leads to the onset of cancer, allowing cells to proliferate when they should be repaired or 
die. Hence, reduced apoptosis or its resistance plays a vital role in carcinogenesis, existing many 
mechanisms by which cell evasion can occur: 1) disrupted balance of pro-apoptotic and anti-apoptotic 
proteins, 2) reduced caspase function and 3) impaired death receptor signaling (Wong, 2011). 
The clarification of apoptotic mechanisms in disease conditions is crucial, as it not only gives 
insights into the pathogenesis of a disease but may also provide clues on possible apoptotic genes or 
pathways targets for the development of drugs with great therapeutic potential (Elmore, 2007; McIlwain, 
Berger, & Mak, 2013; Wong, 2011). 
Robert Horvitz and Junying Yuan initially established the importance of caspases in apoptosis, 
in 1993. Caspases are a family of endoproteases that hydrolyze peptide bonds in a reaction that 
depends on catalytic cysteine residues in the caspase active site, which can result in substrate 
inactivation or generate active signaling molecules that participate in ordered processes such as 
apoptosis and inflammation (McIlwain et al., 2013). They can be organized into three functional groups: 
initiator, executioner and inflammatory caspases (Figure 1.24). 
Such as many other protein systems, initially caspases are synthesized as inactive zymogens, 
pro-caspases. Initiator caspases 8 and 9 inactive procaspase monomers are activated and gain 
catalytic activity following signaling events, promoting their aggregation into stable dimers or 
macromolecular complexes (Boatright & Salvesen, 2003). Executioner caspases 3, 6, and 7, also 
initially as inactive procaspase dimers, are cleaved by initiator caspases, which allows a conformational 
change that brings the two active sites of the executioner caspase dimer together and creates a 
functional mature protease (Riedl & Shi, 2004). Once activated, a single executioner caspase can 
cleave and activate other executioner caspases, leading to a chain reaction and accelerated feedback 
loop of caspase activation. Some procaspases can also aggregate and autoactivate. 
Activation of apoptotic caspases induce inactivation or activation of substrates, and the 
generation of a cascade of amplified signaling events permitting the cleavage of cellular components, 
in order to induce the morphological changes leading to rapid cell death (Elmore, 2007; McIlwain et al., 
2013; Wong, 2011).  
The other caspases that have been identified include the inflammatory caspases (caspase 1, 
4, 5), caspase 11, which is reported to regulate apoptosis and cytokine maturation during septic shock, 
caspase 12, which mediates endoplasmic-specific apoptosis and cytotoxicity by amyloid-β, caspase 
13, which is suggested to be a bovine gene, and caspase 14, which is highly expressed in embryonic 
tissues but not in adult tissues (Elmore, 2007). 
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Figure 1.24 – Caspases domain structures and functions. 




MECHANISMS OF APOPTOSIS  
 
As referred above, caspases are central to the mechanism of apoptosis. It is mediated via 
different highly complex pathways by which caspases can be activated, distinguished by the adapters 
and initiator caspases involved, being capable of inducing programmed cell death following exposure 
to apoptotic insults and the accumulation of excess DNA damage (Malherbe et al., 2016). 
The two commonly described initiation pathways are the intrinsic (or mitochondrial) and 
extrinsic (or death receptor) pathways of apoptosis, represented in Figure 1.25. Other apoptosis 
initiation pathways include the perforin/granzyme dependent pathway, P53 and the less well-known 
intrinsic endoplasmic reticulum pathway. The extrinsic, intrinsic and granzyme B pathways lead to a 
common pathway - the execution phase of apoptosis (Figure 1.25).  
The intrinsic pathway of apoptosis (Figure 1.25) is also known as mitochondrial apoptosis 
because it depends on factors released from the mitochondria, existing a growing evidence that this 
pathway is crucial for tumorigenesis (Brenner & Mak, 2009).  
 
 
GENETIC SUSCEPTIBILITY TO MYELOPROLIFERATIVE NEOPLASMS AND THERAPEUTIC EFFICACY  
 70 
 
Figure 1.25 – Diagrammatic representation of the extrinsic, intrinsic and perforin/granzyme apoptotic 
pathways.  




This pathway is activated by several cellular stresses, including growth factor deprivation, 
cytoskeletal disruption, DNA damage, accumulation of unfolded proteins, extremely high concentrations 
of cytosolic Ca2+, severe oxidative stress, hypoxia, hormones and many others (Brenner & Mak, 2009; 
McIlwain et al., 2013; Wong, 2011). Regardless of the stimuli, intrinsic apoptosis pathway is the result 
of increased mitochondrial permeability and the release of pro-apoptotic molecules such as 
cytochrome-c into the cytoplasm. This molecule binds an adaptor protein (apoptotic protease activating 
factor-1, APAF-1), in an independent way of its mitochondrial electron transport function, as it was 
demonstrated by Hao et al. in 2005 (Hao et al., 2005), and recruit initiator caspase 9 (via CARD-CARD 
interactions).This leads to the formation of a caspase activating multiprotein complex called the 
apoptosome, that will cleave and activate other executioner caspases, such as caspase 3 (Brenner & 
Mak, 2009; McIlwain et al., 2013; Wong, 2011). 
This pathway is closely regulated by a group of proteins belonging to the B-cell lymphoma 2 
(Bcl-2) family (Wong, 2011). These can be divided in two groups, namely the pro-apoptotic proteins 
(e.g. Bax, Bak, Bad, Bcl-Xs, Bid, Bik, Bim and Hrk) and the anti-apoptotic proteins (e.g. Bcl2, BclxL, 
Bcl-W, Bfl-1 and Mcl-1) (Wong, 2011). While the anti-apoptotic proteins regulate apoptosis by blocking 
the mitochondrial release of cytochrome-c, the pro-apoptotic proteins act by promoting such release. It 
is the balance between these pro- and anti-apoptotic proteins that determines whether apoptosis would 
be initiated (Wong, 2011). 
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Other molecules that are released from the mitochondrial intermembrane space into the 
cytoplasm with the capacity of induce caspase activation are apoptosis inducing factor (AIF), second 
mitochondria-derived activator of caspase (Smac), direct IAP Binding protein with Low pI (DIABLO) and 
Omi/high temperature requirement protein A (HtrA2) (Wong, 2011).  These molecules bind to inhibitor 
of apoptosis proteins (IAPs), subsequently leading to disruption of their interaction with caspase 3 or 9 
(Wong, 2011). One of the IAPs that specifically constrain the pro-death actions of caspase 9 via 
DIABLO, conferring a cytoprotective effect, is survinin. Downregulation has been associated with 
progressive disease and poor survival in both solid and hematological malignancies, both leukemias 
and lymphomas (Malherbe et al., 2016). 
In the extrinsic apoptopic pathway (Figure 1.25), the caspase cascade is also activated by 
extracellular ligands, via cell surface death receptors. Although several death receptors have been 
described, the best known are type 1 TNF receptor (TNFR1) and a related protein called Fas (CD95), 
and their ligands are TNF and Fas ligand (FasL), respectively. Others include death receptor 3 (DR3), 
TNF-related apoptosis-inducing ligand receptor-1 (TRAIL-R1; also called DR4), and TRAIL-R2 (also 
called DR5 in humans) (McIlwain et al., 2013; Wong, 2011). These death receptors have an intracellular 
death domain that recruits adapter proteins such as TNF receptor-associated death domain (TRADD) 
and Fas-associated death domain (FADD). Binding of the death ligand to the death receptor results in 
the formation of a binding site for an adaptor protein, with the formation of a multiprotein Death Inducing 
Signaling Complex (DISC) that recruits and activates pro-caspase 8 monomers (McIlwain et al., 2013; 
Wong, 2011). This could lead to either downstream activation of the intrinsic pathway by inducing 
mitochondrial stress, or direct activation of executioner caspases (3, 6 and 7) to degrade cellular 
components, depending on the cell type, based in their content of IAPs, which block executioner 
caspase function unless suppressed by proteins released from the mitochondria (Jost et al., 2009; 
Spencer, Gaudet, Albeck, Burke, & Sorger, 2009). In type I cells, caspase 8 initiates apoptosis directly 
by cleaving and thereby activating executioner caspases, while in type II cells, caspase 8 must first 
activate the intrinsic apoptotic pathway to induce efficient cell death (Samraj, Keil, Ueffing, Schulze-
Osthoff, & Schmitz, 2006). 
The granzyme B dependent pathway (Figure 1.25) involves the release of this protease, 
contained in specialized granules released by cytotoxic T lymphocytes or by natural killer cells, into 
certain target cells. Perforin is also released in those granules, induces oligomerization of cell 
membrane and facilitates the entry of granzyme B, which will participate in executioner caspases 
activation, namely caspase 3 (Taylor, Cullen, & Martin, 2008). 
Granzyme A is also important in cytotoxic T cell induced apoptosis and activates parallel 
caspase independent pathways, contributing to apoptosis by blocking the maintenance of DNA and 
chromatin structure integrity (Elmore, 2007). 
The intrinsic, extrinsic and granzyme B pathways converge on the same terminal, in the 
execution pathway (Figure 1.25). This pathway is initiated by the cleavage of caspase 3, which in turn 
cleaves the inhibitor of the caspase-activated deoxyribonuclease, which is responsible for nuclear 
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apoptosis. Caspase 3 is considered to be the most important of the executioner caspases and is 
activated by any of the initiator caspases (8, 9, or 10). In addition, downstream caspases induce 
cleavage of protein kinases, cytoskeletal proteins, DNA repair proteins and inhibitory subunits of 
endonucleases family. They also have an effect on the cytoskeleton, cell cycle and signaling pathways, 
which together result in DNA fragmentation, degradation of cytoskeletal and nuclear proteins, cross-
linking of proteins, formation of apoptotic bodies, expression of ligands and cell surface markers for 
phagocytic cell receptors and finally uptake by phagocytic cells, contributing to the typical morphological 
changes in apoptosis (Elmore, 2007; Wong, 2011). Although externalization of phosphatidylserine is a 
well-known recognition ligand for phagocytes on the surface of the apoptotic cell, some studies have 
shown that other proteins, such as annexin I and calreticulin that interact with phosphatidylserine, are 
also exposed on the cell surface during apoptotic cell clearance (Elmore, 2007). 
Another pathway of induction of apoptosis involves the P53 nuclear protein, which is activated 
in response to DNA errors. P53 is a regulator of cell cycle, inducing arrest of cell cycle, senescence 
and promoting DNA repair mechanisms. Failing these, p53 activates the intrinsic apoptotic cascade by 
binding Bak/Bax to induce cytochrome-c release, simultaneously inhibits antiapoptotic Bcl2-related 
proteins and survinin (Malherbe et al., 2016) and triggers transcription of genes whose products 
produce reactive oxygen species (Ding et al., 2000; Vousden & Lane, 2007). 
The intrinsic endoplasmic reticulum (ER) pathway is a third pathway and is less well known, 
which is believed to be caspase 12-dependent and mitochondria-independent. When the ER is injured 
by cellular stresses such as hypoxia, free radicals or glucose starvation, there is misfolding of proteins, 
leading to ER stress and reduced protein synthesis in the cell, and an adaptor protein known as TNF 
receptor associated factor 2 (TRAF2) dissociates from procaspase 12, resulting in the activation of the 
latter (Wong, 2011). In turn, caspase 12 activates caspase 9 and ER stress. 
 
 
CASPASES AND CANCER  
 
Tumor cells can acquire resistance to apoptosis by the expression of anti-apoptotic proteins 
such as Bcl2 or by the down-regulation or mutation of pro-apoptotic proteins such as Bax, whose 
expression is regulated by the p53 tumor suppressor gene. Another method of apoptosis suppression 
in cancer involves evasion of immune surveillance (Elmore, 2007). 
Deregulation of caspases and their pathways is involved in the persistence of mutated cells 
and promote tumorigenesis. However, several studies have shown that the inactivation of individual 
caspases is not usually sufficient to either interrupt the caspase cascade, or to disturb alternative 
nonapoptotic cell death mechanisms. Instead, malignant cells appear to more frequently gain a survival 
advantage by inactivating signaling mediators involved in caspase activation (McIlwain et al., 2013). 
Despite the above, the reduced expression of proapoptotic caspases has been reported in a 
great diversity of neoplasms, and specific inactivating mutations, although not frequent, have been 
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linked to various tumor types and stages of transformation. Moreover, certain caspase polymorphisms 
thought to affect caspase abundance or activity have been associated with variable effects on 
tumorigenesis (McIlwain et al., 2013). 
Alterations in caspase biology, including caspase 8 (extrinsic) and caspase 9 (intrinsic), have 
been implicated in a number of malignancies in humans and animal models.  
In caspase 8 deficient mice, B-lymphocytes have impaired cytokinesis and chromosomal 
instability. Isolated, caspase 8 polymorphisms have been associated to multiple cancers, including with 
brain tumors (neuroblastoma) (Cacina et al., 2015; Rihani et al., 2014), non-Hodgkin lymphoma (Lan 
et al., 2009) and in a published meta-analysis study to breast, lung and gastrointestinal cancers 
susceptibility (Ji, Li, Cui, & Wang, 2014; McIlwain et al., 2013; Sun et al., 2007). Another study provided 
evidence that FAS-FASL-CASP8 polymorphisms contributed to a reduced risk of childhood acute 
lymphoblastic leukemia (Tong et al., 2012). 
Both caspase 8 and caspase 9 are potentially important in regulating megakaryocyte turnover 
in the MPNs. In megakaryocytes, caspase 9 activity appears necessary for proplatelet formation and 
caspase 9 loss may enhance the tumorigenic potential of megakaryocytes, promoting their hyperplasia 
and thrombocytosis (Malherbe et al., 2015; Malherbe et al., 2016). The pathobiological basis underlying 
these numerical and morphological megakaryocytic abnormalities is thought to result from multiple 
molecular disruptions promoting proliferation and enhancing survival. Although the mechanism is not 
well clarified, frameshift lesions targeting CALR may disrupt megakaryocyte apoptosis, through its 
inability to facilitate caspase 8 activation and antiapoptotic protein cleavage (Malherbe et al., 2016). 
These megakaryocytes have impaired death mechanisms conferred by overexpression of antiapoptotic 
BclxL and reductions in pro-death BNIP-3. These changes are universal in PN-MPNs, but there are 
differences between entities. Megakaryocytes in ET have been shown to have a more proliferative 
profile, whereas in PMF they exhibit greater proapoptotic impairment. These changes occur irrespective 
of the JAK2 V617F or CALR driver mutations, although those with a CALR lesion have greater 
proapoptotic dysfunction (Malherbe et al., 2015). 
Caspase pathway genes are highly polymorphic and its occurrence have been correlated to 
several disorders. Caspase 9 gene polymorphisms and its downregulation are associated with solid 
tumors and their malignant progression. Alterations of caspase 9 gene and SNPs have been linked to 
non-Hodgkin’s lymphoma and lung cancer (McIlwain et al., 2013). For instance, a recently published 
manuscript come to reinforce the role of caspase 9 gene polymorphisms in the severity of prostate 
cancer (Yilmaz, Yencilek, Yildirim, Yencilek, & Isbir, 2017) and renal cell carcinoma (Marques et al., 
2013). In a study developed in papillary thyroid carcinoma patients, caspase 9 was observed to be 
associated with susceptibility to the disease, while Bcl2 polymorphism evidenced to play a protective 
role (Y. X. Wang, Zhao, Wang, Liu, & Yu, 2012). Cingeetahm et al. also reported its association with 
AML (Cingeetham et al., 2014).  
It is also well known the association of caspase 8 and 9 genes polymorphisms with clinical and 
molecular phenotypes in breast cancer (Brynychová et al., 2016). Both caspase 8 and 10 
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polymorphisms seem to be associated with breast cancer and melanoma (Frank et al., 2005; C. Li et 
al., 2008; MacPherson et al., 2004; McIlwain et al., 2013; H. L. Park et al., 2016). 
Caspase 7 polymorphisms have been associated to cervical cancer (Shi et al., 2015) and 
gastric adenocarcinoma (M. Y. Wang et al., 2013). Park et al. also demonstrated that there is 
association between caspases 7 and 14 genetic polymorphisms and the risk of childhood leukemia 
(Park et al., 2012). 
Polymorphisms in caspase 3 gene have also been associated with lung cancer (David, O'Shea, 
& Kundu, 2007; Lin et al., 2016), esophageal squamous cell carcinoma (Z. Zhang et al., 2012) and 
hepatocellular carcinoma (Deng et al., 2016), as it has been described by several authors.  
Another study reported an association of death receptor 4, caspases 3 and 5 genes 
polymorphisms with increased risk to bladder cancer (Mittal et al., 2011). Caspases 3 and 9 
polymorphisms were found to play a protective role in multiple myeloma (Hosgood et al., 2008), further, 
variants in  caspases 3, 8 and 10 were associated with a decreased risk of marginal zone lymphoma 
and variants in caspases 3 and 10 were associated with a lower risk of chronic lymphocytic leukemia 
and related subtypes (Lan et al., 2007). 
Caspases 1, 4, 5 and 6 have been associated with cancers of colonic or gastric origin and rare 
caspase 10 mutations have also been detected in cases of T-cell acute lymphoblastic leukemia and 
multiple myeloma, as well as in colon, breast, lung, hepatocellular and gastric cancers (McIlwain et al., 
2013). On the other hand, no association was found between caspase 10 polymorphisms and 
susceptibility to lymphoma, myeloma, melanoma, or lung cancer, as it was reported in a meta-analysis 
study (S. Yan et al., 2012).   
Chapters 7 and 9 of this dissertation are dedicated to the study of polymorphisms in caspases 



















CHAPTER 1: GENERAL INTRODUCTION 
 75 
1.4 – GENETIC LESION REPAIR: BASE EXCISION REPAIR 
Organisms’ genome stability is crucial, but every day this equilibrium is subject to the test of 
constant threats. Our cells are systematically exposed to insults, estimated to account daily for 104 
events per cell, from various endogenous and environmental damaging agents, capable of modify the 
structural properties of DNA bases, induce lesion and alter or eliminate fundamental cellular processes, 
such as DNA replication or transcription, and compromise cell viability   (Baute & Depicker, 2008).  
DNA is susceptible to several forms of endogenous damage, such as spontaneous hydrolysis 
(Lindahl, 1993), chemical modification by reactive molecules that are created during normal cellular 
metabolism (ex: reactive oxygen species – ROS, reactive nitrogen species, alkylation) (Apel & Hirt, 
2004; De Bont & van Larebeke, 2004; Marnett, 2000) and physiological DNA processing reactions (ex: 
replication, DNA repair processes themselves) (Bridges, 2005; McCulloch & Kunkel, 2008; Shimizu et 
al., 2003). 
Reactive oxygen species produced during cell metabolism can react randomly with lipids, 
proteins and nucleic acids causing oxidative stress and lesions in these macromolecules. The great 
consequence of oxidative stress, in fact, are the DNA lesions responsible for great genomic instability 
(Maynard, Schurman, Harboe, de Souza-Pinto, & Bohr, 2009).  
Besides the numerous endogenous sources of DNA damage, cellular DNA is also under 
constant attack from exogenous or environmental DNA-damaging agents. These include physical 
stresses, such as ultraviolet light (UV) from the sun (Ravanat, Douki, & Cadet, 2001), ionizing radiation 
(Ward, 1988) and chemical agents (Irigaray & Belpomme, 2010; Wogan, Hecht, Felton, Conney, & 
Loeb, 2004) 
DNA lesions commonly include base and sugar modifications, single- and double-strand 
breaks, DNA-protein cross-links, and base-free sites. Specific DNA lesions can also induce mutations 
that cause cancer or other diseases as well as contribute to the aging process (Dexheimer, Antony, 
Marchand, & Pommier, 2008). 
Depending on the type of damage inflicted on the DNA's double helical structure, and to 
counteract the deleterious effects of DNA damage, a complex set of cellular responses are elicited, 
through a developed and specialized DNA repair system, that senses the DNA damage, signals its 
presence, and mediates its repair, in order to restore lost information. The importance of this mechanism 
is underscored by the prevalence of neurological and cancer susceptibility disorders, such as Ataxia-
telangiectasia, Fanconi anemia, and Xeroderma pigmentosum, that are caused by DNA repair 
deficiencies (McKinnon, 2009).  
In hematopoietic system, DNA damage to precursor cells would appear to be essential to 
malignant transformation and leukemia development, notwithstanding DNA repair systems act to repair 
the DNA damage, thus maintaining genetic integrity (Batar et al., 2009; Bănescu et al., 2014).  
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This coordinated system can be subdivided into five distinct mechanisms based on the type of 
DNA lesion (Baute & Depicker, 2008).  
When only one of the two strands of the double helix is affected, the other strand can be used 
as a template to guide the correction of the damaged strand. There exist a number of excision repair 
mechanisms that remove the damaged nucleotide and replace it with another, which is   complementary 
to that found in the undamaged DNA strand - base excision repair, mismatch repair and nucleotide 
excision repair (Figure 1.26). 
Double-strand breaks, in which both strands in the double helix are severed and neither strand 
can then serve as a template for repair, can lead to genome rearrangements and are particularly 
deleterious to cells. Mechanisms to repair this type of lesions comprise both homologous recombination 
and non-homologous end-joining pathways (Figure 1.26).  
 
 
Figure 1.26 – DNA damage agents and repair mechanisms. 
GG – Global genomic; TC – Transcription coupled repair (Adapted from (Boland, Luciani, Gasche, & Goel, 2005). 
 
 
In this dissertation, base excision repair (BER) pathway will be focused in more detail below. 
The other pathways will be briefly described next. 
Mismatch repair pathway is present in essentially all cells to recognize and repair erroneous 
insertion, deletion, and mis-incorporation of bases that can arise during DNA replication and 
recombination, as well as repair of other forms of DNA lesion. This system consists of at least two 
proteins, in which one detects the mismatch, and the other recruits an endonuclease that cleaves the 
newly synthesized DNA strand close to the region of damage. This is followed by removal of damaged 
region by an exonuclease, re-synthesis by DNA polymerase, and nick sealing by DNA ligase (Larrea, 
Lujan, & Kunkel, 2010). 
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Nucleotide excision repair pathway is a highly evolutionarily conserved repair mechanism, 
repairing damaged DNA which commonly consists of bulky, helix-distorting damage, such as pyrimidine 
dimerization caused by UV light. Damaged regions are removed in 12-24 nucleotide-long strands in a 
three-step process which consists of recognition of damage, excision of damaged DNA by 
endonucleases, both upstream and downstream of damage site, and re-synthesis of removed DNA 
region (Reardon & Sancar, 2006).  
Non-homologous end joining pathway repairs double-strand breaks in DNA. It is referred to 
as "non-homologous" because the break ends are directly joined without the need for a homologous 
template. This pathway typically uses short homologous DNA sequences called microhomologies to 
guide repair, which are often present in single-stranded overhangs on the ends of double-strand breaks. 
When the overhangs are perfectly compatible, usually the break is repaired accurately. Imprecise repair 
leading to loss of nucleotides can also occur, but is much more common when the overhangs are not 
compatible (Budman & Chu, 2005). This pathway dysfunction can lead to translocations and telomere 
fusion, both involved in tumorgenesis (Espejel et al., 2002). 
In contrast, homologous repair pathway requires a homologous sequence to guide repair, in 
which nucleotide sequences are exchanged between two similar or identical molecules of DNA, to 
accurately repair harmful breaks that occur on both strands of DNA (double-strand breaks). This 
pathway also produces new combinations of DNA sequences during meiosis, representing genetic 
variation.  Although it varies widely among different organisms and cell types, most forms involve the 
same basic steps. After a double-strand break occurs, sections of DNA around the 5’ ends of the break 
are resected, followed by an overhanging 3’ end of the broken DNA molecule that "invades" a similar 
or identical DNA molecule that is not broken. Homologous recombination that occurs during DNA repair 
tends to result in non-crossover products, in effect restoring the damaged DNA molecule as it existed 
before the double-strand break (Jasin & Rothstein, 2013). 
Several polymorphisms in DNA repair genes have been identified, with the capacity of affect 
protein function and thus DNA damage repair, leading to susceptibility to malignancy, in spite of their 
low genetic penetrance (Batar et al., 2009; Bolufer et al., 2006; Bănescu et al., 2014; Hoeijmakers, 
2001; C. Q. Wang et al., 2014). A nucleotide excision repair gene polymorphism displayed strong 
association with leukemic transformation and development of non-myeloid malignancies in patients with 
ET and PV (Hernández-Boluda et al., 2012). 
Moreover, the DNA damage theory of aging, supported by several review articles, proposes 
that aging is a consequence of deficient DNA repair, resulting in the accumulation of naturally occurring 
DNA lesions. On the other hand, an increased DNA repair facilitates greater longevity (Best, 2009; M. 
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BASE EXCISION REPAIR PATHWAY 
 
The base excision repair (BER) pathway is critical in maintaining genomic integrity. It is the 
predominant pathway for recognizing, excising, and repairing a broad range of small lesions of a single 
base resulting from oxidation, methylation, deamination alkylation, and hydroxylation, caused by free 
radicals formed endogenously or after exposure to exogenous agents such as ionizing radiation, which 
do not significantly distort the overall structure of the DNA helix (Hoeijmakers, 2001; Wilson, Kim, 
Berquist, & Sigurdson, 2011; Zharkov, 2008). 
This pathway recognizes and repairs modified bases, as well as apurinic/apyrimidinic sites 
(APs) and single-stranded DNA breaks, mostly produced by ROS (Maynard et al., 2009). 
DNA bases are very sensitive to ROS oxidation, especially guanine because of their low redox 
potential, so one of the best characterized ROS-generated lesions is 8-hydroxyguanine (8-oxoG), a 
highly mutagenic lesion (Maynard et al., 2009). 
BER is typically initiated by the series of lesion-specific DNA glycosylases that recognize and 
remove the specific damaged or inappropriate base, forming AP sites. These are then cleaved by an 
AP endonuclease and the resulting single-strand break can then be processed by either short-patch or 
long-patch BER, by which the new strand is correctly synthesized using the complementary strand as 
a template (Figure 1.27) (Liu et al., 2007). 
BER is described as a highly coordinated pathway of consecutive enzymatic reactions, 
involving several proteins, such as 8-oxoguanine DNA glycosylase (OGG1), earlier mutY homolog (E. 
coli) (MUTYH), apurinic/apyrimidinic endodeoxyribonuclease 1 (APEX1), X-ray repair complementing 
defective repair in Chinese hamster cells 1 (XRCC1) or poly (ADP-ribose) polymerase (PARP1 and 
PARP4) (Baute & Depicker, 2008), that act to detect the lesion, remove the single damaged base, and 
fill in the resulting single-stranded gap using the intact complementary strand as template (Hoeijmakers, 
2001; Hung, Hall, Brennan, & Boffetta, 2005; Wilson et al., 2011).  
The BER pathway presents two sub-pathways depending on the type of damage encountered 
at the onset as well as throughout the BER process, and the enzymes involved in this response: the 
shorter and more frequent Short-patch BER, where a single nucleotide is replaced, and the Long-patch 
BER, usually to repair a lesion between 2 to 10 nucleotides that are synthesized (Figure 1.27) 
((Hoeijmakers, 2001; Y. J. Kim & Wilson, 2012; Maynard et al., 2009; Sancar, Lindsey-Boltz, Unsal-
Kaçmaz, & Linn, 2004). Each pathway shares a set of common elements and generally invokes the five 
following steps (Y. J. Kim & Wilson, 2012):  
1) Recognition and removal of an incorrect or damaged substrate base by a DNA glycosylase, 
to cleave the sugar–nitrogen base bond, to delete the base and create an abasic site (AP site) in the 
DNA strand. Each DNA glycosylase has its unique specificity, according to the type of lesion to be 
repaired, and many of them are ubiquitous in microorganisms, mammals, and plants (Baute & Depicker, 
2008). There are DNA glycosylases that recognize oxidized/reduced bases, alkylated bases (usually 
methylated), deaminated bases and mismatch bases (Maynard et al., 2009; Sancar et al., 2004). Their 
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classification is based on their reaction mechanisms, some act as simple glycosylases catalyzing the 
base removal reaction forming an AP site, which will involve the action of another enzyme with lyase 
function (usually APE1) responsible for the cleavage of the chain, while others play the dual glycosylase 
and AP lyase function; 
2) Intermediate abasic site incision by an AP endonuclease or AP lyase; 
3) Removal of the remaining sugar fragment by a lyase or phosphodiesterase; 
4) Gap filling by a DNA polymerase. When the injured base is removed by a glycosylase/AP 
lyase, responsible for the cleavage of the 3'-phosphodiester bond of the abasic site, the APE1 
endonuclease breaks the 5' bond and recruits the DNA Polymerase β (Polβ) which will fill the gap 
formed, the chain binding being effected by the Ligase 3/XRCC1 complex. When the AP site is 
generated by spontaneous hydrolysis, the 5'-phosphate group becomes modified and becomes 
resistant to Polβ elimination, with repair continuing through the long-patch route; 
5) Sealing of the nick by a DNA ligase. After recognition of the lesion, a PCNA/DNA polymerase 
complex δ/ε (Pol δ / ε) is recruited, responsible for adding more nucleotides to the 3' end of the AP site, 
forming a loop that is removed by an endonuclease (FEN1), followed by junction of DNA ends by DNA 




Figure 1.27 – BER pathway. 
LP – Long patch; SP – Short patch. Adapted from (Y. J. Kim & Wilson, 2012). 
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OGG1 is a DNA glycosylase enzyme responsible for the excision of 8-oxoguanine (8-oxoG), a 
mutagenic base byproduct that occurs as a result of exposure to ROS. OGG1 is a bifunctional 
glycosylase, as it is able to both cleave the glycosidic bond of the mutagenic lesion and cause a strand 
break in the DNA backbone (Bjørås, Seeberg, Luna, Pearl, & Barrett, 2002).  
OGG1 facilitates removal of these lesions, producing an AP site in the DNA, that is 
subsequently incised by AP-endonuclease 1 (APE1). APE1 is a multifunctional protein involved in 
stimulation of turnover of several glycosylases by accelerating rate-limiting product release, in base 
excision repair function in its C-terminal domain, and in the redox regulation of transcription factors in 
its N-terminal domain, converting certain transcription factors from inactive oxidized to active reduced 
forms (Parker et al., 2001).  
MUTYH glycosylase is also involved in oxidative DNA damage repair. The enzyme excises 
adenine bases from the DNA backbone at sites where adenine is inappropriately paired with guanine, 
cytosine, or 8-oxo-7,8-dihydroguanine, a major oxidatively damaged DNA lesion. The protein is 
localized to the nucleus and mitochondria (Parker et al., 2001).  
XRCC1 protein is involved in repair of DNA single-strand breaks, formed by exposure to 
ionizing radiation and alkylating agents (base excision repair and nucleotide excision repair), interacting 
with DNA ligase III, polymerase beta and poly(ADP-ribose) polymerase, without individual enzymatic 
activity (London, 2015). But it also has an essential role in double strand breaks repair (homologous 
repair pathway) (Sharma et al., 2015). 
PARP1 has a role in repair of single-stranded DNA breaks, and in conjunction with BRCA acts 
on double strands (homologous repair pathway) (Sharma et al., 2015). It modifies various nuclear 
proteins by poly(ADP-ribosyl)ation and is involved in the regulation of various important cellular 
processes such as differentiation, proliferation, and tumor transformation. Besides DNA repair, PARP1 
also functions as a transcriptional regulator, acts on chromatin remodeling complexes to control DNA 
accessibility for RNA polymerase, and functions as a transcription factor by binding an octamer motif in 
promoter elements to regulate gene expression (Ko & Ren, 2012). 
PARP4, the largest protein of PARP family, is involved in DNA repair and cell cycle regulation 
(Perina et al., 2014). 
In addition to the enzymes referred to as participants in this repair pathway, other protein 
factors have been identified as modulators of BER pathway activity. These auxiliary proteins may 
interact with the major pathway and/or DNA proteins, in order to increase the enzymatic activity or the 
efficiency of the reactions (Fan & Wilson, 2005; Maynard et al., 2009). Among the vast array of proteins 
is emphasized the action of p53, a tumor suppressor protein, which is presumed to facilitate the binding 
activity of Polβ to DNA; and MSH2/MSH6 mismatch recognition complex, that seems to promote the 
repair of the damaged base “marked” to be repaired by BER pathway (Fan & Wilson, 2005). 
BER protects against cancer, aging, and neurodegeneration and takes place both in nuclei and 
mitochondria. More recently, an important role of uracil-DNA glycosylase UNG2 in adaptive immunity 
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was revealed. Furthermore, other DNA glycosylases may have important roles in epigenetics, thus 
expanding the repertoire of BER proteins (Krokan & Bjørås, 2013). 
Previous reports have identified several polymorphisms identified in the XRCC1, OGG1, 
MUTYH, APEX1 and PARP1 genes as being associated with individual susceptibility to several types 
of cancer, including breast, lung, colorectal and skin cancers (Hoeijmakers, 2001; Hung et al., 2005; 
Silva et al., 2007; Wilson et al., 2011; L. Yan, Li, Li, Ji, & Zhang, 2016). However, except for XRCC1 
polymorphisms, it seems that there is no association between BER and thyroid cancer (Santos et al., 
2012). 
Moreover, several polymorphisms in genes of the BER pathway [APEX1, MUTYH, OGG1, 
PARP1, PARP4 and XRCC1] have been identified and studied for their association with the risk of 
leukemia and disease outcome (Annamaneni et al., 2013; Bolufer et al., 2006; Bănescu et al., 2014). 
More considerations related to each one of the several polymorphisms in genes of the BER 
pathway will be discussed in more detail in Chapters 8 and 9 of this dissertation, dedicated to the 
presentation of results obtained on the study of polymorphisms in BER genes and their possible 
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CHAPTER 2: STUDY AIMS AND STRUCTURE  
 
2.1 – STUDY AIMS 
As previously mentioned, the molecular factors that set up and prepare clonal proliferation in 
PN-MPNs remain an important diagnostic criterion according to WHO. Besides, there is evidence that 
the phenotypic diversity of PN-NMPs results from the combination of several factors, namely somatic 
mutations, some of them already identified and characterized, inherited genetic variability, postgenetic 
regulation, and individual conditioners. Identification of the JAK2 V617F mutation developed the 
knowledge of PN-MPNs, contributing to and influencing the definition of the phenotype and prognostic 
impact. 
According to the literature, several SNPs have been identified (ex: polymorphisms associated 
with DNA repair pathways and apoptosis), influencing genetic transcription and/or cell function, which 
may confer genetic predisposition to disease, although less specific than known variations. Not 
all mutations involved in cancer may lead to cancer. This can occur due to different variants within the 
same gene or between variants in different genes. The latter must be considered, as the number of 
passenger mutations in a tumour may modulate the effect of driver mutations, thus acting as putative 
modifier genes. Additionally, epimutations that can silence tumour-suppressor genes must be taken 
into account, which highlights the concept that, probably more important than the genes, are their 
expression levels. 
Independently of what mutation is involved in the development of MPNs, or even if the 
molecular trigger is not known, one of the major points is that hyperactive JAK/STAT signaling pathway 
appears to be a constant. This pathway induces a proliferative activity, but is also characterized for 
having an anti-apoptotic effect, through the upregulation of anti-apoptotic proteins involved in the 
regulation of the caspases that integrate apoptosis pathway. Particularly in PN-MPNs, it appears that 
the deregulation of apoptosis is involved in the pathophysiology of these diseases. 
DNA repair is a ubiquitous process in all living systems. Its universality reflects the constant 
pressure that leads to altered genome integrity resulting from the intrinsic instability of the genetic 
material and limitations on the fidelity of DNA replication. Several agents induce different types of 
lesions in the DNA and according to the lesion they will create and activate a set of proteins responsible 
for the efficient repair of the lesion. Endogenously produced metabolites are also capable of acting as 
carcinogenic agents, in particular ROS, which may be formed by different pathways, or exogenously 
the exposure to genotoxic compounds. These processes can induce specific types of DNA lesion, 
whose repair mechanisms are related to the BER pathway. 
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On the other hand, therapeutic exposure and enviroment factos may lead to modifications at 
the genome level, leading to changes in cell cycle regulation. The universality of the apoptosis and DNA 
repair processes reflects the constant challenge to genome integrity and cell function, given the inherent 
instability of DNA, the natural limitations in DNA synthesis, and interferences in cell cycle. The 
susceptibility to PN-MPNs, therapeutic response and clinical outcome, influencing the prognosis, may 
be mediated, in part, by the genetic variability of genes involved in these pathways. The vast majority 
of the proteins described as being involved are polymorphic enzymes, so changes in the genes 
encoding them may compromise their performance, thus contributing to changes in repairability and 
interfering with mechanisms of programmed cell death and concomitantly create genomic instability into 
cells. Moreover, despite the development of more efficient drugs in the last years, some patients with 
PN-MPNs still progress to conditions more aggressive and difficult to treat such as myelodysplasia, 
myelofibrosis and acute leukemia. 
Concerning the study of the association of polymorphisms with PN-MPNs, the data is scarce. 
The use of population-based association studies, known as case-control studies, through the 
investigation of candidate genes, is a very useful tool that allows the evaluation of the potential 
association of polymorphic genes to a given disease in a population.  
On the other hand, in our country in the last few years several efforts have been done to create 
registries and databases that allow us to organize the relevant data about these patients and 
characterize them, but the amount of Portuguese epidemiological data is scarce and there is still a long 
way to go in this direction. 
Thus, the aims of the present study that conducted to this dissertation consisted of: 
1) Contribute to a database of patients with PN-MPNs, referred to Hematology Consultation 
from Hospital São Francisco Xavier, Centro Hospitalar Lisboa Ocidental (CHLO); 
2) Characterize these patients versus a healthy population in terms of PN-MPNs epidemiology 
and prevalence of JAK2 mutation, and evaluate in the patients population their clinical phenotype and 
clinical outcome, which can be to a certain extent the reflexion of Portuguese state of the art in what 
concerns to this group of disorders; 
3) Present the case of some patients which stood out for some particularity; 
4) Carry out case-control studies in the referred population, with the selection of candidate 
genes that code for proteins with eventual potential involvement in PN-MPNs susceptibility: apoptosis 
and the BER pathway; 
5) To evaluate among the patients under treatment the role of the presence of JAK2 V617F 
mutation, other risk factors and polymorphisms in genes involved in apoptosis and BER pathway, in 
terms of disease progression to mielofibrosis/AML, predisposition to the development of new 









2.2 – STUDY STRUCTURE 
This study has been developed, since the beginning of 2009, in the Centre for Toxicogenomics 
and Human Health, Genetics, Oncology and Human Toxicology (ToxOmics), NOVA Medical 
School/Faculdade de Ciências Médicas from Universidade Nova de Lisboa, in collaboration with the 
Clinical Pathology Department, from Hospital de São Francisco Xavier, Centro Hospitalar de Lisboa 
Ocidental (HSFX, CHLO), which is actively involved in the diagnosis and characterization of this group 
of disorders. The study also has the collaboration of the Clinical Hematology Department of the HSFX, 
namely in the selection and follow-up of patients, in the therapeutic institution and in the correlation of 
laboratory results with clinical data. 
The author has fully participated in the conception of the research project, selection and 
clinical/laboratorial evaluation of the patients, execution of the experimental work and interpretation of 
the results. 
Initially, it was thought to apply this study to MPNs both BCR-ABL1 positive and negative, but 
it turned out to be limited to the study of PN-MPNs only, namely PV, ET and PMF. BCR-ABL1 CML had 
been investigated and was genetically well characterized in some of its aspects by our group and the 
results are published (Dinis et al., 2012; Gromicho et al., 2016; Gromicho et al., 2013; Gromicho et al., 
2011; Rodrigues et al., 2012)*. The mechanisms of PN-MPNs pathogenesis had begun to be explored 
more recently and information about this theme was scarce. Moreover, regarding therapy management 
and clinical outcome, imatinib and the other tyrosine kinase inhibitors discovery brought to BCR-ABL1 
CML patients better quality of life, better disease control and increased survival, almost curative for 
some patients. Whereas, for PN-MPNs the used drugs were not so successful, with the bone marrow 
transplant being the only option to MF, with many patients evidencing disease progression to clinical 
presentations more difficult to control, remaining a great challenge. 
The present study involved 133 Caucasian Portuguese PN-MPNs patients and 281 age- and 
sex-matched control subjects (at least two for each patient), selected since January 2009 to July 2016  
within the Portuguese population recruited at the Departments of Clinical Hematology and of Clinical 
Pathology, HSFX, CHLO, where those individuals were admitted, followed up and treated.  
Patients and healthy controls were selected and a questionnaire was administered to each one 
of the participants (Appendix 1), properly authorized and signed for informed consent, after clarification 
on the nature and objectives of the study by trained interviewers, prior to blood withdrawal and in 
agreement with the Declaration of Helsinki. This questionnaire aimed to characterize epidemiologically 
these disorders and to evaluate some important risk factors associated with susceptibility to their 
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Complete inquiries and respective blood samples were than transferred to the Centre for 
Toxicogenomics and Human Health, Genetics, Oncology and Human Toxicology (ToxOmics), for DNA 
extraction and analysis.  
During the accomplishment of this work, a database has been prepared and organized to 
compile epidemiological, clinical and laboratory data and the obtained results. 
All clinical and hematologic data were obtained from registries of patients, whose hematological 
data was diagnosed with the contribution of the author, and patients were selected on the basis of 
diagnostic criteria for this group of disorders.  
In order to accomplish the aims of this study, we proceed to the selection and identification of 
genetic polymorphisms, from public databases, potentially related to PN-MPNs individual genetic 
susceptibility, clinical outcome and prognostic impact, namely polymorphisms of genes involved in 
apoptosis and BER pathway. 
With regard to apoptosis, nine polymorphisms of four caspases genes were selected and 
genotyped, namely rs1045485 and rs1035142 (CASP8), rs1052576, rs2308950, rs1820204 and 
rs1052571 (CASP9), rs2227309 and rs2227310 (CASP7) and rs13006529 (CASP10). 
Concerning BER pathway, the following eight polymorphisms of six genes were selected and 
genotyped, namely rs1799782 (XRCC1_194), rs25487 (XRCC1_399), rs1052133 (OGG1), rs1136410 
(PARP1), rs13428 and rs1050112 (PARP4), rs1130409 (APEX1) and rs3219489 (MUTYH). 
Regarding the methodology to be used for analysis, all polymorphisms were evaluated using 
Real-time Polymerase Chain Reaction (PCR), and TaqMan genotyping assays specific to each SNP 
under study, according to the manufacturer's instructions and optimizing aspects previously achieved 
trough the evaluation of genetic polymorphisms in the area of breast cancer, in which the working group 
presented a vast experience. Statistical analysis of obtained data was performed using SPSS software 
version 22.0 (SPSS Inc.). 
More details of each step of this study will be provided in the following Chapters. 
The validation of the obtained results and the disclosure of the work that was carried out has 
been done through the publication of manuscripts in international indexed journals with peer-review and 
through their presentation in conferences dedicated to Genetics, Hematology and Laboratory fields. 
The current study was conducted with approval by the Institutional Ethics’ Commissions of the 
involved institutions, namely CHLO (approved the 6th April 2009) and Nova Medical School (approved 
the 27th November 2015) (Appendix 2 and 3), and  since the beginning of the study by the directive 
boards of the Clinical Pathology and the Clinical Hematology Departments from CHLO. 
The study was supported by funding from the Center for Toxicogenomics and Human Health 
(ToxOmics), from Fundação para a Ciência e Tecnologia (FCT), Portugal (grant no. 
UID/BIM/00009/2013).  
This dissertation is divided into ten Chapters, in which the first one is dedicated to a brief 
theorical introduction about PN-MPNs, individual susceptibility, genetic polymorphisms and association 
studies, caspases and BER pathway.   The  following  Chapters refer to the description  of  all  the  work  
 






that has been developed in the context of this thesis. Epidemiological and clinical characterization of 
the subjects involved in this study is discussed in Chapter 3, followed by the description of three 
interesting and rare clinical cases involving patients from the studied population, from Chapter 4 to 6. 
Chapters 7 and 8 are dedicated to each specific mechanistic pathway (caspases and BER) and their 
association with individual susceptibility for this group of disorders. Finally, in Chapter 9 it is discussed 
the potential role of genetic polymorphisms in both caspases and BER pathway, and other factors in 
PN-MPNs survival and prognostic impact and in clinical outcome of patients under treatment, in terms 
of progression to secondary MF/AML, development of new primary nonmyeloid malignancies and 
thrombotic events occurrence. 
The main reflexions and conclusions of this work, which were exposed throughout the several 
Chapters of this dissertation, are summarized in the last Chapter “Conclusions and final remarks” of the 
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Myeloproliferative neoplasms (MPNs) result from the malignant transformation of a hematopoietic stem-
cell (HSC), leading to abnormal amplification and proliferation of myeloid lineages. Identification of the Janus kinase 
2 (JAK2) V617F mutation developed the knowledge of Philadelphia-negative (PN)-MPNs, contributing to and 
influencing the definition of the phenotype and prognostic impact. 
Considering the lack of Portuguese epidemiological data, the present study intends to characterize the 
prevalence of the JAK2 mutation in a PN-MPN versus a control Portuguese population. 
Caucasian Portuguese PN-MPN patients (n=133) and 281 matched control subjects were investigated. 
No significant differences were identified between the case and control groups concerning age distribution or 
smoking habits. Pathology distribution was as follows: 60.2% with essential thrombocythemia (ET), 29.3% with 
polycythemia vera (PV) and 10.5% with primary myelofibrosis (PMF). A total of 75.0% of patients were positive for 
the presence of the JAK2 V617F mutation. In addition, the prevalence of PV was 87.2%, ET was 73.4% and PMF 
was 50.0%. 
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The JAK2 V617F mutation is observed in various MPN phenotypes, and has an increased incidence in 
ET patients and a decreased incidence in PV patients. These data may contribute to improving the knowledge of 
the pathophysiology of these disorders, and to a more rational and efficient selection of therapeutic strategies to 
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CHAPTER 3: PREVALENCE OF JAK2 V617F MUTATION IN 
PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS 
IN A PORTUGUESE POPULATION 
 
3.1 – INTRODUCTION 
Myeloproliferative neoplasms (MPNs) are clonal disorders resulting from malignant 
transformation of hematopoietic stem cells, leading to abnormal amplification and proliferation of one 
or more myeloid lineages. According to the World Health Organization (WHO) 2008 classification and 
the 2016 revision (Arber et al., 2016; Swerdlow et al., 2008), the classic MPNs encompass chronic 
myelogenous leukemia and the BCR/ABL-negative disorders (Philadelphia-negative MPNs; PN-
MPNs), such as polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis 
(PMF). Less frequent MPNs are chronic neutrophilic leukemia, chronic eosinophilic leukemia and other 
unclassifiable entities (Arber et al., 2016; Swerdlow et al., 2008).  
The PN-MPNs have a combined annual incidence rate of 0.84 for PV, 1.03 for ET and 0.47 for 
PMF, per 100,000 respectively (Moulard et al., 2014; Titmarsh et al., 2014).   
The presence of clonal hematopoiesis and cytokine hypersensitivity are fundamental for 
distinguishing PN-MPNs from reactive conditions. In routine practice, clonality is usually determined by 
the presence of an acquired mutation or cytogenetic abnormality, although additional clinical, laboratory 
and morphological information is important in the diagnosis of each specific subtype (Cross, 2011; 
Duletić et al., 2012; Tefferi & Pardanani, 2015).  
Clinically, PV is characterized by excessive production of erythrocytes, increased red cell mass 
and extramedullary hematopoiesis, leading to splenomegaly. In ET there is a high platelet count, often 
associated with thrombotic and hemorrhagic events; however, bone marrow fibrosis is the hallmark of 
PMF, resulting in a variable count of myeloid series cells and hepatosplenomegaly (Arber et al., 2016; 
Swerdlow et al., 2008; Tefferi & Vardiman, 2008). 
Major genetic insights into the pathogenesis of the PN-MPNs include identification of the 
somatic point gain-of-function mutations in the Janus kinase 2 (JAK2) gene (Baxter et al., 2005; James 
et al., 2005; Kralovics et al., 2005; Levine et al., 2005; Scott, Tong, et al., 2007), myeloproliferative 
leukemia (MPL) virus oncogene (more frequently termed W515L/K), and recently calreticulin (CALR) 
mutations, which contributed to an improved understanding of the pathophysiology of these disorders, 
their diagnostic tools and therapeutic management (Baxter et al., 2005; James et al., 2005; Kralovics 
et al., 2005; Levine et al., 2005; Scott, Tong, et al., 2007). According to the available studies, the 
frequencies of these mutations are ~95, 0, and 0% in PV, 60, 3, and 20% in ET, and 60, 7, and 25% in 
PMF, respectively (Cazzola & Kralovics, 2014; Hinds et al., 2016; Levine, 2009; Nangalia et al., 2013; 
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Oh & Gotlib, 2010; Tefferi & Pardanani, 2015). Although it is possible to identify one of these mutations 
in the majority of  the BCR/ABL-negative disorder patients, there are unidentified genetic defects in 
approximately 10-15% of cases, predominantly of ET and PMF and, furthermore, those mutations 
cannot fully explain the phenotypic heterogeneity of PN-MPNs nor the susceptibility of progression to 
myelofibrosis, acute myeloid leukaemia (AML) or myelodysplastic syndromes (MDS) (Hinds et al., 
2016). In addition, the cellular and molecular mechanisms involved in the pathophysiology of MPNs 
have not yet been fully clarified (Beer et al., 2010; Björkholm, Hultcrantz, & Derolf, 2014; Bolufer et al., 
2006; Campregher, Santos, Perini, & Hamerschlak, 2012; Delhommeau, Jeziorowska, Marzac, & 
Casadevall, 2010; Hinds et al., 2016; Kilpivaara & Levine, 2008; Rice et al., 2011; Rueff & Rodrigues, 
2016). 
It is well known that hematopoietic cytokine receptor signaling is largely mediated by JAKs, a 
family of tyrosine kinases, and their downstream transcription factors, termed signal transducer and 
activator of transcription (STAT). JAK2 is essential for normal hematopoiesis, as demonstrated by 
defects in erythropoiesis observed in JAK2-deficient mice (Ebid, Ghareeb, Salaheldin, & Kamel, 2015). 
It is composed of two main domains, one is an enzymatically active kinase domain (JAK homology 1; 
JH1) and the other consists of a catalytically inactive pseudokinase domain (JH2), which exerts an 
inhibitory affect that generally inhibits the kinase activity of JAK2 (Anand et al., 2011; Ebid et al., 2015; 
Jatiani, Baker, Silverman, & Reddy, 2010).  
In MPN patients, even in the absence of the JAK2 mutation, the other genetic changes result 
in activation of the JAK2 signaling pathway (Reuther, 2016). 
The most common mutation of JAK2 consists of a substitution of valine with phenylalanine at 
position 617 in the JH2 domain (JAK2 V617F) in exon 14, which affects the inhibitory function of the 
pseudokinase JH2 domain, inducing an increased activity in myeloid progenitor cells, leading to 
proliferation and excessive production of mature cells (Anand et al., 2011; Chen & Mullally, 2014; Ebid 
et al., 2015; Green & Llambi, 2015; Steensma et al., 2006). JAK2 V617F and exon 12 mutations signal 
through the same C-terminal tyrosine kinase of JAK2, but result in very different phenotypic readouts. 
JAK2 exon 12 mutations are tightly associated with PV in patients and mouse models (Scott, Tong, et 
al., 2007). The reasons for these different abnormal phenotypic outcomes remain unclear and are likely 
to be complex (Godfrey et al., 2016; Passamonti et al., 2011) . 
For the JAK2 V617F mutation to affect hematopoietic progenitor cells, the presence of 
receptors for erythropoietin, thrombopoietin or granulocyte-colony stimulating factor (CSF) is essential, 
leading to enhanced functional activity and increased sensitivity to cytokines and hematopoietic growth 
factors, such as interleukin 3 (IL-3), stem cell factor (SCF), granulocyte-macrophage CSF and insulin-
like growth factor-1 (Ebid et al., 2015). 
Previous data demonstrate the contribution and influence of the presence of the JAK2 V617F 
mutation and the respective gene dosage in the definition of phenotype and prognostic impact in PN-
MPNs (Nielsen, Bojesen, Nordestgaard, Kofoed, & Birgens, 2014). For example, the V617F allele 
burden tends to be higher in PV and PMF, and is associated with the presence of acquired uniparental 
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disomy (UPD), whereas a lower allele burden is generally observed in ET patients (Chen & Mullally, 
2014; Duletić et al., 2012; Ha, Kim, Jung, Jung, & Chung, 2012; Hinds et al., 2016; Larsen, Pallisgaard, 
Møller, & Hasselbalch, 2007).  
In PV and ET, risk factors for survival include older age, leukocytosis and thrombosis, whereas 
in ET, the JAK2 V617F mutation is associated with increased risk of thrombosis, and is incorporated 
into the International Prognostic Score for Thrombosis in ET-thrombosis score (Barbui et al., 2015; 
Baxter et al., 2005). Accumulation of JAK2 mutated allele accompanies the transformation of PV and 
ET to secondary myelofibrosis (Vannucchi, Pieri, & Guglielmelli, 2011). Furthermore, the presence of 
two or more mutations predict a worse survival and is associated with shortened leukemia-free survival 
(Guglielmelli et al., 2014). 
Furthermore, JAK2 V617F is not specific for a particular PN-MPN, nor does its absence exclude 
MPNs. Indeed, this has been reported in certain cases of MDS/MPN, in rare cases of AML (in 
combination with other well-defined genetic abnormalities, such as BCR-ABL1), and in association with 
certain solid tumors (Ebid et al., 2015; Nielsen, Birgens, Nordestgaard, Kjaer, & Bojesen, 2011; 
Steensma et al., 2006; Swerdlow et al., 2008; Thomas, Snowden, Zeidler, & Danson, 2015; 
Vainchenker & Constantinescu, 2013). 
A wider characterization of molecular genetic features in PN-MPNs may contribute to an 
improved knowledge and understanding of the physiopathology of these disorders, allowing 
achievement of novel specific diagnostic, prognostic and therapeutic tools (Delhommeau et al., 2010; 
Mambet, Matei, Necula, & Diaconu, 2016). The identification of JAK2/MPL mutations in the majority of 
patients led to the development of JAK kinase inhibitors. Although ruxolitinib was recently approved for 
use in hydroxyurea-resistant PV, its role in routine clinical practice remains controversial (Hobbs, 
Rozelle, & Mullally, 2017; Tefferi, 2016; Tefferi & Barbui, 2017; Tefferi & Pardanani, 2015; Vannucchi 
& Harrison, 2017). For myelofibrosis patients, stem cell transplant is the current treatment of choice for 
genetically or clinically high-risk disease. For all other patients that require treatment, the currently 
available drugs, including JAK inhibitors, are palliative, as they improve patient symptoms and reduce 
splenomegaly, but have not been identified as disease modifying, nor do they significantly reduce the 
mutant allele burden (Stahl & Zeidan, 2017; Tefferi, 2016).  
The present study describes a hospital based case-control study to evaluate the prevalence of 
the JAK2 mutation in PN-MPNs patients, as well as in healthy individuals without clinical disease, in a 
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3.2 – MATERIALS AND METHODS 
3.2.1 – STUDY SUBJECTS 
The present case-control study involved 133 Caucasian Portuguese PN-MPN patients (80 with 
ET, 39 with PV and 14 with PMF) and 281 age- and sex-matched control subjects selected since 
January 2009 to July 2016  within the Portuguese population recruited at the Departments of Clinical 
Hematology and of Clinical Pathology, Hospital de São Francisco Xavier, Centro Hospitalar de Lisboa 
Ocidental (CHLO; Lisbon, Portugal), a public general hospital that provides healthcare to the western 
population of Lisbon, where those patients were admitted, followed up and treated. The diagnostic 
criteria for all patients were those defined by the World Health Organization in the 2008 and updated 
2016 guidelines (Arber et al., 2016; Swerdlow et al., 2008). For all cases, at least two control individuals 
(n=281), without neoplastic pathology, matched for age (±2 years), gender and ethnicity were recruited, 
with no personal or family history of PN-MPNs, no previous or current malignant disease, nor history of 
blood transfusions. All study subjects were Portuguese, with Portuguese ascendants. Information on 
demographic characteristics, family history of cancer, lifestyle habits (e.g. smoking) and exposure to 
ionizing radiation was collected via a questionnaire administered by trained interviewers. With respect 
to smoking habits, former smokers were considered as non-smokers if they gave up smoking either 2 
years before PN-MPN diagnosis or, for controls, 2 years before the date of inclusion in the study. The 
response rate was >95% for the cases and control subjects. The anonymity of the patients and control 
population was guaranteed, and written informed consent was obtained from all those involved, prior to 
blood withdrawal, in agreement with the Declaration of Helsinki. The current study was conducted with 
approval by the institutional ethics’ boards of the involved institutions - CHLO and Nova Medical School 
(were the practical work was performed), both in Lisbon, Portugal. 
The general characteristics for PN-MPNs patients at the time of diagnosis and the control 
populations are summarized in Tables 3.1 and 3.2. All clinical and hematologic data were obtained from 
registries, and were selected on the basis of diagnostic criteria for this type of disease.  
3.2.2 – DNA EXTRACTION 
Peripheral blood samples (7-8 ml) of all patients and controls were collected by qualified 
personnel into 10 ml EDTA tubes and maintained thereafter at -80ºC. Genomic DNA was obtained from 
each blood sample (250μl) using a commercially available kit, accomplished by cell lysis followed by 
ethanol precipitation and recovery of the DNA by elution in a buffer solution (QIAamp® DNA mini kit 
(Cat. No. 51306);  Qiagen GmbH, Hilden, Germany) according to the manufacturer’s instructions. All 
DNA samples were stored at -20°C until analysis. 
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3.2.3 – GENOTYPING 
The JAK2 V617F mutational status was determined via quantitative real time polymerase chain 
reaction (qPCR; Applied Biosystems 7300 Real-Time PCR System), and TaqMan® single nucleotide 
polymorphism genotyping assay (rs77375493 - Cat. No. C_101301592_10, Thermo Fisher Scientific, 
Inc., Waltham, MA, USA). Amplification was carried out within 96-well microplates containing 10ng of 
genomic DNA, 1xSNP genotyping assay mix and 1xTaqman Universal PCR Master mix per well (final 
volume, 10 μl/well). Initial enzyme activation (10 min, at 95°C) was ensued by 40 cycles of denaturation 
(15 sec at 92°C) and probe annealing/extension (1 min at 60°C). Allelic discrimination was then 
performed by measuring fluorescence emitted by both VIC and FAM dyes in each well (60 sec) and 
computing the results into the System SDS software version. The methodology was performed 
according to the manufacturer’s protocol with minor modifications included in previous reports from our 
group and using primers from the Taqman kit (Bastos et al., 2009; Conde et al., 2009; Gomes et al., 
2010; Silva et al., 2009; Silva et al., 2007), with a minor modification where the final volume of the 
reaction was adjusted to 10 µl. Genotype determination was performed in 20% of samples in 
independent experiments (60 randomly selected individuals for the control group and 30 for the case 
group), and all of the inconclusive samples were reanalyzed.  
3.2.4 – STATISTICAL ANALYSIS 
The analysis of Hardy-Weinberg frequencies for all alleles in the control and patient populations 
was conducted using exact probability tests available in SNPStat website software  
(http://bioinfo.iconcologia.net/SNPstats) (Solé, Guinó, Valls, Iniesta, & Moreno, 2006). Differences in 
genotype frequency, smoking status, age ranges and gender distributions between PN-MPN cancer 
patients and control subjects were evaluated using the χ2 test (P<0.05 was considered to indicate a 
statistically significant difference).  
 
3.3 – RESULTS 
The present study included 133 PN-MPN patients and 281 age- and sex-matched control 
subjects. The baseline characteristics (sex, age and smoking habits) of the case and control populations 
are presented in Table 3.1. The case group included 72 (54.1%) female and 61 (45.9%) male patients, 
with an overall mean age of 68 years (Table 3.1). No significant differences were identified between the 
case and control groups concerning age distribution or smoking habits (Table 3.1).  
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Table 3.1 – General characteristics of the PN-MPNs case (n=133) and control populations (n=281). 
Characteristic Cases, n (%) Controls, n (%) P-value 
Gender 
    Male 









    30-49 
    50-69 











    Never 









    Never 
    Social 










JAK2 V617F mutation 
    Yes 
        Essential thrombocythemia 
        Polycythemia vera 
        Primary myelofibrosis 













         0.020 
 
a




According to the diagnostic criteria, the patient distributions were as follows: 80 (60.2%) with 
ET, 39 (29.3%) with PV and 14 (10.5%) with PMF. The majority of the patients with ET were female 
(60.0%), while in PV and PMF, males predominated (51.3 and 64.3%, respectively; Table 3.2). 
Patient and control populations were stratified according to the presence of the JAK2 V617F 
mutation, demonstrating that 75.0% of patients and none of the controls were positive for JAK2 V617F 
(Table 3.1). The prevalence of the JAK2 V617F mutation for patients with PV was 87.2%, for ET 73.4% 
and for PMF 50.0% (Table 3.2). The allelic distribution of the PN-MPN cases, stratified by diagnosis, is 
presented in Table 3.2.  General characteristics of patients are presented in Table 3.2, according to the 
type of PN-MPN.  
 
Table 3.2 – JAK2 V617F mutation allelic distribution in the PN-MPNs cases (n=133). 
Diagnosis 
Janus kinase 2 
Val/val (%) Val/phe (%) Phe/phe (%) 
Essential thrombocythemia 21 (26.6) 56 (70.9) 2 (2.5) 
Polycythemia vera 5 (12.8) 31 (79.5) 3 (7.7) 
Primary myelofibrosis 7 (50.0) 5 (35.7) 2 (14.3) 
         Phe – Phenilalanin; Val – Valin. 
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3.4 – DISCUSSION AND CONCLUSIONS 
In recent years, investigation on MPNs revealed that there are three driver mutations (JAK2, 
MPL and CALR) essential as clonal markers, activating the cytokine receptor JAK2 signaling pathway 
and the downstream effectors (Reuther, 2016; Rumi & Cazzola, 2017). 
However, it is known that the different driver mutations involved in the pathogenesis of MPNs 
leads to different clinical effects, and that a single mutation may be associated with distinct phenotypes 
and clinical outcomes. This finding may be due to the association with other commutated non-MPN-
driver genes (for example, additional sex combs like 1, transcriptional regulator, enhancer of zeste 2 
polycomb repressive complex 2 subunit, tet methylcytosine dioxygenase 2, isocitrate dehydrogenase 
(NADP+)1/2, cytosolic, splicing factor 3b subunit 1, serine and arginine rich splicing factor 2) (Rumi & 
Cazzola, 2017).  
It is unequivocal that the JAK2 V617F mutation is found in various phenotypes; however, it is 
seemingly also associated with other malignancies  (generally non-hematological types) (Nielsen et al., 
2011).  
The role of the JAK/STAT signaling pathway in the pathogenesis of MPNs and other cancers 
is questionable when considering the example of rare families presenting with germline mutations 
leading to weak JAK activation. The mutations originate a hereditary thrombocytosis, but hematopoiesis 
is polyclonal and there is no development of hematological malignancies or solid tumors, indicating that 
JAK/STAT activation alone does not drive malignant disease (Thomas et al., 2015).  
The JAK2 V617F mutation was screened in the patients and healthy control subjects, to 
evaluate the eventual presence and prevalence of the JAK2 mutation in healthy individuals in our control 
population, reflecting healthy Portuguese general population status, as it is the most prevalent among 
the driver mutations for PN-MPNs. The fact that no JAK2 V617F mutation was identified in healthy 
control subjects during the present study does not dismiss the possible weak effect of this mutation in 
driving MPNs. Although the absence of the JAK2 mutation does not exclude MPN, its presence is not 
specific for any specific PN-MPN and phenotypic expression may depend on various factors. 
However, as the JAK2 V617F mutation is found in the great majority of MPNs indicates that it 
is probably the primary abnormality driving myeloproliferative cells, although it is not definitely clear 
whether it has to be homozygous in all cases; it may become homozygous as a result of the loss of 
heterozygosity (LOH) or UPD (Chen & Mullally, 2014; Jones et al., 2005). Furthermore, it cannot be 
ruled out whether an inherited mutation in one of the alleles may be accompanied by an epigenomic 
inactivation of the other otherwise normal alleles rendering the cell biological homozygous. What seems 
clear, however, and the present data contributes to this conclusion, is that the role of the JAK2 V617F 
mutation in the pathogenicity of the different MPNs may differ amongst different MPNs requiring the 
JAK2 V617F mutation more often than others (e.g. ET vs. PV), which would indicate other oncogenic 
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mutations that may be relevant for certain cases others than JAK2 V617F (Chen & Mullally, 2014; Hinds 
et al., 2016; Jones et al., 2005; Lundberg et al., 2014).  
Besides mutations and other molecular abnormalities, various factors, such as gene burden 
and individual genetic background, may influence the predisposition for developing an MPN, as well as 
their heterogeneity (Hinds et al., 2016; Rumi & Cazzola, 2017). Although JAK2 V617F homozygous 
subclones are present in PV and ET patients, the expansion of a dominant homozygous subclone 
occurs almost exclusively in PV patients (~80% in PV and 50% in ET) (Chen & Mullally, 2014; Rumi & 
Cazzola, 2017), due to either additional genetic or epigenetic events or non-cell-autonomous selective 
pressures, such as low levels of circulating erythropoietin in the context of elevated hematocrit (Chen 
& Mullally, 2014). 
However, the WHO classification of classical MPNs allows that the diagnosis is established on 
the basis of other criteria, even if the criteria concerning the driver mutations is not met, and that 
diagnosis is established on the basis of other criteria. Indeed, these disorders are primarily defined on 
the basis of clinical, pathologic and morphologic/histologic features, with the possibility of diagnosing 
MPN without any evidence of a driver mutation (Arber et al., 2016; Swerdlow et al., 2008). 
The present study revealed a higher incidence of the JAK2 V617F mutation in ET patients and 
a comparatively lower incidence in the PV patients, when compared with the published data for each 
disease (Duletić et al., 2012; Levine, 2009; Nangalia et al., 2013; Tefferi & Pardanani, 2015). The 
discrepancy between published data and the present results is greater in the case of ET, than in PV. 
This may be due to the small size of the investigated population and to the larger number of ET patients 
that was included. The majority of patients presented with ET (80 of a total of 133 patients), leading to 
a more consistent and representative result, reflecting Portuguese reality, when compared with PV. 
This indicates that the population of the present study has a different pattern concerning the presence 
of this mutation, when compared with other already studied populations from other countries, 
highlighting the importance of developing future studies in larger and diversified populations. 
representing a tendency of how relevant could it be for future studies in larger and different populations. 
As described by Rumi and Cazzola (Rumi & Cazzola, 2017), patients with the wild type JAK2 
V617F or exon 12 mutation are extremely rare. However, the current results revealed a prevalence of 
12.8% of patients with the wild type genotype. This finding supports the fact that the JAK2 mutation 
acting alone may not be sufficient to develop the PV phenotype. However, larger studies are required 
to confirm this hypothesis. 
Subsequent to performing a literature review, almost all of the patients diagnosed with PV 
negative for the JAK2 V617F mutation were exon 12-positive (96 vs. ~3%, respectively) (Arber et al., 
2016; Butcher et al., 2008; Pardanani, Lasho, Finke, Hanson, & Tefferi, 2007; Park et al., 2016; 
Passamonti et al., 2011; Passamonti et al., 2010; Rumi et al., 2014; Scott, 2011; Scott, Beer, Bench, 
Erber, & Green, 2007; Scott, Tong, et al., 2007). In the current study, from the five PV patients that 
were exon 14-negative, two underwent exon 12 molecular evaluation, and only one was positive. For 
certain patients, particularly those selected at the beginning of the study, it was no longer possible to 
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obtain blood samples to proceed with the study. 
CALR and MPL mutations were not assessed in the ET and MF patients that were JAK2-
negative when the diagnosis was no doubtful  , and therefore when the diagnosis was certain on the 
basis of clinical, pathologic and morphologic/histologic features. The presence of these mutations may 
thus not be a necessarily met criteria according to the WHO classification.  
The patients and controls included in the present study were recruited from 2009 until 2016. 
The majority of the patients were evaluated according to the WHO 2008 diagnostic criteria, which was 
revised in 2016 (Table 3.1). Although bone marrow biopsies may not be a met criterion (for ET and PV) 
in the two versions of the WHO classification, in our institution this is a type of routine examination for 
these patients, as it is considered to be important for predicting the prognosis. 
Published epidemiology data are scarce (Moulard et al., 2014; Titmarsh et al., 2014).  The 
gender distribution observed in the current population was consistent with previous data regarding this 
group of disorders (Azevedo et al., 2017). Furthermore, although certain published studies consider 
smoking as a contributing factor for PN-MPNs (Hasselbalch, 2015; Lindholm Sørensen & Hasselbalch, 
2015), the present study did not reveal a significant association, potentially due to the small number of 
smoking individuals that was included. 
Additional studies involving larger populations are required to further clarify the potential value 
of different genotypes as predictive biomarkers of susceptibility to PN-MPNs. An improved 
understanding of the pathophysiological mechanisms will enable the development of drugs that are 
more directly and specifically targeted, with high efficacy and fewer adverse effects, thus contributing 
to the compliance of patients with treatments.  
 The discovery of JAK2 was a very important milestone for the studies that followed and for what 
we know today, but the ongoing identification of other mutations in MPNs will make possible the 
signaling of new drug targets and prognostic biomarkers that will for certain improve clinical practice 
and patients’ outcome. All in all, it remains to be fully ascertained whether JAK2 mutations may 
considered as ‘driver mutations’ for MPNs, or if they can act as ‘passenger mutations’ which may 
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Abstract -  Apresentação hematológica atípica num caso de policitémia vera com mutação 
variante detetada no exão 12 – c.1605G>T (P.Met535Ile).  







One of the major genetic insights into the pathogenesis of Polycythemia Vera included the identification 
of the somatic point gain-of-function mutations in Janus kinase 2 gene – first JAK2 V617F on exon 14, present in 
95-97% of the cases, and later on exon 12. 
In the literature we can find some reported studies where different exon 12 mutations are identified.  
Unlike patients with JAK2 V617F mutation in exon 14, the mutation at exon 12 is not usually associated 
with an increase in the 3 hematopoietic series (erythrocytosis, leukocytosis and thrombocytosis). It appears to be 
associated with a distinct syndrome, mostly characterized by isolated and more marked erythrocytosis, 
independently of the mutational variant. 
We report here the case of a patient JAK2 exon 12 positive, presenting a novel mutation – c. 1605G>T 
(p.Met535Ile) - associated with c.1612C>T (p.His538Tyr) mutation previously described, evidencing an atypical 
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clinical phenotype characterized by the presence of  thrombocytosis, instead of erythrocytosis which is the usual 
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CHAPTER 4: ATYPICAL HEMATOLOGICAL PRESENTATION IN A 
CASE OF POLYCYTHEMIA VERA WITH A NEW VARIANT MUTATION 
DETECTED IN EXON 12 – C.1605G>T(P.MET535ILE) 
 
4.1 – INTRODUCTION 
According to the World Health Organization (WHO) 2008 Classification of Tumours of 
Haematopoietic and Lymphoid Tissues and 2016 revision (Arber et al., 2016), Philadelphia-negative 
Myeloproliferative Neoplasms (PN-MPNs) can be classified into major entities, such as Polycythemia 
Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF). 
One of the major genetic insights into the pathogenesis of the PN-MPNs included the 
identification of somatic mutations in Janus kinase 2 gene (JAK2; exon 14 V617F gain-of-function 
mutation first in 2005; then later in 2007 exon 12 mutation), leading to the activation of the JAK/STAT 
signaling pathway (signal transducer and activator of transcription), culminating in exacerbated cellular 
proliferation, resistance to apoptosis and evolution to MPNs (Kralovics et al., 2005; Levine et al., 2005; 
Scott, Tong, et al., 2007). Nevertheless, JAK/STAT activation in MPNs is a nonspecific occurrence and 
there is still much information to be unveiled (Nielsen, Birgens, Nordestgaard, & Bojesen, 2013; Tefferi 
& Pardanani, 2015). 
According to the available published literature, frequencies of JAK2 V617F mutations are 
approximately 95-97% in PV and 60% in ET and PMF (Hinds et al., 2016; James et al., 2005; Scott, 
Tong, et al., 2007; Tefferi & Pardanani, 2015). 
PV is characterized by excessive production of erythrocytes, increased red cell mass and risk 
of thrombosis or haemorrhage (Arber et al., 2016). 
According to the literature, unlike patients with mutation in exon 14 of the JAK2 gene, the 
mutation at exon 12 is not usually associated with an increase in the 3 hematopoietic series 
(erythrocytosis, leukocytosis and thrombocytosis). it appears to be associated with a distinct syndrome, 
mostly characterized by isolated and more marked erythrocytosis, independently of the mutational 
variant (Godfrey et al., 2016; Passamonti et al., 2011; Scott, 2011). 
Moreover, it seems that mitotic recombination, which leads to homozygosity, is more likely to 
occur in PV patients with mutation in exon 14 of the JAK2 gene than in those with exon 12 mutations 
(Pietra et al., 2008). 
We report here the case of the only patient JAK2 exon 12 positive, presenting a novel mutation 
– c. 1605G>T (p.Met535Ile) and an atypical hematological phenotype. This patient was initially part of 
a study which included 39 patients with PV. Among those patients, five were  JAK2 V617F negative, 
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two of which further undertook search for the exon 12 mutation and only one, the patient within 
discussion, was positive for the aforementioned mutation (Azevedo et al., 2017). 
 
4.2 – PATIENT AND METHODS 
A 64-year-old woman, caucasian, who was accompanied by a General Practioner (GP) doctor 
for benign morbidities, namely type 2 diabetes, hypertension and hyperuricemia was referred to an 
Haematology consultation in January 2012.  The reason for the referral was persistent alarming 
alterations in her complete blood counts which were not associated with any signs of malignant disease. 
She had a history of thrombocytosis over the former two years combined with recent erythrocytosis as 
well as microcytic and hypochromic erythrocytes (Table 4.1).  
At the time of the first Haematology appointment, in January of 2012, the patient revealed   no 
symptomatology of PV disorder such as headache, dizziness, visual disturbances, aquagenic pruritus, 
early satiety and constitutional symptoms, physical examination did not reveal splenomegaly.  
Diagnostic tests were performed including complete blood counts (Table 4.1), erythropoietin 
levels (<1 mUI/mL), search for V617F mutation in exon 14 of the JAK2 gene (by PCR; negative). 
Following the initial results, the clinic-laboratorial picture was suggestive of an MPN, not further 
classifiable. However, the presence of iron deficiency, lowering haemoglobin levels, and the very low 
erythropoietin level, led us to consider the hypothesis of prodromal prepolycythaemic phase of PV as a 
possible diagnosis. Subsequently, the patient started treatment with phlebotomies and, after the 
worsening of thrombocytosis, phlebotomies were supplemented with hydroxyurea (Table 4.1).  
The patient was taking acetylsalicylic acid (150 mg/day) since referral. Afterwards, an 
abdominal ultrasound was performed (May 2012) showing non-quantified splenomegaly.  
Treatment was maintained and the patient went clinically and laboratorial stable during the 
following years. 
In 2015, a search for the mutation in exon 12 of the JAK2 gene (by PCR) was positive in 
peripheral blood, revealing a mutation c.1612C>T (p.His538Tyr) and a variant c.1605G> T 
(p.Met535Ile) (Figure 4.1). Afterwards, in 2016 a bone marrow aspirate and biopsy were performed 
showing hypercellularity with trilineage growth (panmyelosis) including prominent erythroid, 
granulocytic, and megakaryocytic proliferation with pleomorphic mature megakaryocytes (differences 
in size and nuclear lobulation) (Figure 4.2), present in intersticial and paratrabecular spaces, confirming 
the PV diagnosis. Also, iron deposits were absent. Search for the mutation in exon 12 was also 
performed in medullary blood, revealing the same mutations previously identified in peripheral blood, 
but in a larger cellular population.  
Currently the patient is still under the same prescription, with a complete haematological 
remission. Occasional adjustments, according to the laboratorial goals (Hematocrit<45%; Leucocytes 
≤ 10x109/L and Platelets<400x109/L), are made. 
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Table 4.1 – Complete blood count and treatment prescription over time. 
CBC 21/2/2011 13/3/2012 17/4/2012 15/5/2012 
Erythrocytes (x1012/L) 5.13 6.15 5.79 5.35 
Haemoglobin (g/L) 149 159 147 134 
Hematocrit (%) 45.1 50.1 45.6 42.1 
VGM (fL) 87.9 81.5 78.9 78.7 
HGM (pg) 29.2 25.8 25.4 25.2 
Leucocytes (×109/L) 14.3 9.9 10.6 8.5 
Neutrophils (×109/L) 12.17 6.74 7.30 5.53 
Lymphocytes (×109/L) 1.49 2.40 2.34 2.24 
Monocytes (×109/L) 0.47 0.42 0.54 0.42 
Eosinophils (×109/L) 0.13 0.25 0.34 0.25 
Basophils (×109/L) 0.04 0.10 0.07 0.07 
Platelets (×109/L) 801 728 806 517 
TREATMENT  P: 400 ml 
P: 350 ml 
HU: 500 mg/7 d/w 
HU: 500 mg/5 d/w 
CBC – Complete Blood Count; HU – Hydroxyurea; P – Phlebotomy; d – days; w – week 
 
 
Figure 4.1 – Exon 12 mutation of the JAK2 gene analysis in peripheral blood. 
It revealed c.1612C>T (p.His538Tyr) mutation and a novel variant c.1605G> T (p.Met535Ile). This result was later 
confirmed in medullary blood. 
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Figure 4.2 – Bone marrow aspirate a) and biopsy b) and c) showing trilinear hyperplasia and 
pleomorphic mature megakaryocytes.  
A) May-Grünwald-Giemsa stain, x40; B) Hematoxylin eosin stain, x40; C) Giemsa stain, x200. 
 
4.3 – DISCUSSION 
PV is a rare neoplasm with an incidence of 0.4 to 2.8 per  100.000 cases per year per person, 
which can strike an individual at any age, with a mean of presentation of 65 years (Rumi & Cazzola, 
2017) and an equal incidence between gender (McMullin et al., 2005). 
Typically, PV initially presents a pre-polycythemic stage, characterized by borderline 
erythrocytosis and thrombocytosis, evolving to a polycythemic phase marked with hyperplasia of the 
three series and eventually post-PV myelofibrosis (Passamonti et al., 2011). 
About 95-97% of patients with PV are carriers of a single V617F mutation in exon 14 of the 
JAK2 gene. This mutation, along with other driver mutations connected with clonal expansion of 
hematopoietic cells, might also represent a feature of the aging hematopoietic system in individuals 
without a malignant disease (Jaiswal et al., 2014; Nielsen et al., 2013).  
This share of the population usually presents higher erythrocyte, platelet and leucocyte counts. 
Moreover, it has been observed that individuals without malignant disease and who are positive to the 
JAK2 V617F somatic mutation were 44/28 risk fold more likely to develop an haematological cancer 
(Nielsen et al., 2013). 
The V617F somatic mutation causes the substitution of phenylalanine for valine at position 617 
in the JAK2 gene, which encodes a cytoplasmic tyrosine kinase. The mutation, which occurs in the JAK 
homology 2 (JH2) negative regulatory domain, increases JAK2 kinase activity and causes cytokine-
independent growth of cell lines and cultured bone marrow cells (Kralovics et al., 2005; Levine et al., 
2005). 
Among the cases negative for V617F, a significant fraction presents mutations in the exon 12 
of the JAK2 gene (about 3% of PV patients) (Arber et al., 2016; Butcher et al., 2008; Pardanani, Lasho,  
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Finke, Hanson, & Tefferi, 2007; Park et al., 2016; Passamonti et al., 2011; Passamonti et al., 2010; 
Rumi et al., 2014; Scott, 2011; Scott, Beer, Bench, Erber, & Green, 2007; Scott, Tong, et al., 2007). At 
least 17 different mutations have been described (Bench et al., 2013) in patients who present exon 12 
mutations and, unlike those who are JAK2 V617F-positive, they are not commonly homozygous for the 
JAK2 mutations (Godfrey et al., 2016; Scott, 2011; Scott, Tong, et al., 2007). 
Like V617F, exon 12 mutations are associated with activation of JAK2, STAT5 and ERK1/2 
(Godfrey et al., 2016; Scott, Tong, et al., 2007). 
According to Passamonti et al (2010), JAK2 exon 12 mutations were detected in 4% of the 
cases, among 338 genotyped patients (Passamonti et al., 2010).  3% of patients have one of four 
different mutations in exon 12 (Arber et al., 2016; Butcher et al., 2008; Rumi et al., 2014; Scott, Beer, 
et al., 2007). Some studies revealed a high incidence of JAK2 exon 12 mutations in oriental patients, 
compared to reports in the Western literature (Table 4.2) (Berndt et al., 2016; Krähling et al., 2014; Park 
et al., 2016; Williams, Kim, Rogers, Spivak, & Moliterno, 2007; Wu et al., 2014). However, there are 
exceptions as it was demonstrated in a Chinese study, in which the mutational profile was tested in 
1648 PN-MPNs patients, revealing that JAK2 exon 12 mutation was found in 1,7% of PV patients (M. 
Y. Li et al., 2017). 
In the literature there is also report of the co-existence of JAK2 V617F and exon 12 mutations, 
as two separate clones (Nussenzveig et al., 2016; Passamonti et al., 2011). 
Patients with a JAK2 exon 12 mutation present at a younger age than those JAK2 V617F 
positive, with approximately 40% of cases being reported at, or below 50 years of age (Langabeer et 
al., 2015; Nussenzveig et al., 2016). 
Compared to PV patients with JAK2 V617F mutation, patients with exon 12 mutations do not 
usually present panmyelosis (Arber et al., 2016). PN-MPNs JAK2 exon 12 positive patients appears to 
be associated with a distinct syndrome, mainly characterized by  isolated erythrocytosis (marked 
erythrocytosis) with higher hemoglobin concentrations, lower white cells and platelets counts (minimal 
thrombocytosis) (Park et al., 2016), and isolated bone marrow erythroid hyperplasia (Godfrey et al., 
2016), independently of the mutational variant (Godfrey et al., 2016; Passamonti et al., 2011). 
The fact that exon 12 mutations are more frequently associated with erythrocytosis is 
compatible with their absence in ET, but possible presence in PMF or AML secondary to PV (Scott, 
2011) 
However, despite the phenotypic differences, the clinical course seems similar between JAK2 
V617F and JAK2 exon 12-positive patients, with similar incidences of thrombosis, myelofibrosis, 
leukemia and death (Passamonti et al., 2011). 
Concerning the case reported by the authors, the first JAK2 exon 12 mutation c.1612C>T 
(p.His538Tyr) is registered in the COSMIC database (COSM1462563) and has already been described 
in other patients by Wu et al (2014) (Wu et al., 2014). The variant c.1605G> T (p.Met535Ile) has not 
yet been described in the literature, as far as we know (Park et al., 2016; Pietra et al., 2008). However, 
a mutation in this same position (c.1605G> C) was previously described by Wu et al (2014) (Wu et al., 
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2014), which results in the same amino acid exchange, indicating that this variant is most likely a 
pathogenic variant. 
Information about whether the Met535leI and His538Tyr substitutions occurred in mutually 
exclusive disease clones or within the same cell is not available, because single colony genotyping was 
not performed. 
The patient’s reported main feature, unlike most patients who are PV exon 12 mutations-
positive, was thrombocytosis. According to literature, even though these mutations are mostly 
associated with erythrocytosis, up to 25% percent of patients present with elevated counts of other 
lineages (Scott, 2011). 
Moreover, the higher platelet count may be due to the fact that this patient harbors two lesions, 
both of which on their own have been associated with erythrocytosis phenotypes. Perhaps the excess  
signaling from either a single clone with two lesions, or two hematopoietic stem cell clones with 
different exon 12 mutations, is driving more JAK2 signaling (and therefore more thrombocytosis) than 
we typically observe with the exon 12 lesions reported (Tables 4.1 and 4.2) (Williams et al., 2007; Kim  
et al., 2016; Pardanani et al., 2007; Park et al., 2016; Scott, Tong, et al., 2007; Siemiatkowska, 
Bieniaszewska, Hellmann, & Limon, 2010; Wu et al., 2014).          
Williams et al identified JAK2 exon 12 lesions in 30% of JAK2 V617F negative PV patients, and 
while the clinical phenotype of JAK2 exon 12 lesions in the MPNs was predominantly erythroid, in those 
patients there was significant disease spectrum overlap between JAK2 V617F and JAK2 exon 12 
mutations, but on average the JAK2 exon 12 patients had significantly lower white blood cell and platelet 
counts than JAK2 V617F patients (Williams et al., 2007). 
Scott et al. Have found similar results in their patients (Scott, Tong, et al., 2007). 
On the other hand, Pardanani et al identified 6 of a total 220 cases with PV that were JAK2 
V617F negative (prevalence of 3%). Although erythroid hyperplasia was the predominant histologic 
feature on bone marrow examination, most PV patients harboring exon 12 mutations revealed 
megakaryocyte abnormalities and reticulin fibrosis, overlapping with what happens in some JAK2 
V617F positive PV cases. Therefore, a distinct genotype-phenotype association could not be 
established (Pardanani et al., 2007). 
Pietra et al. Identified 17 exon 12 positive patients among 37 PV JAK2 V617F negative patients, 
and in this study there is evidence of low white blood cell count, but an increase of mean value of 
platelet count, compared to the other studies (Pietra et al., 2008). 
In the same way, Wu et al. described 10 Chinese patients with diverse exon 12 mutations, 
among 80 PV cases (prevalence of 13%), in which were also evident lower white blood cell and platelet 
counts, compared to what is characteristic of JAK2 V617F patients (Wu et al., 2014). 
In a study developed by Park et al., with 42 PV Korean patients, 12% exon 12 positive, 
genotype-phenotype correlations demonstrated lower white blood cell and platelet counts in exon 12 
mutations than V617F (Park et al., 2016). 
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Meanwhile, in another study also performed in 111 Korean patients, Kim et al. Identified 7 of 
them with exon 12 mutations, with an identical phenotype (Kim et al., 2016). 
The basis for the different phenotype of our unique patient is not known (J. Li et al., 2014). Scott 
et al. suggest that genetic factors might be involved, such as the nature of the mutation or other 
additional MPN-associated mutations (Scott, 2011). An enhanced STAT1 activation might cause 
superior megakaryopoiesis and, therefore, possibly be a contributing factor to the understanding of the 
small share of PV patients with exon 12 mutation who behave differently. On the other hand, the 
absence of thrombocytosis in the majority of patients may be related to stat1-independent mechanisms 
that might cause, for instance, increase platelet destruction (Godfrey et al., 2016). 
Sequencing granulocyte DNA was the first method used to detect the JAK2 V617F mutation 
in exon 14. Afterwards, pcr-based methods were developed and, due to their superior sensitivity, the 
frequency of this mutation in MPNs patients increased. After using an allele-specific PCR assay it was 
found that almost all PV patients were JAK2 V617F positive.  
Evidence of the existence of patients that were JAK2 V617F-negative led to the development 
of further studies, contributing to a better elucidation of MPNs pathogenesis in the following years. In 
2007, JAK2 exons were sequenced in granulocyte DNA acquired from JAK2 V617F negative patients 
and exon 12 mutations were found, further clarifying this subject (Scott, 2011). The rarity of patients 
with JAK2 exon 12 mutations, the variation on the type of mutation and of the low mutant allele burden,  
make selection of an appropriate assay for the diagnostic very challenging, requiring very sensitive 
assays (Bench et al., 2013; Langabeer et al., 2015). 
 
Table 4.2 – Clinical and demographic features of other published exon 12 cases.
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Myeloproliferative neoplasms (MPNs) are classically divided into BCR-ABL positive Chronic Myeloid 
Leukemia (CML) and BCR-ABL negative MPNs, including Essential Thrombocythemia (ET). One of the major 
diagnostic criteria for ET is the absence of the Philadelphia chromosome (Ph), meaning that when present it would 
be almost indicative of CML. ET and CML are considered to be mutually exclusive, however, exceptionally there 
are rare situations in which ET patients present positive BCR-ABL without features of CML. 
Although from the literature review the frequency of coexistence of JAK2 V617F mutation and BCR-ABL 
translocation in myeloproliferative neoplasms is low, it might be higher than expected. 
We present the case report of two patients with the initial diagnosis of ET in the presence of JAK2 V617F 
mutation and BCR-ABL translocation by FISH, with an atypical pattern. Both patients present an heterozygous 
BCR-ABL translocation and absence of identification of p190 and p210 transcripts, seemingly a der(9) in a 
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CHAPTER 5: CONCOMITANT PRESENCE OF JAK2V617F MUTATION 
AND BCR-ABL TRANSLOCATION IN TWO PATIENTS: A NEW 
ENTITY OR A VARIANT OF MYELOPROLIFERATIVE NEOPLASMS 
5.1 – INTRODUCTION 
According to World Health Organization (WHO) 2008 Classification of Tumours of 
Haematopoietic and Lymphoid Tissues and 2016 revision (Arber et al., 2016), Myeloproliferative 
Neoplasms (MPNs) can be classified into two major groups, Chronic Myeloid Leukemia (CML) and 
Philadelphia-negative MPNs (PN-MPNs), such as Polycythemia Vera (PV), Essential 
Thrombocythemia (ET) and Primary Myelofibrosis (PMF). These disorders are more frequently found 
in elderly patients, mostly in men (Arber et al., 2016). 
One of the major genetic insights into the pathogenesis of the PN-MPNs included the 
identification of the somatic point gain-of-function mutations in Janus kinase 2 gene (JAK2), leading to 
the activation of the JAK/STAT signaling pathway (signal transducer and activator of transcription), 
culminating in exacerbated cellular proliferation, resistance to apoptosis and evolution to MPNs (Baxter 
et al., 2005; Kralovics et al., 2005; Levine et al., 2005). On the other hand, the identification of 
Philadelphia chromosome (Ph), a translocation involving chromosomes 9 and 22 that results in the 
formation of the BCR-ABL fusion gene, constitutes the defining leukemogenic event in CML (Nowell, 
1962; Rowley, 1973). ET is characterized by a high platelet count, often associated with thrombotic and 
hemorrhagic events, and the presence of JAK2 mutation in about 50-60% of cases (Hinds et al., 2016; 
Levine, 2009; Tefferi & Pardanani, 2015). 
As far as we know from literature revision, the frequency of concurrent presence of JAK2 V617F 
mutation and BCR-ABL translocation in a single individual with a MPN is a rare event, independently of 
what phenotype expresses earlier, PN-MPN or CML (Pagnano et al., 2016; Qin, Yang, Li, & Wang, 
2014; Ursuleac et al., 2013; Zhou, Knoche, Engle, Fisher, & Oh, 2015). 
Although ET and CML are considered to be mutually exclusive, rare cases of concomitant 
presence of BCR-ABL translocation positive CML and JAK2 V617F mutation positive ET have been 
reported in the literature (Pagnano et al., 2016; Qin et al., 2014). 
We report here the case of two patients initially included in a data base population of 58 patients 
with the diagnosis of ET in the presence of JAK2 V617F mutation, with the suspicion of coexistence 
with BCR-ABL translocation. 
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5.2 – MATERIALS AND METHODS 
CASE STUDY 1: 
A 75-year-old man with a medical history of dyslipidemia, hypertension, acute myocardial 
infarction, and Ischemic stroke in August 2013. In December 2013 this patient was hospitalized with his 
second ischemic stroke. Although he had confirmed poor adherence to the prescribed therapy for 
cardiovascular risk patients, in January 2014 he was referred to the Hematology consultation for 
maintained thrombocytosis and leukocytosis, since at least August 2013 (as there was no previous 
laboratory data available). 
Evaluation revealed platelet count of 1405x109/L, leukocytosis (15x109/L), with normal formula, 
and without immature precursor cells as well as normal hemoglobin (Table 5.1). 
Table 5.1 – Results over time and therapy prescribed for case study 1. 
2014 2016 2017 
January February June September August January 
Platelets 
(×109/L) 
1405 698 375 547 199 1596 
Haemoglobin 
(g/dL) 
14.3 13.4 12.3 12.8 13.9 7.9 
Leucocytes 
(×109/L) 
15.1 6.9 6.2 6.3 3.9 18.9 
JAK2 V617F 
mutation 














Abdominal ultrasound confirmed absent splenomegaly and Bone marrow (BM) aspirate 
showed megakaryocytic hyperplasia and enlarged megakaryocytes, with no abnormalities of the  
myeloid and erythroid series (Figure 5.1). BM biopsy showed a hypercellular marrow (80%), 
megakaryocytic and granulocytic (slight) hyperplasia (Figure 5.2). 
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Figure 5.1 – Case study 1: bone marrow aspirate. 
It showed megakaryocytic hyperplasia and enlarged megakaryocytes, with no abnormalities of the myeloid and 
erythroid series (May-Grünwald-Giemsa stain, x40 and x 100). 
Figure 5.2 – Case study 1: bone marrow biopsy. 
It showed a hypercellular marrow (80%), megakaryocytic and granulocytic (slight) hyperplasia (Hematoxylin eosin 
stain, x40). 
Molecular biology (Figure 5.3) and cytogenetic tests were performed in peripheral blood and 
the results revealed positivity for the JAK2 V617F mutation and a karyotype of 45,X,-Y[5]/46,XY[15]. 
The fluorescence in situ hybridization (FISH) was positive for the BCR-ABL translocation in 16% with 
an atypical pattern. The BCR-ABL transcript was not detected by the conventional reverse 
transcriptase-polymerase chain reaction (RT-PCR) method (specific for p190 and p210 transcripts). 
GENETIC SUSCEPTIBILITY TO MYELOPROLIFERATIVE NEOPLASMS AND THERAPEUTIC EFFICACY 
136 
This high risk patient received a daily hydroxyurea (HU), and low dose aspirin regimen as secondary 
thrombotic prevention. A good response to treatment was achieved, with normalization of leukocytes 
and platelets reduction of greater than 50% after one month and normalization of platelets after five 
months of therapy (Table 5.1). This patient had very poor compliance to the therapy and hospital check-
ups, so Tyrosine Kinase Inhibitor (TKI) that was planned to be introduced, was never started since the 
patient did not come to collect the medication at the hospital.  His clinical and laboratory situation has 
worsened and the patient died by the beginning of 2017, from infectious complications. 
Figure 5.3 – Case study 1: molecular biology test. 
It revealed positivity for the JAK2 V617F mutation (black arrow) in peripheral blood (A1 and A2 – patient; NC 
– negative control; PC – positive control). 
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CASE STUDY 2: 
 
A 76 years old man, with previous history of cardiovascular risk factors, namely Diabetes 
mellitus, dyslipidemia and Ischemic cardiomiopathy submitted to cardiac bypass due to myocardial 
infarction in 2001. 
Presented with isolated thrombocytosis (1022 x109/L) in 2005, which led the patient to the 
Hematology department to study the etiology behind the maintained increased level of platelet count 
(Table 5.2).  
 
Table 5.2 – Results over time and therapy prescribed for case study 2. 
 2005 2009 2013 2016 2017 
 March March September February January August 
Platelets 
(×109/L) 
1022 478 684 909 413 252 
Haemoglobin 
(g/dL) 
14.6 14.7 12.2 13.1 14.1 11.8 
Leucocytes 
(×109/L) 
9.4 6.9 22.4 30.1 38.4 7.3 
JAK2 V617F 
mutation 
-- -- -- -- Positive -- 
BCR/ABL 







    Hydroxyurea            Hydroxyurea   TKI 
                                 TKI     
 
 
In a patient with previous history of thrombotic event, it was imperative to understand the 
etiology of such abnormal changes in blood analysis, since it might have been in close relation to the 
previous cardiac event described.  
At this time, high platelet count was asymptomatic, and there was neither clinical nor analytical 
blood data for detecting an associated inflammatory process or any recent surgeries explaining this 
finding.   
Abdominal ultrasound showed normal spleen morphology, and there were no Howell-Jolly 
bodies nor pitted erythrocytes found in blood smear analysis, that could be interpreted as reactive 
thrombocytosis due to functional hyposplenism. 
Blood sideremia and iron stores were between normal ranges, and no history of hemorrhage 
was present. Excluded secondary causes of thrombocytosis and based on an indolent clinical course, 
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a primary cause was admitted. The MPNs are the most common responsible entities and so 
cytogenetics and molecular biology tests on JAK2 V617F mutation and BCR-ABL t(9;22) were 
performed in peripheral blood. JAK2 V617F was positive and, once again, the fluorescence in situ 
hybridization (FISH) test was positive for the BCR-ABL translocation in 17% with an atypical pattern 
(Figure 5.4), but BCR-ABL transcript was not detected by the conventional (RT-PCR) method. No 
metaphases were observed in the karyotype for evaluation. Having this data discussed, and taking into 
account the presence of these mutations, the diagnosis of ET JAK2 V617F and BCR-ABL positive was 
admitted. The patient started on HU 500mg (alternate day progressing to 1g/alternate day) and TKI 
(Imatinib 400mg/day). A few months later, TKI was suspended and the patient remained under 





Figure 5.4 – Case study 2: FISH test. 




Regarding the methodology used for genetic study, extraction of whole DNA from peripheral 
blood was accomplished by cell lysis followed by ethanol precipitation and recovery of the DNA by 
elution in a buffer solution (QIAamp® DNA Mini kit; Qiagen GmbH, Hilden, Germany). The 
presence/absence of JAK2V617F mutation was determined by amplification refractory mutation system 
(ARMS)-PCR (in-house), based on amplification of a genomic fragment which includes the region 
corresponding to amino acid 617 of the JAK2 protein, and on the differential detection on agarose gel 
of the normal or mutated alleles through the use of allele-specific primers. The test result is qualitative 
and the test sensitivity is 1%. Quantification of JAK2 was obtained by high resolution melting PCR 
(HRM-PCR) (LightCycler® 480 Instrument, Roche), with a sensitivity of about 10% of mutated cells. 
Conventional RT-PCR was performed for the identification of  BCR-ABL  transcripts  (specific  for  p190  
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and p210), after RNA extraction, according to the methodology described by Dongen et al.(van Dongen 
et al., 1999). Results are analyzed on agarose gel electrophoresis. FISH analysis was done on 100 
nuclei after hybridization with specific probes for t(9;22) BCR-ABL (Vysis LSI BCR-ABL Dual Color, 
Dual Fusion Translocation Probe). 
Patients anonymity and consent was guaranteed, in agreement with the Declaration of Helsinki. 
The institutional ethic board approved this report.  
 
5.3 – DISCUSSION 
Several authors have investigated the relationship between JAK2 V617F and BCR-ABL 
anomalies and many theories have been postulated in the last years, especially after the identification 
of JAK2 V617F mutation in 2005.  
The Janus kinase 2 gene (JAK2; cytogenetic location: 9p24.1) provides instructions for making 
a protein that promotes the growth and division (proliferation) of cells. This protein is part of a signaling 
pathway called the JAK/STAT pathway, which transmits chemical signals from outside the cell to the 
cell's nucleus. The JAK2 protein is especially important for controlling the production of blood cells from 
hematopoietic stem cells. These stem cells are located within the bone marrow and have the potential 
to develop into red blood cells, white blood cells, and platelets. 
The Philadelphia chromosome (chromosome 22) results from the reciprocal translocation of 
genetic material between chromosome 9 and chromosome 22, and contains the fusion gene BCR-ABL, 
which codes for a tyrosine kinase signaling protein that causes the cells to divide uncontrollably 
(particularly CML cells). 
From 2007 to 2015, at least 42 patients with this double mutated phenotype were reported in 
the literature (Hummel et al., 2012; Michiels, Ten Kate, De Raeve, & Gadisseur, 2015; Qin et al., 2014; 
Ursuleac et al., 2013). Moreover, the italian group of Pieri et al (Pieri et al., 2011) studied 314 patients 
with CML and identified 8 cases (2.55%) with concomitant JAK2 V617F mutation. Pagnano et al 
(Pagnano et al., 2016) detected only one case with JAK2 V617F mutation among 55 cases of CML 
analyzed.  
Among these different studies reported, several patterns were described: 1) initially diagnosed 
with CML and treated with imatinib that proceeded to a JAK2 V617F myeloproliferative phenotype; 2) 
initially diagnosed with CML coexisting with JAK2 V617F mutation positive PV, ET or PMF; or 3) initially 
diagnosed with JAK2 V617F mutation positive PN-MPN, ET more rarely, evolving years later to CML 
(Qin et al., 2014). Commonly, men above 50 years old were the most frequently affected (Qin et al., 
2014). 
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A question still has to be clarified: which is the first anomaly to occur? Several working groups 
reported that in some cases of PN-MPNs that evolved to CML, JAK2 V617F mutation was the first 
leukemogenic event and BCR-ABL t(9;22) the second positive clone (Qin et al., 2014). Moreover, it was  
also speculated that JAK2 V617F mutations are present in hematopoietic stem cells, with an additional 
BCR-ABL translocation being subsequently acquired in a sub-clone (Heller et al., 2001; Qin et al., 
2014). However, other groups didn’t confirm these results, and postulate that the two anomalies are 
present since the beginning of the process (Qin et al., 2014). Indeed, about the amount of cellular clones 
involved, there are reports that state that two different clones are involved, with the phenotypic 
expression depending on which one of the aberrations is “dominating”, as a result of therapy targeted 
to the other anomaly (Bee, Gan, Nadarajan, Latiff, & Menaka, 2010; Kwong, Chiu, Liang, Chan, & Chan, 
1996; Qin et al., 2014; Zhou et al., 2015). On the other hand, there are some authors evidencing that 
all the myeloid cells bear JAK2 V617F mutation, including granulocytic and erythroid colonies, while 
BCR-ABL translocation is confined to a small compartment of myeloid progenitor cells, only in 
granulocytic colonies (Qin et al., 2014). In contrast, other reports showed the simultaneous presence 
of both BCR-ABL transcript and JAK2 V617F mutation in the majority of granulocytic and erythroid 
colonies at the time CML diagnosis was established, corroborating the hypothesis that only one cellular 
clone is bearing concomitantly the two anomalies (Qin et al., 2014; Zhou et al., 2015). 
Therefore, the phenotypic heterogeneity can be the result of the expression of a pre-existing 
mutated clone previously “silent” or of the accumulation of several genetic events conferring genetic 
instability and leading to a “new” anomaly (Ursuleac et al., 2013). 
As far as we know from literature revision, there are no other reports of positivity for JAK2 
mutations, other than V617F, with the concomitant presence of BCR-ABL translocation. 
One of the diagnostic criteria for ET, is the absence of the Ph chromosome. BCR-ABL positive 
ET without features of CML in blood and bone marrow is a rare entity and constitute less than 5% of 
ET diagnosis. Some authors have proposed to consider those cases as CML associated with a rather 
poor prognosis because of the high tendency to progress to myelofibrosis and blastic transformation 
after a few to several years (Kwong et al., 1996; LeBrun et al., 1991; Michiels et al., 2015). 
An important difference between BCR-ABL positive ET and BCR-ABL positive CML at time of 
presentation is the absence of splenomegaly in the first situation (Michiels et al., 2015). 
The bone marrow in BCR-ABL positive ET is featured by predominant smaller than normal and 
hypo/mononucleated megakaryocytes caused by BCR-ABL gene and protein induced maturation 
defect of the hematopoietic stem cells. This contrasts with clustered enlarged megakaryocytes in BCR-
ABL negative ET due to growth advantage and proliferation of constitutively activated JAK2 or MPL 
somatic mutated megakaryocytes (Michiels et al., 2015). 
The first patient reported had diagnostic features that matched CML and ET. However, his 
overall clinical presentation including bone marrow features was more commonly suggestive of ET. 
Since the t(9;22) was positive in FISH,  according to the results, there should have been found a positive 
result in molecular biology tests as well. Moreover, no Ph chromosome was detected by karyotype.  
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The second patient reported was more suggestive of ET and did not have typical clinical, nor 
morphologic findings for CML. The t(9;22)  was also positive only by FISH, with a negative result in 
molecular biology tests. In this case it was not possible to evaluate karyotype due to metaphases 
absence. 
In both patients, search for JAK2 V617F mutation and BCR-ABL translocation was 
concomitant, making very difficult to know if both mutations were present from the beginning or the 
order of appearance of each one of them. The fact that the study has been performed before therapy 
institution, excludes the possible inhibitory effect of it over one of the altered clones, making the other 
more expressive. 
Given the above, several questions have to be raised: are these genomic alterations found in 
these two patients and their atypical pattern really true and clinically significant or are they false positive 
results? May those be new/distinct clinical entities? Should we consider Ph positive ET as distinct entity, 
separate from Ph negative ET and Ph positive CML? 
As mentioned above, studies describing cases initially diagnosed with JAK2 V617F mutation 
positive PN-MPN, evolving later to CML, were rarely ET patients (Qin et al., 2014), in contrast to our 
report. 
Although, the concomitant presence of these two anomalies in these patients didn’t seemed to 
exclude the diagnosis of ET, at diagnosis or in some point of their clinical course, both patients 
evidenced a distinct clinical (thrombocytosis with associated leukocytosis) or morpho-histological 
(megakaryocytic) phenotype from what was expected for ET with isolated JAK2 V617F positive or Ph 
positive CML, but apparently not influencing the course of the disease. 
Both patients showed an atypical pattern for BCR-ABL translocation search by FISH, said to 
be atypical because only one fusion signal was observed, instead of the two signals expected, with a 
percentage of BCR-ABL translocation of approximately 20%. RT-PCR was performed using only a 
single primer pair, failing the identification of p190 and p210 transcripts of BCR-ABL fusion gene, and 
making the presence of BCR-ABL tyrosine kinase activity questionable. Real time PCR was a distinct 
possible technique to be used for the identification and quantification of BCR-ABL p210 (mainly b3a2 
and b2a2 types) transcripts, however it was not performed. 
Since no BCR-ABL transcripts were detected by RT-PCR, one hypothesis is that the unique 
fusion signal detected by FISH could correspond only to der(9), and not to Ph chromosome with 
associated tyrosine kinase activity (on chromosome 22). Confirmation could be achieved doing FISH in 
metaphases, which was only possible in the first case, since the second patient had no metaphases to 
allow it.  However, this was not done and this way, we were not able to be sure of the localization of 
breakpoints and consequent fusion. 
On the other hand, a missense on the primer site or the probe pairing region could explain such 
RT-PCR result, but there is a vast experience with the used primers, internationally designed and 
certified. 
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Regarding clarification of the possible mechanism of association of JAK2 V617F mutation and 
a “true” BCR-ABL translocation involved in our patients, it would be useful to analyze JAK2 V617F 
mutation and BCR-ABL gene in each colony of BFU-E or CFU-C. 
Given the above, probably these cases correspond to two patients with a variant ET, in which 
we possibly can hypothesize that the presence of der(9) chromosome might be involved in those 
phenotypic differences. As far as we are aware, no other studies describing these two “truly” genomic 
alterations have found a BCR-ABL aberrant pattern similar to our cases. However, Larsen et al  (Larsen, 
Hasselbalch, Pallisgaard, & Kerndrup, 2007) described the case of four patients JAK2 V617F positive 
with associated distinct karyotypic aberrations (including der(9;18)), presenting with a distinct clinical 
and prognostic profile. Likewise, another study also reported the association of der(9) chromosome and 
acute lymphoblastic leukemia (Specchia et al., 2003), with prognostic impact. 
Moreover, WHO does not currently address the classification of MPNs that have more than one 
genetic abnormality, but it is well established that the presence of additional co-operating mutations in 
myeloid genes (along with other important risk factors) has a straight relationship with phenotype and 
clinical outcome definition (Rumi & Cazzola, 2017; Tefferi, 2016). Cytogenetic analysis allows to identify 
subgroups of patients with a distinct phenotype and prognostic profile, and should be performed in 
conjunction with JAK2 mutation analysis PN-MPNs patients (Larsen et al., 2007). 
Furthermore, the concomitant presence of two molecular markers is well defined for certain 
diseases, and raises several issues, including the best therapeutic strategy to adopt. But, therapeutic 
decisions should not be based only on molecular biology test results (Heller et al., 2001). 
CML can express on the background of a JAK2 V617F positive PN-MPN, and treatment with 
TKI might reveal/make more expressive the PN-phenotype. It is of great importance to recognize and 
investigate the association of both anomalies, especially in CML patients who have an unusual 
clinical/laboratorial course, with hemoglobin and/or platelets count increase, or when they do not 
respond to therapy, making the diagnosis of other MPNs to have practical therapeutic consequences. 
It seems that for these complex patients the most efficient therapeutic choice is to associate a 
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The identification of BCR-ABL expression as the defining leukemogenic event in Chronic Myeloid 
Leukemia (CML) and the introduction of BCR-ABL tyrosine kinase inhibitors in 2001 have revolutionized disease 
management, leading to a reduction in mortality rates and accordingly in an increase of the estimated prevalence 
of CML. 
Based on medical records and clinical follow-up, the authors present the case of a Philadelphia 
chromosome-positive CML patient who developed resistance to imatinib.  qRT-PCR testing revealed a V280G 
BCR-ABL mutation.  
This is the first report describing a new BCR-ABL kinase domain mutation - V280G, which might be 
associated with resistance to imatinib. Approximately 15% to 30% of patients treated with imatinib discontinue 
treatment due to resistance or intolerance. More than 90 BCR-ABL mutations were detected so far, conferring 
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CHAPTER 6: BCR-ABL V280G MUTATION POTENTIAL ROLE IN 
IMATINIB RESISTANCE: FIRST CASE REPORT 
 
6.1 – INTRODUCTION 
The identification of BCR-ABL expression as the defining leukemogenic event in Chronic 
Myeloid Leukemia (CML) and the introduction of BCR-ABL tyrosine kinase inhibitors (TKIs) in 2001 has 
marked a paradigm shift in the management of the disease, leading to a reduction in mortality rates and 
accordingly to an increase of the estimated prevalence of CML (Radich, Shah, & Mauro, 2014; Savona, 
2014). 
Imatinib was initially the standard of care for the first-line treatment of CML patients in chronic-
phase, due to its high long-term response rates and favorable tolerability profile compared to previous 
standard therapies (Kantarjian, Cortes, La Rosée, & Hochhaus, 2010; Savona, 2014; Weisberg, 
Manley, Cowan-Jacob, Hochhaus, & Griffin, 2007). 
Approximately 15% to 30% (2% to 4% annually) of patients treated with imatinib discontinue 
treatment after 6 years due to resistance or intolerance, particularly in the accelerated and blast phase 
(Kantarjian et al., 2010; Nicolini et al., 2006; Radich et al., 2014; Weisberg et al., 2007). 
Inadequate response to TKI therapy is associated with poor long-term outcome. More than 90 
BCR-ABL mutations were detected so far, most frequently the T315I and E255K mutations, conferring 
variable degrees of drug resistance (Nicolini et al., 2006; Soverini et al., 2006). 
Below we report the case of a CML patient who developed resistance to imatinib, presenting a 
new kinase domain mutation - V280G – that has never been described in the literature. 
The patient’s anonymity and consent was guaranteed, in agreement with the Declaration of 
Helsinki. The institutional ethic board approved this report.  
 
6.2 – CASE REPORT 
A 75 years old female patient, leucodermic, referred to the Oncology consultation, was 
diagnosed with chronic phase CML in April 2003 after routine tests, compatible bone marrow study and 
cytogenetics with a classic Philadelphia chromosome involving the reciprocal translocation of 
chromosomes 9 and 22 (BCR-ABL transcripts not evaluated). Complete blood count results, BCR-ABL 
transcript levels evaluation and treatment options over time are presented in Tables 6.1 and 6.2).  Past 
medical history was not relevant and physical examination did not reveal splenomegaly, nor 
constitutional symptoms. Abdominal ultrasound showed a spleen with 10,05,9 cm. She was given an 
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intermediate-risk Sokal score (Sokal et al., 1984) (0,84) and Hasford score (Hasford et al., 1998) 
(931,5), but low-risk EUTOS score (Hasford et al., 2011) (40). At that time, she started hydroxyurea 
500mg/day and alpha-interferon 3 million units/5 times per week, with a complete hematological 
response (CHR) three months later. Repetition of the bone marrow study in December 2003 showed a 




Table 6.1 – Complete blood count results over time. 
 April 2003 January 2005 May 2013 
Haemoglobin (g/L) 117 121 137 
Leucocytes (×109/L) 29.9 24.0 8.59 
Blasts (×109/L; %) 0.32; 1 0 0 
Myelocytes (×109/L) 0.32 1.53 0 
Metamyelocytes (×109/L) 2.6 0.65 0 
Neutrophils (×109/L) 18.51 13.30 5.25 
Lymphocytes (×109/L) 6.17 2.83 2.70 
Monocytes (×109/L) 0.32 0.65 0.59 
Eosinophils (×109/L) 1.62 0.65 0.03 
Basophils (×109/L) 0 4.36 0.02 




Table 6.2 –  BCR-ABL transcript levels evaluation and treatment over time. 

















2.74 8.0 to 0.0 
Treatment 
HU 500mg/day 








HU – Hydroxyurea; Alfa-IF – alfa-interferon 
 
 
The patient continued initial therapy until January 2005, when she revealed signs of disease 
progression and therapeutic failure. Abdominal ultrasound did not reveal splenomegaly. She was 
started on imatinib at a dose of 300mg/day, obtaining a  partial cytogenetic response (BCR-ABL p210 
– 4.3% on the International Scale (IS)) in June 2007. A marrow study revealed some degree of fibrosis, 
with no disease infiltration. 
 






In January 2010, BCR-ABL p210 was positive (maximum 0.98%) and an increase (maximum 
2.07%) was detected by December 2010, which motivated her referral to our Hematology consultation  
by February 2011. Although the bone marrow maintained in remission, the BCR-ABL p210 transcript 
number was persistently increased (maximum 2.63%), which led us to increase the imatinib dose from 
300mg to 400mg/day.  
After six months of imatinib dose increase, the number of BCR-ABL p210 transcripts decreased 
(0.53%) and, given the good hematological and molecular responses, the imatinib dose was 
maintained.  
By October 2012, although the patient maintained a CHR, a major molecular response (MMR) 
was never achieved, with a progressive increase of the BCR-ABL transcripts (2.74%). As a result of the 
failure to obtain an adequate molecular response, resistance to imatinib was investigated. We 
performed a nested qRT-PCR and bidirectional sequencing (as previously described (Gromicho et al., 
2013)) to carry-out a BCR-ABL kinase domain mutational analysis. This study showed a mutation on 
the amino acid 280, resulting in the substitution of valine (V) by glycine (G), present in all transcripts 
(c.839T>G V280G mutation) (Figure 6.1), and negative in DNA samples from the gum mucosa.  
On February 2013 BCR-ABL p210 was positive (8.0%). Imatinib was discontinued due to 
resistance and the patient was started on nilotinib 400mg/twice a day.  
In May 2013, the patient revealed a good clinical and laboratorial response to therapy, with 
CCyR and CMR.  
Currently, the patient maintains the same nilotinib dose, without evidence of loss of 




Figure 6.1 –  BCR-ABL tyrosine kinase domain mutation analysis in peripheral blood. 
It revealed c.839T>G (V280G mutation), in which GTG->GGG (valine to glycine). 
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6.3 – DISCUSSION AND CONCLUSIONS 
TKI therapy with imatinib, dasatinib or nilotinib has resulted in a remarkable improvement in 
clinical outcomes for CML patients diagnosed in chronic phase. The optimization of monitoring methods 
and the identification of factors associated with response and long-term outcomes has thus been a 
major clinical research focus, contributing to recent updates to clinical practice guidelines (Savona, 
2014). 
In the case presented here, the patient had been previously diagnosed and followed in another 
hospital center and there was no registry in the process file about the reason why it was decided to start 
treatment with a subtherapeutic imatinib dose. Although not consensual in the literature (Hayakawa et 
al., 2013; Liu, Li, Pao, & Michor, 2015; Santos et al., 2010; Tang et al., 2011; Van Obbergh et al., 2016; 
Vine et al., 2014), this probably contributed to a worse molecular response and to imatinib treatment 
failure, even after increase of the dose in 2011, when the patient was referred to our consultation. At 
the moment, it is not specified which of the three TKIs currently approved for the first-line treatment of 
chronic phase CML is preferred, and although no evidence from clinical trials is available to support the  
superiority of second-generation TKIs over imatinib with respect to survival outcomes, they induce the 
achievement of faster and deeper molecular responses, associated with better long-term outcomes, 
less progression to advanced phases, and the possibility of treatment discontinuation (Cortes et al., 
2016; Hochhaus et al., 2016; McDougall, Ramsey, & Radich, 2016; Sundar & Radich, 2016). 
The IRIS trial has demonstrated that imatinib induces high durable responses and improves 
survival in a large proportion of patients with newly diagnosed chronic phase, compared to interferon 
(Druker et al., 2006; Sundar & Radich, 2016). On the other hand, DASISION and ENESTnd studies 
showed that dasatinib and nilotinib induce superior cytogenetic and molecular responses and lower 
rates of progression to accelerated or blast phase, when compared to imatinib (Cortes et al., 2016; 
Hochhaus et al., 2016). 
Although imatinib is still recommended as a reasonable first-line option for patients with newly 
diagnosed chronic phase, the selection of first-line TKI depends on the risk score (Sokal and Hasford), 
physician’s experience, toxicity profile, patient’s age, tolerance and adherence to therapy as well as 
comorbidities (Sundar & Radich, 2016). 
Allogeneic HCT, which was the treatment of choice for CML before the advent of TKI therapy, 
is now generally reserved for patients in chronic phase resistant to multiple or unable to tolerate TKIs,  
those who have the T315I mutation and who are not suitable for prolonged ponatinib therapy, or for 
those progressing to accelerated or blast phases (Sundar & Radich, 2016). 
Because most CML patients treated with imatinib achieve CCyR (CCyR roughly corresponds 
to a BCR-ABL level of <1% IS), both the National Comprehensive Cancer Network (NCCN) and the 
European Leukemia Net (ELN) guidelines emphasize adequate monitoring and measurement of 
residual disease through sensitive molecular methods such as quantification of BCR-ABL transcript 
levels and real-time  quantitative  PCR (qRT-PCR),  to  ensure  that  patients  are  meeting  the  treatment  
 






milestones (Baccarani et al., 2013; Cortes et al., 2016; Deininger, 2015; O'Brien et al., 2014; Soverini, 
de Benedittis, Mancini, & Martinelli, 2015). 
Although most of these patients respond to first-line TKI therapy, the use of TKIs is hindered 
by the development of resistance or intolerance in some patients, resulting in a loss of response or 
discontinuation of treatment. This is most commonly associated with the acquisition of resistance-
conferring kinase domain point mutations within BCR-ABL, which prevent the binding of imatinib to the 
kinase domain, additional chromosome abnormalities to the Philadelphia chromosome, and/or 
mutations in genes such as ASXL1, TET2, RUNX1, DNMT3A, EZH2, and TP53 among others (Radich 
et al., 2014; Soverini et al., 2015; Soverini et al., 2011). According to ELN 2013 criteria it is 
recommended in these cases to perform a mutational analysis (Cortes et al., 2016; Soverini et al., 
2014). The recommended methodology is direct sequencing, although it may be preceded by screening 
with other techniques, such as denaturing-high performance liquid chromatography (Deininger, 2015; 
Soverini et al., 2011). 
Next-generation deep sequencing, complemented with bioinformatics support, mass 
spectrometry and digital PCR are emerging promising techniques to ensure reliable detection of BCR-
ABL mutations, allowing early therapy switch and selection of the most appropriate therapy (Machova 
Polakova et al., 2015; Soverini et al., 2014). 
Current data support that for CML patients who fail treatment goals, with primary resistance or 
intolerance to imatinib, hematologic disease recurrence, or emergent BCR-ABL kinase domain 
mutations, imatinib dose escalation may not be sufficient to control the disease and substitution with 
another TKI will be necessary (Baccarani et al., 2013; Jabbour, Saglio, Hughes, & Kantarjian, 2012; 
Kantarjian et al., 2010; Soverini et al., 2014; Soverini et al., 2011; Sundar & Radich, 2016). Patients 
should be carefully evaluated for alternative treatment options, including dasatinib, nilotinib, bosutinib, 
and ponatinib, as well as the non-TKI salvage agent omacetaxine mepesuccinate. Treatment selection 
is based on factors such as the patient’s disease state, prior therapies, type of mutation, comorbidities, 
treatment toxicity, and therapy goals (Kantarjian et al., 2010; Radich et al., 2014). 
A literature review shows that pre-existing mutations at baseline confer a more aggressive 
disease phenotype and patients with advanced stages of the disease often do not respond to therapy 
or relapse (Nicolini et al., 2006; Soverini et al., 2006; Sundar & Radich, 2016). 
There is no reference in the literature on the association between CML/other pathology and the 
c.839T>G V280G mutation, as detected in this case. Gruber et al. have used the V280G variant in their 
study about the biological significance of aberrant AID expression in a murine model of BCR-ABL1 
driven B-cell lineage Acute Lymphoblastic Leukemia (Gruber, Chang, Sposto, & Müschen, 2010), but 
this was based on the results presented in a previous publication of Soverini et al (2006) (Soverini et 
al., 2006).  However, Soverini et al. described in 2011 (Soverini et al., 2011) a mutation in the same 
codon position, involving different amino acids, associated with imatinib resistance in CML patients. 
The mutation presented in this case report causes a substitution of a valine by a glycine at amino acid 
280, in the kinase active domain, being the only alteration found in this patient after BCR-ABL mutation 
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analysis. A DNA sample of gum mucosa was negative for this type of mutation, which allowed us to 
conclude that acquired V280G variant was indeed a characteristic of the leukemic clone, rather than a 
polymorphism. This finding led us to hypothesize that this mutation might be associated with de novo 
resistance to treatment with imatinib. The favorable clinical and hematological parameters to nilotinib 
also support this statement. However, studies in a larger population and of functional character should 
be performed in order to evaluate the prevalence of this mutation and its association with imatinib 
resistance and to determine whether this mutation can be grouped with other similar mutations to better 
indicate nilotinib as a first-choice treatment. It will also be useful to have functional analyses to better 
characterize this mutation and show if it affects the ability of imatinib to bind or inhibit BCR-ABL. 
Regular monitoring of BCR-ABL levels, effective management of toxicities, and patient 
education on adherence to TKI therapy are essential to provide optimal treatment.  
The possibility of resistance to treatment should promote a rational development of alternative, 
synergistic and potentially curative strategies.  
The more complete knowledge about the disease and its mutational characterization will allow 
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CHAPTER 7:  
THE ROLE OF CASPASE GENES POLYMORPHISMS IN  
GENETIC SUSCEPTIBILITY TO PHILADELPHIA-NEGATIVE 
MYELOPROLIFERATIVE NEOPLASMS  
IN A PORTUGUESE POPULATION 





Our main aim was to evaluate the role of caspases’ genes SNPs in Philadelphia-chromosome negative 
chronic myeloproliferative neoplasms (PN-MPNs) susceptibility. 
We carried-out a case-control study in 133 Caucasian Portuguese PN-MPNs patients and 281 matched 
controls, studying SNPs in apoptosis related caspases: rs1045485 and rs1035142 (CASP8), rs1052576, 
rs2308950, rs1132312 and rs1052571 (CASP9), rs2227309 and rs2227310 (CASP7) and rs13006529 (CASP10).  
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After stratification by pathology diagnosis for essential thrombocythemia (ET), female gender or JAK2 
positive, there is a significant increased risk to those carrying at least one variant allele for CASP9 (C653T) 
polymorphism (OR 2.203 CI 95% [1.163 – 4.176], P=0.015; OR 4.370 CI95% [1.608 – 11.873], P=0.004; and OR 
2.886 CI 95% [1.303 – 6.393], P=0.009, respectively). However, when considered individually, none of the studied 
caspases polymorphisms was associated with PN-MPNs risk.  
Our results do not reveal a significant involvement of caspase genes polymorphisms on the individually 
susceptibility towards PN-MPNs as a whole. However, for essential thrombocythemia (ET), female gender or JAK2 
positive, there is a significant increased risk to those carrying at least one variant allele for CASP9. Although larger 
studies are required to confirm these results and to provide conclusive evidence of association between these and 
other caspases variants and PN-MPNs susceptibility, these new data may contribute to a best knowledge of the 
pathophysiology of these disorders and, in the future, to a more rational and efficient choice of therapeutic 
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CHAPTER 7: THE ROLE OF CASPASE GENES POLYMORPHISMS 
AND GENETIC SUSCEPTIBILITY TO PHILADELPHIA-NEGATIVE 




7.1 – INTRODUCTION 
According to the World Health Organization (WHO-IARC) classification myeloproliferative 
neoplasms (MPNs) encompass various conditions including chronic myelogenous leukemia (CML) and 
the most common Philadelphia-negative myeloproliferative neoplasms (PN-MPNs), polycythemia vera 
(PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) (Arber et al., 2016; Swerdlow 
& SH, 2008). 
Genetic insights into the pathogenesis of the PN-MPNs include the discovery of the somatic 
point gain-of-function mutations in the Janus kinase 2 gene (JAK2; exon 14 V617F and exon 12 
mutations) (Baxter et al., 2005; James et al., 2005; Kralovics et al., 2005; Levine et al., 2005; Scott et 
al., 2007), the myeloproliferative leukemia virus oncogene (MPL; more frequently W515), and recently 
calreticulin (CALR) mutations, which modified the understanding of these diseases, their diagnosis and 
management (Baxter et al., 2005; James et al., 2005; Kralovics et al., 2005; Levine et al., 2005; Scott 
et al., 2007; Tognon, Nunes, & Castro, 2013). Frequencies of these mutations are approximately 95%, 
0%, and 0% in PV, 60%, 3%, and 20% in ET, and 60%, 7%, and 25% in PMF, respectively (Nangalia 
et al., 2013; Tefferi & Pardanani, 2015). However, the cellular and molecular mechanisms involved in 
the pathophysiology of MPNs have not yet been fully clarified. Genetic alterations still await 
identification in around 40% of ET and PMF cases and, moreover, these mutations cannot fully explain 
the phenotypic heterogeneity of PN-MPNs. One possible reason is that the outcome of a mutation can 
depend upon other genetic variants in the genome (Rice et al., 2011; Rueff & Rodrigues, 2016). Indeed, 
the possible role of silencing of SOCS (suppressors of cytokine signalling) by mutations or epigenomic 
silencing may result in the loss of negative regulators of JAK/STAT pathways. SOCS proteins bind to 
phosphotyrosine residues of JAK and may act as tumor suppressor genes, unless mutated or 
epigenetically silenced which may occur in PN-MPNs even if no mutation is present in the JAK2 gene 
(Valentino & Pierre, 2006).   
Besides modifier genes such as the SOCS genes whose proteins inhibit STAT phosphorylation 
by binding and inhibiting JAKs, polymorphic variants of several genes together with environmental 
exposure/dietary exposure and immune system characteristics, could predispose to the susceptibility 
to these disorders (Beer et al., 2010; Björkholm, Hultcrantz, & Derolf, 2014; Bolufer et al., 2006; 
Delhommeau, Jeziorowska, Marzac, & Casadevall, 2010; Kilpivaara & Levine, 2008). Thus, Single 
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Nucleotide Polymorphisms (SNP’s) at various loci may be important for individual susceptibility risk to 
PN-MPNs, although less specific, but prognostically relevant (Campregher, Santos, Perini, & 
Hamerschlak, 2012; Delhommeau et al., 2010; Levine, 2009; Nangalia et al., 2013; Tefferi & Pardanani, 
2015). 
Apoptosis is a programmed cell death process, acting as a defense mechanism against 
damaged or stressed cells, to prevent accumulation of non-functional or damaged cells in the tissues. 
Identification of apoptotic mechanisms is critical and disturbed apoptosis pathways may lead to an 
accumulation of mutations that may eventually lead to cancer (Goldar, Khaniani, Derakhshan, & 
Baradaran, 2015; Kiraz, Adan, Kartal Yandim, & Baran, 2016).  
The hematopoietic system is particularly sensitive to deregulation of the apoptotic process as 
these cells undergo a high turnover rate, requiring a tight balance between apoptosis and proliferation. 
Accordingly, apoptosis is frequently deregulated in  hematologic malignancies (Zaman, Wang, & 
Gandhi, 2014). 
Activation of apoptosis occurs through two major routes: the intrinsic and the extrinsic ones. 
The intrinsic or mitochondrial route may be initiated by various apoptogenic stimuli, such as agents that 
cause DNA damage, rupture of microtubules, and deficiency or absence of cell growth factors. The 
extrinsic route is activated by death receptors of the tumor necrosis factor (TNF) family (Green & Llambi, 
2015; Kiraz et al., 2016; Tognon et al., 2013). Caspases play a key regulatory role in both intrinsic and 
extrinsic pathways. Three groups of mammalian caspases exists on the basis of specific functions in 
different pathways, including developmental, inflammatory, and apoptotic pathways (Goldar et al., 2015; 
Green & Llambi, 2015). The executioner caspases act in various substrates in the cytoplasm and 
nucleus, resulting in cellular death.  
Deregulation of pro- and anti-apoptotic genes express as cell resistance to apoptosis, 
culminating with the accumulation of myeloid cells and the establishing of neoplasms (Nunes et al., 
2013; Olsson & Zhivotovsky, 2011; Tognon et al., 2011; Tognon et al., 2012; Tognon et al., 2013; 
Tognon et al., 2016). 
A wider characterization of molecular genetic features in PN-MPNs may contribute to a better 
understanding of the pathogenesis of these diseases and provide new specific diagnostic, prognostic, 
and therapeutic tools (Delhommeau et al., 2010; Mambet, Matei, Necula, & Diaconu, 2016). However, 
to date no studies have associated polymorphisms in caspases genes and risk for PN-MPNs.  
Thus, the present work describes a hospital based case-control study in a Caucasian 
Portuguese population in order to evaluate the potential modifying role of nine apoptosis related 
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7.2 – MATERIALS AND METHODS 
7.2.1 – STUDY SUBJECTS 
The description given in Chapter 3, section 3.2.1 applies in this new chapter. 
General characteristics for PN-MPNs patients and control populations are summarized in Table 
7.1. 
7.2.2 – DNA EXTRACTION 
The methodology used is described in Chapter 3, section 3.2.2. 
7.2.3 – SNP SELECTION (CASPASES) 
Publicly available on-line databases such as NCBI (http://www.ncbi.nlm.nih.gov/projects/snp/), 
GeneCards (http://www.genecards.org) and SNP500Cancer 
(http://variantgps.nci.nih.gov/cgfseq/pages/snp500.do) were used to search for SNP’s reported to date 
on genes coding for mediators of apoptosis, to be included in this work. The eligible SNP’s in the present 
study had to be located in a coding region giving rise to an amino acid change (non-synonymous SNP’s) 
and exhibit a minor allele frequency (MAF) >0.1 in Caucasian populations (Table 7.2). 
 
7.2.4 – GENOTYPING 
The polymorphisms rs2227309 and rs2227310 (CASP7), rs1045485 and rs1035142 (CASP8), 
rs2308950, rs1132312 and rs1052571 (CASP9) and rs13006529 (CASP10) and JAK2 V617F mutation 
were genotyped using the same methodology described in Chapter 3, section 3.2.3. 
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7.2.5 – STATISTICAL ANALYSIS 
 
The analysis of Hardy-Weinberg frequencies for all alleles in the control and patients’ 
populations and the differences in genotype frequency, smoking/alcohol consumption status, age class 
and gender distributions between PN-MPNs cancer patients and controls were evaluated using the 
same statistical approach described in Chapter 3, section 3.2.4. 
The crude and adjusted odds ratio (OR) and the corresponding 95% confidence intervals (CI) 
were calculated using unconditional multiple logistic regression. The model for adjusted OR included 
terms for gender, age at diagnosis (30-49, 50-69 and ≥70 years), smoking habits (smokers/non-
smokers), and alcohol habits (never, social and regular consumption) with male sex, lower age group 
and non-smokers/non-alcohol consumers being considered as the reference groups for each of these 
variables. For the purpose of these calculations, age at diagnosis for controls was the age at the time 
of diagnosis for the matched case. All analyses were performed using the Statistical Package for the 
Social Sciences for Windows 22.0 version (SPSS, Inc.) (Table 7.3, 7.4 and 7.5). Since this is not a 
conclusive final study but an exploratory one on the role of apoptosis related caspases polymorphisms 
in PN-MPNs and the data to be obtained should be looked at as proof of concept, the Bonferroni 
adjustment was deemed as not necessary as it is too conservative. 
 
7.3 – RESULTS 
7.3.1 – CHARACTERIZATION OF POPULATIONS 
This study included 133 PN-MPNs patients and 281 age- and sex-matched controls. The 
baseline characteristics (sex, age alcohol consumption and smoking habits) of both case and control 
populations are listed in Table 7.1. The case group included 72 (54.1%) females and 61 (45.9%) male 
patients, with an overall mean age of 68 years, in agreement with the gender distribution usually 
observed in this type of pathology. No significant differences were found between the case and control 
groups concerning age distribution or smoking habits (see Table 7.1).  However, alcohol consumption 
is significantly increased in patients when compared with control group (P<0.0001) (see Table 7.1).  
According to diagnosis criteria patients’ distribution was as follows: 80 (60.2%) with ET, 39 
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Table 7.1 – General characteristics for the PN-MPNs case and control populations and gender 
distribution for the PN-MPNs cases. 
PN-MPNs cases n=133; Control population n=281. 
 
Characteristics Cases, n (%) Controls, n (%) P value 
Gender 
    Male 









    30-49 
    50-69 











    Never 









    Never 
    Social 










Diagnosis                                                            n 
                                                          Male n (%); Female n (%) 
    ET                                                                  80                             
                                                             32 (40.0); 48 (60.0) 
    PV                                                                  39 
                                                             20 (51.3); 19 (48.7) 
    PMF                                                               14 
                                                                9 (64.3); 5 (35.7) 
 
 
JAK2 V617F mutation 
    Yes 
        ET 
        PV 
        PMF 












Age of diagnosis for cases. 
b
 Age of control population at the time of diagnosis for the matched case. 
 
7.3.2 – SNP’S GENOTYPING 
The characteristics of each SNP under study are described in Table 7.2, while the genotype 
frequencies determined for all of them are shown in Table 7.3. All of the SNP’s studied were in 
agreement with expectation of the Hardy-Weinberg law (P>0.05, exact probability test), except for 
CASP8_rs1045485 and for CASP9_rs2308950 (P=0.006 and P=0.034 respectively, exact probability 
test). 
The results obtained revealed that after stratification by pathology diagnosis our results showed 
(Table 7.3) a significant increased risk for patients diagnosed with ET presenting at least one variant 
allele (T) of CASP9_rs1132312 polymorphism: for heterozygous individuals (OR 2.300 CI 95% [1.180 
– 4.484], P=0.014) as well as for the combination of heterozygous with homozygous for variant allele 
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(OR 2.203 CI 95% [1.163 – 4.176], P=0.015). The same effect was found, after stratification by gender, 
in women (OR 4.370 CI95% [1.608 – 11.873], P=0.004) considering the presence of at least one variant 
allele. According to our results, the increased risk was verified in all sub-groups, as can be seen in 
Table 7.3, although when considered individually, none of the polymorphisms studied were associated 
with PN-MPNs risk (Table 7.4). No significant difference was found between the case and control 
groups concerning age distribution, gender, smoking habits or genotype frequencies (Table 7.4).  The 
relevance of JAK2 mutation in PN-MPNs is well known. Thus, the population was also stratified 
according to the presence of JAK2 mutation in patients, showing that there is also a significant 
increased risk for patients diagnosed with ET when at least one variant allele (T) for CASP9_rs1132312 
polymorphism is present (OR 2.886 CI 95% [1.303 – 6.393], P=0.009) (Table 7.3). 
 
 
Table 7.2 – Selected SNPs and detailed information on the corresponding base and amino acid 
exchanges as well as minor allele frequency. 
Gene dsSNP Codon 
Nucleotide 
exchange 
        Minor allele frequency, 
                 MAF (%)a 
 
     
CASP7  
(Chr 10) 









































(Chr 2)  rs13006529 522 
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Table 7.3 – Genotype distribution and myeloproliferative risk. 
For the CASP7Lys249Arg, CASP7Asp255Glu, CASP8Asp302His, CASP8Tyr12STOP, CASP9Arg173His, 
CASP9Phe136Phe, CASP9Val28Ala, and CASP10Ile522Leu polymorphisms in the MNPs case (n=133) and 




Controls, n (%) Cases, n (%) P 
valuea 




CASP7 (Lys249Arg; rs2227309)     
    G/G 
    G/A 
    A/A 












0.917 (0.595 – 1.414) 
0.750 (0.282 – 1.993) 
0.896 (0.590 – 1.360) 
1 (Reference) 
0.899 (0.578 – 1.398) 
0.855 (0.309 – 2.364) 
0.894 (0.583 – 1.370) 
CASP7 (Asp255Glu; rs2227310)     
    C/C 
    C/G 
    G/G 












1.035 (0.671 – 1.596) 
0.923 (0.364 – 2.341) 
1.020 (0.672 – 1.549) 
1 (Reference) 
1.032 (0.662 – 1.608) 
1.014 (0.386 – 2.669) 
1.030 (0.671 – 1.580) 
CASP8 (Asp270His; rs1045485)     
    G/G 
    G/C 
    C/C 













1.110 (0.655 – 1.882) 
1.361 (0.435 – 4.265) 
1.144 (0.698 – 1.877) 
1 (Reference) 
1.092 (0.634 – 1.881) 
1.194 (0.372 – 3.829) 
1.083 (0.643 – 1.823) 
CASP8 (3’UTR; rs1035142)     
    G/G 
    G/T 
    T/T 












0.864 (0.548 – 1.362) 
0.948 (0.514 – 1.752) 
0.885 (0.576 – 1.358) 
1 (Reference) 
0.861 (0.540 – 1.375) 
1.072 (0.568 – 2.025 
0.912 (0.581 – 1.432) 
CASP9 (Arg173His; rs2308950)     
    G/G 
    G/A 
    A/A 












2.140 (0.426 – 10.746) 
ND 
2.853 (0.629 – 12.932) 
1 (Reference) 
1.704 (0.335 – 8.661) 
ND 
2.170 (0.472 – 9.983) 
CASP9 (Phe136Phe; rs1132312)     
    C/C 
    C/T 
    T/T 












1.622 (0.984 – 2.675) 
1.228 (0.671 – 2.247) 
1.491 (0.927 – 2.398) 
1 (Reference) 
1.669 (1.000 – 2.783) 
1.299 (0.699 – 2.413) 
1.548 (0.952 – 2.517) 
CASP9 (Ala28Val; rs1052571)     
    C/C 
    C/T 
    T/T 
    C/T + T/T 
70 (25.1) 










1.606 (0.937 – 2.753) 
1.190 (0.648 – 2.186) 
1.447 (0.861 – 2.415) 
1 (Reference) 
1.580 (0.911 – 2.743) 
1.150 (0.618 – 2.142) 
1.415 (0.838 – 2.390) 
CASP10 (Ile522Leu; rs13006529)     
    A/A 
    A/T 
    T/T 
    A/T + T/T 
82 (29.4) 










1.074 (0.651 – 1.773) 
0.831 (0.461 – 1.499) 
0.983 (0.616 – 1.568) 
1 (Reference) 
1.113 (0.675 – 1.834) 
0.893 (0.496 – 1.608) 
0.973 (0.602 – 1.572) 
a P-value determined by χ2 test. b ORs were adjusted for age (30–49, 50–69, >70 years), smoking status (never and former, and current) and 
alcohol consumption (never, social and regular drinkers). 
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  C/C 
  C/T 
  T/T 
  C//T + T/T 
0.050 
1 (Reference) 
2.233 (1.157 – 4.309) 
1.942 (0.912 – 4.133) 
2.136 (1.138 – 4.010) 
1 (Reference) 
2.300 (1.180 – 4.484) 
2.009 (0.932 – 4.330) 





  C/C 
  C/T 
  T/T 
  C//T + T/T 
0.009 
1 (Reference) 
4.403 (1.599 – 12.126)† 
3.920 (1.256 – 12.231) 
4.257 (1.586 – 11.425)* 
1 (Reference) 
4.663 (1.667 – 13.045)†† 
3.777 (1.198 – 11.911) 






  C/C 
  C/T 
  T/T 
  C//T + T/T 
0.021 
1 (Reference) 
3.059 (1.356 – 6.896)‡ 
2.379 (0.942 – 6.009) 
2.832 (1.288 – 6.229)+ 
1 (Reference) 
3.104 (1.366 – 7.052)‡‡ 
2.447 (0.960 – 6.239) 
2.886 (1.303 – 6.393)++ 
PCrude = 0.017; PAdjusted = 0.014 (P-values are adjusted by unconditional multiplicative logistic regression). 
PCrude = 0.018; PAdjusted = 0.015 (P-values are adjusted by unconditional multiplicative logistic regression). 
†PCrude = 0.004; ††PAdjusted = 0.003 (P-values are adjusted by unconditional multiplicative logistic regression).  
PCrude = 0.019; PAdjusted = 0.023 (P-values are adjusted by unconditional multiplicative logistic regression).  
*PCrude = 0.004; **PAdjusted = 0.004 (P-values are adjusted by unconditional multiplicative logistic regression). 
‡PCrude = 0.007; ‡‡PAdjusted = 0.007 (P-values are adjusted by unconditional multiplicative logistic regression) 
+PCrude = 0.010; ++PAdjusted = 0.009 (P-values are adjusted by unconditional multiplicative logistic regression) 
 
a P-value determined by χ2 test. 




7.3.3 – HAPLOGROUP ASSOCIATION 
A key point that should be explored in studies such as this, is the effect of the combination of 
all genotypes since the real situation is the effect of the variants altogether. That was achieved using 
the SNPStat software and the results yielded fifty-one different combinations (data not shown). It should 
be noted that of all genetic variants under study, only the SNPs of CASP8 and CASP7 genes were in 
linkage disequilibrium (LD). According to the results obtained (Table 7.5), we could only establish a 
positive haplotype for CASP9 gene correlated with a decreased risk for PN-MPN diseases in 
individuals. 
Concerning the number of SNPs of the different genes under study, and grouping the effector 
caspase genes as a whole, we stablished a new haplogroup (Table 7.6). The result obtained 
substantiate the decreased risk for PN-MPN in our population, as observed for CASP9 haplogroup. To 
our knowledge, this is the first study where this kind of association is described. 
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Table 7.5 – Haplotype association response for SNPs of CASP9 gene. 
These genetic variants did not reveal the presence of LD. 
 
Haplotype association response  
CASP9 
OR (95% CI) P Value 
rs2308950 rs1132312 rs1052571 
G C T 1.00 (Reference)  
G T C 1.15 (0.79 – 1.68) 0.46 
G C C 0.24 (0.11 – 0.52) 3e-4 
G T T 0.41 (0.25 – 0.70) 0.001 
 
 




7.4 – DISCUSSION AND CONCLUSIONS 
Polymorphisms in apoptosis related genes may contribute to individual susceptibility to MPNs 
and, hence, modify disease risk. However, to the best of our knowledge, no clinical association studies 
have been performed thus far to evaluate the role of caspases genes polymorphisms on PN-MPNs 
susceptibility.  
The present study revealed an increased incidence of JAK2 V617F mutation in ET patients and 
a decreased incidence in PV patients, compared with the literature (Nangalia et al., 2013; Tefferi & 
Pardanani, 2015), probably due to the small population studied. Moreover, the cases included were 
incident cases diagnosed in a hospital hematological consultation.  
This study was intended to ascertain the possible role of genetic polymorphisms CASP8 
(Asp302His and 3’UTR_G/T), CASP9 (Arg221Gln, Arg173His, Phe136Phe and Ala28Val), CASP7 
(Lys249Arg and Asp255Glu) and CASP10 (Ile522Leu), on the individual susceptibility for PN-MPNs. 
Caspases are main components of apoptosis pathway. This specific group of cysteine aspartate 
proteases are a family of intracellular proteins involved in the initiation and execution of apoptotic 
processes, responsible for the dismantling and destruction of the cell components (Green & Llambi, 
2015; Riedl & Salvesen, 2007). These proteins are produced as proenzymes (zymogens) and can be 
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activated by proteolytic cleavage in response to various apoptotic stimuli. Each caspase is cleaved to 
produce a large and a small subunits, forming an active tetrameric form from two molecules of pro-
enzyme (Cho & Choi, 2002).  
There are 14 different caspases can be classified as initiator, effector and cytokine activators 
(Kiraz et al., 2016). The initiator caspases (caspase-2, 8, 9, 10) activate the effector caspases (caspase 
3, 6, 7 and 14), which are capable of degrading direct multiple substrates leading to deregulation of vital 
cellular processes and cellular death (Kiraz et al., 2016; Ng, Porter, & Jänicke, 1999; Oliver & Vallette, 
2005; Philchenkov, Zavelevich, Kroczak, & Los, 2004; Riedl & Salvesen, 2007), and also the cytokine 
activator caspases (caspase 1, 4, 5, 11, 12 and 13).   
While initiator caspases are self-activated, effector caspases activation is dependent of initiator 
caspases via internal cleavages. Furthermore, most of caspase family members are functional in 
cellular proliferation, survival, and inflammation, whereas some of them are essential for apoptosis 
(Kiraz et al., 2016). 
All stimuli that lead to apoptosis appear to initiate a sequence of events that culminate in the 
activation of caspases, but they do it in different ways. Three pathways are associated with activation 
of caspases: (1) the intrinsic or mitochondrial pathway, which is initiated by cellular stress signals such 
as DNA damage (induced by genotoxic agents or defects in DNA repair), endoplasmic reticulum (ER) 
stress (induced by the accumulation of unfolded proteins), rupture of microtubules, this pathway 
converge on mitochondria, resulting in permeabilization of the outer membrane and subsequent 
cytochrome c release (Green & Kroemer, 2004; Petit, Oliver, & Vallette, 2009); (2) the extrinsic pathway, 
which is initiated by the activation of death membrane receptors of the tumor necrosis factor (TNF) 
family, induced by ligands; and (3) the pathway involving granzyme B (Creagh, Conroy, & Martin, 2003; 
Green & Llambi, 2015; Kiraz et al., 2016; Peter & Krammer, 2003; Tognon et al., 2013; Wang, 2001). 
Various proteins promote pro- or anti- apoptotic activity in the cell. The ratio of the pro-and anti-
apoptotic proteins plays an important role in the regulation of cell death, and disruption in the balance 
between these proteins has been established to contribute to carcinogenesis by reducing apoptosis in 
malignant cells (Ding et al., 2000; Goldar et al., 2015; Olsson & Zhivotovsky, 2011). In particular in 
MPNs, the deregulation of apoptosis is involved in the pathophysiology of these diseases (Malherbe et 
al., 2016; Testa, 2004; Tognon et al., 2013). 
The present study involved four different genes and nine polymorphisms from the caspase 
cascade, and our results didn’t confirm the correlation between different SNPs in PN-MPN diseases as 
a whole. However, the results reveal that for ET patients alone, or after stratification by female gender 
or when applied to JAK2 positive cases, there is a significant increased risk when cases of these sub-
groups carried at least one variant allele for CASP9_rs1132312 (C653T) polymorphism.  Previous 
studies have described the involvement of CASP9 gene polymorphisms in the pathogenesis of various 
types of cancer, such as non-Hodgkin’s lymphoma (Kelly et al., 2010; Lan et al., 2009), lung cancer 
(Lin et al., 2012; Park et al., 2006), breast cancer  (Theodoropoulos et al., 2012), and gastric cancer 
(Liamarkopoulos et al., 2011).  
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By definition, MPNs are a group of clonal disorders derived from the proliferation of one or more  
myeloid lineages, in which megakaryocytes are the ‘key-cells’ for diagnostic histological features 
(Florena et al., 2009; Malherbe et al., 2016). Previous studies have correlated the uncontrolled 
proliferation of megakaryocytes to dysregulation of pro-apoptotic and anti-apoptotic mechanisms 
(Florena et al., 2009; Malherbe et al., 2016).  
Caspase 9 is important in regulating megakaryocyte turnover in MPNs. Malherbe and 
colleagues (Malherbe et al., 2016) showed that disruptions targeting the intrinsic apoptotic cascade 
(caspase-9 action) apparently promote megakaryocyte accumulation and thrombocytosis in MPNs. 
Considering that our results revealed an increased risk for ET in patients who present at least one 
variant allele, we might anticipate that polymorphisms in CASP9 gene might be responsible for a high 
proliferation inducing and increased risk for ET.  
With regard to the analyses of haplogroups’ association response, our results didn’t establish 
a global haplogroup. However, the correlation for SNPs of CASP9 gene showed a decreased risk for 
two haplogroups (GCC and GTT), as shown in Table 7.5. Interestingly, a similar effect was obtained 
when effector caspases where grouped. However, the mechanism by which the studied haplogroups 
lead to a decreased risk for MPNs remains unknown. These results should suggest that polymorphisms 
may exert independent or interactive effects on the development of MPNs. 
With regard to smoking habits, although some published studies refer smoking as a contributing 
factor for PN-MPNs (Hasselbalch, 2015; Lindholm Sørensen & Hasselbalch, 2015), this study did not 
reveal an important association, probably due to the small number of smoking individuals included. 
Additional studies involving larger populations should be pursued to further clarify the potential 
value of the different apoptosis related caspases genotypes as predictive biomarkers of susceptibility 
to PN-MPNs and also allow for the study of gene-environment and gene-gene interactions as well as 
stratified analysis according to histological subtype and disease stage.  
A better understanding of the pathophysiological mechanisms will allow the development of 
more directly and specifically targeted drugs, with high efficacy, fewer adverse effects, contributing to 
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The role of base excision repair (BER) genes in Philadelphia-negative (PN)-myeloproliferative neoplasms 
(MPNs) susceptibility was evaluated by genotyping eight polymorphisms [apurinic/apyrimidinic 
endodeoxyribonuclease 1, mutY DNA glycosylase, earlier mutY homolog (E. coli) (MUTYH), 8-oxoguanine DNA 
glycosylase 1, poly (ADP-ribose) polymerase (PARP)1, PARP4 and X-ray repair cross-complementing 1 (XRCC1)] 
in a case-control study involving 133 Caucasian Portuguese patients. The results did not reveal a correlation 
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between individual BER polymorphisms and PN-MPNs when considered as a whole. However, stratification for 
essential thrombocythaemia revealed i) borderline effect/tendency to increased risk when carrying at least one 
variant allele for XRCC1_399 single-nucleotide polymorphism (SNP); ii) decreased risk for Janus kinase 2-positive 
patients carrying at least one variant allele for XRCC1_399 SNP; and iii) decreased risk in females carrying at least 
one variant allele for MUTYH SNP. Combination of alleles demonstrated an increased risk to PN-MPNs for one 
specific haplogroup. These findings may provide evidence for gene variants in susceptibility to MPNs. Indeed, 
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CHAPTER 8: DNA REPAIR GENES POLYMORPHISMS AND GENETIC 
SUSCEPTIBILITY TO PHILADELPHIA-NEGATIVE 
MYELOPROLIFERATIVE NEOPLASMS IN A PORTUGUESE 
POPULATION: THE ROLE OF BASE EXCISION REPAIR GENES 
POLYMORPHISMS 
 
8.1 – INTRODUCTION 
Among myeloproliferative neoplasms (MPNs), and besides chronic myelogenous leukemia, the 
World Health Organization (WHO) classification includes Philadelphia-negative (PN)-MPNs, namely, 
polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) (Arber et 
al., 2016; Swerdlow et al., 2008).    
Major genetic insights into the pathogenesis of PN-MPNs include the identification of somatic 
point gain-of-function mutations in the Janus kinase 2 (JAK2) gene (V617F mutation in exon 14 first in 
2005, then in exon 12) (Baxter et al., 2005; James et al., 2005; Kralovics et al., 2005; Levine et al., 
2005; Scott et al., 2007) and the myeloproliferative leukemia virus oncogene (most frequently 
W515L/K), in addition to recently identified calreticulin mutations (Chi et al., 2015; Ha & Kim, 2015; 
Klampfl et al., 2013; Rumi et al., 2014), with implications in the understanding of these diseases, their 
diagnosis and management. The corresponding frequencies of these mutations are ~95, 0 and 0% in 
PV; 60, 3 and 20% in ET; and 60, 7 and 25% in PMF, respectively (Nangalia et al., 2013; Tefferi & 
Pardanani, 2015). 
Those mutations, however, could not fully explain the phenotypic heterogeneity of PN-MPNs. 
Furthermore, genetic defects still await identification in ~40% of ET and PMF cases (Delhommeau, 
Jeziorowska, Marzac, & Casadevall, 2010; Nangalia et al., 2013; Tefferi & Pardanani, 2015). Single-
nucleotide polymorphisms (SNPs) at various loci and additional somatic genetic effects may be 
important for PN-MPNs phenotype definition and for prognosis evaluation, although less specific than 
known variations (Campregher, Santos, Perini, & Hamerschlak, 2012; Delhommeau et al., 2010; 
Levine, 2009; Nangalia et al., 2013; Tefferi & Pardanani, 2015). Not all mutations involved in cancer 
initiation may lead to cancer. This can occur due to different variants within the same gene or between 
variants in different genes. The latter must be considered, as the number of passenger mutations in a 
tumour may modulate the effect of driver mutations, thus acting as putative modifier genes (Rueff & 
Rodrigues, 2016). Additionally, epimutations that can silence tumour-suppressor genes must be taken 
into account (Rueff & Rodrigues, 2016), which highlights the concept that, probably more important 
than the genes, are their levels of expression. 
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MPNs have high morbidity with thrombohaemorrhagic complications and risk of progression to 
acute myeloid leukemia (AML), in occasions preceded by a phase of myelofibrosis or myelodysplastic 
syndromes (MDS) (Mesa et al., 2016). Life expectancy in patients with PV or ET is reduced compared 
with that in the general population (Passamonti et al., 2004; Wolanskyj, Schwager, McClure, Larson, & 
Tefferi, 2006).The "true" rate of transformation is not accurate due to selection bias in clinical trials and 
underreporting in population-based studies (Björkholm, Hultcrantz, & Derolf, 2014). The occurrence of 
leukemia in ET and PV is associated with a bad prognosis, and has been reported to occur in 5-10% of 
patients 10 years following the initial diagnosis (Rampal et al., 2014; Swerdlow et al., 2008). It is well 
known that high doses of alkylating agents and combined cytoreductive treatments undoubtedly 
increase the risk of malignant transformation (Björkholm et al., 2014). However, there is also an intrinsic 
propensity in MPNs to progress to AML/MDS, in an extent that is not fully known (Björkholm et al., 2014; 
Hernández-Boluda et al., 2012). It cannot be ruled out that mutational burden, polymorphic variants of 
several genes, ambient/dietary exposure and immune system characteristics could be predisposing 
factors to susceptibility to these disorders (Beer et al., 2010; Bolufer et al., 2006; Delhommeau et al., 
2010; Hasselbalch et al., 2014; Kilpivaara & Levine, 2008). 
DNA damage to haematopoietic precursor cells would appear to be essential for the 
development of leukaemia, notwithstanding DNA repair systems act to repair the DNA damage, thus 
maintaining genetic integrity (Batar, Güven, Bariş, Celkan, & Yildiz, 2009; Bănescu et al., 2014).  
Several polymorphisms in DNA repair genes have been identified that may affect protein 
function and thus DNA damage repair, leading to susceptibility to malignancy, in spite of their low 
genetic penetrance (Batar et al., 2009; Bolufer et al., 2006; Bănescu et al., 2014; Hoeijmakers, 2001; 
C. Q. Wang et al., 2014). Previous reports have identified base excision repair (BER) genes 
polymorphisms associated with breast and thyroid cancer risk (Santos et al., 2012; Silva et al., 2007; 
Yan, Li, Li, Ji, & Zhang, 2016) among other malignancies, and a nucleotide excision repair gene 
polymorphism displayed strong association with leukaemic transformation and development of non-
myeloid malignancies in patients with ET and PV (Hernández-Boluda et al., 2012). 
The BER pathway typically repairs a small region (1-13 nucleotides) around the damaged base, 
involving apurinic/apyrimidinic endodeoxyribonuclease 1 (APEX1), 8-oxoguanine DNA glycosylase 1 
(OGG1), poly (ADP-ribose) polymerase (PARP)1 or X-ray repair cross-complementing 1 (XRCC1) 
(Baute & Depicker, 2008). 
Several SNPs in genes of the BER pathway [APEX1, mutY DNA glycosylase, earlier mutY 
homolog (E. coli) (MUTYH), OGG1, PARP1, PARP4 and XRCC1] have been identified and studied for 
their association with the risk of leukaemia and disease outcome (Annamaneni et al., 2013; Bolufer et 
al., 2006; Bănescu et al., 2014). 
A wider characterization of molecular genetic features in PN-MPNs may contribute to a better 
understanding of the pathogenesis of these diseases and provide new specific diagnostic, prognostic 
and therapeutic tools (Delhommeau et al., 2010). 
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Since data on the role of BER gene variants in PN-MPNs are absent in the literature, the present 
study describes a hospital-based, case-control study in a Caucasian Portuguese population in order to 
help assessing a possible role of BER genes on the individual susceptibility to PN-MPNs. 
 
8.2 – MATERIALS AND METHODS 
8.2.1 – STUDY SUBJECTS 
The description given in Chapter 3, section 3.2.1 applies in this new chapter. 
 General characteristics for PN-MPNs patients and control populations are summarized in 
Tables 8.2 and 8.3. 
8.2.2 – DNA EXTRACTION 
The methodology used is described in Chapter 3, section 3.2.2. 
8.2.3 – SNP SELECTION (BASE EXCISION REPAIR PATHWAY) 
The appropriate SNPs analyzed in the present study were selected concerning their relevance 
in the DNA repair pathway (Santos et al., 2012; Silva et al., 2007). All SNPs had a minor allele frequency 
of >0.1 in Caucasian populations (Table 8.1). 
 
Table 8.1 – Selected SNPs and detailed information on the corresponding base and amino acid 
exchanges, as well as MAF. 
Gene Codon Exchange, base (amino acid) MAF (%)a 
APEX1 
(Chr 14) 
148 TG (Asp/Glu) 44.0 
MUTYH 
(Chr 1) 
335 GC (Gln/His) 31.9 
OGG1 
(Chr 3) 
326 CG (Ser/Cys) 29.9 
 









1,280 GC (Gly/Arg) 45.8 






194 CT (Arg/Trp) 13.1 
399 GA (Arg/Gln) 26.6 
                 aAccording to http://www.ncbi.nlm.nih.gov/snp/. MAF, minor allele frequency; APEX1,  
            apurinic/apyrimidinic endonuclease 1; MUTYH, mutY DNA glycosylase, earlier mutY homolog  
           (E. coli); OGG1, 8-oxoguanine DNA glycosylase 1; PARP, poly (ADP-ribose) polymerase; XRCC1,  
            X-ray repair cross-complementing 1. 
 
8.2.4 – GENOTYPING 
The polymorphisms rs1130409 (APEX1), rs3219489 (MUTYH), rs1052133 (OGG1), 
rs1136410 (PARP1), rs13428 and rs1050112 (PARP4), and rs1799782 and rs25487 (XRCC1) and 
JAK2 V617F mutation were genotyped using the same methodology described in Chapter 3, section 
3.2.3. 
Table 8.1 summarizes the information on the SNP genotyping assay. 
8.2.5 – STATISTICAL ANALYSIS 
The statistical approach is described in Chapter 7, section 7.2.5. 
 
8.3 – RESULTS 
8.3.1 – CHARACTERIZATION OF POPULATIONS 
The present study included 133 PN-MPNs patients and 281 age- and gender-matched controls. 
According to the diagnosis criteria, the patients’ distribution was as follows: 80 patients (60.2%) with 
ET, 39 (29.3%) with PV and 14 (10.5%) with PMF (Table 8.2). The baseline characteristics (gender, 
age, alcohol consumption and tobacco smoking habits) of the case and control populations are listed 
in Table 8.2 and Table 8.3.  
The case group included 72 (54.1%) females and 61 (45.9%) males, with an overall mean age 
of 68 years, in agreement with the gender distribution usually observed in this type of pathology (Geyer  
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et al., 2017; Swerdlow et al., 2008). No significant differences were observed between the control and 
patient groups concerning age distribution or tobacco smoking habits (Table 8.3). However, alcohol 




Table 8.2 – Gender distribution for the PN-MPNs cases. 
PN-MPNs cases n=133. 
 
Diagnosis Patients, n Male, n (%) Female, n (%) 
ET 80 32 (40.0) 48 (60.0) 
PV 39 20 (51.3) 19 (48.7) 
PMF 14 9 (64.3) 5 (35.7) 
ET, essential thrombocythaemia; PV, polycythaemia vera; PMF, primary myelofibrosis. 
 
 
Table 8.3 – General characteristics of the PN-MPNs case and control populations.  
PN-MPNs cases n=133; Control population n=281. 
 
Characteristics Cases, n (%) Controls, n (%) P-valuec 
Gender 
    Male 









    30-49 
    50-69 












Tobacco smoking habits 
    Never 









Alcohol consumption habits 
    Never 
    Social 












JAK2 V617F mutation 
    Yes 
        ET 
        PV 
        PMF 










aAge at diagnosis for cases. bAge of control population at the time of diagnosis for the matched case. cP-value determined by χ2 test. ET, 
essential thrombocythaemia; PV, polycythaemia vera; PMF, primary myelofibrosis. 
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8.3.2 – SNP’S GENOTYPING 
Of the eight SNPs included in the study, only seven were completely genotyped (Table 8.1), 
since both SNPs of the PARP4 gene were in linkage disequilibrium (r2>0.80), thus behaving as tag 
SNPs.  
The genotype frequencies determined for all polymorphisms under study are shown in Table 
8.4. When considered individually, no correlation between polymorphisms of the BER pathway genes 
and individual susceptibility to PN-MPNs as a whole could be identified. All the SNPs studied were in 
agreement with the Hardy-Weinberg law (P>0.05, exact probability test), with the exception of PARP1 
Val762Ala (P=0.029, exact probability test). 
The genotypic frequencies obtained in the control populations are similar to those reported 
previously in other Caucasian populations (Conde et al., 2009; Figueroa et al., 2007; Santos et al., 
2012; Silva et al., 2007). 
As shown in Table 8.4, no significant differences in genotypic frequencies were observed for 
any of the seven polymorphisms between cases and controls as a whole (P>0.05, χ2 test). However, 
when the population was stratified for pathology status, gender and presence of JAK2 mutation, a 
tendency for decrease risk was noticed for MUTYH Gln335His and XRCC1 Gln399Arg polymorphisms 
(Table 8.5).  
Upon stratification for pathology status, the results revealed that, for ET, the presence of at 
least one variant allele for the XRCC1 Gln399Arg gene polymorphism displayed a borderline effect on 
the population (crude OR, 0.623; 95% CI, 0.378-1.028; P=0.069) (Table 8.5).  
The results demonstrated a decreased risk in the female group with ET diagnosis and with at 
least one variant allele for MUTYH Gln335His gene polymorphism (OR, 0.478; 95% CI, 0.238-0.962) 
upon adjustment for potential risk factors (Table 8.5).  
The relevance of JAK2 mutation in PN-MPNs is well known (Baxter et al., 2005; James et al., 
2005; Kralovics et al., 2005; Levine et al., 2005; Scott et al., 2007). Therefore, the population was also 
stratified according to the presence of JAK2 mutation in patients, showing that the presence of at least 
one variant allele for XRCC1 Gln399Arg gene polymorphism constitutes a decreased risk for ET 
patients (OR, 0.500; 95% CI, 0.278-0.896) (Table 8.5). 
Overall, the results indicate that only XRCC1 Gln399Arg and MUTYH Gln335His gene 
polymorphisms appeared to be associated with PN-MPNs risk. For the remaining polymorphisms under 
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Table 8.4 – Genotype distribution and myeloproliferative risk. 
For the APEX1 Asp148Glu, MUTYH Gln335His, OGG1 Ser326Cys, PARP1 Val762Ala, PARP4 Gly1280Arg, and 
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113 (40.8) 



















aP-value determined by χ2 test. bORs were adjusted for age (30-49, 50-69 and >70 years), tobacco smoking status (never or former and 
current) and alcohol consumption (never, social and regular drinkers). APEX1, apurinic/apyrimidinic endonuclease 1; MUTYH, mutY DNA 
glycosylase, earlier mutY homolog (E. coli); OGG1, 8-oxoguanine DNA glycosylase 1; PARP, poly (ADP-ribose) polymerase; XRCC1, X-
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SNP P-valuea OR crude (95% CI) OR adjusted (95% CI)b 






























































aP-value determined by χ2 test. bORs were adjusted for age (30-49, 50-69 and >70 years), tobacco smoking status (never or former and 
current) and alcohol consumption (never, social and regular drinkers). cPcrude = 0.010; dPadjusted = 0.008 (P-values are adjusted by 
unconditional multiplicative logistic regression). ePcrude = 0.016; fPadjusted = 0.025 (P-values are adjusted by unconditional multiplicative 
logistic regression). gPcrude = 0.014; hPadjusted = 0.020 (P-values are adjusted by unconditional multiplicative logistic regression). •Represents 
results that almost reached the significance threshold, demonstrating a borderline effect. **Padjusted = 0.039 (P-values are adjusted by 
unconditional multiplicative logistic regression). SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval; MUTYH, 
mutY DNA glycosylase, earlier mutY homolog (E. coli); XRCC1, X-ray repair cross-complementing 1; ET, essential thrombocythaemia; 
JAK2, Janus kinase 2. 
 
 
8.3.3 – HAPLOGROUP ASSOCIATION 
A key point that should be explored in studies such as the present one is the effect of the 
combination of all genotypes, since the real situation is the effect of the variants altogether. The results 
provided by the SNPstat software yielded 60 different combinations, the most frequent of which are 
shown in Table 8.6. Analyzing the results as haplogroup association response, an increased risk to 
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D H S V G R R 0.116 0.167 0.068 
E H S V G R R 0.084 0.060 0.130 
E H S V G R Q 0.069 0.065 0.062 
E H S V R R R 0.050 0.058 0.044 
D H S V R R Q 0.045 0.036 0.060 
D H S V R R R 0.045 0.030 0.060 
E H C V G R R 0.033 0.025 0.042 
E Q S V R R R 0.032 0.028 0.053 
APEX1, apurinic/apyrimidinic endonuclease 1; MUTYH, mutY DNA glycosylase, earlier mutY homolog (E. coli); OGG1, 8-oxoguanine 
DNA glycosylase 1; PARP, poly (ADP-ribose) polymerase; XRCC1, X-ray repair cross-complementing 1. 
 
 
Table 8.7 – Haplogroup association response for the SNPs under study. 
Haplotype association response 
OR (95% CI) P-value APEX MUTYH OGG1 PARP1 PARP4 XRCC1_194 XRCC1_399 
D148E Q335H S326C V762A G1280R R194W R399Q 
D H S V G R R 1.00 (Reference)  
E H S V G R R 3.17 (0.99-10.17) 0.05 
E H S V G R Q 0.92 (0.34-2.53) 0.88 
E H S V R R R 1.55 (0.50-4.76) 0.45 
D H S V R R Q 2.13 (0.60-7.53) 0.24 
D H S V R R R 1.90 (0.41-8.79) 0.41 
E H C V G R R 3.41 (0.87-13.36) 0.08 
E Q S V R R R 3.91 (1.02-14.95) 0.05* 
APEX1, apurinic/apyrimidinic endonuclease 1; MUTYH, mutY DNA glycosylase, earlier mutY homolog (E. coli); OGG1, 8-oxoguanine 




8.4 – DISCUSSION AND CONCLUSIONS 
DNA repair deficiencies and genetic or epigenetic changes may decrease the efficiency of DNA 
repair, thus contributing to individual susceptibility to DNA damaging agents and to cancer risk (Hirotsu 
et al., 2015; Walter et al., 2015; Wilson, Kim, Berquist, & Sigurdson, 2011). However, to the best of our 
knowledge, no clinical association studies have been performed to evaluate the role of BER pathway 
polymorphisms on PN-MPNs susceptibility.  
The present study revealed a higher incidence of JAK2 V617F mutation in ET patients and a 
lower  incidence  in  PV  patients,  compared  with  that  reported  in the literature (Nangalia et al., 2013;  
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Tefferi & Pardanani, 2015). This finding is probably due to the small population studied and to the fact 
that ET was the most frequent diagnosis among the patients included in the current case group.  
The present study was intended to ascertain the possible role of the genetic polymorphisms 
APEX1 Asp148Glu, MUTYH Gln335His, OGG1 Ser326Cys, PARP1 Val762Ala, PARP4 Gly1280Arg, 
and XRCC1 Arg194Trp and Arg399Gln on the individual susceptibility for PN-MPNs. The genotypic 
frequencies of the different SNPs in the control population are similar to those reported in other 
Caucasian populations (Conde et al., 2009; Santos et al., 2012; Silva et al., 2007). 
The MUTYH protein acts as a BER glycosylase and is mainly involved in the repair of oxidative 
DNA lesions (Cheadle & Sampson, 2007; Conde et al., 2009; Das et al., 2015; Huang et al., 2007; 
Picelli et al., 2010; Przybylowska et al., 2013; Qian et al., 2011; Santos et al., 2012; Tao et al., 2008; 
Wilson et al., 2011; Zhang et al., 2006). MUTYH dysfunction may therefore be of special relevance in 
human tumourigenesis, since it is the only mechanism for repairing 8-oxo-dG/adenine mismatches 
(Cheadle & Sampson, 2007). Indeed, two specific germline mutations in this gene, Tyr165Cys and 
Gly382Asp, have been associated with a colorectal adenoma and carcinoma predisposition syndrome 
that is now referred to as MUTYH-associated polyposis (Cheadle & Sampson, 2007). However, various 
others mutations and SNPs have been described to date, for which a specific phenotypic consequence 
is unknown (Cheadle & Sampson, 2007). An example of one common SNP in the MUTYH gene is the 
nonsynonymous Gln335His variation in codon 12 (Cheadle & Sampson, 2007; Picelli et al., 2010). The 
enzyme encoded by this variant has been demonstrated to have partially impaired glycosylase activity 
in vitro, and could therefore contribute to cancer susceptibility, being much more frequently detected in 
Japanese and Chinese populations than in European populations (Santos et al., 2012; Tao et al., 2008). 
The Gln335His variant allele has been suggested to be associated with increased risk of colorectal 
cancer (Picelli et al., 2013; Picelli et al., 2010; Tao et al., 2008) and less consistently with lung cancer 
(Qian et al., 2011). For the latter, however, existing evidence is conflicting or significant only when 
taking into account gene-gene interactions (Qian et al., 2011). Notably, an almost significant decrease 
in breast cancer risk (OR, 0.80; 95% CI, 0.59-1.07) was described previously by our group in MUTYH 
Gln335His heterozygotes (Conde et al., 2009). Furthermore, gene-gene interactions among BER 
polymorphisms were observed in ever tobacco smokers in a bladder cancer susceptibility study (Huang 
et al., 2007). Those previous results suggest that genetic variation in BER genes may contribute to 
cancer risk through gene-gene and gene-environmental interactions.  
To the best of our knowledge, there are no clinical association studies in which the role of the 
MUTYH Gln335His polymorphism had been evaluated on PN-MPNs susceptibility. The results reported 
in the present study suggest that, when considering females with ET, a consistent decrease in overall 
PN-MPNs risk was observed when at least one variant allele carrying MUTYH Gln335His is present 
(Table 8.5).  
The XRCC1 nuclear protein serves an important role in assisting and enabling the repair of 
single-strand breaks by interacting and recruiting to the DNA lesion sites multiple enzymatic 
components  of  repair  reactions  (Lévy et al., 2006).  Arg194Trp  and  Arg399Gln  polymorphisms  are  
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among the most extensively studied SNPs in the XRCC1 gene (Annamaneni et al., 2013; Batar et al., 
2009; Bolufer et al., 2006; Bănescu et al., 2014; Ginsberg, Angle, Guyton, & Sonawane, 2011; Huang 
et al., 2007; Hung, Hall, Brennan, & Boffetta, 2005; Jiang, Zhang, Yang, & Wang, 2009; Miao et al., 
2006; Przybylowska et al., 2013; Qian et al., 2011; Santos et al., 2012; Silva et al., 2007; Wilson et al.,  
2011; Yan et al., 2016; Zhai et al., 2006; Zhang et al., 2006). These two SNPs have been shown to 
alter the functional activity of the resulting protein in vitro and to interfere with cancer susceptibility. The  
Arg194Trp variant allele has been associated with decreased risk of certain cancers, particularly among 
tobacco smokers (Hung et al., 2005). Conversely, the Arg399Gln variant allele has been suggested to 
be associated with decreased DNA repair capacity and higher sensitivity to genotoxicants compared 
with the Arg194Trp variant allele (Z. Hu, Ma, Chen, Wei, & Shen, 2005). However, previous 
epidemiological results have been inconsistent and dependent on the cancer type (Chen, Zhou, Yang, 
& Wu, 2012; Przybylowska et al., 2013; A. Srivastava, Srivastava, Pandey, Choudhuri, & Mittal, 2009). 
Several interactions such as gene-environment (e.g. alcohol consumption or menopausal age) and 
gene-gene (e.g. other DNA repair or chemical metabolizing enzymes) have also been reported for both 
SNPs (Wilson et al., 2011). However, several well-powered studies and meta-analyses have not 
confirmed these supposed effects (Ginsberg et al., 2011; Wilson et al., 2011). Generally, the results 
reported to date suggest a modest impact of both XRCC1 gene polymorphisms on protein activity and 
cancer susceptibility. However, certain studies have suggested that they may represent a risk factor for  
hematological malignancies such as leukaemia, according to previous studies on XRCC1 
polymorphisms in association with AML, acute lymphoblastic leukaemia, chronic lymphocytic leukaemia 
and lymphoma (Batar et al., 2009; Bolufer et al., 2006; Bănescu et al., 2014). The present results 
support a borderline effect for ET patients and a protective effect in overall PN-MPNs risk when 
considering ET patients presenting JAK2 mutation, as observed under the presence of at least one 
variant allele carrying XRCC1 Arg399Gln (Table 8.5). Although the Arg194Trp allele did not show any 
association with the risk of developing PN-MPNs, it should be noted that the Arg194Trp variant allele 
may be associated with higher DNA repair capacity, lower sensitivity to genotoxicants and decreased 
risk of other cancers, when compared with other variants. In addition, other factors may influence the 
biological effect of the Arg194Trp polymorphism, such as disease development stage, specific 
environmental factors and even different genetic background among populations. In order to clarify the 
role of XRCC1 polymorphisms in PN-MPNs susceptibility, larger studies and/or a meta-analysis are 
required. 
Regarding the OGG1 Ser326Cys polymorphism, the current results did not reveal a significant 
contribution on individual susceptibility towards PN-MPNs (Tables 8.1 and 8.4). The OGG1 Ser326Cys 
polymorphism has been demonstrated to impair protein function (Wilson et al., 2011), and therefore, it 
has been widely evaluated in different case-control studies (Zou et al., 2016). Significant results were  
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observed in lung (Hung et al., 2005; B. Wei et al., 2011), head and neck (Kumar, Pant, Singh, & 
Khandelwal, 2011; W. Wang et al., 2012), colorectal (Canbay et al., 2011; Przybylowska et al., 2013) 
and gallbladder cancer (A. Srivastava et al., 2009; K. Srivastava, Srivastava, & Mittal, 2010). However, 
several previous meta-analyses (Das, Nath, Bhowmik, Ghosh, & Choudhury, 2016; Gu, Wang, Zhang, 
& Chen, 2010; W. Wang et al., 2012; B. Wei et al., 2011; Wenjuan et al., 2016) did not reveal any 
significant association between this OGG1 polymorphism and other cancers risk. 
Human APEX1 is a multifunctional enzyme that holds complementary key roles in cancer. 
Notably, this enzyme is a crucial component of the BER pathway due to its ability to process AP sites 
and other 3′ DNA termini that may result, for example, from exposure to ionizing radiation or direct 
attack by free radicals (Abbotts & Madhusudan, 2010; Dyrkheeva, Lebedeva, & Lavrik, 2016; Hung et  
al., 2005). Among the 18 identified SNPs for the APEX1 gene, the most studied one is the T>G transition 
at codon 148 of exon 5, which leads to a change in amino acid from Asp to Glu (Das et al., 2015). Its 
potential role on cancer was evaluated in four meta-analyses on breast cancer susceptibility (Peng et 
al., 2014; Wu, Liu, Zhang, Dong, & Wu, 2012; Zhang et al., 2006; Zhao et al., 2014), two meta-analyses 
on prostate cancer (X. Li, Zhang, Huai, & Cao, 2014; Zhou et al., 2015) and several studies on other 
types of cancer (Dai et al., 2015; D. Hu, Lin, Zhang, Zheng, & Niu, 2013; Jin et al., 2014; H. Li et al., 
2015). However, the results published remain inconclusive. Concerning the present results, the 
association of APEX1 Asp148Glu with PN-MPNs risk did not exhibit any association.  
PARP1 is an abundant nuclear protein that can bind to DNA and promote the poly (ADP-
ribosylation) of a variety of proteins. PARP1 acts on single- and double-stranded DNA breaks by 
recruiting DNA repair factors (Talhaoui et al., 2016). It has a major signaling role in DNA damage 
detection and repair, acting as a molecular nick sensor to initiate the recruitment of XRCC1 and the 
assembly of the single-strand break repair machinery (H. Wei & Yu, 2016). PARP1 Val762Ala is one of 
the most common nonsynonymous SNPs studied in this gene, resulting in an amino acid substitution 
within the COOH-terminal catalytic domain of the enzyme (Hua et al., 2014; Qin et al., 2014). This 
variant has been associated with reduced enzymatic activity (Jiang et al., 2009) and limited capacity for 
interaction with XRCC1 (Miao et al., 2006). This may result in decreased BER capacity, thus increasing 
cancer predisposition in PARP1 Val762Ala carriers. Indeed, this variant form has been associated in 
various well-powered clinical association studies with increased cancer susceptibility, namely to lung 
(Jiang et al., 2009) and gastrointestinal tract (Y. Hu et al., 2014; Miao et al., 2006) cancer, while Adel 
Fahmideh et al.  (Adel Fahmideh, Schwartzbaum, Frumento, & Feychting, 2014) described a decreased 
risk for glioma associated with this SNP. Studies regarding other types of cancer such as breast cancer 
(Zhai et al., 2006; Zhang et al., 2006) failed to demonstrate an association between PARP1 Val762Ala 
and cancer susceptibility. The present results do not suggest any association between PARP1 
Val762Ala polymorphism and PN-MPNs risk (Table 8.4).  
Concerning the analysis of haplogroups’ association response, an increased risk to PN-MPNs 
could be observed for one specific combination (Table 8.7). This result should, however, be taken with  
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care when evaluating this parameter risk for PN-MPNs due to its low frequency (3.2%) in the studied 
population, even though it may represent a tendency on how SNPs in BER genes influence PN-MPNs. 
Overall, the present results reveal that the XRCC1 Gln399Arg and MUTYH Gln335His gene 
polymorphisms appear to be associated with PN-MPNs risk. For all other polymorphisms under study, 
no significant change was observed (Tables 8.4 and 8.5). 
Although certain published studies consider tobacco smoking as a contributing factor for PN-
MPNs (Hasselbalch, 2015; Lindholm Sørensen & Hasselbalch, 2015), the present study did not reveal 
an important association, probably due to the small number of tobacco smokers included. 
Additional studies involving larger populations should be conducted to further clarify the 
potential value of the different BER genotypes as predictive biomarkers of susceptibility to PN-MPNs 
and to study gene-environment and gene-gene interactions. In addition, stratified analysis according to 
histological subtype and disease stage should be conducted.  
The MUTYH protein acts as a BER glycosylase and is mainly involved in the repair of oxidative 
DNA lesions (Cheadle & Sampson, 2007; Conde et al., 2009; Das et al., 2015; Huang et al., 2007; 
Picelli et al., 2010; Przybylowska et al., 2013; Qian et al., 2011; Santos et al., 2012; Tao et al., 2008; 
Wilson et al., 2011; Zhang et al., 2006). MUTYH dysfunction may therefore be of special relevance in 
human tumourigenesis, since it is the only mechanism for repairing 8-oxo-dG/adenine mismatches 
(Cheadle & Sampson, 2007). Indeed, two specific germline mutations in this gene, Tyr165Cys and 
Gly382Asp, have been associated with a colorectal adenoma and carcinoma predisposition syndrome  
that is now referred to as MUTYH-associated polyposis (Cheadle & Sampson, 2007). However, various 
others mutations and SNPs have been described to date, for which a specific phenotypic consequence  
is unknown (Cheadle & Sampson, 2007). An example of one common SNP in the MUTYH gene is the 
nonsynonymous Gln335His variation in codon 12 (Cheadle & Sampson, 2007; Picelli et al., 2010). The 
enzyme encoded by this variant has been demonstrated to have partially impaired glycosylase activity 
in vitro, and could therefore contribute to cancer susceptibility, being much more frequently detected in 
Japanese and Chinese populations than in European populations (Santos et al., 2012; Tao et al., 2008). 
The Gln335His variant allele has been suggested to be associated with increased risk of colorectal 
cancer (Picelli et al., 2013; Picelli et al., 2010; Tao et al., 2008) and less consistently with lung cancer 
(Qian et al., 2011). For the latter, however, existing evidence is conflicting or significant only when 
taking into account gene-gene interactions (Qian et al., 2011). Notably, an almost significant decrease 
in breast cancer risk (OR, 0.80; 95% CI, 0.59-1.07) was described previously by our group in MUTYH 
Gln335His heterozygotes (Conde et al., 2009). Furthermore, gene-gene interactions among BER 
polymorphisms were observed in ever tobacco smokers in a bladder cancer susceptibility study (Huang 
et al., 2007). Those previous results suggest that genetic variation in BER genes may contribute to 
cancer risk through gene-gene and gene-environmental interactions.  
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To the best of our knowledge, there are no clinical association studies in which the role of the 
MUTYH Gln335His polymorphism had been evaluated on PN-MPNs susceptibility. The results reported 
in the present study suggest that, when considering females with ET, a consistent decrease in overall 
PN-MPNs risk was observed when at least one variant allele carrying MUTYH Gln335His is present 
(Table 8.5).  
The XRCC1 nuclear protein serves an important role in assisting and enabling the repair of 
single-strand breaks by interacting and recruiting to the DNA lesion sites multiple enzymatic 
components of repair reactions (Lévy et al., 2006). Arg194Trp and Arg399Gln polymorphisms are 
among the most extensively studied SNPs in the XRCC1 gene (Annamaneni et al., 2013; Batar et al., 
2009; Bolufer et al., 2006; Bănescu et al., 2014; Ginsberg, Angle, Guyton, & Sonawane, 2011; Huang 
et al., 2007; Hung, Hall, Brennan, & Boffetta, 2005; Jiang, Zhang, Yang, & Wang, 2009; Miao et al., 
2006; Przybylowska et al., 2013; Qian et al., 2011; Santos et al., 2012; Silva et al., 2007; Wilson et al., 
2011; Yan et al., 2016; Zhai et al., 2006; Zhang et al., 2006). These two SNPs have been shown to 
alter the functional activity of the resulting protein in vitro and to interfere with cancer susceptibility. The 
Arg194Trp variant allele has been associated with decreased risk of certain cancers, particularly among 
tobacco smokers (Hung et al., 2005). Conversely, the Arg399Gln variant allele has been suggested to 
be associated with decreased DNA repair capacity and higher sensitivity to genotoxicants compared 
with the Arg194Trp variant allele (Z. Hu, Ma, Chen, Wei, & Shen, 2005). However, previous 
epidemiological results have been inconsistent and dependent on the cancer type (Chen, Zhou, Yang, 
& Wu, 2012; Przybylowska et al., 2013; A. Srivastava, Srivastava, Pandey, Choudhuri, & Mittal, 2009). 
Several interactions such as gene-environment (e.g. alcohol consumption or menopausal age) and 
gene-gene (e.g. other DNA repair or chemical metabolizing enzymes) have also been reported for both 
SNPs (Wilson et al., 2011). However, several well-powered studies and meta-analyses have not 
confirmed these supposed effects (Ginsberg et al., 2011; Wilson et al., 2011). Generally, the results 
reported to date suggest a modest impact of both XRCC1 gene polymorphisms on protein activity and 
cancer susceptibility. However, certain studies have suggested that they may represent a risk factor for 
haematological malignancies such as leukaemia, according to previous studies on XRCC1 
polymorphisms in association with AML, acute lymphoblastic leukaemia, chronic lymphocytic leukaemia 
and lymphoma (Batar et al., 2009; Bolufer et al., 2006; Bănescu et al., 2014). The present results 
support a borderline effect for ET patients and a protective effect in overall PN-MPNs risk when 
considering ET patients presenting JAK2 mutation, as observed under the presence of at least one 
variant allele carrying XRCC1 Arg399Gln (Table 8.5). Although the Arg194Trp allele did not show any 
association with the risk of developing PN-MPNs, it should be noted that the Arg194Trp variant allele 
may be associated with higher DNA repair capacity, lower sensitivity to genotoxicants and decreased 
risk of other cancers, when compared with other variants. In addition, other factors may influence the 
biological effect of the Arg194Trp polymorphism, such as disease development stage, specific 
environmental factors and even different genetic background among populations. In order to clarify the  
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role of XRCC1 polymorphisms in PN-MPNs susceptibility, larger studies and/or a meta-analysis are 
required. 
Regarding the OGG1 Ser326Cys polymorphism, the current results did not reveal a significant 
contribution on individual susceptibility towards PN-MPNs (Tables 8.1 and 8.4). The OGG1 Ser326Cys 
polymorphism has been demonstrated to impair protein function (Wilson et al., 2011), and therefore, it 
has been widely evaluated in different case-control studies (Zou et al., 2016). Significant results were 
observed in lung (Hung et al., 2005; B. Wei et al., 2011), head and neck (Kumar, Pant, Singh, & 
Khandelwal, 2011; W. Wang et al., 2012), colorectal (Canbay et al., 2011; Przybylowska et al., 2013)  
and gallbladder cancer (A. Srivastava et al., 2009; K. Srivastava, Srivastava, & Mittal, 2010). However, 
several previous meta-analyses (Das, Nath, Bhowmik, Ghosh, & Choudhury, 2016; Gu, Wang, Zhang, 
& Chen, 2010; W. Wang et al., 2012; B. Wei et al., 2011; Wenjuan et al., 2016) did not reveal any 
significant association between this OGG1 polymorphism and other cancers risk. 
Human APEX1 is a multifunctional enzyme that holds complementary key roles in cancer. 
Notably, this enzyme is a crucial component of the BER pathway due to its ability to process AP sites 
and other 3′ DNA termini that may result, for example, from exposure to ionizing radiation or direct 
attack by free radicals (Abbotts & Madhusudan, 2010; Dyrkheeva, Lebedeva, & Lavrik, 2016; Hung et  
al., 2005). Among the 18 identified SNPs for the APEX1 gene, the most studied one is the T>G 
transition at codon 148 of exon 5, which leads to a change in amino acid from Asp to Glu (Das et al., 
2015). Its potential role on cancer was evaluated in four meta-analyses on breast cancer susceptibility 
(Peng et al., 2014; Wu, Liu, Zhang, Dong, & Wu, 2012; Zhang et al., 2006; Zhao et al., 2014), two meta- 
analyses on prostate cancer (X. Li, Zhang, Huai, & Cao, 2014; Zhou et al., 2015) and several studies 
on other types of cancer (Dai et al., 2015; D. Hu, Lin, Zhang, Zheng, & Niu, 2013; Jin et al., 2014; H. Li  
et al., 2015). However, the results published remain inconclusive. Concerning the present results, the 
association of APEX1 Asp148Glu with PN-MPNs risk did not exhibit any association.  
PARP1 is an abundant nuclear protein that can bind to DNA and promote the poly (ADP-
ribosylation) of a variety of proteins. PARP1 acts on single- and double-stranded DNA breaks by 
recruiting DNA repair factors (Talhaoui et al., 2016). It has a major signaling role in DNA damage 
detection and repair, acting as a molecular nick sensor to initiate the recruitment of XRCC1 and the 
assembly of the single-strand break repair machinery (H. Wei & Yu, 2016). PARP1 Val762Ala is one of 
the most common nonsynonymous SNPs studied in this gene, resulting in an amino acid substitution 
within the COOH-terminal catalytic domain of the enzyme (Hua et al., 2014; Qin et al., 2014). This 
variant has been associated with reduced enzymatic activity (Jiang et al., 2009) and limited capacity for 
interaction with XRCC1 (Miao et al., 2006). This may result in decreased BER capacity, thus increasing 
cancer predisposition in PARP1 Val762Ala carriers. Indeed, this variant form has been associated in 
various well-powered clinical association studies with increased cancer susceptibility, namely to lung 
(Jiang et al., 2009) and gastrointestinal tract (Y. Hu et al., 2014; Miao et al., 2006) cancer, while Adel 
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Fahmideh et al.  (Adel Fahmideh, Schwartzbaum, Frumento, & Feychting, 2014) described a decreased 
risk for glioma associated with this SNP. Studies regarding other types of cancer such as breast cancer 
(Zhai et al., 2006; Zhang et al., 2006) failed to demonstrate an association between PARP1 Val762Ala 
and cancer susceptibility. The present results do not suggest any association between PARP1 
Val762Ala polymorphism and PN-MPNs risk (Table 8.4).  
Concerning the analysis of haplogroups’ association response, an increased risk to PN-MPNs 
could be observed for one specific combination (Table 8.7). This result should, however, be taken with  
care when evaluating this parameter risk for PN-MPNs due to its low frequency (3.2%) in the studied 
population, even though it may represent a tendency on how SNPs in BER genes influence PN-MPNs. 
Overall, the present results reveal that the XRCC1 Gln399Arg and MUTYH Gln335His gene 
polymorphisms appear to be associated with PN-MPNs risk. For all other polymorphisms under study, 
no significant change was observed (Tables 8.4 and 8.5). 
Although certain published studies consider tobacco smoking as a contributing factor for PN-
MPNs (Hasselbalch, 2015; Lindholm Sørensen & Hasselbalch, 2015), the present study did not reveal 
an important association, probably due to the small number of tobacco smokers included. 
Additional studies involving larger populations should be conducted to further clarify the 
potential value of the different BER genotypes as predictive biomarkers of susceptibility to PN-MPNs 
and to study gene-environment and gene-gene interactions. In addition, stratified analysis according to 
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ABSTRACT  
Several single nucleotide polymorphisms (SNPs), influencing DNA repair capacity and apoptotic status, 
may confer genetic predisposition to Philadelphia-chromosome negative myeloproliferative neoplasms (PN-
MPNs), and influence therapeutic response and clinical course. Moreover, despite the development of more 
efficient drugs in the last years, some patients with PN-MPNs still progress to conditions more aggressive and 
difficult to treat such as myelodysplasia, myelofibrosis and acute leukaemia. The aim of this work was to help in 
evaluating whether SNPs in genes involved in apoptosis and base excision repair (BER) pathway and of some 
known risk factors in PN-MPNs may have an effect on survival and therapeutic response to hydroxyurea, the 
standard drug used, in terms of disease progression and predisposition to new non-myeloid neoplasms and 
thrombotic events in patients according to the type of MPN.   
This study comprise 133 Caucasian Portuguese patients diagnosed with PN-MPNs, during the period 
1992-2016, and under treatment with hydroxyurea (isolated in 104 patients and in combination with other agents 
in 6 patients), with a total of 17 cases with progression to myelofibrosis/leukemia, 11 who developed new non-
myeloid neoplasms and 22 who presented thrombotic events. All apoptosis and BER pathway SNPs included in 
this study were genotyped using real-time PCR (RT-PCR 7300 Applied Biosystem), through TaqMan® SNP 
genotyping assays (Life Technology), according to manufacturer instructions, and were evaluated using regression 
analysis by SPSS 22.0 (SPSS Inc.). The informed consent of the subjects and acceptance of the study protocol by 
a local ethics committee has been obtained. 
Concerning progression to secondary myelofibrosis/leukemia, there is an association with the survival 
and the exposure to cytoreductive agents. Globally, the presence of at least one variant allele carriers for CASP8 
3’UTR variant is associated with a decreased effect in disease progression (OR=0.24; 95% CI, 0.08-0.69) and the 
presence of XRCC1 Arg194Trp variant showed a border-line effect (OR=3.58; 95%CI, 0.98-13.01) for the same 
outcome, representing a worse prognosis.  When stratified for ET patients, the presence of at least one variant 
allele for CASP9 Arg173His polymorphism is associated with a worse prognosis for these patients, increasing the 
frequency of development of secondary myelofibrosis/leukemia (OR=11.27; 95%CI, 1.13-112.28). On the other 
hand, BER polymorphism APEX1 Asp148Glu showed a border-line effect for the presence of at least one variant 
allele representing a better prognosis (OR=0.28; 95%CI, 0.74-1.03). Conversely, an increased effect was found for 
XRCC1 Arg194Trp variant (OR=6.60; 95%CI, 1.60-27.06) for the progression to secondary myelofibrosis/leukemia.  
Concerning the development of new nonmyeloid malignancies, globally, the presence of CASP8 
Asp270His variant is associated with a worse prognosis (OR=5.90; 95%CI, 1.42-24.62) and the presence of at 
least one variant allele carriers for XRCC1 Arg399Gln polymorphism revealed a better prognosis for these patients 
concerning the same factor (OR=0.27; 95%CI, 0.07-1.03).  
With regard to the presence of thrombotic events, there is a decreased incidence to develop these 
episodes in patients who carrier at least one variant allele carriers for XRCC1 Gln399Arg (OR=0.35; 95%CI, 0.14-
0.88).  
No significant change in OR was observed for any of the other genotypes considered.  
According to present reported results, progression to secondary myelofibrosis/leukemia is influenced by 
the exposure to cytoreductive agents and caspase and BER polymorphisms. Moreover, caspase and BER 
polymorphisms also influence the development of new nonmyeloid malignancies. On the other hand, only BER 
pathway has a role in the presence of thrombotic events. According to our results, the presence of JAK2 mutation 
has no influence for the development of any of these complications. 
Larger studies are required to confirm these results and to provide conclusive evidence of association 
between these and other variants with PN-MPNs therapeutic response and clinical evolution. 
Identification of the main molecules that are altered in MPNs and the concurrent presence of 
polymorphisms/variants in key genes involved in DNA repair and cell survival (e.g. caspases) may allow the 
development of drugs more directly targeted to the pathophysiology of the disease, with high efficacy, fewer 
adverse effects, contributing to compliance of the patients with treatments. Also, the clinical indication of the 
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CHAPTER 9: EFFECTS OF POLYMORPHIC DNA GENES INVOLVED 
IN BER AND CASPASE PATHWAYS ON THE CLINICAL OUTCOME 
OF MYELOPROLIFERATIVE NEOPLASMS UNDER TREATMENT 
WITH HYDROXYUREA 
9.1 – INTRODUCTION 
Polycythemia vera (PV), Essential thrombocythemia (ET) and Primary myelofibrosis (PMF) are 
included in Philadelphia-chromosome negative myeloproliferative neoplasms (PN-MPNs).  
There is an intrinsic tendency of PN-MPNs to progress to acute myeloid leukemia (AML), in 
occasions preceded by a phase of secondary myelofibrosis or myelodysplastic syndromes (MDS) 
(Mesa et al., 2016), and to concurrently present thrombohaemorhagic complications, to  an extent that 
is not fully known (Björkholm, Hultcrantz, & Derolf, 2014; Hernández-Boluda et al., 2012) and with a life 
expectancy reduced compared with that in the general population (Passamonti et al., 2004; Wolanskyj, 
Schwager, McClure, Larson, & Tefferi, 2006). 
It is  well known that  high doses of alkylating agents and combined cytoreductive treatments 
are associated with enhancement of malignant transformation in PN-MPNs (Björkholm et al., 2014; 
Hernández-Boluda et al., 2012), reported in the literature to occur in 5-10% of patients 10 years 
following the initial diagnosis, correlated with a bad prognosis (Rampal et al., 2014; Swerdlow et al., 
2008).  
Moreover, there are other determinant factors not related to therapy that cannot be ruled out,  
affecting the clinical course of these disorders and the response to therapy, namely mutational burden, 
polymorphic variants of several genes, ambient/dietary exposure and immune system (Beer et al., 
2010; Bolufer et al., 2006; Delhommeau, Jeziorowska, Marzac, & Casadevall, 2010; Hasselbalch et al., 
2014; Kilpivaara & Levine, 2008). 
Another important concern refers to the tendency of development of new nonhematological and 
nonmyeloid neoplasms in MPNs, with an incidence ratio of 1.2-1.4 and 3.4, respectively, when 
compared to the general population (Hernández-Boluda et al., 2012). There is evidence that this risk is 
higher when JAK2 V617F mutation is present and other patient factors may be also involved, although 
the association with cytoreductive therapy is not so well established (Hernández-Boluda et al., 2012; 
Santoro et al., 2017). 
 Reported thromboembolic complications range from 7% to 57% at diagnosis and rise to 41%-
91% during follow-up, and arterial thrombotic events being much more common than venous ones in 
both PV and ET (Andıç et al., 2016). 
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Thrombotic and haemorrhagic events are observed in up to 39% and 39.6% of PV patients, 
respectively (Griesshammer, Gisslinger, & Mesa, 2015). The cumulative rate of nonfatal thrombosis in 
PV is 3.8 events per 100 persons per year, and in ET the rate of fatal and nonfatal thrombotic events 
ranges from 2% to 4% per 100 persons per year (Andıç et al., 2016). PMF seems less susceptible for 
thrombotic events, with a cumulative percentage of 2.23% per 100 persons per year. Age, previous 
thrombosis, leukocytosis and the presence of JAK2 mutation are known risk factors for thrombosis 
occurrence in MPNs (Andıç et al., 2016). Extreme thrombocytosis (count over 1000 or 1500x109/L) is 
found to be related to haemorrhagic complications but not thrombosis, due to induced reduction of high-
molecular-weight von Willebrand factor levels (Andıç et al., 2016). 
On the other hand, several single nucleotide polymorphisms (SNPs) at various loci, influencing 
DNA repair capacity and apoptotic status, and additional somatic genetic effects may confer genetic 
predisposition to PN-MPNs (A. P. Azevedo et al., 2017), influencing  phenotype definition and 
determining therapeutic response (Bănescu et al., 2014; Campregher, Santos, Perini, & Hamerschlak, 
2012; Delhommeau et al., 2010; Levine, 2009; Nangalia et al., 2013; Tefferi & Pardanani, 2015; 
Tognon, Nunes, & Castro, 2013; Wang et al., 2014). Moreover, despite the development of more 
efficient drugs in the last years, some patients with PN-MPNs still evidence disease progression to 
conditions more aggressive and difficult to treat (Björkholm et al., 2014; Mesa et al., 2016).  
As a matter of  fact, DNA damage induced to haematopoietic precursor cells would appear to 
be crucial for leukemic transformation, despite DNA repair systems act to repair the DNA lesions, thus 
maintaining genetic integrity (Batar, Güven, Bariş, Celkan, & Yildiz, 2009; Baute & Depicker, 2008; 
Bănescu et al., 2014). Several polymorphisms in DNA repair genes have been associated to protein 
dysfunction, compromising DNA damage repair (Batar et al., 2009; Bolufer et al., 2006; Bănescu et al., 
2014; Hoeijmakers, 2001; Wang et al., 2014). 
Previous data described in the literature  reported the identification and study of various SNPs 
in genes involved in the BER pathway [APEX1, mutY DNA glycosylase, earlier mutY homolog (E. coli) 
(MUTYH), OGG1, PARP1, PARP4 and XRCC1] for their association with progression to leukaemia and 
disease outcome (Annamaneni et al., 2013; Bolufer et al., 2006; Bănescu et al., 2014) in patients with 
ET and PV. Likewise, there is also evidence that a nucleotide excision repair gene polymorphism is 
strongly associated with leukaemic transformation and development of non-myeloid malignancies in 
these disorders (Hernández-Boluda et al., 2012). 
On the other hand, apoptosis is considered as the most important pathway of cell death, 
through regulatory proteins, the caspases, organized in both intrinsic and extrinsic pathways, acting as 
a defense mechanism against damaged, stressed, or stimulated cells by any agents, preventing 
accumulation of non-functional cells in the tissues. 
The haematopoietic system is subject to a high cellular turnover rate, which makes it particularly 
sensitive to disturbance in the apoptosis process (Zaman, Wang, & Gandhi, 2014). Altered control of 
pro- and anti-apoptotic genes and in the relation with JAK2 or STAT5 signaling routes, seem to lead to 
myeloaccumulation and myeloproliferation, participating in the pathogenesis of MPNs (Malherbe et al., 
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2016; Nunes et al., 2013; Olsson & Zhivotovsky, 2011; Testa, 2004; Tognon et al., 2011; Tognon et al., 
2012; Tognon et al., 2013; Tognon et al., 2016). 
Since the end of 60’s, several groups as the American Polycythemia Vera study Group (PVSG) 
and the Italian group for hematological diseases in adults (GIMEMA) devoted their efforts to the study 
of natural history of PV, ET, and PMF and the best treatment options (Tefferi, 2016). 
Nowadays therapeutic goals in PV and ET are mostly directed to prevention of 
thrombohemorrhagic complications and relieve of symptoms, without curative potential nor capacity of 
prolonging life or preventing disease progression (Griesshammer et al., 2015). Drug therapy towards 
PMF intend especially to control symptoms and splenomegaly, with the possibility of remission in a 
limited number of patients undergoing allogeneic stem cell transplant (ASCT) (Rumi & Cazzola, 2017; 
Tefferi, 2016).   
According to contemporary treatment algorithms, based on risk stratification (Tefferi, 2016), all 
the patients with PV require phlebotomies to a hematocrit target of <45%. In PV and ET patients it is 
very important to identify those whose risk of vascular and thrombotic complications is high enough to 
justify the use of risk-adapted treatment strategies, including aspirin, anticoagulants, hydroxyurea (HU), 
anagrelide, interferon alfa (IFN-alpha) or the recent JAK2 inhibitors (eg. Ruxolitinib) (Tefferi, 2016). 
Patients are stratified and treatment is prescribed according to evaluation of the three major risk factors 
for thrombosis, namely previous history of arterial or venous thrombosis, eventual presence of JAK2 
mutation and age >60 years (Tefferi, 2016; Treliński, Chojnowski, Cebula-Obrzut, & Smolewski, 2012). 
The risk of thrombosis in older JAK2-unmutated without thrombosis history the risk is low enough to 
occasionally consider, on an individual basis, skipping cytoreductive therapy (Tefferi, 2016). 
HU is widely used as first-line cytoreductive therapy in “high risk” patients, as result of 
consensus of randomized clinical trials (Rumi & Cazzola, 2017; Treliński et al., 2012). This drug is an 
antimetabolite, capable of inhibition of ribonucleoside diphosphate reductase necessary for synthesis 
and repair of DNA, with a subsequent myelosuppressive activity (Treliński et al., 2012). Moreover, HU 
affects polymorphonuclear leukocytes function and interferes in their interactions with platelets, having 
an antithrombotic effect (Treliński et al., 2012).  Several authors have shown that HU can also induce 
apoptosis in many types of cells (endothelial cells, human mesenchymal stem cells and mouse 
embryonic stem cells),  promoting cell death by regulating the expression levels of Bcl-2 and the tumor 
suppressor p53 protein (Treliński et al., 2012).  
However, patients treated with HU can develop intolerance or become resistant to therapy, 
leading to an increased risk of death and progression to secondary myelofibrosis (Griesshammer et al., 
2015). 
An alternative to first-line treatment is INF-alpha, which has antiproliferative effects on 
hematopoietic primordial cells, reduce JAK2 V617F allele burden and induce cytogenetic remission, 
but it also associated with intolerable adverse effects, leading to noncompliance and therapy 
discontinuation (Griesshammer et al., 2015). 
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Second line cytoreductive therapy include busulfan or 32P, but these agents have been  
associated with a very high propensity to leukemic transformation, being reserved to very precise 
situations (Griesshammer et al., 2015).    
The discovery of JAK2 mutation led to the study and development of more targeted agents with 
the propose of JAK2 inhibition (ex: ruxolitinib), revealing better tolerability, clinical and quality of life 
improvement and increased survival (Griesshammer et al., 2015).  
In this study, we intend to characterize the way as SNPs in caspase and base excision repair 
(BER) genes might be relevant in PN-MPNs patients’ survival and therapeutic response concerning 




9.2 – MATERIALS AND METHODS 
9.2.1 – STUDY SUBJECTS 
The present study involves 133 Caucasian Portuguese patients diagnosed with PN-MPNs (80 
with ET, 39 with PV and 14 with PMF), during the period of 1992-2016, for evaluation of the 
predisposition to fibrotic/leukemic progression, development of new primary non-myeloid neoplasms 
and thrombotic events. Among these patients, 104 were medicated with isolated HU and 6 with HU in 
combination with other agents. 
The study population included a total of 17 cases of ET/PV with fibrotic/leukemic (2ry MF/AML) 
progression and 76 ET/PV patients who did not progress, 11 cases of ET/PV/PMF who developed new 
primary non-myeloid neoplasms and 30 patients who did not and 22 cases of ET/PV/PMF who 
presented thrombotic events and 56 patients who did not present this type of event.  
For each case patient 1 to several control patients were selected from the group who did not 
presented the event in question. Cases and controls were matched for the type of PN-MPN and duration 
of follow-up, ensuring that controls were followed at least for the same amount of time than the matched 
case, having the same chance to develop the event.   
The patients were selected within the Portuguese population, with Portuguese ascendants, 
recruited in the Departments of Clinical Hematology and of Clinical Pathology, Hospital of S. Francisco 
Xavier, West Lisbon Hospital Centre, a public general hospital that provides health care to the western 
population of Lisbon, where those patients were followed and treated. Diagnosis criteria for all patients 
were those updated by the World Health Organization (Arber et al., 2016; Tefferi & Vardiman, 2008) 
and all clinical, hematologic and treatment data were obtained from registries. 
A written informed consent was obtained from all those involved, prior to blood withdrawal, in 
agreement with the Declaration of Helsinki. The blood samples were coded to guarantee anonymity.  
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 This study was also conducted with approval by the institutional ethics’ boards of the involved 
institutions. 
General characteristics for PN-MPNs patients at time of diagnosis and related to disease 
outcome are summarized in Table 9.1.  
9.2.2 – DNA EXTRACTION 
The methodology used is described in Chapter 3, section 3.2.2. 
9.2.3 – SNP SELECTION (CASPASES AND BASE EXCISION REPAIR PATHWAY) 
The appropriate SNPs analized in the present study were selected according the described in 
Chapters 7 and 8, sections 7.2.3 and 8.2.3 (Table 9.2). 
The selected apoptosis polymorphisms were rs2227309 and rs2227310 (CASP7), rs1045485 
and rs1035142 (CASP8), rs2308950, rs1132312 and rs1052571 (CASP9) and rs13006529 (CASP10) 
and BER pathway polymorphisms (A. P. Azevedo et al., 2017) were rs1130409 (APEX1), rs3219489 
(MUTYH), rs1052133 (OGG1), rs1136410 (PARP1), rs13428 and rs1050112 (PARP4), and rs1799782 
and rs25487 (XRCC1) (Table 9.2). 
9.2.4 – GENOTYPING 
The apoptosis and BER polymorphisms were genotyped and JAK2 V617F (rs77375493) 
mutational status was determined using the same methodology described in Chapter 3, section 3.2.3 
The SNP genotyping assay information for apoptosis and BER polymorphisms (A. P. Azevedo 
et al., 2017), according to the event in question and aspect to analyze is summarized in Tables 9.3-9.7. 
JAK2 V617F mutational status (A. P. Azevedo et al., 2017) is summarized in Table 9.1.    
9.2.5 – STATISTICAL ANALYSIS 
The analysis of Hardy-Weinberg frequencies for all alleles in the control and patient populations 
was carried out using exact probability tests available in SNPStat software. Differences in genotype 
frequency, gender, hematological values, therapeutic and pathology distributions, progression to 
secondary 2ry MF/AML, development of a new primary nonmyeloid malignancy and thrombotic events 
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occurrence distributions between PN-MPNs patient cases and controls were evaluated by the Chi-
Square (χ2) test.  
Hazard ratios (HR) and 95% confidence intervals (95% CI) were estimated for each variable 
using the Cox univariate model. For the purpose of these calculations, the association between selected 
SNPs and their effect over 2ry MF/AML progression, was evaluated using logistic regression conditional 
for the matched cases and controls. The covariates selected, including clinic-laboratorial data at the 
time of MPN diagnosis, JAK2 mutational status and therapy related aspects (exposure to HU and/or 
other cytoreductive agents), were reported in the literature from previous studies as associated with 
disease progression (Griesshammer et al., 2015; Hernández-Boluda et al., 2012).  
Because there were few patients who received other therapy than HU, exposure to 
cytoreductive therapy was considered as “no exposure” (including IFN or anagrelide isolated, as these 
drugs are not leukemogenic), “HU only” and “other agents alone or in combination”. 
All analyses were performed using the Statistical Package for the Social Sciences for Windows 
22.0 version (SPSS, Inc.) (Tables 9.3-9.7). Since this is not a conclusive final study but an exploratory 
one on the role of apoptosis and BER pathway polymorphisms and some known risk factors in PN-
MPNs clinical outcome, and the data to be obtained should be looked at as proof of concept, the 
Bonferroni adjustment was deemed as not necessary as it is too conservative. 
 
 
9.3 – RESULTS 
9.3.1 – GENERAL CHARACTERISTICS OF PATIENTS AND SURVIVAL 
 
This study included 133 PN-MPNs patients, whose general characteristics are summarized in 
Table 9.1. According to diagnosis criteria patients’ distribution was as follows: 80 (60.2%) with ET, 39 
(29.3%) with PV and 14 (10.5%) with PMF. 
 
Table 9.1 – Characteristics of patients according to the type of MPN. 
Characteristic ET PV PMF 
No. of patients 80 39 14 
Sex, male/female, n/% 32 (40.0) / 48 (60.0) 20 (51.3) / 19 (48.7)  9 (64.3) / 5 (35.7) 
Age, ya 66 (33-100) 69 (46-96) 73 (55-84) 
Hb, g/La 131 (85-168) 165 (129-213) 114 (74-151) 
HTC 0.4 (0.261-0.498) 0.5 (0.429-0.660) 0.4 (0.218-0.491) 
WBC, x109/La 10.0 (2.7-26.6) 12.7 (4.5-33.5) 10.8 (2.2- 17.7) 
Platelets, x109/La 777 (241-2485) 411 (164-1316) 232 (34-461) 
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JAK2 V617F mutation, n(%)            
      Val/Val 21 (25.6) 5 (12.8) 7 (50.0) 
      Val/Phe 56 (70.9) 31 (79.5) 5 (35.7) 
      Phe/Phe 2 (2.5) 3 (7.7) 2 (14.3) 
Exposure to cytoreductive agentes, n (%) 
      No exposure 8 (10.1) 5 (12.8) 5 (35.7)  
      HU only 65 (82.3) 33 (84.6) 6 (42.9) 
      HU+other agents 6 (7.6) 0 (0.0) 0 (0.0) 
      Other agents 0 (0.0) 1 (2.6) 3 (21.4) 
Follow-up, ya 8.6 (1-25) 7.4 (1-17) 6.0 (1-15) 
Deathb, n (%) 12 (54.5) 7 (31.8) 3 (13.6) 
      ≤ 5 years 7 (58.3) 2 (28.6) 3 (100.0) 
      6–10 years 0 (0.0) 3 (42.9) 0 (0.0) 
      10–20 years 5 (41.7) 2 (28.6) 0 (0.0) 
aMedian (range) 
bP=0.044; P=0.146; OR, 95% CI: 1.42 (0.89-2.28) 
 
 
Globally, the study included 72 (54.1%) females and 61 (45.9%) male patients, with an overall 
mean age of 68 years, in agreement with the gender distribution usually observed in this type of 
pathology.  
Mean values for laboratorial data at time of diagnosis for each disorder are listed in Table 9.1, 
reflecting the different clinical-hematological pattern characteristic of each one of them. Hemoglobin 
was significantly higher in PV than in other groups and significantly lower in PMF than in other groups. 
Platelet count was higher in ET than in other groups.  
Concerning the presence of JAK2 V617F mutation, 73.4% of ET, 87.2% of PV and 50.0% of 
PMF patients were positive (Table 9.1).  
Hydroxyurea was the first choice drug in the majority of ET, PV, and PMF cases, used alone in 
104 patients and in combination with other agents in 6 patients. Anagrelide and interferon-alpha were 
used in a minority of patients. Acetylsalicylic acid was used in approximately 35% of both PV and ET 
cases (Table 9.1). 
Patients were followed up for a mean of 7.6 years. Myelofibrosis patients presented the shorter 
survival, with the majority of them dying less than five years after diagnosis, followed by PV (20.5%) 
and ET (13.8%) patients (Table 9.1). 
Survival is influenced by progression to 2ryMF/AML and the presence of JAK2 V617F mutation 
(Table 9.3). None of the other evaluated factors evidenced to influence PN-MPNs survival. 
The characteristics of each SNP under study are described in Table 9.2, while the genotype 
frequencies and therapeutic distribution determined according to survival are shown in Table 9.3.  
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Table 9.2 – Selected caspases and BER pathway SNPs and detailed information on the corresponding 
base and amino acid exchanges as well as MAF. 
Gene dsSNP Codon 
Nucleotide 
exchange 




     
CASP7  
 









































 rs13006529 522 
A  T 
(Ile/Leu) 
44.0 
BER SNPs     









  OGG1 
 





  PARP1 
 




     
  PARP4 
 









  XRCC1 
 








aAccording to http://www.ncbi.nlm.nih.gov/snp/.  
MAF, minor allele frequency; APEX1, apurinic/apyrimidinic endonuclease 1; MUTYH, mutY DNA glycosylase, 
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Table 9.3 – Factors influencing survival. 
 Alive (n=109 Died: ≤ 5 
years (n=12) 





Cases (n=17) with 
progression to 2ry MF/AML, n 
(%) 
10 (58.8) 2 (11.8) 0 (0.0) 5 (29.4) <0.001 
Cases with  
non-myeloid neoplasms 
(n=11), n (%) 
7 (63.6) 2 (18.2) 1 (9.1) 1 (9.1) 0.720 
Cases with thrombotic 
events (n=22), n (%) 
16 (72.7) 2 (9.1) 2 (9.1) 2 (9.1) 0.088 
Exposure to cytoreductive agentes, n (%)   0.205 
   No exposure 13 (12.0) 2 (16.7) 3 (50.0) 0 (0.0)  
   HU only 88 (81.5) 8 (66.7) 3 (50.0) 5 (83.3)  
   HU+other agents 4 (3.7) 1 (8.3) 0 (0.0) 1 (16.7)  
   Other agents 3 (2.8) 1 (8.3) 0 (0.0) 0 (0.0)  
JAK2 V617F mutation genotype, n (%)    0.009 
   Val/Val 26 (24.1) 5 (41.7) 2 (33.3) 0 (0.0)  
   Val/Phe 79 (73.1) 6 (50.0) 2 (33.3) 5 (83.3)  
   Phe/Phe 3 (2.8) 1 (8.3) 2 (33.3) 1 (16.7)  
Caspases SNPs 
CASP7 (Arg249Lys; rs2227309)    0.902 
   Arg/Arg 
   Arg/Lys 














CASP7 (Asp255Glu; rs2227310)    0.883 
   Asp/Asp 
   Asp/Glu 














CASP8 (3’UTR G>T; rs1035142)    0.668 
   G/G 
   G/T 














CASP8 (Asp270His; rs1045485)    0.570 
   Asp/Asp 
   Asp/His 














CASP9 (Arg173His; rs2308950)    0.989 
   Arg/Arg 
   Arg/His 














CASP9 (Phe136Phe; rs1132312)    0.902 
   TTC/TTC 
   TTC/TTT 














CASP9 (Ala28Val; rs1052571)    0.913 
   Ala/Ala 
   Ala/Val 














CASP10 (Ile522Leu; rs13006529)    0.611 
   Ile/Ile 
   Ile/Leu 















APEX1 (Asp148Glu; rs1130409)    0.141 
   Asp/Asp 
   Asp/Glu 
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MUTYH (Gln335His; rs3219489)    0.381 
   His/His 
   His/Gln 














OGG1 (Ser326Cys; rs1052133)    0.837 
   Ser/Ser 
   Ser/Cys 














PARP1 (Val762Ala; rs1136410)    0.174 
   Val/Val 
   Val/Ala 














PARP4 (Gly1280Arg; rs13428)    0.506 
   Gly/Gly 
   Gly/Arg 














XRCC1 (Arg194Trp; rs1799782)    0.211 
   Arg/Arg 
   Arg/Trp 














XRCC1 (Gln399Arg; rs25487)    0.292 
   Arg/Arg 
   Arg/Gln 















**Patients who received IFN or anagrelide as the only cytoreductive drugs were included in the “no exposure” group 
a Pvalue determined by χ2 test 
APEX1, apurinic/apyrimidinic endonuclease 1; MUTYH, mutY DNA glycosylase, earlier mutY homolog (E. coli); 
OGG1, 8-oxoguanine DNA glycosylase 1; PARP, poly (ADP-ribose) polymerase; XRCC1, X-ray repair cross-
complementing 1; OR, odds ratio; CI, confidence interval; ND, none determined. 
 
9.3.2 – ANALYSIS OF PATIENTS WHO PROGRESSED TO SECONDARY MF/AML 
The study included 17 patients with PV (8 patients) or ET (9 patients) who progressed to 
2ryMF/AML, corresponding to 20.5% and 11.2% of each disorder population respectively, and 76 
controls who did not (Table 9.1 and 9.4). 
The characteristics of these cases/controls patients are summarized in Table 9.4.  
Median follow-up time for diagnosis of progression in cases patients was 7.6 years, ranging 
from 1 to 18 years. There was no significant difference in age among cases and controls patients 
(median of 67.7 years), but the first ones had higher WBC counts at presentation and displayed more 
frequently JAK2 mutation. JAK2 V617F mutation was also tested, but no association was found with 
the propensity of leukemic transformation (Table 9.4). Regarding the number of individuals with marked 
thrombocytosis (>1000x109/L), there is no significant difference among cases and controls patients 
(Table 9.4). 
Globally, there is an association with progression to 2ry MF/AML and the exposure to 
cytoreductive agents (Table 9.4). Twelve of the total patients who progressed to 2ryMF/AML were 
medicated with HU only (Table 9.4). The result obtained in the group of patients medicated with “other 
agents”  than  HU  is  not  statistically  relevant  because  it  represents  typical  statistical  error  type I.  
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Genotypes distribution was found to be in Hardy-Weinberg equilibrium.  
The presence of at least one variant allele carriers for CASP8 3’UTR variant is associated with  
a lower effect in disease progression to 2ry MF/AML (OR=0.24; 95%CI, 0.08-0.69) and the presence of 
XRCC1 Arg194Trp variant showed a border-line effect (OR=3.58; 95%CI, 0.98-13.01) (Tables 9.4 and 
9.7) suggesting a higher risk of developing 2ry MF/AML, representing a worse prognosis.   
When stratified for ET patients, the presence of at least one variant allele carriers for CASP9 
Arg173His polymorphisms is associated with a worse effect in progression to 2ry MF/AML (OR=11.27; 
95%CI, 1.13-112.28). While for BER polymorphisms the APEX1 Asp148Glu showed a border-line effect 
related to a probable better prognosis concerning the progression to 2ry MF/AML for patients who 
present at least one variant allele (OR=0.28; 95%CI, 0.74-1.03), an increased effect in disease 
progression was found for XRCC1 Arg194Trp variant (OR=6.60; 95%CI, 1.60-27.06), which might be 
related to a worse prognosis (Table 9.7).  
No significant change in OR was observed for any of the other genotypes considered (Tables 
9.4 and 9.7).   
 
Table 9.4 – Factors investigated for their association with fibrotic/leukemic progression in ET and PV. 















ET/PV, n/% 9 (52.9)/8 (47.1) 54 (71.1)/22 (28.9) 0.149 -- 
Sex, male/female, n/% 8 (47.1)/9 (52.9) 31 (40.8)/45 (59.2) 0.636 1.25 (0.46-3.42) 
Age, y* 67.3 (46-91) 68.0 (37-100) 0.231 1.01 (0.97-1.05) 
Years to progression* 7.6 (1-18)  -- -- -- 
WBC* 
   >10 x109/L* 













PLT >1000x109/L 4 (23.5) 16 (21.1) -- -- 
JAK2 V617F mutation, n/%  0.716  
   Val/Val 
   Val/Phe 







 1 (Reference) 
1.59 (0.36-7.09) 
0.69 (0.15-18.29) 
Exposure to cytoreductive agentes** 0.011  
   No exposure 
   HU only 
   HU+other agents 













Caspases SNPs     
CASP7 (Arg249Lys; rs2227309) 0.201  
   Arg/Arg 
   Arg/Lys 
   Lys/Lys 
   Arg/Lys+Lys/Lys 
6 (35.3) 











CASP7 (Asp255Glu; rs2227310) 0.353  
   Asp/Asp 
   Asp/Glu 
   Glu/Glu 
   Asp/Glu+Glu/Glu 
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CASP8 (3’UTR; rs1035142) 0.084  
   G/G 
   G/T 
   T/T  






39 (51.3)  
14 (18.4)  
53 (69.7) 




CASP8 (Asp270His; rs1045485) 0.468  
   Asp/Asp 
   Asp/His 
   His/His 













CASP9 (Arg173His; rs2308950) 0.710  
   Arg/Arg 
   Arg/His 
   His/His 













CASP9 (Phe136Phe; rs1132312) 0.119  
   TTC/TTC  
   TTC/TTT 
   TTT/TTT 













CASP9 (Ala28Val; rs1052571) 0.261  
   Val/Val 
   Val/Ala 
   Ala/Ala 













CASP10 (Ile522Leu; rs13006529) 0.461  
   Ile/Ile 
   Ile/Leu 
   Leu/Leu 














APEX1 (Asp148Glu; rs1130409) 0.128  
   Asp/Asp 
   Asp/Glu 
   Glu/Glu 













MUTYH (Gln335His; rs3219489) 0.315  
   His/His 
   His/Gln 
   Gln/Gln 













OGG1 (Ser326Cys; rs1052133) 0.861  
   Ser/Ser 
   Ser/Cys 
   Cys/Cys 













PARP1 (Val762Ala; rs1136410) 0.456  
   Val/Val 
   Val/Ala 
   Ala/Ala 













PARP4 (Gly1280Arg; rs13428) 0.019  
   Gly/Gly 
   Gly/Arg 
   Arg/Arg 













XRCC1 (Arg194Trp; rs1799782) 0.099  
   Arg/Arg 
   Arg/Trp 
   Trp/Trp 
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XRCC1 (Gln399Arg; rs25487) 0.911  
   Arg/Arg 
   Arg/Gln 
   Gln/Gln 














**Patients who received IFN or anagrelide as the only cytoreductive drugs were included in the “no exposure” group 
a P value determined by χ2 test 
b P determined by conditional logistic regression 
c P=0.022; d P=0.013; e P= 0.009; f P= 0.053 (borderline effect) 
APEX1, apurinic/apyrimidinic endonuclease 1; MUTYH, mutY DNA glycosylase, earlier mutY homolog (E. coli); 
OGG1, 8-oxoguanine DNA glycosylase 1; PARP, poly (ADP-ribose) polymerase; XRCC1, X-ray repair cross-
complementing 1; OR, odds ratio; CI, confidence interval; ND, none determined. 
 
 
9.3.3 – ANALYSIS OF PATIENTS WHO DEVELOPED NEW  NONMYELOID 
MALIGNANCIES 
The study included 11 ET/PV/PMF patients who developed a new primary nonmyeloid 
malignancy during follow-up and 30 control patients who did not (Tables 9.1 and 9.5). One of these 
case patients developed a lymphoid malignancy and the others developed solid organ new 
malignancies, the most affected being lung, thyroid, adrenal gland and digestive tract. 
The characteristics of these cases/controls patients are summarized in Table 9.5. 
There is a predominance of male patients among cases, but there is no significant difference 
in age among cases and controls patients (median of 70.1 years) (Table 9.5). 
PMF patients present the highest incidence of new primary nonmyeloid malignancies (21.4% 
against 10.2 and 5.0% of PV and ET patients, respectively) (Tables 9.1 and 9.5). 
No significant association with exposure to cytoreductive agents or the presence of JAK2 
mutation was found (Table 9.5). 
Globally, the presence of CASP8 Asp270His variant allele is associated with an increased 
incidence to develop new non-myeloid malignancies (OR=5.90; 95%CI, 1.42-24.62), while the presence 
of at least one variant allele carriers for XRCC1 Arg399Gln (OR=0.27; 95%CI, 0.07-1.03) showed a 
border-line effect related to a decreased incidence to develop new non-myeloid malignancies (Tables 
9.5 and 9.7).  
Genotypes distribution was found to be in Hardy-Weinberg equilibrium. 
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Table 9.5 – Factors investigated for their association with new nonmyeloid malignancy in ET, PV and 
PMF. 












ET/PV/PMF, n/% 4 (36.4)/4 (36.4)/  
3 (27.3) 
17 (56.7)/7 (23.3)/ 6 (20.0) 0.509 
-- 
Sex, male/female, n/% 8 (72.7)/3 (27.3) 17 (56.7)/13 (43.3) 0.350 -- 
Age, y*  70.3 (60-84)  69.9 (45-100) 0.552 -- 
JAK2 V617F mutation, n/% 0.027  
   Val/Val 
   Val/Phe 







 1 (Reference) 
0.62 (0.18-2.07) 
ND 
Exposure to cytoreductive agentes** 0.649  
   No exposure 
   HU only 
   Other agents alone          









CASP7 (Arg249Lys; rs2227309) 0.137  
   Arg/Arg 
   Arg/Lys 
   Lys/Lys 













CASP7 (Asp255Glu; rs2227310) 0.124  
   Asp/Asp 
   Asp/Glu 
   Glu/Glu 













CASP8 (3’UTR; rs1035142) 0.174  
   G/G 
   G/T 
   T/T  













CASP8 (Asp270His; rs1045485) 0.011  
   Asp/Asp 
   Asp/His 
   His/His 













CASP9 (Arg173His; rs2308950) -  
   Arg/Arg 
   Arg/His 
   His/His 






 1 (Reference) 
- 
- 
CASP9 (Phe136Phe; rs1132312) 0.815  
   TTC/TTC  
   TTC/TTT 














CASP9 (Ala28Val; rs1052571) 0.977  
   Val/Val 
   Val/Ala 
   Ala/Ala 













CASP10 (Ile522Leu; rs13006529) 0.476  
   Ile/Ile 
   Ile/Leu 
   Leu/Leu 
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APEX1 (Asp148Glu; rs1130409) 0.341  
   Asp/Asp 
   Asp/Glu 
   Glu/Glu 













MUTYH (Gln335His; rs3219489) 0.647  
   His/His 
   His/Gln 
   Gln/Gln 













OGG1 (Ser326Cys; rs1052133) 0.673  
   Ser/Ser 
   Ser/Cys 
   Cys/Cys 













PARP1 (Val762Ala; rs1136410) 0.252  
   Val/Val 
   Val/Ala 






0 (0.0)  
 1 (Reference) 
1.73 (0.52-5.72) 
- 
PARP4 (Gly1280Arg; rs13428) 0.795  
   Gly/Gly 
   Gly/Arg 
   Arg/Arg 













XRCC1 (Arg194Trp; rs1799782) 0.964  
   Arg/Arg 
   Arg/Trp 
   Trp/Trp 













XRCC1 (Gln399Arg; rs25487) 0.047  
   Arg/Arg 
   Arg/Gln 
   Gln/Gln 














**Patients who received IFN or anagrelide as the only cytoreductive drugs were included in the “no exposure” group 
a Pvalue determined by χ2 test 
b P determined by conditional logistic regression 
c P=0.015; d P=0.056 
APEX1, apurinic/apyrimidinic endonuclease 1; MUTYH, mutY DNA glycosylase, earlier mutY homolog (E. coli); 
OGG1, 8-oxoguanine DNA glycosylase 1; PARP, poly (ADP-ribose) polymerase; XRCC1, X-ray repair cross-
complementing 1; OR, odds ratio; CI, confidence interval; ND, none determined. 
 
9.3.4 – ANALYSIS OF PATIENTS WHO PRESENTED WITH THROMBOTIC EVENTS 
The study included 22 ET/PV/PMF patients who developed a thrombotic event and 56 patients 
who did not (Table 9.1 and 9.6). Thrombotic events are slightly more common in PV patients (17.9%), 
followed by ET and PMF patients (Tables 9.1 and 9.6). In our studied population contrariwise, more 
than a half are ET patients (Table 9.6). 
In the population here studied, the most frequent types of major thrombosis observed in our 
patients included stroke, myocardial infarction, peripheral arterial thrombosis and deep vein thrombosis. 
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There is no significant difference in age (median of 67.9 years) and platelets count (difference 
in median values of 100x109/L, higher in control patients) between cases and controls patients (Table 
9.6). 
No significant association with the presence of JAK2 V617F mutation, nor the exposure to 
cytoreductive agents were found (Table 9.6). 
Globally, the thrombotic events where less frequent, revealing a decreased incidence, in 
patients with at least one variant allele carriers for XRCC1 Gln399Arg (OR=0.35; 95%CI, 0.14-0.88) 
(Tables 9.6 and 9.7).  
Genotypes distribution was found to be in Hardy-Weinberg equilibrium. 




Table 9.6 – Factors investigated for their association with thrombotic events in ET, PV and PMF. 
Distribution in case patients who developed a thrombotic event and control patients who did not. 
 







ET/PV/PMF, n/% 13 (59.1) / 7 (31.8) / 
2 (9.1) 
34 (60.7)/ 19 
(33.9)/ 3 (5.4) 
0.830  
Sex, male/female, n/% 13 (59.1)/9 (40.9) 24 (42.9)/32 (57.1) 0.196  
Age, y* 68.5 (45-88) 67.3 (54-96) 0.810  
Platelets, x109/L* 576.6 (134-1518) 676.9 (63-1473) -- -- 
JAK2 V617 mutation, n/%  0.945  
   Val/Val 
   Val/Phe 







 1 (Reference) 
1.03 (0.37-2.90) 
0.70 (0.13-3.69) 
Exposure to cytoreductive agentes** 0.624  
   No exposure 
   HU only 
   HU+other agents 











CASP7 (Arg249Lys; rs2227309) 0.743  
   Arg/Arg 
   Arg/Lys 
   Lys/Lys 













CASP7 (Asp255Glu; rs2227310) 0.654  
   Asp/Asp 
   Asp/Glu 
   Glu/Glu 













CASP8 (3’UTR; rs1035142) 0.765  
   G/G 
   G/T 
   T/T  













CASP8 (Asp270His; rs1045485) 0.497  
   Asp/Asp 
   Asp/His 
   His/His 
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CASP9 (Arg173His; rs2308950) 0.268  
   Arg/Arg 
   Arg/His 
   His/His 













CASP9 (Phe136Phe; rs1132312) 0.601  
   TTC/TTC  
   TTC/TTT 














CASP9 (Ala28Val; rs1052571) 0.306  
   Val/Val 
   Ala/Val 
   Ala/Ala 













CASP10 (Ile522Leu; rs13006529) 0.232  
   Ile/Ile 
   Ile/Leu 
   Leu/Leu 














APEX1 (Asp148Glu; rs1130409) 0.575  
   Asp/Asp 
   Asp/Glu 
   Glu/Glu 













MUTYH (Gln335His; rs3219489) 0.629  
   His/His 
   His/Gln 
   Gln/Gln 













OGG1 (Ser326Cys; rs1052133) 0.308  
   Ser/Ser 
   Ser/Cys 
   Cys/Cys 













PARP1 (Val762Ala; rs1136410) 0.215  
   Val/Val 
   Val/Ala 







 1 (Reference) 
0.70 (0.20-2.39) 
- 
PARP4 (Gly1280Arg; rs13428) 0.067  
   Gly/Gly 
   Gly/Arg 
   Arg/Arg 













XRCC1 (Arg194Trp; rs1799782) 0.382  
   Arg/Arg 
   Arg/Trp 
   Trp/Trp 











XRCC1 (Gln399Arg; rs25487) 0.386  
   Arg/Arg 
   Arg/Gln 
   Gln/Gln 













**Patients who received IFN or anagrelide as the only cytoreductive drugs were included in the “no exposure” group 
a P value determined by χ2 test 
b P determined by conditional logistic regression 
c P=0.058; d P=0.025; 
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APEX1, apurinic/apyrimidinic endonuclease 1; MUTYH, mutY DNA glycosylase, earlier mutY homolog (E. coli); 
OGG1, 8-oxoguanine DNA glycosylase 1; PARP, poly (ADP-ribose) polymerase; XRCC1, X-ray repair cross-





Table 9.7 – ORs (95% CI) for polymorphisms and PN-MPNs association. 
Pathology 
stratification 
n SNP OR (95% CI) P value 
PROGRESSION TO 2RY MF/AML (n=17) 
Globally 17 
CASP8 (3’UTR; rs1035142) 
   G/Ga 
   G/T 







  XRCC1_194 (Arg194Trp; rs1799782) 
     Arg/Arga 






CASP9 (Arg173His; rs2308950)  
   Arg/Arga 
   Arg/His 






APEX1 (Asp148Glu; rs1130409) 
  Asp/Aspa 
  Asp/Glu 




    
0.049 
0.055 
XRCC1_194 (Arg194Trp; rs1799782) 
   Arg/Arga 





DEVELOPMENT OF NEW NONMYELOID NEOPLASMS (n=11) 
Globally 11 
CASP8 (Asp270His; rs1045485) 
   Asp/Aspa 
   His/His 
1 (Reference) 
5.90 (1.42-24.62) 
    
0.015 
XRCC1_399 (Gln399Arg; rs25487) 
   Arg/Arga 
   Arg/Gln+Gln/Gln 
1 (Reference) 
0.27 (0.07-1.03) 
    
0.056 
PRESENCE OF THROMBOTIC EVENTS (n=22) 
Globally 22 
XRCC1_399 (Gln399Arg; rs25487) 
   Arg/Arga 
   Gln/Gln 




    
0.058 
0.025 
a The genotype considered as reference class 
APEX1, apurinic/apyrimidinic endonuclease 1; XRCC1, X-ray repair cross-complementing 1; OR, odds ratio; CI, 
confidence interval; ND, none determined. 
 
 
9.4 – DISCUSSION AND CONCLUSIONS 
This study was aimed to evaluate the general characteristics and clinical outcome of PN-MPNs 
in a Portuguese population, the majority of patients under therapeutic scheme with HU . 
Median age of 68 years old at time of diagnosis and gender distribution are similar to what is 
usually described in the literature (Andıç et al., 2016; Srour et al., 2016). Moreover, there is knowledge  
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in the literature that ET is more common in women and PV more common in men (Bai et al., 2008; 
Passamonti et al., 2008), sustained in our study especially in the case of ET patients. 
General laboratorial characteristics of the patients included in this study were in agreement with 
diagnostic WHO classification criteria (Arber et al., 2016; Swerdlow et al., 2008). Hemoglobin, 
hematocrit and leukocytes’ levels were higher in PV and platelet levels were higher in ET, and they 
were lower in PMF, as expected. 
We found JAK2 mutation in 87.2% of the PV group, 72.5% of the ET group, and 50.0% of PMF 
group. Although, the frequency of JAK2 mutation in the PV and ET groups is similar to that reported by 
another author, from a work developed in Turkey (Andıç et al., 2016),  these results differ from what is 
described in the general literature (Ana Paula Azevedo et al., 2017). Regarding PMF group, the current 
results are in accordance with previous ones we had obtained (Ana Paula Azevedo et al., 2017). 
Survival was highest in ET and lowest in PMF cases. However, the majority of deaths occurred 
through five years after diagnosis and involved ET and PMF patients, followed by PV patients six to ten 
years after diagnosis. According to literature, PV has a life expectancy of 10 to 20 years (Passamonti  
et al., 2004), ET patients ranges from 13 to 22.3 years (Gangat et al., 2007; Passamonti et al., 2008), 
and PMF patients have a mean overall survival of 5.5 years (Tefferi, 2000). 
Progression to 2ry MF/AML and the presence of JAK2 V617F mutation shortened the survival 
significantly, consistent with the literature (Andıç et al., 2016). However, according to our results 
development of new primary nonmyeloid malignancies and occurrence of thrombotic events did not 
influenced survival, not corroborating what is described in the literature (Andıç et al., 2016), probably 
because of the dimension  of the studied populations. Likewise, none of the caspase and BER pathway 
studied polymorphisms influenced survival. 
It is known that prognosis of MPNs is determined by progression to secondary MF and AML, 
development on new primary nonmyeloid malignancies and  thromboembolic and hemorrhagic 
complications, reflecting the impact that therapeutics and other inherited genetic factors may play in 
disease outcome (Andıç et al., 2016; Hernández-Boluda et al., 2012).  
Therapy should be directed towards preventing leukemic transformation in PN-MPNs. 
Progression to AML is a relatively rare complication, usually appearing late in the clinical course of ET 
and PV, requiring studies involving large cohorts of patients and extended follow-up periods 
(Hernández-Boluda et al., 2012). We here describe the development of a case control-study, comparing 
a population composed of ET and PV patients demonstrating fibrotic/leukemic progression with a 
control population including patients who did not progress, monitored for at least the same period of 
time, to investigate the role of clinical, genetic and therapy related factors potentially involved in 
fibrotic/leukemic transformation in PN-MPNs. 
According to our results, 12.8% of all PN-MPNs patients progressed to 2ry MF/AML, with a mean 
time of 7.6 years. ET and PV revealed the same incidence of progression, but none of the PMF cases 
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transformed to leukemia, similarly with other authors (Andıç et al., 2016). Patients who developed 
leukemia were not significantly different from others by means of sex and age. 
Leukemic transformation was influenced by the exposure to cytoreductive agents (Hernández-
Boluda et al., 2012), but the mutagenic and carcinogenic potential of HU, through reduction of DNA 
repair,  in PN-MPNs is controversial, with significant discrepancies among the several studies reported 
in the literature (Hernández-Boluda et al., 2012).  
Our results revealed that previous treatment with HU was not found to be an influencing factor 
for leukemic transformation.  Although not statistically significant in our results, it appears that 
leukocytosis and marked thrombocytosis could be involved in leukemic transformation, in agreement 
with the literature (Griesshammer et al., 2015; Hernández-Boluda et al., 2012; Passamonti et al., 2008; 
Passamonti et al., 2004). 
There is published evidence of the involvement of genetic polymorphisms and the susceptibility 
to leukemic progression (Hernández-Boluda et al., 2012), consistent with our results, in which an 
association between caspase and BER gene polymorphisms was found.  Altogether, the presence of 
at least one variant allele in carriers for CASP8 3’UTR variant is associated with a lower effect in disease 
progression, and the presence of XRCC1 Arg194Trp variant showed a border-line effect, suggesting a 
higher effect associated with a worse prognosis for 2ry MF/AML development. 
When stratified for ET patients, the presence of at least one variant allele carriers for CASP9 
Arg173His polymorphisms is associated with an increased effect and a worse prognosis. Regarding 
BER polymorphisms, APEX1 Asp148Glu showed a border-line effect related to an ensuing better 
prognosis for the presence of at least one variant allele carriers. A worse prognosis in disease 
progression was found for XRCC1 Arg194Trp variant. 
Development of new nonmyeloid malignancies was observed in 8.3% of all PN-MPNs patients, 
approximately equally distributed among ET, PV and PMF, with a male predominance. Regarding age, 
it appears that there is no significant difference among case and control patients.  
The majority of cases corresponded to solid organ new malignancies, the most affected being 
lung, thyroid, adrenal gland and digestive tract, and on case developed a lymphoid malignancy.  
The association of long-term HU use with development of nonmyeloid malignancies is 
controversial, with some authors reporting no association and others a weak relation (Hernández-
Boluda et al., 2012; Santoro et al., 2017). In fact, in the present study, no association was observed. 
According to previous studies (Hernández-Boluda et al., 2012),  JAK2 V617F mutation and caspase  
and BER polymorphisms constitute significant influencing factors for the occurrence of new primary 
nonmyeloid malignancies in PN-MPNs,  conditioning these disorders clinical evolution. Our results 
revealed no association with the presence of JAK2 mutation. However, globally, an increased incidence 
to develop new non-myeloid malignancies was found for the presence of CASP8 Asp270His variant, 
while a border-line effect related to a decreased incidence to develop new non-myeloid malignancies 
was observed for the presence of at least one variant allele carriers for XRCC1 Arg399Gln. 
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Thrombotic complications were seen in 16.5% of all PN-MPNs patients in our study, the majority 
of them occurring during follow-up, with a similar incidence between PV, ET and PMF patients, slightly 
lower in the last group. In the literature, it is reported that about 41% of all deaths in PN-MPNs (1.5 
deaths per 100 persons per year) were due to cardiovascular complications (Barbui, Finazzi, & Falanga, 
2013), with an increase of thromboembolic events during follow-up (ranging from 41% to 91%), in 
comparison with a variation from 7% to 57% at PN-MPN diagnosis, with fewer PMF patients being 
affected compared to other PN-MPNs (Andıç et al., 2016). In our patients, arterial events were more 
frequent than venous, in agreement to what is described by other authors (Andıç et al., 2016), including 
stroke, myocardial infarction, peripheral arterial thrombosis and deep vein thrombosis. Apparently, 
according to our results, the occurrence of this type of events is not related to age, sex, platelet counts, 
the presence of JAK2 mutation, nor the exposure to cytoreductive agents, differing from the results 
previously published by some authors (Andıç et al., 2016). 
Leukocytosis and JAK2 V617F allele burden have been identified as thrombotic risk factors 
and in the case of PV patients, leukocytosis at diagnosis has been considered to be associated with an  
increased risk to develop arterial thrombosis and progress to acute leukemia, resulting in shorter 
survival (Griesshammer et al., 2015).  
In the present study, only BER pathway showed a role in the presence of thrombotic events, 
revealing a decreased incidence when at least one variant allele carriers for XRCC1 Gln399Arg is 
present, making thrombotic episodes less frequent in these patients. 
The caspases, a specific group of cysteine aspartate proteases, are a family of intracellular 
proteins involved in the initiation and execution of apoptosis processes, responsible for the dismantling 
and destruction of the cell (Green & Llambi, 2015; Riedl & Salvesen, 2007). There are 14 different 
caspases and they can be classified as initiator, effector and cytokine activators (Kiraz, Adan, Kartal 
Yandim, & Baran, 2016). The initiators caspases (caspase-2, 8, 9, 10) activate the effectors caspases 
(caspase 3, 6, 7 and 14), which are capable of degrading direct multiple substrates leading to 
deregulation of vital cellular processes and cellular death (Kiraz et al., 2016; Ng, Porter, & Jänicke, 
1999; Oliver & Vallette, 2005; Philchenkov, Zavelevich, Kroczak, & Los, 2004; Riedl & Salvesen, 2007), 
and also the cytokine activators caspases (caspase 1, 4, 5, 11, 12 and 13).  Several proteins have been 
described that promote pro- or anti- apoptotic activity in the cell. The ratio of these pro-and anti-apoptotic 
proteins plays an important role in the regulation of cell death, and disruption in the balance between 
these proteins has been established to contribute to carcinogenesis by reducing apoptosis in malignant 
cells (Ding et al., 2000; Goldar, Khaniani, Derakhshan, & Baradaran, 2015; Olsson & Zhivotovsky, 
2011).  
Several studies described modifications in the expression of molecules that participate in the 
regulation of intrinsic and extrinsic routes of apoptosis, as well as functional studies that showed 
resistance to apoptosis, indicating that the deregulation of apoptosis in MPNs is a mechanism involved 
in the pathophysiology and clinic-hematological outcome of these diseases (Malherbe et al., 2016; 
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Testa, 2004; Tognon et al., 2013).  
Uphold of genetic integrity, through DNA repair mechanisms, is essential for preventing cellular 
damage and the development of leukaemia (A. P. Azevedo et al., 2017). Protein function and thus DNA 
damage repair may be affected by several polymorphisms in DNA repair genes,  leading to susceptibility 
to malignancy (A. P. Azevedo et al., 2017). Previous reports have identified BER pathway 
polymorphisms associated solid tumors development (A. P. Azevedo et al., 2017), and a nucleotide 
excision repair gene polymorphism displayed strong association with leukaemic transformation and 
development of non-myeloid malignancies in ET and PV patients (Hernández-Boluda et al., 2012). 
The BER pathway typically repairs a small region (1-13 nucleotides) around the damaged base, 
and several polymorphisms have been identified and studied for their association with progression to 
leukemia and disease outcome (A. P. Azevedo et al., 2017). 
Previous studies performed by our working group in which we tested the contribution of 
apoptosis and BER related genes to individual susceptibility to MPNs, also revealed involvement of the 
same family of polymorphisms (A. P. Azevedo et al., 2017) that were found to be associated with 
disease outcome as described in this present work.  
HU, an antimetabolite, and anagrelide are the most commonly used drugs in the treatment of 
all PN-MPNs groups. The former was shown to reduce the incidence of thrombotic events in several 
studies, but there is some evidence that it may increase the risk of leukemic transformation (Andıç et 
al., 2016; Hernández-Boluda et al., 2012). Anagrelide is effective in reducing platelet counts in ET and 
PV patients who are resistant or intolerant to HU. Increment of leukemia progression has not been 
shown for this drug (Andıç et al., 2016). 
HU is the initial choice of treatment because of its proven efficiency, especially in reducing 
thrombotic complications. However, HU is recommended to be used with caution in young patients 
regarding the data showing an increment of leukemia incidence in long-term usage of HU (Andıç et al., 
2016). In the ANAHYDRET study, it was shown that anagrelide is as effective as hydroxyurea. 
Secondary leukemia has not been reported with anagrelide treatment yet. Interferon alpha was the least 
commonly used agent in all MPN groups, probably because of its parenteral usage and poor tolerability 
(Andıç et al., 2016). 
In our study, we did not find any relation between the complications of MPN and the treatment 
options. 
In summary, in the present study there is evidence of influence of fibrotic/leukemic 
transformation and the presence of JAK2 mutation in PN-MPNs survival. Caspase (CASP8 and CASP9) 
and BER pathway (XRCC1 and APEX1) polymorphisms are associated with leukemic transformation 
and occurrence of new primary nonmyeloid malignancies, whereas only BER pathway (XRCC1) 
polymorphisms are associated with the presence of thrombotic events. Apparently, therapeutics only 
influences the tendency to 2ryMF/AML transformation.   
Despite all the advances in the last few years, leading to the development of more targeted 
treatments, there are still lacking long-term effective and well-tolerated therapies for both low and high  
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risk patients (Griesshammer et al., 2015). 
Larger studies are required to confirm these results and to provide conclusive evidence of 
association between these and other variants and PN-MPNs and therapeutic response. 
Identification of the main molecules that are altered in MPNs will allow the development of drugs 
more directly targeted to the pathophysiology of the disease, with high efficacy, fewer adverse effects, 
contributing to compliance of the patients with treatments. 
In the future, these new data may contribute to a best knowledge of these diseases course and 
to a more rational and efficient choice of therapeutic strategies to be adopted in the treatment of PN-
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CHAPTER 10:  
CONCLUSIONS AND FINAL REMARKS 
Myeloproliferative neoplasms are classically divided into BCR-ABL1 (Philadelphia 
chromosome) positive chronic myeloid leukemia and PN-MPNS, including PV, ET and PMF, according 
to WHO classification (Arber et al., 2016; Swerdlow et al., 2008). It has been on these last three entities 
that this dissertation has bent over.   
PN-MPNs are rare diseases worldwide, predominantly diagnosed in the age range of 50–60 
years (Bellanné-Chantelot et al., 2006). Among the various registries worldwide, this group of disorders 
has a combined annual incidence rate of 0.4-2.8 for PV, 0.38-1.7 for ET and  0.1-1.0  for  PMF,  per  
100 000 persons (Moulard et al., 2014; Titmarsh et al., 2014).  
From the various published reports, PN-MPNs patients overall have a reduced life expectancy 
compared with general population, with PMF having the lowest overall survival, followed by PV and ET 
(Rumi & Cazzola, 2017; Tefferi, 2008). It was also reported that mortality in PN-MPNs patients is 
decreasing in the last few years and is generally attributed to disease progression to other hematologic 
malignancies, such as AML and MDS, bacterial infections and cardio- and cerebrovascular diseases, 
especially in younger patients (Hultcrantz et al., 2015; Rumi & Cazzola, 2017). 
The discovery of JAK2 V617F in 2005 and the other mutations that followed, such as JAK2 
exon12, MPL and CALR, which took place as driver mutations, was a very important milestone in the 
knowledge and understanding of the biological and molecular mechanisms that were behind the 
pathogenesis of these disorders, contributing to and influencing the definition of the phenotype and 
having a prognostic impact. Although they are different mutations located in distinct genes in several 
chromosomes, all of them share the same concept of having been the result of a clonal malignant 
transformation of hematopoietic stem-cells, characterized by evidencing cytokine hypersensitivity and 
deregulation of downstream signaling pathways, leading to abnormal amplification and proliferation of 
myeloid lineages and a tendency to transform to AML (Cross, 2011; Duletić et al., 2012; Tefferi & 
Pardanani, 2015).  
JAK2 V617F is found in approximately 95% of PV cases, and 50 to 60% of ET and PMF 
patients. Mutations in MPL W515 and CALR genes have practically only been detected in ET (3-4% 
and 20-25%, respectively) and PMF (6-7% and 20-25%, respectively) patients. These three mutations 
are mutually exclusive in the majority of cases. 
It is known that the different driver mutations involved in the pathogenesis of PN-MPNs can 
lead to different clinical effects and that a single mutation may be associated with distinct phenotypes 
and clinical outcomes (Rumi & Cazzola, 2017). For example, homozygosity for JAK2 V617F is more 
common in PV compared with ET, leading to the suggestion that increased JAK2 V617F signaling is 
associated with a more erythrocytic phenotype; approximately one third of JAK2 V617F positive PV 
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cases are homozygous with mutation burdens greater than 50%, associated with a more aggressive 
phenotype; one third of the remaining JAK2 V617F negative PV cases carry JAK2 exon 12 mutations, 
often accompanied by an apparently isolated erythrocytosis; MPL and CALR mutations are  usually 
associated to a thrombocytosis phenotype, with CALR revealing better prognosis (Jones & Cross, 
2013). 
According to WHO, classical PN-MPNs classification is based on molecular evaluation but also 
in specific standardized clinical-histopathological criteria, in order to an accurate diagnosis and capacity 
of predicting prognosis.  Phenotypic differences depend on which myeloid cell lineage is predominantly 
expanded in the peripheral blood, namely elevated red cell mass in PV, and elevated platelet numbers 
in essential ET, while PMF patients display bone marrow fibrosis, a variable myeloid cell number, 
extramedullary hematopoiesis, and hepatosplenomegaly. Patients with PV and ET are at an increased 
risk of developing thrombotic or hemorrhagic events and may progress to an accelerated myelofibrosis 
phase, but all three subtypes are associated with a long-term risk of transformation to AML or MDS 
(Jones & Cross, 2013).  
Considering the lack of Portuguese epidemiological data, the present dissertation had as the 
initial purpose to show data related to the characterization of the studied population, according to the 
type of PN-MPN, its prevalence and the presence of JAK2 mutation. To achieve this aim, case-control 
studies, which are powerfull tools for the study of candidate polymorphic genes and their potential 
association to a given disease in a population, were carried out in a Caucasian Portuguese sample of 
133 patients and 281 age- and sex-matched control subjects, recruited in a hospital setting, from 2009 
until 2016. 
All the patients included in the study were diagnosed accordingly WHO Classification criteria, 
on the basis of molecular, clinical, pathologic and morphologic/histologic features. 
The results from this study revealed that in the studied population, ET was the more prevalent, 
corresponding to 60.2% of patients, followed by PV (29.3%) and finally PMF (10.5%), with a discrete 
predominance of females (54.1%). No significant differences between the case and control groups were 
found, concerning smoking habits or age distribution (median of 68 years old at time of diagnosis), in 
agreement with the literature (Andıç et al., 2016; Bai et al., 2008; Passamonti et al., 2008; Srour et al., 
2016). A total of 75.0% of patients were positive for the presence of the JAK2 V617F mutation (Azevedo 
et al., 2017, for detailed information see Chapter 3), with an increased incidence in ET (73.4%) and a 
decreased incidence in PV (87.2%) patients than expected, when compared to the published literature, 
indicating that the population of the present study has a different pattern regarding the presence of this 
mutation, in comparison with other already studied populations from other countries. On the other hand, 
the fact that patients with the wild type JAK2 V617F or exon 12 mutation are extremely rare as it is 
reinforced in very recent reports (Rumi & Cazzola, 2017), wereas our results reveal a prevalence of 
12.8% of these patients, supports the idea that the JAK2 mutation acting alone may not be sufficient to 
develop the PV phenotype.  
 
 






The clinical-hematological features of the patients were also accessed and described 
throughout the work, detailed in Chapter 9 (Azevedo et al., submitted for publication), and were 
accordingly to what is defined for each entity. As expected, hemoglobin levels were significantly higher 
in PV and lower in PMF, whereas platelet count was higher in ET than in other groups.  
Among the patients that were JAK2 V617F mutation negative, it was highlighted a very 
interesting and unique patient with a new JAK2 exon 12 mutation - c.1605G>T (p.Met535Ile), 
associated with another mutation in the same exon already identified (Pita & Azevedo et al., 2017, for 
detailed information see Chapter 4), among the great diversity of exon 12 mutations (Vorechovsky, 
Jones, & Cross, 2013). This patient revealed the peculiarity of presenting a marked thrombocytosis, 
unlike the  usual phenotype for exon 12 mutation patients, mostly characterized by erythrocytosis and 
normal leukocyte and platelet counts  (Arber et al., 2016; Godfrey et al., 2016; Koopmans, Schouten, 
& van Marion, 2015). This could be an example of how the result of the association of two abnormalities 
may give rise to a different pattern than one would expected to achieve with each individual change. 
The higher platelet count may be due to the fact that this patient harbors two lesions, both of which on 
their own have been associated with erythrocytosis phenotypes, resulting in an excess of JAK2 
signaling or enhanced STAT activation and therefore more thrombocytosis than the usual (Williams, 
Kim, Rogers, Spivak, & Moliterno, 2007; Kim et al., 2016; Pardanani, Lasho, Finke, Hanson, & Tefferi, 
2007; Park et al., 2016; Scott et al., 2007; Siemiatkowska, Bieniaszewska, Hellmann, & Limon, 2010; 
Wu et al., 2014; Scott, 2011). 
Another peculiar clinical case that was presented and discussed in this dissertation refers to 
two patients who raised the suspition of the rare coexistence of JAK2 V617F mutation and BCR-ABL1 
translocation (Mousinho & Azevedo et al., for detailed information see Chapter 5). One of the major 
diagnostic criteria for ET is the absence of the Philadelphia chromosome (Ph), meaning that when 
present it would be almost indicative of CML. However, exceptionally there are rare situations in which 
ET patients present positive BCR-ABL translocation without features of CML (Pagnano et al., 2016; Qin 
et al., 2014). From the literature review, the frequency of coexistence of JAK2 V617F mutation and 
BCR-ABL translocation in MPNs is low, and besides V617F there are no other types of JAK2 mutation 
involved among the several cases reported. Several hypothesis have been advanced, but doubt still 
persists and it was not yet clarified which is the first anomaly to occur and to dominate, the amount of 
affected clones and if the presence of two molecular abnormalities may correspond to a new clinical 
entity, with the two mutations acting together and influencing one another, sharing phenotypes and 
varying levels of expression (Bee, Gan, Nadarajan, Latiff, & Menaka, 2010; Kwong, Chiu, Liang, Chan, 
& Chan, 1996; Qin et al., 2014; Zhou et al., 2015). Moreover, WHO classification does not address 
these atypical cases. Both patients reported revealed diagnostic clinical features matching ET, and in 
the first case also CML. Search for JAK2 V6217F mutation was positive in both cases, and t(9,22) was 
positive in FISH analysis with an atypical pattern with only one fusion signal observed, being negative 
in molecular tests. One of the possible explanations is that this unique fusion signal detected by FISH 
can correspond only to der(9), and not to Ph chromosome with associated tyrosine kinase activity (on 
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chromosome 22). From literature review, there are no reports of a “true” positive BCR-ABL with an 
aberrant pattern similar to our cases, but instead there are descriptions of karyotipic aberrations 
associated with JAK2 V617F mutation (Larsen, Hasselbalch, Pallisgaard, & Kerndrup, 2007). On the 
other hand, it has been published a der(9) chromosome coexistence with acute lymphoblastic leukemia 
(Specchia et al., 2003). So, these two patients are a good example of the probable importance and 
influence of the presence of der(9) chromosome, contributing to the phenotypic variations observed in 
some ET cases. Moreover, the coexistence of these two genetic abnormalities may also have 
therapeutic strategy implications. 
Initially, it was thought to apply this study to MPNs both BCR-ABL1 positive and negative, but 
it turned out to be limited to the study of PN-MPNs only. However, another particular patient was found 
and was decided to be presented in this work (Azevedo et al., 2017, for detailed information see Chapter 
6). This was the case of a BCR-ABL1 positive CML patient who developed resistance to imatinib. 
Quantitative real time polymerase chain reaction technique (qRT-PCR) testing was performed and 
revealed a new mutation - c.839T>G (p.Val280Gly). This is the first report describing this new BCR-
ABL kinase domain mutation, which might be associated with resistance to imatinib. The identification 
of BCR-ABL expression as the defining leukemogenic event in CML and the introduction of BCR-ABL 
tyrosine kinase inhibitors in 2001 have revolutionized disease management, leading to a reduction in 
mortality rates and accordingly to an increase of the estimated prevalence of CML.  However, 
approximately 15% to 30% of patients treated with imatinib discontinue treatment due to resistance or 
intolerance (Radich et al., 2014; Soverini et al., 2015; Soverini et al., 2011). More than 90 BCR-ABL 
mutations were detected so far, conferring variable degrees of drug resistance, with consequent clinical, 
therapeutic and prognostic impact (Nicolini et al., 2006; Soverini et al., 2006). 
Although it is possible to identify a molecular marker in the majority of PN-MPNs patients, driver 
mutations cannot fully explain the phenotypic heterogeneity of PN-MPNs, nor the susceptibility of 
progression to myelofibrosis, acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) 
(Hinds et al., 2016). On the other hand, it is possible to identify one of the driver mutations in the majority 
of the patients, but genetic defects still await identification in about 10-15% of cases (triple-negative), 
mostly of ET and PMF patients, who meet the WHO criteria for MPN  and are associated with a poor 
clinical outcome  (Delhommeau et al., 2010; Nangalia et al., 2013; Rumi & Cazzola, 2017; Tefferi & 
Pardanani, 2015) . This finding may probably be due to the association with other commutated non-
MPNs-driver genes (ex: ASXL1, EZH2, TET2, IDH1/2,  SF3B1, SRSF2), karyotypic abnormalities, and 
the occurrence of genetic variation (SNPs) that contribute to disease onset, phenotypic variability and 
severity, phenotypic shifts and progression to more aggressive neoplasms (Rumi & Cazzola, 2017).  
With the recent sequencing of the human genome, the study and discovery of genetic 
polymorphisms emerges as one of the research areas of modern genetics (Singh et al., 2008), in that 
it drives the studies of genetic association (Gaspar et al., 2006). In recent years, the study of 
polymorphic   genes   has   been  the  main  and  most  frequent  approach  in  describing  inter-individual  
 
 






differences and showing consistent evidence of their involvement in different types of cancer. In the 
case of PN-MPNs, there are some studies developed in this field, mainly related to DNA repair (Adel 
Fahmideh, Schwartzbaum, Frumento, & Feychting, 2014; Batar, Güven, Bariş, Celkan, & Yildiz, 2009; 
Bănescu et al., 2014; Canbay et al., 2011; Chiang et al., 2014; Costa et al., 2007; Das et al., 2015; Du 
et al., 2014; Hernández-Boluda et al., 2012; Sorour, Ayad, & Kassem, 2013). However, to the best of 
our knowledge, no clinical association studies have been performed thus far to evaluate the role of 
caspases genes polymorphisms on PN-MPNs susceptibility.  
Following this line of reasoning, and studying the same patient and control populations, different 
polymorphisms of caspases genes involved in apoptosis (nine polymorphisms of four genes) and base 
excision repair pathway (BER) (eight polymorphisms of six genes) were selected and genotyped using 
qRT-PCR, and statistical analysis performed using SPSS version 22.0 (Caspases: Azevedo et al., 
2017, for detailed information see Chapter 7; and BER: Azevedo et al., 2017, for detailed information 
see Chapter 8).  
The caspases are a specific group of cysteine aspartate proteases, a family of intracellular 
proteins involved in the initiation and execution of apoptosis processes, responsible for the dismantling 
and destruction of the cell (Green & Llambi, 2015; Riedl & Salvesen, 2007). The disruption in the 
balance between pro- or anti- apoptotic proteins has been established to contribute to carcinogenesis 
by reducing apoptosis in malignant cells (Ding et al., 2000; Goldar, Khaniani, Derakhshan, & Baradaran, 
2015; Olsson & Zhivotovsky, 2011), and to be involved in the pathophysiology and clinical-
hematological outcome of PN-MPNs (Malherbe et al., 2016; Testa, 2004; Tognon et al., 2013).  
On the other hand, DNA repair mechanisms are essential for preventing cellular damage and 
the development of leukemia (Azevedo et al., 2017). Previous reports have identified BER pathway 
polymorphisms associated with overall solid tumors development (Azevedo et al., 2017), and leukemic 
transformation and development of non-myeloid malignancies in ET and PV patients (Hernández-
Boluda et al., 2012). 
We concluded that polymorphisms in apoptosis and BER related genes may contribute to 
individual susceptibility to MPNs and, hence, modify disease risk. Considering the polymorphisms 
investigated as a whole, our results revealed that none of the studied polymorphisms was involved in 
individual susceptibility to these disorders. However, potential associations were found after disease 
stratification. In fact, our results suggest the potential involvement of a CASP9 (Phe136Phe) gene and 
a XRCC1_399 (Gln399Arg), and a MUTYH (Gln335His) gene polymorphisms after stratification by 
pathology diagnosis for ET female patients, and when they are JAK2 positive an association with a 
CASP9 (Phe136Phe) gene and a XRCC1_399 (Gln399Arg) gene polymorphisms. In BER genes, 
combination of alleles also demonstrated an association with the disease for one specific haplogroup.  
Although the cellular and molecular mechanisms involved in the pathophysiology of MPNs have 
not yet been fully clarified (Beer et al., 2010; Björkholm, Hultcrantz, & Derolf, 2014; Bolufer et al., 2006; 
Campregher, Santos, Perini, & Hamerschlak, 2012; Delhommeau et al., 2010; Hinds et al., 2016; 
Kilpivaara & Levine, 2008; Rice et al., 2011; Rueff & Rodrigues, 2016), there is evidence that in PN-
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MPNs patients, hyperactive JAK/STAT signaling pathway appears to be a constant, even when the 
driver gene mutation is still unknown (Reuther, 2016; Skoda et al., 2015). Furthermore, JAK/STAT 
pathway regulates several biological processes including cell proliferation, differentiation, cell migration 
and also apoptosis (Becerra-Díaz et al., 2011).  Despite its capacity to induce a proliferative activity, 
JAK/STAT pathway has also an anti-apoptotic effect, through the upregulation of anti-apoptotic 
proteins, thereby allowing myeloid differentiation to proceed (Kieslinger et al., 2000). In turn, these anti-
apoptotic proteins regulate the caspases that integrate apoptosis pathway. In particular in PN-MPNs, 
the deregulation of apoptosis is involved in the pathophysiology of these diseases (Malherbe et al., 
2016; Testa, 2004; Tognon et al., 2013). Moreover, there is also evidence from previous studies that 
CASP9 gene polymorphisms are involved in the pathogenesis of various types of cancer and that 
abnormalities affecting the intrinsic apoptotic cascade apparently promote megakaryocyte 
accumulation and thrombocytosis in PN-MPNs (Malherbe et al., 2016). 
DNA repair is a ubiquitous process in all living systems. Its universality reflects the constant 
pressure that leads to altered genome integrity resulting from the intrinsic instability of the genetic 
material and limitations on the fidelity of DNA replication. Several agents induce different types of 
lesions in the DNA and according to the lesion they will create and activate a set of proteins responsible 
for the efficient repair of the lesion. Endogenously produced metabolites, namely reactive oxygen 
species, and also exogenous exposure, for example, to genotoxic compounds, have the ability to injure 
the cells and thereby increase genomic instability favoring the development of cancer. These specific 
DNA lesions caused by these metabolites can be repaired by mechanisms related to the BER pathway. 
Our findings may provide evidence for BER gene variants in susceptibility to PN-MPNs. Indeed, 
common variants in DNA repair genes may hamper the capacity to repair DNA, thus increasing cancer 
susceptibility. 
The study of haplogroups is of more value, as it allows to test the genetic effect of combinations, 
not individualy, of relevant functional SNPs, which may contribute to the increased risk of cancer 
(Ponder, 2001). 
It is well known that PN-MPNs have an intrinsic tendency to evidence progression to AML, 
sometimes preceded by a phase of secondary MF or MDS (Mesa et al., 2016), and to develop 
thrombohemorhagic complications, mainly arterial thrombotic events (Andıç et al., 2016), to  an extent 
that is not fully known, but less frequent in PMF (Björkholm, Hultcrantz, & Derolf, 2014; Hernández-
Boluda et al., 2012). These aspects have a considerable impact in PN-MPNs life expectancy, that is 
reduced when compared to general population (Passamonti et al., 2004; Wolanskyj, Schwager, 
McClure, Larson, & Tefferi, 2006). Moreover, therapy with cytoreductive and alkylating agents is also 
associated with an increased risk for malignant transformation, and consequently worse prognosis 
(Rampal et al., 2014; Swerdlow et al., 2008). On the other hand, regarding the development of new 
nonhematological and nonmyeloid neoplasms in PN-MPNs, there is evidence that the risk is higher 
when JAK2 V617F mutation is present and that other individual factors may be also involved. However  
 
 






the association with cytoreductive therapy is not so well established (Hernández-Boluda et al., 2012; 
Santoro et al., 2017).  
Besides their role in genetic susceptibility, documented by some authors and evidenced by this 
work (Azevedo et al., 2017), it appears that SNPs involved in DNA repair capacity and apoptotic status, 
as well as additional somatic genetic effects, may also influnce phenotype definition, determine  
therapeutic response and modulate clinical outcome in PN-MPNs (Bănescu et al., 2014; Campregher, 
Santos, Perini, & Hamerschlak, 2012; Delhommeau et al., 2010; Levine, 2009; Nangalia et al., 2013; 
Tefferi & Pardanani, 2015; Tognon, Nunes, & Castro, 2013; Wang et al., 2014). 
In this way, one of the last chapters of this dissertation (Azevedo et al., for detailed information 
see Chapter 9), was dedicated to the presentation of the obtained results regarding the impact that 
SNPs in caspase and BER pathway genes might have in PN-MPNs patients’ survival and therapeutic 
response, their role in disease progression and risk predisposition to new non-myeloid neoplasms and 
thrombotic events, in patients under treatment. This is probably one of the most complex sections in 
this dissertation, not only for the large amount of data obtained, but also for the multiplicity of 
factors/variants tested, requiring special approach strategies. 
Patients were followed up for a mean of 7.6 years and hydroxyurea (HU) was the first option 
drug in the majority of ET, PV, and PMF cases included in the study. According to international 
guidelines, HU is the initial option for treatment because of its proven efficiency, especially in reducing 
thrombotic complications (Andıç et al., 2016). 
According to our results, survival was influenced by progression to 2ryMF/AML and the 
presence of JAK2 V617F mutation, in agreement with the literature (Andıç et al., 2016), being shorter 
in PMF patients, with the majority of deaths occurring through five years after diagnosis and involving 
ET and PMF patients. However, according to our results survival was not influenced by the development 
of new primary nonmyeloid malignancies, nor the occurrence of thrombotic events, not corroborating 
what is described in the literature (Andıç et al., 2016). None of the caspase and BER pathway studied 
polymorphisms influenced survival. 
Regarding the study of the role of clinical, genetic and therapy related factors potentially 
influencing PN-MPNs prognosis, namely progression to 2ry MF/AML, the study included 12.8% of all 
PN-MPNs case patients (8 with PV and 9 with ET) that progressed and were matched with 76 control 
patients who did not, monitored for at least the same period of time. There was evidence of no significant 
difference in age (median of 67.7 years), nor in the number of patients with marked thrombocytosis, but 
with PV patients having higher white blood cells count at presentation and more frequently JAK2 
mutation, both not associated with the propensity for leukemic transformation. On the other hand, 
globally, there is an association with progression to 2ry MF/AML and the exposure to cytoreductive 
agents, consistent with the literature (Hernández-Boluda et al., 2012), however our results showed that 
previous treatment with HU was not found to be an influencing factor for leukemic transformation. On 
the other hand, although not statistically significant in our results, leukocytosis and marked 
thrombocytosis could be involved in leukemic transformation, in agreement with the literature 
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(Griesshammer et al., 2015; Hernández-Boluda et al., 2012; Passamonti et al., 2008; Passamonti et 
al., 2004). 
Concerning SNPs, it appears to exist a correlation in the studied population, consistent with 
other authors reports  (Hernández-Boluda et al., 2012). Globally, our results revealed a lower effect of 
a CASP8 (3’UTR) gene polymorphism in disease progression to 2ry MF/AML, and a higher risk 
associated with the presence of a XRCC1 (Arg194Trp) gene polymorphism, representing a worse 
prognosis. Stratification for ET patients revealed a CASP9 (Arg173His) and a XRCC1 (Arg194Trp) 
genes polymorphisms associated with a worse effect in progression to 2ry MF/AML, whereas an APEX1 
(Asp148Glu) gene polymorphism showed a probable better prognosis. 
The development of new primary nonmyeloid malignancies during follow-up occurred in 8.3% 
(11 patients) PN-MPNs cases patients, which were matched with 30 control patients who did not, with 
solid organ malignancies being more frequent than hematological ones, affecting more frequently 
PMFpatients. There was a predominance among males, but no significant difference in age, and no 
significant association was found for the presence of JAK2 mutation, nor for the exposure to 
cytoreductive agents. The association of long-term HU use with development of nonmyeloid 
malignancies is controversial among the several authors (Hernández-Boluda et al., 2012; Santoro et 
al., 2017).  
Globally, a CASP8 (Asp270His) gene polymorphism evidenced association with an increased 
incidence, while a XRCC1 (Arg399Gln) gene polymorphism appeared to be related to a decreased 
incidence for new non-myeloid malignancies development. 
Finally, thrombotic events were reported in 16.5% (22 patients) PN-MPNs cases patients, more 
frequently with PV and ET, which were matched with 56 control patients. In our population, the most 
frequent types of major thrombosis occur in arterial territories, along with deep vein thrombosis, in 
agreement with the literature (Andıç et al., 2016). There was no significant difference in age, nor 
platelets levels between cases and controls patients. In the same way, no significant association was 
found for exposure to cytoreductive agents, nor the presence of JAK2 mutation, differing from some 
authors (Andıç et al., 2016). 
In general, only BER pathway evidenced an association with the presence of thrombotic events, 
patients bearing a XRCC1 (Gln399Arg) gene polymorphism have a decreased incidence for thrombotic 
events.  
In conclusion, the results obtained in the present dissertation helped to characterize a 
population of PN-MPNs patients, which can reflect Portuguese reality, and have suggested that some 
of the polymorphic variations studied, which are part of different mechanistic pathways, may constitute 
an important risk factor for the development and clinical progression of PN-MPNs.  
Additional studies involving larger and diversified populations are required to further clarify the 
potential value of different genotypes as predictive biomarkers of susceptibility to PN-MPNs, so that the 
obtained results can be validated. 
 
 






The use of association studies has been criticized for several reasons, namely that 
retrospective determination of an association between being an allele or genotype and a given 
pathology does not necessarily mean that there is an etiological link between them. Only prospective 
studies (cohort studies) in large, primarily healthy populations can provide direct and reliable evidence. 
(Tempfer et al., 2006). 
It is also possible to continue this work through the evaluation of other polymorphisms present 
in both the pathways described and in other pathways that are thought to be relevant, such as those 
involved in DNA repair (ex. homologous, non-homologous and nucleotide excision repair). Another 
possibility is the study of specific regulatory proteins involve in apoptosis, such as SOCs. The relevance 
of the association studies can also be consolidated with the use of functional studies. 
Some works for the development of new techniques of genetic classification of these tumors 
are in course, involving important reference centres and relevant resources. We hope these data may 
be a contribute to the clarification of the pathophysiology of these disorders, to the identification of 
subgroups of patients and to the elaboration of tighter therapeutic strategies, which may allow to identify 
in advance what will be the potential response of a patient to a given therapeutic protocol, with 
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APPENDIX 1: INFORMED CONSENT AND MEDICAL QUESTIONNAIRE 
       
HOSPITAL SÃO FRANCSICO XAVIER 
Exmo Senhor/a 
 
O Serviço de Patologia Clínica do Hospital de São Francisco Xavier e o Departamento de Genética da 
Faculdade de Ciências Médicas da Universidade Nova de Lisboa encontram-se envolvidos num projecto de 
investigação com vista a identificar factores de pré-disposição para tumores hematológicos. 
A identificação destes factores de risco genético poderá vir a ser de extrema importância uma vez que 
poderá permitir no futuro a identificação de indivíduos de risco para este tipo de patologia. Esta abordagem, a ser 
conseguida, poderá permitir um conjunto de dados visando, num futuro próximo, o rasteio precoce de indivíduos 
com risco acrescido para este tipo de patologia e consequentemente o diagnóstico precoce. 
Em função destes objectivos solicitamos a sua colaboração, a qual se traduzirá apenas pela resposta a 
um pequeno questionário confidencial e anónimo e a colheita de um pequeno volume de sangue, que ficará 
guardado no Departamento de Genética da FCM para estudo. 
Agradecendo antecipadamente a sua colaboração, 
Dra. Ana Paula Azevedo 
Serviço de Patologia Clínica do HSFX – CHLO 
 
DECLARAÇÃO 
Eu, ___________________________________________________________, declaro ter sido 
devidamente esclarecido sobre a natureza e objectivos do estudo “Polimorfismos genéticos: potenciais factores 
de risco para doença oncológica” tendo decidido colaborar voluntariamente neste estudo. 
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INQUÉRITO  
Código: __________ (a preencher pelo Médico) 
Data de Nascimento: _____/______/______ Sexo: ________________________  Etnia: ____________________   
Diagnóstico: __________________________________________      Data de Diagnóstico: _____/______/______   
Data de colheita: _____/_____/_____   Terapêutica: ________________________________________________ 
Peso: ______________  Altura:  _____________   Naturalidade:  ______________________________________ 
Local de residência:  _________________________________________________________________________ 
Reside numa rua com muito trânsito? ____________________________________________________________ 
Reside perto de alguma fábrica, refinaria, bomba de gasolina? Especifique: .______________________________ 
__________________________________________________________________________________________ 
Profissão: _________________________________________________________________________________  
Trabalha com produtos químicos?  _____________    Especifique tanto quanto possível: ____________________ 
__________________________________________________________________________________________ 
No seu ambiente de trabalho está exposta a produtos químicos? _________________ Especifique tanto quanto 
possível:  __________________________________________________________________________________ 
__________________________________________________________________________________________ 
Trabalha numa rua com muito trânsito? __________________________________________________________ 
Trabalha perto de alguma fábrica, refinaria, bomba de gasolina? Especifique: _____________________________ 
__________________________________________________________________________________________ 
Esteve exposto a radiação ionizante por razões ocupacionais?_____________Especifique tanto quanto possível: 
__________________________________________________________________________________________ 
Esteve exposto (durante algum período de tempo) a radiação ionizante por razões médicas (ex: RX, TAC)?-
____________________ Especifique tanto quanto possível: _____________________________________-
__________________________________________________________________________________________ 
Realizou transfusões de sangue nos últimos 12 meses? (Se sim qual a razão?) 
__________________________________________________________________________________________ 
Hábitos alcoólicos:  
Vinho tinto (Quantidade/Anos de Consumo): ______________________________________________________ 
 





Vinho branco (Quantidade/Anos de Consumo): ____________________________________________________ 
Cerveja (Quantidade/Anos de Consumo): _________________________________________________________ 
Outras bebidas (Quantidade/Anos de Consumo): ___________________________________________________ 
Hábitos tabágicos: n.º de cigarros por dia ____________________ anos de consumo ______________________ 
Toma regularmente algum tipo de medicação? ________________________________________(Qual, Duração): 
__________________________________________________________________________________________ 
Está a tomar, ou tomou, suplementos vitamínicos? ____________________________________ (Qual, Duração): 
__________________________________________________________________________________________ 
 Qual o seu tipo de  alimentação?  
         Todas as refeições                Frequentemente                Raramente                Ocasionalmente 






Fumados:   
Enlatados:   
 
1.1.1 Chá: sim/não _____________________________________________________ Quantas vezes por dia? 
__________________________________________________________________________________________ 
1.1.2 Café: sim/não ____________________________________________________ Quantas vezes por dia? 
__________________________________________________________________________________________ 
1.1.3      Água: só às refeições ___________ também fora das refeições ______________ Quantos litros por dia  
(aproximadamente)? _________________________________________________________________________ 
Existem antecedentes familiares de cancro, nomeadamente hematológicos?_____________________________-
__________________________________________________________________________________________ 
Especifique o(s) tipo(s) de tumor(es) e o parentesco do familiar. ________________________________________ 
 




Foi-lhe diagnosticado anteriormente qualquer outro tipo de tumor? _____________________ Qual? Em que data? 
__________________________________________________________________________________________ 
__________________________________________________________________________________________ 
Outra doença associada: _____________________________________________________________________ 
__________________________________________________________________________________________
__________________________________________________________________________________________ 
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